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Abstract 
 
Background:  
Viral acute respiratory infections (ARIs) are the commonest illnesses experienced by all age groups, 
especially in infants where infection rates are highest.  Nevertheless, during the molecular era, 
outside of hospital-based studies, little is known about the current aetiology and community burden 
of viral ARIs in infants and young children.     
 
The observational research in childhood infectious disease (ORChID) project is a prospective 
community-based birth-cohort study of healthy Australian infants and children. It began in 2010 to 
investigate respiratory virus infections until two-years of age. My PhD established laboratory 
quality control techniques for studies of this nature and describes the respiratory viruses and 
molecular epidemiology of human rhinoviruses (RV) during the first year of life in a nested 
subgroup of this cohort.  
 
The hypotheses were: 
(i) During the first year of life and in otherwise healthy infants, RV is the most 
commonly detected respiratory virus in respiratory secretions. 
(ii) Various factors impact upon successful viral detection, including the ability of 
parents to collect appropriate samples and other laboratory-based technical issues.  
(iii)  Repeated detection of RV-RNA in respiratory secretions over periods of more 
than 4-weeks results from genotype replacement and new infection events rather 
than from prolonged shedding of the same genotype. 
(iv) Many RV genotypes circulate in a single location in 1 year period.  
 
Methods 
The ongoing ORChID study completed sample collection at the end of 2014. Parents were 
approached antenatally and asked to collect weekly anterior nasal swabs from the time of their 
child’s birth until their second birthday.  Swabs were mailed to the laboratory where they were 
stored at -80ºC until analysis. Parents also completed a daily symptom diary, which was submitted 
monthly. My PhD focused on samples collected from an infant subgroup within this cohort and the 
first two-years of the ORChID study.   
 
Samples were extracted using an automated robotic system after spiking each sample with equid 
herpes virus (EHV-1). The extraction quality and presence of human DNA in extracts were assessed 
by real-time PCR for EHV-1 and endogenous retrovirus 3 (ERV-3) respectively. Respiratory virus 
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PCR testing included: RV, influenza viruses (IFVs: A/B), parainfluenza viruses (PIV: 1-3), 
respiratory syncytial virus (RSV; A/B), human metapneumovirus (hMPV); human coronaviruses 
(hCoV; NL63, 229E, OC43 and HKU); human polyomaviruses (PyV: WU and KI), adenovirus 
(AdV), and human bocavirus (hBoV).  
 
In a subset of 3366 nasal swab samples, the impact of ERV-3 load upon respiratory virus detection 
was determined. Mould was observed incidentally in some samples reaching the laboratory. The 
impact of different mould levels upon ERV-3 and respiratory virus detection was therefore 
investigated.  
 
The influence of sequence variation upon target sequences was assessed for HAdV detection. Two 
new HAdV real-time PCR assays utilising combinations of degenerate oligonucleotides were tested 
in parallel with a previously designed and well established real-time PCR assay. ORChID (n=8800) 
and routine clinical (n=779) samples were then tested and the results compared.  
 
The nature and shedding patterns of respiratory viruses, including the molecular epidemiology of 
RV was investigated in the nested infant cohort. Viral protein regions 4 and 2 were targeted to 
investigate RV-genotypes.  
 
Simple descriptive statistics and regression models analysed associations and outcomes of interest.  
 
Results 
My nested subgroup of 72 infants provided 3446 swabs. Of these, RV (19.1%) had the highest 
detection rates followed by PyV-KIV (1.7%), hBoV (1.6%), AdV (1.1%), PyV-WUV (0.9%), RSV-
A (0.6%), hCoV-OC43 (0.3%), PIV-3 (0.3%), hCoV-NL63 (0.3%), RSV-B (0.2%), hMPV (0.2%), 
PIV-1 (0.1%), IFV-A (0.09%), IFV-B (0.06%), hCoV-229E (0.06%), PIV-2 (0.03%) and         
hCoV-HKU1 (0.03 %).   
 
Failure to detect ERV-3 was associated with 60% reduction in virus detection rates in nasal swabs. 
Mould was observed in 23% of samples and  associated with delays in transportation, season and 
reduced ERV-3 and respiratory virus detection.  
 
Degenerate oligonucleotides may overcome season-to-season variation in viral gene targets. 
Compared with the established assay, the new HAdV assays provided similar qualitative, but 
superior quantitative results.     
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Serial RV-detection for more than 3-4 weeks was from genotype replacement rather than prolonged 
shedding. Although detected in asymptomatic infants, an association was found between RV and 
respiratory symptoms, especially for the RV-C species.  
 
Conclusions 
Longitudinal studies help further understand respiratory virus detection, viral shedding and disease 
burden in the community. The quality of nasal swab collection and transportation can be monitored 
in real-time using the human DNA marker ERV-3.  Gene target variation is a potential problem for 
longitudinal studies and was addressed successfully in HAdV real-time PCR assays by using 
combinations of degenerate oligonucleotides. This developmental work allowed me to show that in 
otherwise healthy Australian infants RVs were the dominant respiratory pathogens, followed by the 
DNA respiratory viruses. The apparent prolonged shedding of RVs over more than 3-4 weeks was 
from genotype replacement rather than persistent infection. RV-C appeared more pathogenic than 
the other RV-species and if confirmed this will help identify a viral target for future novel 
therapeutic and public health interventions.   
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1.1 Background 
Viral acute respiratory infections (ARIs) encompassing upper respiratory tract infections (URTIs) 
and lower respiratory tract infections (LRTIs) are the most common illnesses experienced by people 
of all ages. The highest rates of these illnesses occur during the first 24 months of life with annual 
episodes of 6-8 ARIs causing many complications and a high incidence of infant and child mortality 
worldwide (Monto, 2002). Indeed, for respiratory syncytial virus (RSV) alone, it is estimated that 
each year in children under five years of age there are 34 million episodes of LRTI, 3.4 million 
hospitalisations and as many as 199,000 deaths globally (Nair et al., 2010). Locally in Australia 
during 2003, almost half of those younger than five years of age were taken to their family doctor 
for ARI symptoms or were advised by a primary care health consultant (Lambert et al., 2008b; 
Lambert et al., 2007). Nearly 40% of new primary care consultations in children in the same age 
group are for respiratory illnesses (Bridges-Webb et al., 1993). Young children transmit respiratory 
viruses to their family and other household members (Peltola et al., 2008). In a population study of 
healthy Australian adults, the risk of household respiratory virus transmission was higher if a child 
lived in the house (McCaw et al., 2012). Complication rates are also higher in younger children. 
The risk of acute otitis media (AOM) complicating URTIs can be as high as 33%, while as many as 
13% of URTIs can also be complicated by sinusitis (Revai et al., 2007). Viral LRTIs are responsible 
for hospitalising 3-5% of infants with bronchiolitis, pneumonia, croup or from secondary bacterial 
pneumonia (van Woensel et al., 2003).  
Traditionally, the common viruses associated with childhood ARIs are RSV, parainfluenza viruses 
(PIVs), influenza viruses (IFVs) and adenoviruses (HAdVs) with human rhinoviruses (RVs) 
causing most URTIs (Lambert et al., 2008b; Monto, 2002). However, with the recent development 
of molecular-based detection techniques, such as polymerase chain reaction (PCR) assays, several 
new human viruses have been discovered in patients with respiratory symptoms since 2001. These  
include human metapneumovirus (hMPV), human bocavirus (hBoV), two novel human 
coronaviruses, (hCoV), hCov-NL63 and hCoV-HKU1, and two polyomaviruses (PyVs), WUV and 
KIV (Kahn, 2006; Lambert et al., 2008a; van der Hoek et al., 2006; Woo et al., 2006). Studies of 
RV revealed a new human rhinovirus C (RV-C) species after the complete coding sequence of a 
member of a divergent cluster of RV strains was reported in 2007 (McErlean et al., 2007). RVs 
have also been identified as important causes of asthma exacerbations (Busse et al., 2010; Hayden, 
2006; Saraya et al., 2014). Deployment of highly sensitive molecular assays has raised concerns 
over the co-detection of multiple respiratory viral pathogens in samples from both symptomatic 
patients and healthy controls, as well as the persistence of some viruses in respiratory secretions 
following a full clinical recovery (Fleming and Elliot, 2007; Hayden, 2006). Further questions 
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emerge when comparing hospital and community-based populations. Recently, PCR-based methods 
were used in community-based cohort studies to identify viruses in 69-83% of infants and young 
children with ARI (Lambert et al., 2007; Lambert et al., 2008). However, only about half of these 
children received medical attention during their illness and less than 2% were hospitalised (Kusel et 
al., 2006; Lambert et al., 2007).  
Community-based studies have determined the incidence and prevalence of viral ARIs in early life. 
However, as outlined in subsequent sections many have important methodological limitations or 
have studied only a few agents. The Observational Research in Childhood Infectious Diseases 
(ORChID) study is an ongoing, prospective community-based, dynamic, longitudinal cohort study 
that began in 2010 to investigate the patterns of respiratory virus detections in healthy infants 
during their first two years of life. Parents collected weekly nasal swabs from their children and 
mailed them directly to the laboratory where they were comprehensively screened for 17 respiratory 
viruses, including six newly identified viruses.  In addition, parents record a daily symptom diary 
for their child, which they return monthly to the ORChID project coordinator. The infants are 
followed from birth until their second birthday. This study will help to provide new insights into the 
nature of respiratory viruses infecting young Australian children, including their shedding 
characteristics and relationship with respiratory illnesses. My PhD thesis describes the respiratory 
viruses detected within a subgroup of infants nested within the ORChID cohort. It also focuses 
upon laboratory factors that may impact upon longitudinal community-based studies of respiratory 
viruses, including the importance of establishing laboratory quality control techniques, before 
finally describing the molecular epidemiology of RV during the first year of life.   
 
1.2 Community-based studies 
1.2.1 The importance of community-based cohort studies compared with 
hospital-based studies 
Much more needs to be done to understand the contemporary causes of viral ARIs within the 
community. Most studies published recently have been confined to either hospital cohorts or closed 
populations ( Arden et al., 2010; Lambert et al., 2007; Lambert et al., 2008; Sloots et al., 2006). In 
paediatric hospital-based studies, more than 80% of cases are younger than two years of age 
representing the sickest 2-3% of young children seen and are thus not representative of the general 
child population (Lambert et al., 2007) (Table 1.1).  
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Table 1.1 Distribution of viruses detected by RT-PCR in hospital and community-based studies in several regions 
 % of respiratory virus 
detection in hospital-based 
studies in Australia 
 % of respiratory virus detection in previous community-based studies 
 
Virus 
QPID 
(n =2866 )† 
0-97 yrs‡ 
UK 
(n=123) 
< 1 yr 
Switzerland 
(n=112) 
< 1yr 
Perth 
(n=976) 
< 1yr 
Perth controls 
(n=456) 
< 1yr 
Melbourne 
(n=543) 
0-4 yrs 
Netherlands 
symptomatic 
(n=165) 
0-7 yr 
Netherlands 
asymptomatic 
(n=65) 
0-7 yr 
Peru 
(n=3957) 
RSV 11 27 15 11 5 7 2 0 3.3 
IFV A,B or C         4.7 
IFV-A and B 4  4 4.5 0 3.7 1 0  
PIV  13  5.2 0.9 4.1   5.5 
   PIV-1 1.1  3       
   PIV-2 0.4  4       
   PIV-3 2.8  11       
HAdV 6  3 1.5 0.4 3.1 1 0 5.5 
hMPV 7  13 1.8 0.2 3.7 0 0 2.1 
RVs 31 46 23 49 11 41 23 22 31.8 
hCoV    5.5 4.4  9 8  
   hCoV-229E 0.8 6.5 3    4 2  
   hCoV-OC43 0.5 2.4 6    4 6  
   hCoV-NL63 2.0  8   1.5 2 0  
   hCoV-HKU1 0.8  1       
hBoV 5  5       
KIV 2.6         
WUV 4.5         
Enterovirus < 1.0  1    4 3  
M. pneumoniae  2.4  1.4 2.6  0 0  
C. pneumoniae  2.4  1.3 1.1  1 5  
Co-detections 10 20 20 11 1.5 10 17 3 13.7 
No pathogens 
detected 
20 17 21 31 76    33.08 
References (McErlean et al., 2007)
,(Arden et 
al., 2006; Sloots et al., 2006), 
(Lambert et al., 2007) 
(Legg et al., 
2005) 
(Regamey et al., 
2008) 
(Kusel et al., 
2006) 
(Kusel et al., 
2006) 
(Lambert et al., 
2007) 
(van der Zalm et 
al., 2009) 
(van der Zalm et al., 
2009) 
(Budge et al., 
2013) 
† No. of hospital-based samples tested in the Queensland Paediatric Infectious Disease Laboratory-Brisbane. ‡ 78% aged less than five years. 
HAdV: human adenovirus; hBoV: human bocavirus; hCoV: human coronavirus; HMPV: human metapneumovirus; IFV: influenza virus; PIV: parainfluenzavirus;  
PyV: polyomavirus; RSV: respiratory syncytial virus; RV: rhinovirus. 
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The accurate identification of ARI disease burden and it’s causes in the community is important for 
developing public health interventions, such as vaccination programmes, and avoiding possible bias 
caused by overestimating the severity of a particular virus, especially during pandemics (Hayward 
et al., 2014). Recent community-based studies (Table 1.1) have further characterised the aetiology 
of viral ARIs using modern molecular diagnostic techniques. 
 In studies of infants at high risk of atopy (Kusel et al., 2006; Lemanske et al., 2005) or those 
attending day-care (Fairchok et al., 2010; Martin et al., 2013; Regamey et al., 2008), RV was 
identified as the most common respiratory virus associated with ARIs, a finding which needs to be 
confirmed in other studies recruiting healthy infants (van der Zalm et al., 2009). A recent study by 
van der Zalm and colleagues investigated the nature of frequent RV detections in 18 healthy 
children, younger than eight years of age (van der Zalm et al., 2011). Over a six month winter 
period, fortnightly nasal swab specimens were collected by parents and mailed to the research 
laboratory. RV was detected in 101/272 (37%) respiratory samples identifying 27 different RV 
subtypes. This longitudinal study confirmed the diversity of RV subtypes in the study population, 
and identified the importance in future studies of determining the pathogenic role of RV subtypes 
causing respiratory infections (van der Zalm et al., 2011).  
Thus extrapolating data only from hospital-based studies leads to an underestimate of the causes of 
ARI and the overall disease burden. Even for IFVs, that represent one of the most studied groups of 
viral respiratory pathogens, the economic burden of infection have been estimated from 
assumptions or retrospectively collected data, usually from surveys, rather than from the results of 
community-based studies (Lambert et al., 2007; Lambert et al., 2008).  
From two early cohort studies that relied, partially, on molecular methods, the prevalence of RV in 
asymptomatic infants was 11-26% (Copenhaver et al., 2004; Kusel et al., 2006). Discounting the 
potential for technical false positive results, the detection of viral sequences by PCR in 
immunocompetent, asymptomatic individuals could be explained by (i) mild or unrecognised 
symptoms of an actual symptomatic infection, (ii) nascent infection before symptoms develop,   (iii) 
post infection shedding of residual viral genetic material, or (iv) genuine subclinical infection (Jartti 
et al., 2008; Peltola et al., 2008). The importance of PCR positive findings in asymptomatic 
children is yet to be clarified, as there are no large, comprehensive molecular-based studies 
intensely sampling cohorts of unselected, healthy children. Such studies are important when seeking 
to determine the relevance of viral concentrations in respiratory secretions before, during, and after 
the onset of respiratory symptoms. 
Longer-term, community-based studies (e.g. exceeding one year) are important when determining 
the seasonal distribution and variation of respiratory viruses. Olofsson et al (2011) identified the 
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seasonal distribution of ten respiratory virus species from five different virus families by comparing 
several studies that used molecular techniques. In the Northern Hemisphere, both picornaviruses 
and HAdVs were detected all year round, as were IFVs in the Tropics. In contrast, RSV, IFVs, 
hMPV and hCoVs had noticeable seasonal peaks during the winter and early spring months in the 
temperate regions of both the Northern and Southern Hemispheres. Little information is available 
for seasonal patterns from the newly described hCoVs (NL63 and HKU1) and PyVs (WUV and 
KIV).  Seasonality is strongly dependent upon geographic location, and with the limited data 
available on the patterns of respiratory infections occurring in communities from the Southern 
Hemisphere and tropical regions in particular, additional studies using molecular detection methods 
in these areas are needed (Olofsson et al., 2011).  
 
1.2.2 Cohort studies performed to date and critique 
The few published community-based studies in infants have important methodological limitations, 
such as using less sensitive approaches for viral detection (e.g. cell culture-based methods or 
serological testing) or reporting on a limited number of closely related or common agents (Budge et 
al., 2013; Legg et al., 2005; Manoha et al., 2007; van Woensel et al., 2003). For example, the 
epidemiology of RSV, hMPV and RV in children aged younger than three years was studied for 
two winter seasons in France (Manoha et al., 2007). Although the study found a significant 
difference in the prevalence of hMPV between the two seasons (10.1% and 3.3%), it excluded viral 
co-detections (Manoha et al., 2007). Another, more recent study, investigated ARIs  in children 
younger than three years of age living in high altitude regions of the Andes mountains, but testing 
was limited to ten of the established respiratory viruses (Budge et al., 2013).  
In addition to geographic diversity and seasonal variation, methodological differences can result in 
different outcomes for community cohort studies. For example, in five recent infant birth cohort 
studies (Table 1.2), no demographic data were available for one (Regamey et al., 2008), while two 
studies recruited only infants with atopic parents (Kusel et al., 2006; Legg et al., 2005), the fourth 
study recruited healthy urban infants (van der Zalm et al., 2009) while the fifth study recruited 
families with children under three years of age from rural communities in the Andes (Budge et al., 
2013).  
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Table 1.2 Comparison between five community study designs of infant birth cohorts  
Location (Ref). 
Duration  
UK (Legg et al., 
2005) 
<1y 
Perth (Kusel et al., 2006) 
<1y 
Switzerland (Regamey et al., 
2008)  
<1y 
 
Netherlands (van der Zalm 
et al., 2009) 
<1y 
Peru (Budge et al., 2013) 
Median follow-up 14.5 mths 
Similarities   The four studies recruited small families with high socioeconomic status  
 Families in rural 
agricultural areas. 
Demographic data  
At least one atopic, 
asthmatic parent  
At least one atopic, 
asthmatic parent  
Not reported 
 
Healthy infants  Not provided  
Timing of specimen 
collection  
Onset of 
symptoms, done 
by study team  
Within 48h of symptom 
onset, done by study team 
At onset of symptoms (cough 
or wheeze), done by study 
team  
On the 2nd day of illness, 
done by parents  
 During seven days of ARI 
symptoms.  
 
Samples and collection  
 
Nasal lavage  
 
Nasopharyngeal aspirate 
 
Nasal and throat swabs  
 
Nasal and throat swabs 
 
Nasal swabs  
 
Viral shedding  
Not reported 
 
Not reported 
 
Single sample collected 3 
weeks later 
Not reported 
 
Not reported 
 
Control samples  
 
None  
Two control samples (one 
in winter and another in 
summer, but only if no 
symptoms were recorded in 
previous four  weeks) 
 
None   
 
None 
 
None  
 
Novel respiratory 
viruses. 
 
Not tested  
 
hMPV 
 
hCoV-NL63 and HKU-1  
hBoV and hMPV 
 
hCoV-NL63 and hMPV 
 
hMPV.  
Bacterial agents 
C. pneumoniae &  
M. pneumoniae 
C. pneumoniae & 
M. pneumoniae 
Not reported   
C. pneumoniae & 
M. pneumoniae 
Not reported 
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The first four studies had enrolled predominantly small families with a high socioeconomic status 
where subjects were more likely to be breast-fed and less likely to be exposed to tobacco smoke. 
The fifth study recruited families with distinct characteristics; families were labourers, mainly in 
agriculture living in small, apparently, crowded households (Budge et al., 2013). Different types of 
samples were collected in each study. Nasal lavage (Legg et al., 2005) and nasopharyngeal aspirates 
(NPA) (Kusel et al., 2006) were collected by research staff during an ARI in two of the studies, 
while in the remaining two combined nasal and throat swabs (Regamey et al., 2008) (Marieke M. 
van der Zalm et al., 2009) were collected by parents. For the fifth study, trained research staff 
collected nasal swabs when ARI were identified in child subjects (Budge et al., 2013). Control 
samples were collected in just one study. They were collected from subjects (one in winter and 
another in summer) when they were without respiratory symptoms for at least a preceding four 
week period (Kusel et al., 2006). Viral shedding was measured in another study, but this was from a 
single specimen collected three weeks after an ARI (Regamey et al., 2008). Limitations of all five 
studies included: none tested for all the newly discovered respiratory viruses, subjects were 
followed for no more than one year, except for the fifth study where subjects were followed for 28 
months, and in one study observations and microbiological sampling were confined to just the first 
winter (Legg et al., 2005; van der Zalm et al., 2009) or the only first ARI with cough and wheeze 
(Regamey et al., 2008).  
The overall incidence and prevalence of respiratory viruses in asymptomatic infants in these 
community-based studies cannot be determined as either samples were not collected at all or not 
collected routinely throughout the year. As only three of these studies recruited over several years 
(Budge et al., 2013; Kusel et al., 2006; van der Zalm et al., 2009) data on season-to-season variation 
are limited. In addition, the impact of newly discovered viruses on ARIs in the cohorts studied was 
not explored and the possibilities of new agents were also not investigated. Although different 
specimen collection methods were used across each of the five studies, all had similar detection 
rates for RV; and of these methods nasal swabs were the ones most preferred by parents (Heikkinen 
et al., 2002; Ipp et al., 2002; Regamey et al., 2008).  
 
1.3 Respiratory viruses in early childhood 
There is now considerable evidence to indicate a relationship between viral ARIs in the first two 
years of life and intermittent wheeze triggered by respiratory viruses in nearly one-third of 
preschool children ( Arden et al., 2010; Carroll and Hartert, 2008; Jackson et al., 2008; Lambert et 
al., 2007; Lemanske et al., 2005). This relationship is underpinned by the occurrence of viral 
respiratory infections during the critical phase of alveolar and airway development. In addition, the 
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combination of these infections with allergic sensitisation and other environmental exposures (e.g. 
noxious gases, including tobacco smoke) may lead to airway injury and remodelling in genetically 
susceptible individuals and ultimately to asthma and even (non-smoking) chronic obstructive 
pulmonary disease (COPD) (Tregoning and Schwarze, 2010). Sly et al suggested that the 
contribution of respiratory viral infections in early childhood and atopic sensitisation may lead to 
asthma (Arbes et al., 2007; Oddy et al., 2002; Sly et al., 2008). M. pneumoniae and chlamydial 
respiratory infections have also been implicated in the aetiology of chronic pulmonary disorders, 
including asthma (Principi and Esposito, 2001; Webley et al., 2009). Taken together, ARIs in 
children result in enormous costs to the healthcare system, families and society (Lambert et al., 
2008). 
These infections are also responsible for several complications involving both the upper and lower 
respiratory tracts. A recent longitudinal cohort study showed that 61% of URTIs were complicated 
by either AOM (33%) or otitis media with effusion (OME) (24%) (Chonmaitree et al., 2008). The 
same study showed that 59% of tested specimens were positive for one or more respiratory viruses 
and that the most common viruses detected in OME were RSV and RV (Chonmaitree et al., 2008). 
Viral agents are also responsible for disrupting mucociliary clearance and damaging the ciliated 
epithelial cells that line the eustachian tubes, the latter being shorter, straighter and narrower in 
infants (Revai et al., 2007). Middle ear pressure is also reduced by eustachian tube dysfunction and 
this draws respiratory secretions, mucus and bacteria into the middle ear. These changes in the 
middle ear environment increase the chance of AOM after a viral ARI (Revai et al., 2007).  
Although complications with sinusitis are less common than OM, about 5-13% of viral ARIs are 
complicated by sinusitis (Alho, 2005; Brook and Journal, 2005; Steele, 2005). Substantial 
radiographic abnormalities in the para-nasal sinuses can be found early in the course of viral ARIs 
as many imaging studies in both adults and children have shown (Alho, 2005). RV, IFV, HAdV and 
PIV are the most common viruses associated with sinusitis (Brook and Journal, 2005). Although 
many of these viral infections resolve spontaneously, respiratory viruses may predispose to sinusitis 
by microbial synergy and inducing local inflammation that blocks the sinus ostia. This mechanism 
increases the chance of bacterial attachment to epithelial cells and disturbs local innate immune 
defence mechanisms (Alho, 2005; Brook and Journal, 2005). 
LRTIs, which lead to 3-5% of infants being hospitalised, include bronchiolitis, pneumonia, croup 
and secondary bacterial pneumonia (van Woensel et al., 2003). Annually, 120,000 infants are 
hospitalised in the United States with bronchiolitis, the most common acute LRTI and the main 
cause of infant hospitalisations worldwide (Carroll and Hartert, 2008; Nair et al., 2010). Although 
many viruses are responsible for bronchiolitis, different viruses may act at different ages. For 
example, RSV infections that cause 60-90% of bronchiolitis episodes, are more common in younger 
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infants than the closely related hMPV (Calvo et al., 2010; Kahn, 2006). RSV, RV, hMPV, PIVs, 
hBoV and hCoVs are all known to be associated with wheezing in the very young, but RV seem to 
be the most important viral risk factor for subsequent preschool wheezing and diagnosis of asthma 
(Calışkan et al., 2013).   
 
1.3.1 Aetiological agents 
The established respiratory viruses include HAdVs, RSV, IFVs, PIVs and RV. These agents have 
been well studied previously and are known to affect all age groups with epidemics and outbreaks 
recorded annually worldwide for RSV and IFVs. In addition, the advent of molecular detection 
techniques has resulted in the discovery of several new respiratory viruses and provided new 
insights for established pathogens, especially RV. These are summarised below.  
 
1.3.1.1 Human metapneumovirus (hMPV) 
Using a randomly primed PCR technique, hMPV was first identified in 2001 from children with 
ARIs in the Netherlands. Further, the initial data indicated that hMPV was a common human 
respiratory pathogen. Screening of banked sera and parallel use of serological tests, based on both 
immunofluorescence and viral neutralization assays, suggested that hMPV was circulating in the 
human population and was not a mutated animal virus. Further, almost all individuals tested showed 
evidence of hMPV infection by five years of age (Kahn, 2006).   
hMPV is an RNA virus of the family Paramyxoviridae, subfamily Pneumovirinae and is related to 
RSV. Based on phylogenetic analysis and genomic sequencing of five hMPV genes (N,M,F,G or 
L), two distinct lineages were subsequently identified for hMPV (A and B), with two serotypes for 
each (A1, A2, B1 and B2) (Kahn, 2006; Manoha et al., 2007; Williams et al., 2004). With no cross-
protection between types, hMPV infections may recur on more than one occasion (Kahn, 2006).  
A strong association between hMPV infection, wheezing exacerbations and hospitalisation has been 
found among children aged younger than three years. However, this association decreases in 
children older than three years of age (Busse et al., 2010). hMPV is closely related to RSV and is 
detected worldwide in 5-20% of young children with ARI or asthma exacerbations (Hayden, 2006). 
In a small study of 30 children with severe RSV bronchiolitis, 70% of cases were co-infected with 
hMPV (Greensill et al., 2003). In Queensland, Australia, of 10,125 respiratory samples collected 
between 2001-2004 from patients presenting to health facilities with symptoms of LRTIs (78% 
were children younger than five years of age) 7.1% had hMPV detected in the respiratory secretions 
and co-detection of hMPV with other respiratory viruses was only 6.8% (Sloots, 2006a). Diseases 
caused by hMPV are the same as those associated with RSV, with seasonal outbreaks (mainly in 
spring) and variation of severity from year to year. However, the peak of hMPV activity often 
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interferes with or follows the peak of RSV activity (Kahn, 2006; Williams et al., 2004). The most 
common LRTIs associated with hMPV are bronchiolitis and pneumonia. However, the severity of 
infections caused by hMPV is less than that observed with RSV in young children.  
In the upper respiratory tract, hMPV is responsible for 5-15% of ARIs in children. In three studies 
of AOM, hMPV appeared to play a role in 6-50% of cases (Arden et al., 2010; Greensill et al., 
2003). In contrast, hMPV is uncommonly detected in healthy children and adults (Williams et al., 
2004). Taken together, these data confirm that hMPV is a major respiratory pathogen in children 
hospitalised because of ARI and is a predisposing factor for AOM. However, little is known about 
its overall impact in the community. 
 
1.3.1.2 Human bocavirus (hBoV) 
Since the original description of hBoV in 2005, the presence of this agent in children with ARIs and 
asthma exacerbations has been confirmed worldwide with most studies detecting hBoV DNA in 
1.5-19% of those with symptoms of an ARI (Choi et al., 2008; Uršič et al., 2012). The virus was 
identified by “molecular virus screening”, a procedure based on DNase treatment of nasopharyngeal 
specimens, random amplification and cloning, followed by large scale sequencing and 
bioinformatic analyses (Allander, 2008). hBoV has also been detected in faeces from children with 
gastroenteritis. More recently two further species have been identified, hBoV2 and hBoV3, in 
association with acute diarrhoea in children (Arthur et al., 2009).  
Until the identification of hBoV, human parvovirus B19, the causative agent of fifth disease, had 
been the only human virus in the family Parvoviridae. The subfamily Parvovirinea includes two 
genera: Bocavirus and Erythrovirus. hBoV was included in the genus Bocavirus according to its 
similarity in genomic and amino acid sequences shared with other viruses in this genus. The 
members of the family Parvoviridae are small, nonenveloped viruses with isometric nucleocapsids, 
18 – 26 nm in diameters, and include a single molecule of either linear, positive or negative sense, 
single-stranded DNA. The complete length of the genome for this family is between 4,000 to 6,000 
nucleotides (nt). Although the complete genome length for hBoV has not yet been determined, 
5,299 nt have already been identified in one of the reference strains (Choi et al., 2008; Schildgen et 
al., 2008). It is speculated that the genomic DNA of hBoV is flanked by hairpin structures as has 
been shown for other parvoviruses (Schildgen et al., 2008).  
To date, detection of hBoV in clinical samples has been by PCR-based methods and no virus 
culture method, animal model of infection or antibody preparation for antigen detection is available 
currently. In addition, the optimal sampling site is yet to be identified, although the viral DNA may 
be readily detected in both respiratory and gastrointestinal specimens. For detection purposes, PCR 
primers usually target more conserved genetic regions and the limited variability of hBoV has 
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provided multiple targets, including NS1, which is the most preferred, followed by the NP1 gene 
(Schildgen et al., 2008).  Using quantitative PCR, high loads of hBoV are often present when it is 
the sole agent detected in an acutely wheezing child, while low or moderate viral loads are often 
found in association with other respiratory viruses being present (Allander et al., 2007). In a study 
by Redshaw et al. (2007), the virus was detected in samples from eight of 230 (3.5%) New Zealand 
children hospitalised with bronchiolitis. No other agent was detected in five of these samples, while 
RSV was found in the remaining three (Redshaw et al., 2007). In Brisbane, 18% of 96 respiratory 
samples collected from children with ARI had hBoV detected (Tozer et al., 2009). Nevertheless, the 
role of this virus as a respiratory pathogen is still to be confirmed. In larger studies it was co-
detected with other respiratory viruses in 40-60% of 225 cases and in 43% of 100 asymptomatic 
children ( Longtin et al., 2008). Examining 1154 NPA specimens collected from children with ARIs 
and healthy controls, 10% of case samples provided positive results for hBoV, while 17% of 
healthy controls were also positive. Also, when hBoV was identified, at least one other pathogen 
was detected in 75% of cases. Other studies however support hBoV as a causative agent of ARIs 
because in high viral loads it is usually the only agent found and is accompanied by viraemia and 
serological evidence of primary infection (Christensen et al., 2010; Kantola et al., 2008). To help 
further confirm hBoV as a respiratory pathogen, the duration of viral shedding from the respiratory 
tract and how often it is present in asymptomatic controls needs to be determined systematically. 
 
1.3.1.3 Human coronaviruses (hCoVs) 
hCoVs are members of the subfamily Coronavirus of the Coronoviridae family, and are enveloped 
viruses with a large plus-strand RNA genome. Originally, two serologically distinct groups were 
identified, hCoV-229E and hCoV-OC43 in the 1960s and were considered responsible for only 
mild URTIs. However, a third group was identified earlier this century with the discovery of SARS-
CoV as the aetiological agent for the severe acute respiratory syndrome (SARS) (Williams, 2007; 
Woo et al., 2009). Subsequently, two novel coronaviruses hCoV-Nl63 and hCoV-HKU1 were 
discovered (Fielding, 2011). Recently, a new hCoV was identified as the aetiological agent for 
Middle East respiratory syndrome (MERS), and is now termed MERS-CoV (Zaki et al., 2012).   
hCoV-NL63 was first isolated in 2004 from a Dutch child with bronchiolitis and since its discovery, 
several studies have demonstrated it to be associated with both upper and lower respiratory 
symptoms. However, in a birth cohort study of 82 healthy infants followed throughout the first year 
of life, the virus was detected in six (7%) infants experiencing their first symptoms of a LRTI and in 
three of the six cases the virus was cleared within three weeks of symptom onset (Kaiser et al., 
2005). The study also reported that it was the first ARI episode for two of the six hCoV-NL63 
positive cases and in each instance it was the only agent detected, thereby supporting the role of 
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hCoV-NL63 as a respiratory pathogen. The seroprevalence of hCoV-NL63 in six to 12 month old 
infants is in the range of 29-40%, and by three and a half years the age 75% of children are 
seropositive (Dijkman and van der Hoek, 2009; Shao et al., 2007). Overall, in 2-9% of children the 
virus is associated with many different ARI illnesses, including the common cold, bronchiolitis, 
pneumonia and croup (Hayden, 2006). 
The early studies on hCoV-NL63 reported seasonal variations (Fielding, 2011; van der Hoek et al., 
2006). In contrast, in tropical climates the virus was detected throughout the year (Fielding, 2011). 
In one population-based study for children aged under three years with LRTI, it was found that 
winter was more likely to be the peak season for hCoV-NL63 (van der Hoek et al., 2010). The 
results also indicated an inter-epidemic period of two years (van der Hoek et al., 2010). In 
Queensland, 2% of 315 children hospitalised with ARI were found to have hCoV-NL63 and in 38% 
of these children, another virus was detected (Arden et al., 2006).  
A second novel coronavirus, hCoV-HKU1, was isolated in 2005 from an adult with pneumonia 
(Woo et al., 2005). It too is distributed worldwide in both adults and children causing a range of 
respiratory symptoms and illness including, the common cold, wheezing, bronchiolitis and 
pneumonia (Kahn, 2006; Pyrc et al., 2007). The virus may also play a role in gastrointestinal 
disease as it was detected in stool samples from two patients with acute enteric symptoms (Pyrc et 
al., 2007). Two distinct groups (genotypes A and B) of hCoV-HKU1, and another (genotype C) the 
result of recombination events between genotype A and B viruses, circulate globally (Sloots et al., 
2006; Woo et al., 2006, 2005). Isolates from Australia belong to genotype A (Sloots et al., 2006).  
In Brisbane hCoV-HKU1 was detected in 3% of 324 specimens collected from children presenting 
to hospital with severe ARI (Sloots et al., 2006). Co-detection of other viruses was reported in 11-
43% of specimens containing hCoV RNA (Arden et al., 2006; Kuypers et al., 2007; Sloots et al., 
2006). Overall, the newly discovered hCoVs appear to be more prevalent than other hCoVs, they 
are associated with more severe disease and appear to be acquired at an early age.  
 
1.3.1.4 Human polyomaviruses (PyVs) 
PyVs are small, double stranded circular DNA viruses that can infect several mammals and birds. 
Two human PyVs (JCV and BKV) are widely distributed in the human population and are thought 
to be acquired either via the respiratory tract or the oral-faecal route early in life (Oddy et al., 2002). 
They can cause persistent infection and have oncogenic potential in both animals and humans. 
Using “shotgun sequencing”, two novel PyVs were identified from respiratory secretions of 
hospitalised patients with ARI (Allander et al., 2007; Gaynor et al., 2007).  Swedish scientists found 
KIV in 6/637 (0.9%) NPA specimens from patients with ARI; half of whom were younger than two 
years of age and in five of the six cases another respiratory virus was also present (Allander et al., 
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2007). Shortly afterwards, WUV was first described following its detection in respiratory specimens 
from children hospitalised with severe ARI in St Louis (6/890; 0.7%) and Brisbane (37/1245; 3.0%) 
(Gaynor et al., 2007). Most cases were aged under three years with bronchiolitis, pneumonia and 
croup reflecting the patient population being tested. However, as with KIV, 72% of samples had 
other respiratory viruses detected. Follow-up studies from Brisbane and St Louis detected WUV in 
128/2866 (4.5%) and 70/2637 (2.7%) in various respiratory specimens (Bialasiewicz et al., 2008, 
2007; Gaynor et al., 2007). Global prevalence rates in young children with ARI are 0.5-2.7% for 
KIV and 0.4-7.1% for WUV, with 55-80% co-detection rates for other viruses and 0-6.4% in 
asymptomatic controls (Bialasiewicz et al., 2007; Gaynor et al., 2007; Lee et al., 2007). The high 
co-detection rates are similar to those found in hBoV and the role of all three viruses in ARIs is still 
uncertain (Bialasiewicz et al., 2008). WUV was found in a one day old infant delivered by 
caesarean section who developed respiratory distress with pulmonary infiltrates raising the 
possibility of vertical transmission (Le et al., 2007). A limited six month study (18 children, aged 0-
7yrs), using fortnightly parent collected nasal/throat swabs detected WUV and KIV in 44% and 
17% of children with and without respiratory symptoms respectively, and both viruses were shed 
for two-to-eight weeks (van der Zalm et al., 2008). The picture emerging is of human PyV infection 
early in life, followed by prolonged viral shedding, the clinical significance of which is uncertain, 
but requires a prospective, longitudinal study for confirmation. 
 
1.3.1.5 Newly identified rhinoviruses, including novel RV-C/QPM 
RVs are well recognised as the most common cause of ARIs, and amongst respiratory viruses, they 
are the most commonly detected viruses in respiratory secretions from asymptomatic individuals 
(Monto, 2002; Winther et al., 2006). They circulate year round with noticeable peaks in both spring 
and autumn. Although they affect all age groups, the highest rates of symptoms due to RV 
infections occur in the very young (Peltola et al., 2008). Previously, it was thought that they just 
caused the common cold and upper respiratory symptoms, but there is now an increasing 
recognition of a role of these viruses in LRTIs in infants, the elderly and the immunocompromised 
(Mackay, 2007). After RSV, they are the second most commonly detected respiratory viral agent in 
infants hospitalised with an ARI and the most frequent agents associated with ARI and wheezing 
illness. For the first three years of life, RV infections are more severe and are more likely to result 
in wheeze in those at high risk of developing asthma than are other respiratory viruses (Jackson et 
al., 2008). Moreover, RV-related illness may predict subsequent asthma development and it may 
play a major role in the “double hit” hypothesis of the aetiology of asthma (Jackson et al., 2008; Sly 
et al., 2008).  Recently, a novel RV, RV-QPM, was discovered amongst a cluster of unusual 
picornavirus nt) sequences (McErlean et al., 2007). Overall, 17/1244 (1.4%) respiratory specimens 
15 
 
collected from patients in Brisbane presenting to a public hospital or to family doctors with ARI had 
RV-QPM RNA detected. This new genotype was closely associated with hospitalised bronchiolitis 
cases and appeared to be part of a novel RV clade, genogroup C. This was subsequent recognised as 
a third species RV-C being present worldwide and associated in some, but not all studies, with more 
severe disease (Denlinger et al., 2011; Khetsuriani et al., 2008; Mackay et al., 2008). This further 
emphasises the importance of RVs as a cause of ARI and reinforces suggestions that biological 
variations in RVs may also result in different clinical severity (Brownlee and Turner, 2008). 
RV RNA can nonetheless be detected in 15-35% of asymptomatic individuals, but the clinical 
significance of these findings is unknown (Mackay et al., 2008; Peltola et al., 2008; Winther et al., 
2006). Whether viral RNA detected weeks after a symptomatic illness is from persistent shedding 
or a subclinical infection from a newly acquired RV strain has yet to be fully resolved (Jartti et al., 
2008).  However, this is now achievable by sequencing of isolates from well characterised, serially 
collected specimens. Such data will better define the role of RVs when detected in asymptomatic 
individuals or with other viruses during an ARI.  
 
1.4 Recent developments in respiratory virus detection 
The four main approaches for detecting respiratory viruses are: virus culture, serology, 
immunofluorescence/antigen detection and nucleic acid amplification-based tests (NAATs). Virus 
culture, which is based on infecting cell lines with a clinical sample, and serology that relies upon 
blood samples for detecting viral specific antibodies and testing biological fluids or tissues for viral 
antigen, are both labour intensive and time consuming. For tissue culture, expertise is required for 
interpreting results, that may take up to ten days, and for serological methods seroconversion can 
take two weeks or more to develop (Beck and Henrickson, 2010; Tregoning and Schwarze, 2010). 
For many novel viruses traditional detection techniques are demanding. For example, limited cell 
types are suitable for culturing hMPV and adding trypsin is required for viral replication, a reagent 
which is not routinely used in viral diagnostic laboratories (Williams, 2007). While for the recently 
identified RV-C, cell culture was not feasible until 2011 by using a cell culture system based on 
propagation of RV-C in sinus mucosal organ culture (Bochkov et al., 2011); a method that is not 
practical for routine laboratories. Antigen detection relies upon detecting aetiological agents from 
various respiratory specimens by using monoclonal antibodies directed against specific viral target 
antigens. The viral antigens are detected using a conjugated enzyme or fluorescence (Tregoning and 
Schwarze, 2010). This method is relatively sensitive and rapid. However, the main difficulty 
limiting the comprehensive use of these techniques is that suitable monoclonal antibodies are only 
available for a limited number of targets, especially for novel respiratory agents (Fox, 2007).  
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 Although antigen detection tests are still used widely, they are being replaced by the more rapid, 
sensitive and highly specific NAATs. Compared with tissue culture and serology, NAATs are able 
to provide results within two to 24 hours from the time of sample collection (Beck and Henrickson, 
2010).  Well optimised assays are more sensitive than culture by 5-10%, even with low viral 
concentrations (Mahony, 2010). Using genetic markers, NAATs are able to identify changes in 
virus characteristics, such as detecting antiviral resistance in IFVs and with the ability to multiplex 
assays by using different targets, these tests are superior to all other detection methods. The 
continuous development and enrichment of genetic information allows the rapid update of NAAT 
approaches (Beck and Henrickson, 2010).  
Generally, NAATs rely upon three major steps: extracting the genetic material (DNA/RNA) from a 
clinical sample by releasing it from infected cells and virus components, amplifying the extracted 
genetic molecule and obtaining results by detecting the amplified genetic material (Mackay, 2007). 
Different techniques use different endpoints to detect the amplified genetic material (Mahony, 
2010). In conventional polymerase chain reaction (PCR) assays, two primers are used to thermally 
amplify the genetic target and gel electrophoresis is employed to detect the amplified target. For 
real-time PCR, visualising the different phases of amplification is possible by either using a DNA 
intercalating fluorescent dye, such as SYBR® green or a fluorescent-labelled oligonucleotide probe 
(Beck and Henrickson, 2010). There are many types of probes available. However, TaqManTM 
probes are preferred for respiratory virus detection, being more specific and less sensitive to 
possible mismatches in genome targets compared to other fluorescent dyes (Gunson et al., 2006). 
Multiplexing NAATs allows the rapid detection of several viruses concurrently (Mahony, 2010). 
The principle of multiplexing relies upon using different sets of primers to amplify several gene 
targets, either from different pathogens or, as in the case of the novel virus KIV, amplifying 
different targets from the same pathogen (Bialasiewicz et al., 2007; Busse et al., 2010).  
The original community-based cohort studies relied upon serology or cell culture-based methods. 
Kusel et al, applied the first comprehensive study using molecular based methods in 2006 (Kusel et 
al., 2006). Since that time the use of these techniques in epidemiological studies has been widely 
reported. However, PCR does still have some limitations and potential problems should be 
considered when using these techniques in long-term cohort studies that are conducted over several 
years. The major potential problem when using PCR in such studies is sequence variation in gene 
targets, which is considered one of the main challenges for respiratory virus screening (Mackay, 
2007). For example, in a study investigating hMPV during different seasons (2000-2004), the rate 
of detection failure increased from 19% to 76% during the study period resulting in a significant 
decrease in prevalence estimates from 7% to 1.6% (Mackay, 2007; Mahony, 2010). For quantitative 
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PCR, sequence variation in primers targets can have a negative impact on the accuracy of the 
amplification and, as a result, underestimate viral loads. This is especially important when 
mismatches were located in the 3` end of a primer (Whiley and Sloots, 2005).  For real-time PCR 
using fluorescence dyes, mismatches in the probe location may decrease the sensitivity of the assay 
(Whiley and Sloots, 2006). However, variation will not necessarily affect the performance. Over a 
period of 21 months, hBoV showed some genetic variation within two target genes, NP1 and NS1. 
Nevertheless, the performance of the amplification and overall prevalence was unaffected by this 
variation (Arnold et al., 2006). 
   
1.4.1 Determining pathogenicity of novel agents in the molecular era 
Koch’s postulates provided traditional standards to identify the role of a new agent as a potential 
pathogen. However, it became necessary to modify these postulates as recent and rapid 
development in molecular detection techniques challenged orthodox views of viruses and their roles  
various infectious diseases. Fredreicks and Relman presented a modification in Koch’s postulates to 
establish a relationship between a new agent and a disease. This may be occur if:  
““ i) A nucleic acid sequence belonging to a putative pathogen should be 
present in most cases of an infectious disease. Microbial nucleic acids 
should be found preferentially in those organs or gross anatomic sites 
known to be diseased (i.e., with anatomic, histologic, chemical, or clinical 
evidence of pathology) and not in those organs that lack pathology. (ii) 
Fewer, or no, copy numbers of pathogen-associated nucleic acid sequences 
should occur in hosts or tissues without disease. (iii) With resolution of 
disease (for example, with clinically effective treatment), the copy number of 
pathogen-associated nucleic acid sequences should decrease or become 
undetectable. With clinical relapse, the opposite should occur. (iv) When 
sequence detection predates disease, or sequence copy number correlates 
with severity of disease or pathology, the sequence-disease association is 
more likely to be a causal relationship. (v) The nature of the microorganism 
inferred from the available sequence should be consistent with the known 
biological characteristics of that group of organisms. When phenotypes 
(e.g., pathology, microbial morphology, and clinical features) are predicted 
by sequence-based phylogenetic relationships, the meaningfulness of the 
sequence is enhanced. (vi) Tissue-sequence correlates should be sought at 
the cellular level: efforts should be made to demonstrate specific in situ 
hybridization of microbial sequence to areas of tissue pathology and to 
visible microorganisms or to areas where microorganisms are presumed to 
be located. (vii) These sequence-based forms of evidence for microbial 
causation should be reproducible”. (Fredreicks and Relman, 1996).  
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In terms of real-time PCR and for novel respiratory viruses other guidelines should also be 
considered. These were highlighted by Mackay et al and focused on defining the aspects of an 
infection in order to establish a relationship between the novel virus and each of the following:      
(i) the illness/symptoms, (ii) PCR results, and (iii) the presence of other respiratory viruses 
(Mackay, 2007).  
Molecular methods played a significant role, not only with identifying and characterising new 
respiratory agents, but also in determining the impact of viral loads on disease severity.  A strong 
association between high viral load and severe respiratory symptoms was indicated in a study 
testing 1154 samples for hBoV from children with ARIs and 162 control samples from 
asymptomatic children (Christensen et al., 2010). In this particular study hBoV was detected in 10% 
of patients and 17% of the control samples. In 75% of hBoV positive samples, another respiratory 
virus was detected. The study then categorised the hBoV positive samples into one of three 
categories; high (106-1010 copies/ml), moderate (104-106 copies/ml) and low viral loads     (103-104 
copies/ml).  After adjusting for age, gender and other viruses, a high viral load was associated with 
LRTI (odds ratio 3.6, 95% confidence interval 1,2-10.7). Viraemia was found in 45% of these 
cases, and in none of the controls, and was confined to patients younger than two years of age 
(Christensen et al., 2010). Other studies have also found an association between high RV viral load 
and asthma exacerbation. A reduced type1 interferon response is thought to lead to high viral loads 
and delayed viral clearance in infants as the immune system in early life is skewed to a 
hyporesponsive phenotype. However, higher viral loads might also result in greater 
proinflammatory stimuli and this may explain the more severe symptoms (Tregoning and Schwarze, 
2010).  
 
1.4.2 Respiratory specimens and transport for pragmatic community-based 
studies 
To avoid the methodological limitations of the previous studies, the ORChID study utilises real-
time PCR to detect 17 respiratory viruses, including six recently described viruses. Parental weekly 
collection maximises respiratory episode capture and overcomes Hawthorne effects, when 
behaviour of research participants changes due to their awareness of being monitored or examined. 
This may influence compliance with specimen collection (Lambert et al., 2008a; van der Zalm et 
al., 2006). Weekly sample collections allow the dynamic relationships between; (i) pathogen 
acquisition, (ii) co-detection with other infectious agents, (iii) shedding of pathogen(s) in respiratory 
secretions, and (iv) symptoms of ARI to be examined systematically. However, there are some 
potential challenges with ensuring consistent quality of nasal swab collection and transportation.  
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Although combined nose and throat swabs were considered as alternatives, the traditional 
specimens for viral detection by PCR are NPAs and in certain circumstances bronchoalveolar 
lavage fluid (BAL) (Schuller et al., 2010). For community-based studies that rely on parental 
collection, simpler and more acceptable approaches are required to optimise cohort retention and 
regular specimen collection. Thus evaluating an alternative approach became necessary. Lambert et 
al compared PCR assay results for respiratory viruses from parent-collected combined nose and 
throat swab specimens with NPA samples collected by health care workers from 303 children 
presenting to hospital with respiratory symptoms (Lambert et al., 2008b). Samples were screened 
for eight respiratory viruses and both sampling techniques performed similarly with virus detection 
sensitivity levels of 91.9% and 93% respectively. Other studies indicated that nose swabs are well 
tolerated by subjects, easy to perform, and cause few problems for parents (Lambert et al., 2008b; 
Lambert et al., 2008; van der Zalm et al., 2006) Earlier studies have shown that using nasal swabs is 
the collection method preferred by most parents and will likely maximise cohort retention and 
specimen collection (Lambert et al., 2007). Importantly, studies are now emerging that show the 
sensitivity of PCR-based techniques for detecting respiratory viruses is not substantially 
compromised by using nasal swab specimens when compared with those obtained by NPA 
(Meerhoff et al., 2010; She et al., 2010; Waris et al., 2007) .  
A study by O’Grady et al. explored the effect on respiratory virus detection by PCR of transporting 
nasal swabs from remote communities in Central Australia to a research laboratory in Brisbane, 
Queensland  (O’Grady et al., 2011). Two anterior nasal swabs were collected from each study 
participant. The left nostril specimen was mailed to the laboratory by the routine postal services at 
ambient temperature, while the right nostril specimen was transported frozen. The extracts were 
then screened by real-time PCR for 16 respiratory viruses and similar results were obtained from 
the two groups, which confirmed that mailing unfrozen respiratory swabs over large distances 
within Australia did not adversely affect the PCR results.  
Sampling regularly from individuals throughout the year helps to determine the influence of 
seasonal factors and also allows subjects to act as their own controls, helping to account for 
demographic features and factors such as family structure, environmental conditions and 
socioeconomic determinants. In the Melbourne community-based study, surveys indicated that 
approximately 90% of families were willing to continue the study for two more years even with 
using more invasive throat swabs (Lambert et al., 2008b). 
 Weekly parent collected nasal swabs are expected to increase the likelihood of obtaining samples 
during an ARI, especially for episodes that might be missed by the inconvenience of having to 
organise visits by research personnel (van der Zalm et al., 2006). It also allows the exploration of 
the temporal relationships between respiratory viruses and symptomatic illness, making this 
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particularly helpful when interpreting virus co-detections and their shedding in asymptomatic 
children.  
 
1.5 Summary and development of hypotheses  
Overall, relatively little is known about the nature and types of viral ARIs in otherwise healthy 
children whose early life respiratory illnesses are managed within the community. The need of more 
comprehensive community-based studies is essential in providing more data about the role of 
recently identified novel respiratory viruses as causes of ARIs. The high prevalence of RV in both 
symptomatic and asymptomatic children and the range of co-detections of various viruses and RV 
strains both raise many questions over pathogenicity and strain replacement. Some data suggest a 
significant association between the high loads of respiratory viruses and the severity of associated 
ARIs (See hBoV section). Therefore, the use and development of accurate real-time PCR assays is 
important in community-based studies. Little information is available on the shedding kinetics of 
respiratory viruses, although some have suggested for certain viruses it is for a period of up to four 
weeks after their first detection. Despite the recent and continuous developments in NAAT, many 
technical and logistical challenges remain when choosing to study respiratory viruses longitudinally 
in community settings.  
 
1.5.1 Aims and objectives 
The main aims of this thesis are to 
1- Describe respiratory virus infections and ARIs during the first year of life in a subset of 72 
healthy infants from the ORChID study,  
2- Examine the effect of some technical issues upon respiratory virus detection during this 
longitudinal study, such as the quality of nasal swab samples collection and transportation 
and sequence variation in DNA viruses,  
3- Describe the nature of any observed sequential RV infections.  
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1.5.2 Hypotheses 
(i) During the first year of life and in otherwise healthy infants, RV is the most 
commonly detected respiratory virus in respiratory secretions. 
(ii) Various factors impact upon successful viral detection, including the ability of 
parents to collect appropriate samples and other laboratory-based technical issues.  
(iii)  Repeated detection of RV-RNA in respiratory secretions over periods of more 
than four weeks results from strain replacement and new infection events rather 
than from prolonged shedding of the same genotype. 
(iv) Many RV genotypes circulate in a single location in one year period.  
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Chapter 2 
The Observational Research in Childhood Infectious Diseases 
(ORChID) Study: 
General methodology and laboratory protocols   
 35 
 
2.1 Methods 
The following provides an overview of the principal methods that underpin the ORChID study and 
form the basis of my PhD studies. These comprise sample collection, nucleic acid extraction, real-
time PCR testing and data analysis. Note that additional procedures used during the course of my 
PhD studies, but not central to the main ORChID study are described in subsequent chapters where 
relevant. 
 
2.1.1 Study Design and cohort  
ORChID is an unselected, dynamic, community-based birth cohort study designed originally to 
determine the burden and aetiology of ARIs in healthy Australian infants during their first two years 
of life (Lambert et al., 2012).  Parents were asked to record a daily symptom diary and to collect 
weekly nasal swab specimens from their infants. This began within the first few days of life and 
continued until they reached their second birthday. The symptom diaries were submitted monthly, 
while the weekly nasal swab specimens were mailed to the laboratory as soon as possible after their 
collection. The study was designed to avoid any unnecessary contact with the study team, in terms 
of sample and data collection, so as to minimise any potential bias due to a Hawthorne effect 
discussed in chapter-1; section 1.4.2).  The study recruitment, cohort maintenance, ongoing 
oversight of specimen collection and transport, and recording of socio-demographic and clinical 
data were conducted by the QPID clinical trials staff as part of the ORChID project.   
 
2.1.1.1 Antenatal recruitment 
Recruitment of parents and infants was conducted by the study nurses at participating antenatal 
clinics in either the Royal Brisbane and Women’s or the North Western Private Hospitals. The two 
hospitals are located in the north of Brisbane, a subtropical Australian city of more than 2.2 million 
people. Annually, each hospital has about 5,200 and 1,700 deliveries respectively. From September 
2010 to October 2012, 165 healthy babies were recruited antenatally. The progressive recruitment 
plan was designed to enrol infants from throughout the year, so as to account for seasonal and year-
to-year variation in respiratory virus activity.    
 
Prior to enrollment, and during antenatal visits, a description of the study objectives and tasks was 
provided to parents. The Queensland Children’s Hospital and Health Service, Royal Brisbane and 
Women’s Hospital, and the University of Queensland Medical Research Ethics Committees 
approved the study.   
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2.1.1.2 Inclusion and exclusion criteria 
Eligible infants were healthy full-term infants of English-speaking parents who anticipated living in 
the Brisbane metropolitan region for the next two-years. The full enrolment inclusion and exclusion 
criteria are summarised in Table 2.1.  
 
Table 2.1 Enrolment inclusion and exclusion criteria 
Inclusion criteria  Definition and or explanation.  
Pregnant women expecting a healthy 
term baby 
Gestational age >36 weeks, without evidence of an underlying congenital 
disorder.  
 Written informed consent  This is provided initially by the enrolled woman during pregnancy and is 
confirmed following the birth of her baby.    
Sample collection agreement   Parents are expected to collect single weekly anterior nasal swabs (from 
both nostrils) from their study child and to return them to the QPID 
laboratory by regular mail using one of the self-addressed padded 
envelopes provided by the study team.  
Sufficient English skills  This is needed to ensure the parents or guardians understand the tasks 
required of them during the study.  
 Exclusion criteria   
Premature babies   Gestational age ≤ 36 weeks    
Neonates and infants with major 
congenital abnormalities or 
underlying chronic disorders 
Including chronic heart, respiratory (excluding asthma), neurological or 
immunological disorders (congenital immunodeficiency, human 
immunodeficiency virus infection, or if receiving immune system 
suppressing medications, other than inhaled corticosteroids). 
Planning to move from Brisbane 
during the course of the study. 
   
 
 
2.1.2 Sample and data collection 
2.1.2.1 Initial visits 
Once an enrolled baby was born, and while both mother and their newborn baby were still in 
hospital, an initial visit was undertaken by the study nurses. During this visit, parents provided 
written, informed consent to confirm their participation in the study.  
 
The parents then received written instructions on the tasks they were being asked to perform (see 
below) as well as various study materials. At the same time they underwent instruction on how to 
collect nasal swab specimens from both anterior nares (Lambert et al., 2012). Baseline demographic 
and medical history details were also recorded at this visit. These included the infant’s date of birth, 
gender, ascribed ethnicity, parental occupation and educational level, maternal obstetric history, 
family history of asthma and atopy, tobacco smoke exposure, breast feeding, medications, 
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immunisations, day care attendance, number of siblings, illness in other household members and 
household size.  
The study nurses also collected an initial anterior nasal swab by demonstrating the optimal method 
of nasal swab collection. In addition, nasal swabs were collected from both parents during this visit. 
All swabs were delivered at ambient temperature by the study nurses to the QPID research 
laboratory immediately after collection where they were stored at -80ºC until the time of analysis.    
 
2.1.2.2 Post discharge 
Follow-up commenced once the mother and baby were discharged from hospital. Parents were 
asked to complete several tasks that included a daily symptom diary and weekly nasal swab 
collection and mail out. ARIs were defined ‘a priori’ by the study investigators and parents were 
taught how to identify and differentiate between the various symptoms they recorded in the daily 
symptom diary. URTIs were identified as any episode of nasal discharge or congestion, or cough, 
without breathing difficulty, wheezing, or rattly breathing, while LRTIs were defined as any 
episode of breathing difficulty, wheeze or rattly chest (Kusel et al., 2006). Parents were instructed 
to identify breathing difficulty (chest wall retractions), wheeze (high pitched whistling sound from 
the chest in expiration) and rattly chest (wet, noisy breath sounds from the child’s chest). For the 
purposes of demarcating ARIs, a new episode occurred only if there had been more than three 
symptom-free days since the end of the previous ARI episode (Lambert et al., 2007).  
 
2.1.2.2.1 Cohort maintenance 
Participants received text messages and phone calls from the ORChID project manager to remind 
them of their study tasks, to collect further data or to complete any missing data. Text messages 
were sent every week to remind parents of sample collection and mailing, while monthly text 
messages were sent as reminders for mailing in symptom diary cards. Every three months, phone 
calls were made to collect updates about immunisation status, breastfeeding, childcare attendance 
and changes in household composition.  Additional phone calls could be made if the ORChID study 
manager encountered any gaps in the monthly diary card data. The timing for these additional 
phone calls was not fixed and to ensure the accuracy of the provided data, the calls were made 
shortly after the arrival of cards where gaps in data were observed. Biannually, a study newsletter 
was sent to the participating families either by email or by post in accordance to family preference. 
Every issue included information about the progress of the study, attaining important milestones 
and, where relevant, any changes in contact information. 
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2.1.2.2.2 Symptom diary card 
As outlined previously, parents were provided a simple daily symptom diary card, which recorded 
the presence or absence of various respiratory symptoms (Appendix 2-1). The design of the diary 
card was based on one used successfully in a previous community-based study for a twelve month 
period in Melbourne preschool children (Lambert et al., 2007). Each group of symptoms was 
presented in a distinct colour to help differentiate between upper and lower respiratory symptoms.  
In addition to teaching parents how to distinguish between each symptom, they were also instructed 
how to complete the card using tick boxes and numbers. When the infant showed no symptoms, 
parents were asked to tick an additional box to also record the infant’s wellbeing.  Whenever fever 
was reported as a symptom for a specific day, the infant’s axillary temperature was also recorded at 
that time.  This was accomplished using a digital thermometer provided to each participating 
family, all of whom had been instructed on its use. The diary card was returned each month to the 
ORChID project manager and its contents double entered onto the customised study subject 
database. 
  
2.1.2.2.3 Nasal swab collection 
Parents were asked to collect a nasal swab from their infants on a weekly basis. The study nurses 
demonstrated the optimal method of collection to the parents during the initial visit and written 
instructions were also provided for the long-term sample collections. The plastic-shaft, rayon 
budded swab came with its own transport tube, which contained a foam pad reservoir soaked with 
viral transport medium (VTM) located in the base of the tube (Virocult MW950, Medical Wire & 
Equipment, Wiltshire, England). Rayon budded swabs complied with Australia Post regulations 
(see below) and were chosen following their successful deployment in other community-based 
studies (Lambert et al., 2007; O’Grady et al., 2011; Yin et al., 2011). After performing hand 
hygiene and ensuring the child was positioned comfortably and securely, parents placed and then 
rotated the sterile cotton swab against the internal anterior walls of one nostril before using the 
same swab to repeat the same procedure in the other nostril.  When the child had a nasal discharge 
at the time of collection, this too was swabbed by the parent. The swab was then placed in the tube 
and the cap pushed down until the lid was sealed securely. The base of the tube was squeezed to 
release the VTM, which then bathed the swab.  Some basic information including: the infant’s 
name, date of birth, date and time of collection, who had taken the sample and any other comments 
were recorded on a collection form. This form and the accompanying nasal swab were placed first 
into a biohazard bag and then into a padded envelope before being sent as soon as possible by 
regular postal mail (in accordance with Australia Post regulations (Australia Post, 2009) at ambient 
temperature to the QPID research laboratory.   
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2.1.3 Sample processing and screening 
2.1.3.1 Overview 
Sample processing, screening and archiving were all located at the QPID laboratory. The QPID 
laboratory provided access to:  (i) -800C freezers for long-term storage of swabs, processed samples 
and extracts; (ii) validated and purpose programmed automated extraction and liquid handling 
systems for high-throughput sample processing; and (iii) various conventional PCR and real-time 
PCR instruments for sample testing. Once a sample had arrived at the laboratory, a database, 
specially designed for swab lodgement, was used to enter the data provided in the collection form 
and the swabs were stored at -80°C until analysis (see section 2.1.8 of this chapter for databases and 
data management). Figure 2.1 illustrates the laboratory workflow for this part of my PhD project.  
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Figure 2.1 Workflow of ORChID study's respiratory specimens from collection 
by parents until data analysis.  
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2.1.3.2 Specimen processing 
The swabs were processed in batches of 96, which included 92 nasal swabs and 4 negative controls. 
For each swab, 2mL of phosphate buffered saline (PBS) was added, the pad in the base of the 
swab’s transfer tube was squeezed and the tube was vortexed for ten seconds. The suspension was 
then transferred to a 2mL tube (Sterile SmartScan tubes, Thermo Scientific, Australia) and the swab 
and its tube were discarded. The 2D barcoded tubes came in a 48-place rack format, which allowed 
for efficient sealing and long-term sample archiving at -80°C.  All samples were handled in 
physical containment level 2 laboratory (PC2 laboratory). Samples were opened and aliquots were 
prepared in Class II Biological Safety Cabinet in accordance with IBC safety approvals.      
 
2.1.3.3 Nucleic acid extraction 
Nucleic acid extraction employed the QIAxtractor robotic extraction system (Qiagen, Australia), 
along with the genomic DNA extraction kit (DX, Qiagen, Australia). Each extraction run was 
performed with a single batch of specimens. To prepare an extraction run, 200µL of each sample 
was manually loaded into the 96-well lysis plates provided by the manufacturer and spiked with 
5µL of an Equid herpesvirus-1 (EHV-1) culture that was normalised to produce a Ct value of 
approximately 30 cycles in the standard conditions of the ORChID study’s real-time PCR. This 
served to detect the presence of inhibitors within the sample and to assess the quality of extraction. 
Purification was performed following the manufacturer’s instructions. Briefly, fully automated 
lysing, binding, washing and elution steps, resulted in the allocation of specimen extracts into a 96-
well 2D barcoded extraction storage rack (Matrix, Thermo Scientific, Australia). This semi-
automated system allowed the purification of nucleic acid components without extensive manual 
interference and minimised human error when processing large numbers of samples. It also reduced 
the turnaround time, requiring only two hours per 96 specimen extractions instead of approximately 
eight hours required for manual extraction). After extracting the samples, the final elution volume 
of 150µL was checked visually to ensure that the elution step was consistent for each of the 96-
wells.   
 
2.1.3.4 Individual extract screening and pooling approach 
To screen sample extracts, two approaches were applied, which depended upon the expected 
proportion of the pathogen of interest in the community. The first approach tested individual 
extracts in each real-time PCR assay. The second approach screened pooled sample extracts, which 
involved combining aliquots from ten extracts into a single tube and then testing that by PCR. The 
pooling approach is useful in maximising throughput, while also saving resources and minimising 
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costs. Such pooling strategies have been used successfully to screen for sexually transmitted 
pathogens (Currie et al., 2004; Johnson et al., 2002; Kacena et al., 1998), and more recently for 
respiratory viruses (Johnson et al., 2002; Van et al., 2012). 
 
In the ORChID study, samples in each batch were screened individually to assess the quality of 
nucleic acid extraction. According to specific criteria (see section 2.1.4.2), extracts that passed the 
quality control test were then approved for pathogen testing. The first respiratory virus group to 
undergo screening were the human rhinoviruses (RV; figure-2.1). Here the extracts were screened 
individually because based upon the literature, and our experience at QPID, I anticipated RVs to be 
present in 18-30% of our community-based samples.  
 
In contrast, the extracts were pooled for the remaining respiratory viruses. This was performed 
using the CAS1200 liquid handling system (Corbett Robotics, Australia), which is a compact 
robotic workstation for automated pipetting and pre-PCR liquid handling. During a pooling run, the 
special liquid level sensing (LLS) tips allowed the electronic detection of liquid levels in real-time. 
An initial calibration was required to adjust the dimensions of the 96-well 2D barcoded extraction 
rack (Matrix, Thermo Scientific, Australia) to the platform. The CAS1200 software was then 
programmed to pool 10µL aliquots from ten extracts both by row and by column. All pools were 
then added to an extract pools rack (EPR). This allowed each extract to be tested in the EPR twice; 
once via the pool for the corresponding row and another by pool for that extract’s column 
(Appendix 2-2).  
 
Respiratory virus real-time PCR testing (except for RV testing) was performed initially on an EPR. 
Once a pooled tube was found positive, the row or column in the corresponding EPR was subject to 
confirmatory testing.  If two pools from a row and a column were found positive, only the tube 
located in the junction point would undergo confirmatory testing (Appendix 2-2).  
  
2.1.4 Real-time PCR 
Real-time PCR is a highly sensitive and specific technique for amplifying, detecting and 
quantifying targeted nucleic acid components. It is now used commonly for detecting respiratory 
viruses (Mackay, 2004). The principle of real-time PCR is similar to conventional PCR in terms of 
amplification, with the only difference being with how amplicons are detected.  By combining the 
usual PCR reagents with fluorescent dyes or labelled oligonucleotides, this technique allows kinetic 
detection of the amplified target nucleic acids, decreasing both turnaround time and risk of cross-
contamination, (Espy et al., 2006) which are critical factors for the high-throughput processing 
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required for this study. Several fluorescent dyes have been used for respiratory virus detection, 
however the most widely used involve dual-labelled probes (e.g. TaqMan™ probes). TaqMan™ 
probes have a linear structure specific to the targeted gene and contain a fluorescent dye molecule 
located in the 5` base and a quenching dye molecule on the 3` base. Through the Förster resonance 
energy transfer (FRET) mechanism, the close proximity between the two molecules allows a non-
radiative energy transfer from the excited fluorescent dye, which acts as a donor, to the quenching 
dye, which acts as an acceptor. The separation of the two molecules occurs during the elongation 
step of the PCR reaction via the nuclease activity of the polymerase enzyme. This separation omits 
the FRET activity and allows the detection of the signal from the fluorescent dye and according to 
the rate of probe cleavage, the signal increases in each PCR cycle (Gunson et al., 2006; Mackay, 
2007, 2004). In ORChID, TaqMan™ dual-labelled probes were used for all of the 17 real-time PCR 
assays. The basis of selecting the real-time PCR reaction mixes are described in appendix 2-3. 
Under standardised conditions, the real-time PCR runs were performed on several instruments 
located at the QPID laboratory and included; ABI7500 (Applied Biosystem, Australia), ViiA-7 
(Applied Biosystem, Australia), LightCycler480 (Roche Applied Science, Australia) and Rotor-
Gene 6000 and Rotor-Gene-Q (Qiagen, Australia). These instruments were used to increase the 
productivity during this dynamic study, which required screening large numbers of samples for 
many real-time PCR assays. 
  
2.1.4.1 Singleplex and multiplex real-time PCR assays 
Multiplex real-time PCR assays were also adopted to increase sample throughput and reduce the 
expense of sample screening. In this approach, several oligonucleotides that target different 
respiratory viruses were combined into a single reaction tube. The multiplex assays were designed 
and optimised previously. Five multiplex assays were employed to screen for 12 respiratory viruses 
(described in detail below). Additional, minor optimisation for each TaqMan™ probe used in these 
assays was undertaken to further enhance PCR performance when processing large numbers of 
samples or when used as multiplex assays. This involved choosing appropriate fluorophore dyes 
with distinct emission maxima to avoid crosstalk between channels in the multiplex real-time PCR 
assays. For the accompanying quencher, the Black Hole Quencher family (BHQ1-BHQ3) was used 
as an alternative to the more conventional tetramethylrhodamine dye (TAMRA®) (Heim et al., 
2003; Matsuzaki et al., 2009; van Elden et al., 2003). This was because TAMRA® is unable to 
quench emissions that exceed 560nm. Also, using TAMRA® as a quencher prevents the 
designation of donor fluorophores at higher wavelengths, further limiting its role in multiplex real-
time PCR assays.  
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2.1.4.2 Quality control of real-time PCR assays 
Two tests were used to monitor the quality of sample extraction and collection: EHV-1 and 
endogenous retrovirus-3 (ERV-3) PCR assays respectively. EHV-1 was added to the samples prior 
to extraction, ERV-3 as an endogenous proviral DNA sequence located near to the centromere of 
chromosome 7 in every human cell    (Lower et al., 1996; Shih et al., 1991) and its detection was 
used as an internal control to determine the presence of human DNA in each extract. It was utilised 
as a marker of sample quality indicating the successful extraction of nucleic acids from human 
epithelial cells and/or white blood cells present in the nasal swab specimen (Chin Yuan et al., 
2001).  
 
A duplex PCR was used to test for both targets, and included two TaqMan™ probe assays that 
target the nucleocapsid gene of the EHV-1 genome (Bialasiewicz et al., 2009) and the envelope 
gene in the ERV-3 genome (Chin Yuan et al., 2001) (see table 2.2 for oligonucleotides). 
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Table 2.2 Oligonucleotide sequences, reporting and quenching dyes and the target genes used in each real-time PCR assay for respiratory virus detection 
Name  Sequence  Target in the genome Type of assay References 
EHV-1-Fa  
EHV-1-Rb  
EHV-1-TMc  
GATGACACTAGCGACTTCGA 
CAGGGCAGAAACCATAGACA 
QUASAR670-TTTCGCGTGCCTCCTCCAG-BHQ3 
Nucleocapsid 
Duplex   
(Schuller et al., 2010) 
ERV-3-F  
ERV-3-R  
ERV-3-TM  
CATGGGAAGCAAGGGAACTAATG 
CCCAGCGAGCAATACAGAATTT 
FAM-TCTTCCCTCGAACCTGCACCATCAAGTCA-BHQ1 
envelope (Chin Yuan et al., 2001) 
RV-F 
RV-R 
RV-TM 
CY+AGCC+TGCGTGGY 
GAAACACGGACACCCAAAGTA 
FAM-TCCTCCGGCCCCTGAATGYGGC-BHQ1 
5`UTR Singleplex   
(Arden and Mackay, 
2010) (Khetsuriani et al., 
2008) 
IFV-A-F 
IFV-A-R 
IFV-A-TM 
CTTCTAACCGAGGTCGAAACGTA  
GGTGACAGGATTGGTCTTGTCTTTA 
QUASAR570-TCAGGCCCCCTCAAAGCCGAG-BHQ2 
Matrix  
Duplex   
(Whiley and Sloots, 
2005) 
IFV-B-F 
IFV-B-R 
IFV-B-TM 
GCATCTTTTGTTTTTTATCCATTCC 
CACAATTGCCTACCTGCTTTCA 
FAM-TGCTAGTTCTGCTTTGCCTTCTCCATCTTCT-BHQ1 
Matrix  
(Whiley and Sloots, 
2005) 
PIV-1-F 
PIV-1-R 
PIV-1-TM 
TTTAAACCCGGTAATTTCTCATACCT  
CCCCTTGTTCCTGCAGCTATT 
FAM-TGACATCAACGACAACAGGAAATCATGTTCTG-BHQ1 
Hemagglutinin-
neuraminidase 
Multiplex   
(Whiley and Sloots, 
2006) 
PIV-2-F 
PIV-2-R 
PIV-2-TM 
AGAGTTCCAACATTCAATGAATCAGT  
CTCAAGAGAAATGTCATTCCCATCT 
YAK-CCTCTGTATTGCTCATGCATAGCACGGA-BHQ1 
Nucleocapsid 
(Whiley and Sloots, 
2006) 
PIV-3-F 
PIV-3-R 
PIV-3-TM 
CGGTGACACAGTGGATCAGATT 
AGGTCATTTCTGCTAGTATTCATTGTTATT 
QUASAR670-TCAATCATGCGGTCTCAACAGAGCTTG-BHQ3 
Nucleocapsid 
(Whiley and Sloots, 
2006) 
RSV-A-F 
RSV-A-R 
RSV-A-TM 
AGATCAACTTCTGTCATCCAGCAA  
TTCTGCACATCATAATTAGGAGTATCAAT  
FAM-CACCATCCAACGGAGCACAGGAGAT-BHQ1 
Polymerase (L) 
 
Duplex   
(van Elden et al., 2003) 
 
RSV-B-F 
RSV-B-R 
RSV-B-TM 
AAGATGCAAATCATAAATTCACAGGA 
TGATATCCAGCATCTTTAAGTATCTTTATAGTG  
YAK-TATGTCC+AGG+TTAGGAAG+G+G+AA-BHQ1 
Polymerase (L) 
(van Elden et al., 2003) 
 
hMPV-F 
hMPV-R 
hMPV-TM 
CATAYAARCATGCTATATTAAAAGAGTCTCA 
CCTATYTCWGCAGCATATTTGTARTCAG 
FAM- CAACHGCAGTRACACCYTCATCATTRCA -BHQ1 
Nucleocapsid Singleplex   (Maertzdorf et al., 2004) 
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Table 2.2-Continued. Oligonucleotide sequences, reporting and quenching dyes and the target genes used in each real-time PCR assay for respiratory virus detection 
Name  Sequence  Target in the genome Type of assay References 
hCoV- 229E-F 
hCoV- 229E-R 
hCoV- 229E-TM 
CAGTCAAATGGGCTGATGCA 
AAAGGGCTATAAAGAGAATAAGGTATTCT 
FAM-CCCTGACGACCACGTTGTGGTTCA-BHQ1 
Nucleoprotein 
Multiplex   
(Dare et al., 2007; 
Schuller et al., 2010; van 
Elden et al., 2004). 
hCoV- NL63-F 
hCoV- NL63-R 
hCoV- NL63-TM 
ACGTACTTCTATTATGAAGCATGATATTAA 
AGCAGATCTAATGTTATACTTAAAACTACG 
YAK-ATTGCCAAGGCTCCTAAACGTACAGGTGTT-BHQ1 
1a   
hCoV- OC43-F 
hCoV- OC43-R 
hCoV- OC43-TM 
CGATGAGGCTATTCCGACTAGGT 
CCTTCCTGAGCCTTCAATATAGTAACC 
QUASAR670- TCCGCCTGGCACGGTACTCCCT-BHQ3 
Nucleocapsid  
hCoV- HKU1-F 
hCoV- HKU1-R 
hCoV- HKU1-TM 
CCTTGCGAATGAATGTGCT  
TTGCATCACCACTGCTAGTACCAC 
FAM-TGTGTGGCGGTTGCTATTATGTTAAGCCTG-BHQ1 
Replicase 1b Singleplex   
(Lambert et al., 2008; 
Schuller et al., 2010) 
WU-F 
WU-R 
WU-TM 
GCCGACAGCCGTTGGATATA 
TTTCAGGCACAGCAAGCAAT 
FAM-AGGGTCACCATTTTTATTTCAGATGGGCA-BHQ1 
VP-2 
Multiplex   
(Dang et al., 2011) 
KIV-D-F 
KIV-D-R 
KIV-D-TM 
CACAGGTGGTTTTCTATAAATTTTGTACTT 
GAATGCATACATCCCACTGCTTC 
YAK-TGCATTGGCATTCGTGATTGTAGCCA-BHQ1 
Small T antigen (Dang et al., 2011) 
KIV-E-F 
KIV-E-R 
KIV-E-TM 
GAACTTCTACTGTCCTTGACACAGGTA 
GGATTAGAACTTACAGTCTTAGCATTTCAG 
QUASAR670-TGGGAAACATCCGGTTTCCTCTCACTTCC-BHQ3 
Regulatory region (Dang et al., 2011) 
hBoV-F 
hBoV-R 
hBoV-TM 
GGCAGAATTCAGCCATACTCAAA 
TCTGGGTTAGTGCAAACCATGA 
QUASAR670-AGAGTAGGACCACAGTCATCAGACACTGCTCC-BHQ3 
VP-1 Singleplex   (Tozer et al., 2009) 
HAdV-TM1 
HAdV-TM2 
TCGGRGTACCTSAGTCCGGGTCTGGTGCA 
TCGGAGTACCTGAGCCCSGGKCTGGTGCA 
Hexon  Singleplex   (Alsaleh et al., 2013) 
HAdV-F1 
HAdV-F2 
HAdV-F3 
GCCSCARTGGGCATACATGCACATC 
GCCGCAGTGGKCKTACATGCACATC 
GCCCCAGTGGKCKTACATGCACATC 
HAdV-R1 
HAdV-R2 
HAdV-R3 
GCCACTGTGGGGTTTCTAAAYTT 
GCCACSGTGGGGTTYCTAAACTT 
GCTACGGTRGGATTTCTAAACTT 
a F:Forward primer ; b R: Reverse primer ; c TM: Taq-Man probe 
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 Once an extraction run was completed, the batch of 96 sample extracts was screened individually 
(i.e. not pooled) with this duplex assay.  The following criteria were applied to assess the quality of 
sample extraction. For EHV-1, the value of an extract’s Ct in a specific batch should not exceed    
±2 standard deviations from the average Ct value calculated for this batch. Results with Ct values 
beyond this range, or where EHV-1 was not detected, were considered extraction failures and this 
step was repeated. For ERV-3, positive or negative results indicated the presence or absence of 
human DNA respectively in that sample and was recorded in the database. 
 
2.1.4.3 Human rhinovirus real-time reverse transcription (RT)-PCR assay  
Samples that passed the quality control test were screened individually for RV using a 
comprehensive real-time RT-PCR assay developed in 2008 (Lu et al., 2008) The assay targeted the 
5`untranslated region (5`UTR) in the RV genome, which contains the most highly conserved 
stretches of nt conservation among the genus Enterovirus. The primers were designed to amplify 
~212 nt of the 5`UTR. The original assay had a relatively short forward primer of 14 nt that was 
stabilised using two locked nucleic acid (LNA™) nt; an Adenine (dA) and a Thymidine (dT) (Table 
2.2 for oligonucleotides). Unlike the common nucleic acid analogues, the ribose ring in an LNA™ 
is locked with a methylene bridge linking the 2`-O atom and the 4`-C atom. This structure allows 
rapid annealing to a complementary strand, increasing the stability of the duplex, and by raising the 
melting temperature, it optimises the use of short oligonucleotides and balances the melting 
temperature between the two primers. The modification applied to the forward primer involved 
replacing the Cytosine nucleotide (dC) in the 3` end of the primer with a pYrimidine (Y) derivative, 
which is a degenerate base that mimics a dC/dT mix (Lu et al., 2008). The aim of this designation 
was to avoid possible mismatches with more recently characterised RV types. For the TaqMan 
probe, the 5` end was labelled with 6-carboxyfluorescein (FAM) as a reporter and a BHQ-1 
molecule at the 3` end as a quencher. To perform real-time reverse transcription (RT)-PCR, a 
SensiFast No Rox one-step RT kit (Bioline, Australia) was used. The reaction mix consisted of a 
total reaction volume of 20.0µL, including 10.0µL of SensiFast No Rox one-step mix (Bioline-
Australia) and 2.0µL of sample extract, 0.1µM of the TaqMan probe, 0.4µM of each of the forward 
and reverse primers and 2mM of MgCl2. Amplification was performed under the following cycling 
conditions: a RT step at 45ºC for 20 minutes followed by an activation step of 94ºC for 2 minutes, 
then 55 cycles of (1) a denaturation step at 94 ºC for 15 seconds and (2) annealing and elongation 
steps at 60ºC for 60 seconds. The acquisition of the PCR product signal occurred during the 
annealing and elongation step.   
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2.1.4.4 Influenza A and B virus (IFV-A and IFV-B) real-time RT-PCR duplex assay 
The testing for IFVs (A and B) involved screening EPRs and then confirming positive pools. For 
this purpose, a previously described and optimised real-time RT-PCR duplex assay was used 
(Lambert et al., 2008; Whiley and Sloots, 2005). For IFV-A, the assay comprised one forward and 
one reverse primer and a TaqMan™ probe that was labelled with Quasar 570 at the 5` end and 
BHQ2 as a quencher at the 3` end. This assay targeted a highly conserved sequence in the M1 gene 
that encodes the matrix protein in the IFV-A (Neumann and Kawaoka, 2011). Similarly, the IFV-B 
assay comprised one forward and one reverse primer and a TaqMan™ probe, which was labelled 
with FAM as a reporter in the 5` end and BHQ-1 as a quencher at the 3` end. The IFV-B assay 
targeted the M2 gene, which encodes the integral membrane protein BM2 (Neumann and Kawaoka, 
2011). The 20 µL reaction mix comprised: 10.0µL of SensiFast No Rox one-step mix (Bioline-
Australia) and 2.0µL of sample extract, 0.4µM of each primer, 0.32µM of IFV-A TaqMan™ probe 
and 0. 16µM of IFV-B TaqMan™ probe. The amplification was performed under the following 
thermo cycling conditions: a RT step at 45ºC for 20 minutes followed by an activation step of 94ºC 
for 2 minutes, then 45 cycles of (1) a denaturation step at 94 ºC for 15 seconds and (2) annealing 
and elongation steps at 60ºC for 60 seconds. The acquisition of the PCR product signal occurred 
during the annealing and elongation step. Once a pool tube provided a positive result (as described 
previously), the confirmatory testing was performed on the individual samples using similar 
reaction and cycling conditions.  
 
2.1.4.5 Parainfluenza virus (PIV) 1, 2 and 3 multiplex real-time RT-PCR   
EPRs were screened for three PIVs. These were; PIV-1, PIV-2 and PIV-3. The multiplex, that was 
previously designed and optimised, (Lambert et al., 2008; Whiley and Sloots, 2006) comprised a 
single set of primers in addition to a single TaqMan™ probe for each of the three assays. For PIV-
1, the assay amplified approximately 81 nt from the HN gene that encodes the Hemagglutinin-
neuraminidase protein. The TaqMan™ probe for PIV-1 assay was labelled with FAM as a 5` 
reporter and BHQ1 as a 3`quencher. The PIV-2 assay targeted nearly 111 nucleotides of the NP 
gene that encodes the nucleocapsid protein. The TaqMan™ probe for PIV-2 assay was labelled with 
YAK fluorescent dye as a 5` reporter and BHQ1 as a 3`quencher. The PIV-3 PCR assay amplified 
approximately 104 nt of the NP gene, which similar to PIV-2 encodes the nucleocapsid protein. The 
TaqMan™ probe was labelled with Quasar670 fluorescent dye as a 5` reporter and BHQ3 as a 
3`quencher. The 20µL multiplex reaction mix comprised the following: 10.0µL of SensiFast No 
Rox one-step mix (Bioline-Australia) and 2.0µL of sample extract, 0.4µM of each primer and 
0.16µM of each TaqMan™ probe. The amplification was performed under the following thermo-
cycling conditions: a RT step at 45ºC for 20 minutes followed by an activation step of 94ºC for        
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2 minutes, then 45 cycles of (1) a denaturation step at 94 ºC for 15 seconds and (2) annealing and 
elongation steps at 60ºC for 60 seconds. The acquisition of the PCR product signal occurred during 
the annealing and elongation step. Once a pool tube provided a positive result (as described 
previously), the confirmatory testing was performed on the individual samples using similar 
reaction and cycling conditions. 
 
2.1.4.6 Human respiratory syncytial viruses (RSV; A and B) duplex real-time RT-PCR 
Pools were screened for both RSV-A and RSV-B using a duplex assay that was slightly modified 
from its original version. The two assays were first developed and optimised in 2003, (van Elden et 
al., 2003) however the RSV-B TaqMan™ probe was replaced with a LNA probe to assist in 
developing the duplex. Similar to the previous multiplexes, a single set of primers and a single 
TaqMan™ probe were used in each assay. The TaqMan™ probes were labelled with FAM for 
RSV-A and YAK for RSV-B at the 5` ends, whilst BHQ-1 molecules were used as a quencher dye 
for both. The 20µL multiplex reaction mix comprised the following: 10.0µL of SensiFast No Rox 
one-step mix (Bioline-Australia) and 2.0µL of sample extract, 0.4µM of each primer and 0.16µM of 
each TaqMan™ probe. The amplification was performed under the following thermo-cycling 
conditions: a RT step at 45ºC for 20 minutes followed by an activation step of 94ºC for 2 minutes, 
then 45 cycles of (1) a denaturation step at 94 ºC for 15 seconds and (2) annealing and elongation 
steps at 60ºC for 60 seconds. The acquisition of the PCR product signal occurred during the 
annealing and elongation step. Once a pool tube provided a positive result (as described 
previously), the confirmatory testing was performed on the individual samples using similar 
reaction and cycling conditions. 
 
2.1.4.7 Human metapneumovirus (hMPV) singleplex real-time RT-PCR   
One of the most targeted genome regions for designing real-time RT-PCR assays for detecting 
hMPV is a well conserved region of 162 nt located within the N gene that encodes the nucleocapsid 
protein (Maertzdorf et al., 2004; Matsuzaki et al., 2009). However, even for this highly conserved 
sequence, there is a considerable difficulty in designing diagnostic assays for the comprehensive 
detection and quantification of different hMPV genotypes. Therefore, we optimised a previously 
developed assay that consisted of several degenerate bases to cover the high numbers of 
mutationswithin the N gene of different hMPV types (Matsuzaki et al., 2009). Pools were tested for 
hMPV using this singleplex assay in similar reaction compositions and cycling conditions. The 
20µL singleplex reaction mix comprised the following: 10.0µL of SensiFast No Rox one-step mix 
(Bioline-Australia) and 2.0µL of sample extract, 0.4µM of each primer and 0.16µM of the 
TaqMan™ probe. The amplification was performed under the following thermo-cycling conditions: 
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a RT step at 45ºC for 20 minutes followed by an activation step of 94ºC for 2 minutes, then 45 
cycles of (1) a denaturation step at 94 ºC for 15 seconds and (2) annealing and elongation steps at 
60ºC for 60 seconds. The acquisition of the PCR product signal occurred during the annealing and 
elongation step. Once a pool tube provided a positive result (as described previously), the 
confirmatory testing was performed on the individual samples using the same reaction and cycling 
conditions.  
 
2.1.4.8 Human coronaviruses (hCoV) 229E, NL63 and OC43 multiplex real-time RT-PCR 
To test the pools for the three hCoVs 229E, NL63 and OC43, a previously developed and evaluated 
multiplex assay was used (Schuller et al., 2010). The original assays for both hCoV-229E and 
hCoV-OC43 were designed to amplify approximately 75 nt of the N gene that encodes the 
nucleocapsid protein in the two viruses, (van Elden et al., 2004) while for hCoV-NL63, the assay 
amplified 102 nt of the same gene (Dare et al., 2007). The multiplex, as in the previous multiplexes, 
used a single set of primers and a single TaqMan™ probe for each assay. The probes were labelled 
with FAM for hCoV-229E, YAK for hCoV-NL63 and Quasar670 for hCoV-OC43 as fluorescent 
dyes at the 5`ends, and BHQ1 for hCoV-229E and hCoV-NL63, and BHQ-3 for hCoV-OC43, as 
quenching dyes at the 3` ends. The 20µL multiplex reaction mix comprised the following: 10.0µL 
of SensiFast No Rox one-step mix (Bioline-Australia) and 2.0µL of sample extract, 0.4µM of each 
primer and 0.16µM of each TaqMan™ probe. The amplification was performed under the following 
thermo-cycling conditions: a RT step at 45ºC for 20 minutes followed by an activation step of 94ºC 
for 2 minutes, then 45 cycles of (1) a denaturation step at 94 ºC for 15 seconds and (2) annealing 
and elongation steps at 60ºC for 60 seconds. The acquisition of the PCR product signal occurred 
during the annealing and elongation step. Once a pool tube provided a positive result (as described 
previously), the confirmatory testing was performed on the individual samples using the same 
reaction and cycling conditions 
 
2.1.4.9 hCoV HKU1 singleplex real-time RT-PCR  
Pools were tested for the hCoV HKU1 using a singleplex assay that was designed and optimised 
previously (Dare et al., 2007; Lambert et al., 2008; Schuller et al., 2010). The assay targets 
approximately 76 nt of the Pp1a gene that encodes the replicase polyprotein 1a. A single set of 
primers was used in this assay along with a single TaqMan™ probe that was labelled with FAM as 
a fluorescent dye and BHQ1 as a quenching dye at the 5` and 3` ends respectively. The 20µL 
singleplex reaction mix comprised the following: 10.0µL of SensiFast No Rox one-step mix 
(Bioline-Australia) and 2.0µL of sample extract, 0.4µM of each primer and 0.16µM of the 
TaqMan™ probe. The amplification was performed under the following thermo-cycling conditions: 
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a RT step at 45ºC for 20 minutes followed by an activation step of 94ºC for 2 minutes, then 45 
cycles of (1) a denaturation step at 94 ºC for 15 seconds and (2) annealing and elongation steps at 
60ºC for 60 seconds. The acquisition of the PCR product signal occurred during the annealing and 
elongation step. Once a pool tube provided a positive result (as described previously), the 
confirmatory testing was performed on the individual samples using the same reaction and cycling 
conditions. 
 
2.1.4.10 Human polyomaviruses (PyV) WU and KI real-time PCR  
Pools were tested for the two novel human PyVs WU and KI (WUV and KIV) using a multiplex of 
three previously described and evaluated real-time PCR assays (Bialasiewicz et al., 2007; Dang et 
al., 2011; Payungporn et al., 2008). WUV real-time PCR assay targeted approximately 71 nt of the 
VP2 gene that encodes a nucleocapsid protein and was comprised of a single set of primers and a 
single TaqMan™ probe that was labelled with FAM and BHQ1. While for KIV the lack of 
sequence data for this virus meant that two real-time PCR assays were used. Each of these assays 
was specific for a different sequence in the genome. The first real-time PCR assay amplified 82 nt 
of the small T antigen gene. This assay comprised a single set of primers and a TaqMan™ probe 
that was labelled with YAK and BHQ1 (KIV-D real-time PCR assay in table 2.2). The second KIV 
assay was designed to amplify 72 nt located in the regulatory region and, similarly, it comprised a 
single set of primers and a TaqMan™ probe labelled with Quasar670 and BHQ3 (KIV-E real-time 
PCR assay in table 2.2). The 20µL multiplex reaction mix comprised the following: 10.0µL of 
SesiMix™ II Probe Mix (Bioline-Australia) and 2.0µL of sample extract, 0.4µM of each primer and 
0.16µM of each TaqMan™ probe. The amplification was performed under the following thermo-
cycling conditions: an activation step of 94ºC for 10 minutes, then 45 cycles of (1) a denaturation 
step at 94 ºC for 15 seconds and (2) annealing and elongation steps at 60ºC for 60 seconds. The 
acquisition of the PCR product signal occurred during the annealing and elongation step. Once a 
pool tube provided a positive result (as described previously), the confirmatory testing was 
performed on the individual samples using the same reaction and cycling conditions. 
 
2.1.4.11 Human bocavirus (hBoV) real-time PCR 
A singleplex assay was used to screen the pools for hBoV. Similar to the previous assays, the hBoV 
real-time PCR assay comprised a single set of primers, that amplified 96 nt of the VP1 gene, and a 
TaqMan™ probe that was labelled with FAM and BHQ1 (Tozer et al., 2009). The 20µL singleplex 
reaction mix comprised the following: 10.0µL of SesiMix™ II Probe Mix (Bioline-Australia) and 
2.0µL of sample extract, 0.4µM of each primer and 0.16µM of each TaqMan™ probe. The 
amplification was performed under the following thermo-cycling conditions: an activation step of 
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94ºC for 10 minutes, then 45 cycles of (1) a denaturation step at 94 ºC for 15 seconds and (2) 
annealing and elongation steps at 60ºC for 60 seconds. The acquisition of the PCR product signal 
occurred during the annealing and elongation step. Once a pool tube provided a positive result (as 
described previously), the confirmatory testing was performed on the individual samples using the 
same reaction and cycling conditions. 
 
2.1.4.12 Human adenovirus (HAdV) real-time PCR 
Pools were tested for HAdV using a singleplex real-time PCR assay, which was designed and 
evaluated specially for this study (Alsaleh et al., 2013). This assay comprised a set of three forward 
primers, three reverse primers and a set of two TaqMan™ probes. The oligonucleotide sequences 
(forward and reverse primers and TaqMan™ probe) were identical to a previously described and 
widely used real-time PCR assay (Heim et al., 2003). However, several degenerate bases were 
incorporated at specific positions to accommodate sequence mismatches. The two TaqMan™ 
probes were labelled with FAM and BHQ1. The 20µL reaction mix consisted of: 10.0µL of 
SesiMix™ II Probe Mix (Bioline-Australia) and 2.0µL of sample extract, 0.13 µM of each of the 
three forward primers (mod1-F1, F2 and F3; Table 2.2), 0.13 µM of each of the three reverse 
primers (mod1-R1, R2, and R3; Table 2.2), and 0.16µM of each probe (Mod1-P1 and P2; Table 
2.2). The amplification was performed under the following thermo-cycling conditions: an activation 
step of 94ºC for 10 minutes, then 45 cycles of (1) a denaturation step at 94 ºC for 15 seconds and 
(2) annealing and elongation steps at 60ºC for 60 seconds. The acquisition of the PCR product 
signal occurred during the annealing and elongation step. Once a pool tube provided a positive 
result (as described previously), the confirmatory testing was performed on the individual samples 
using the same reaction and cycling conditions. 
 
2.1.5 Real-time PCR quality control approaches 
To ensure the quality of real-time PCR data, strict quality control measures were applied throughout 
the study. One of the main aspects of quality control was to standardise all real-time PCR reaction 
components to maximise reproducibility and to minimise variability, each of which negatively 
impact upon the generated data.   
 
2.1.5.1 Standardised positive control 
All positive controls for the respiratory viruses of interest were prepared by the study team in the 
QPID laboratory. Briefly, nucleic acids from a previously archival respiratory virus culture or 
positive sample of interest were extracted using the Roche High Pure Viral Nucleic Acid extraction 
kit (Roche, Australia) following the manufacturer’s instructions. The extract was then tested by 
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real-time PCR assays. Depending on the Ct values obtained, the extract was diluted using Baxter 
water to obtain a Ct value of 20-22 cycles noting that a ten-fold dilution increases the Ct value by 
one Log (approximately 3.3 cycles). The diluted extract was tested under standard conditions to 
further ensure the optimal concentration was obtained. Positive controls were stored in labelled 
50µL aliquots and placed in a -80ºC freezer for long-term storage. No pooled positive controls were 
used in this study. 
 
2.1.5.2 Quality control of real-time PCR reagents 
Real-time PCR reagents, including newly purchased reaction kits and oligonucleotides, were tested 
under standard conditions before being used to test study samples. This was to address lot-to-lot 
variation amongst the reagents. Newly arrived oligonucleotides were first dissolved in 
RNase/DNase free water to stock concentration solutions of 200 µM for primers and 100µM for 
probes. New oligonucleotides were then run in parallel with old oligonucleotides in singleplex 
reactions to examine their sensitivity and performance. For a standard singleplex, three new 
oligonucleotides (one each of a forward and a reverse primer and a Taqman™ probe) were each 
optimised separately. All runs were performed under standard conditions and using the 
corresponding positive controls. 
 
2.1.6 Rhinovirus genotyping 
Samples that provided positive results for RV were subjected to genotyping using the sequences 
obtained from a viral protein (VP) or 5`UTR targets. The variable region VP4/VP2 genes was 
amplified using a nested PCR assay that comprised two sets of primers as previously described 
(Wisdom et al., 2009).  Samples that could not be amplified twice by the VP4/VP2 assay, were 
further investigated by amplifying a 390nt from the 5`UTR (Gama et al., 1989). PCR products from 
either VP4/VP2 or 5`UTR were purified using the QIAquick PCR purification kit (Qiagen, 
Australia) and then submitted for DNA sequencing to the Australian Genome Research Facility 
(The University of Queensland, Brisbane, Australia). Sequence data were analysed using Geneious 
version 5.5.7 (Biomatters Ltd) and blasted against Genbank. To assign a sequence to a specific 
subtype, VP4/VP2 sequences should share ≥ 90% nt identity while 5`UTR sequences should share 
≥ 96% nt identity (Gama et al., 1989; Wisdom et al., 2009). Phylogenetic trees were constructed 
using MEGA version 5.2 and parameters are further discussed in chapter-6 (Tamura et al., 2011).  
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2.1.7 Real-time PCR results interpretation   
The interpretation of real-time PCR results relied upon numerical Ct values. The Ct value is defined 
as the cycle number at which a fluorescent signal exceeds an arbitrarily defined signal threshold. 
The Ct value fort each cycle is proportional to the accumulated level of PCR products. It can also be 
used as an indirect and approximate measure of the initial concentration of the gene target in a 
reaction (i.e. target load) (Mackay, 2004; Schuller et al., 2010). The threshold line in every real-
time PCR run was manually set for each reporter dye by placing the threshold line across all 
exponential amplification curves and above the background noise lines (figure 2.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.2 The above are examples of the WUV and KIV real-time PCR assay; (A) Illustrates the amplification 
curves results prior to analysis. The multicomponent plot shows the three reporter dyes;    FAM,    YAK and                           
    Quasuar 670. In (B), (C) and (D) threshold lines were set manually to cross all exponential amplification            
curves.;  (B) amplification curves from PyV-WU real-time PCR assay, (C) amplification curves from KIV-D real-tie 
PCR and (D) from KIV-E real-time PCR.  
(B) 
(C) (D) 
(A) 
Threshold line  
Threshold line  Threshold line  
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 The manual threshold setting avoided over-estimating the number of positive results that could 
arise from signal drifts, which was defined as a non-exponential rise in the fluorescent signal 
unrelated to amplification of the target sequence (Wong and Medrano, 2005; Yuan et al., 2006). 
Signal drifts can also occur from non-specific breakdown of the TaqMan™ probe, poorly made 
probe or from accumulation of reaction traces towards the end of a real-time PCR run (Gunson et 
al., 2006). The latter can cause confusion when interpreting true positives with relatively low target 
load as often obtained from screening pooled samples. Therefore, to interpret positive results from 
screening pooled samples, any curves that showed an exponential increase in signal were 
considered a true positive, even if they were obtained after 42 cycles. When such a situation arose, 
individual samples were then tested to confirm the positive result.  
 
Real-time PCR testing was performed using several instruments that have different sample loading 
and sealing formats. Some real-time PCR tests were performed using Rotor-Gene thermo-cycler 
series (RG-6000, RG-Q; Qiagen, Australia). Reaction mixes for these particular instruments were 
loaded into 100-well disks using the CAS1200 liquid handling system, which were then closed with 
heat sealing films. For other real-time PCR tests, alternative instruments with a 96-well plate format 
and complementary clear sealing films were used, such as ABI7500, ViiA 7 (Applied Biosystems, 
Australia) and the LC480 (Roche, Australia).  
 
2.1.8 Sample and extract databases and data management 
Starting with samples collected by parents and ending with their various real-time PCR results, 
samples in each stage of the study were monitored and their details recorded in customised 
databases. Upon receiving nasal swabs and collection forms, a simple excel database was used for 
sample and data lodgement. For each swab received, the infant identity ID number, nasal swab 
number and collection form details were recorded, as well as the -80ºC specimen batch rack where 
the swab was stored. Additional details recorded during the lodgement by the laboratory team 
included; the date received and stored frozen in the laboratory, days between swab collection and 
freezing, and whether any visible mould was present according to a semi-quantitative score using a 
sliding scale (0-3; where 0 = no mould observed, 1 = low, 2 = medium, and 3 = high levels of 
visible mould present). When needed, any further comments were included to assist describing the 
condition of the swab upon arrival.  
 
Another simple Microsoft Excel database was designed to assist monitoring swab return rates per 
month for each infant. For swab processing and extraction, a different electronic record was used to 
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assign and combine the 2mL 2D barcoded tubes in the 48-place racks (Sterile Smart Scan Racks, 
Thermo Scientific, Australia) and the 96-well 2D barcoded extraction storage rack (Sterile Matrix, 
Thermo Scientific, Australia) by recording the infant’s identifying information (study ID number 
and date of birth), swab information (the swab number and date of collection) and specimen batch 
rack details. This information was imported manually from the sample log database.  
 
For real-time PCR screening, quality control results were recorded in a separate database whereby 
Ct values obtained from EHV-1 and ERV-3 individual extract testing were recorded next to the 
tube’s 2D barcode numbers only. This allowed easier examination of Ct values and a direct 
application of the quality control criteria using simple descriptive statistics such as mean ±2 
standard deviation values. For respiratory viruses, real-time PCR results were obtained and 
recorded for each EPR (i.e. four individual extract racks) separately. A pooled sample result file 
included (1) the EPR map, which is the layout of the four extract racks used in the EPR along with 
the 2D barcode IDs for all of the racks used; and (2) respiratory virus real-time PCR results for all 
individual, pool and confirmatory testing. The Ct values obtained from respiratory virus real-time 
PCR were recorded after importing sample identifiers from the processing and extracting database. 
All databases were designed using Microsoft Office Excel (version 2010).   
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Appendix 2-1 
Symptom Diary Card 
The symptom diary card was designed to collect ARI symptoms from participating infants every 
day and to return the cards to the ORChID project manager on a monthly basis. A separate diary 
card was used every month until the child reached their second birthday. Each participating family 
was therefore provided a total of 24 diary cards. For each diary card, the month and year were 
indicated at the top right-hand corner of the card, while the infant’s basic information (Name and 
number in the study) was typed by either the care provider or study personnel. The card layout 
directed parents to record the type of symptoms they observed from their child. To differentiate 
between LRTIs and URTIs, a colour coding system was used whereby the yellow colour illustrated 
LRTIs and the blue colour illustrated URTIs. Parents were also asked to record the axillary 
temperature whenever fever was reported, a sign of a systemic reaction. This was accomplished 
using a digital thermometer provided to each participating family, each of whom had been 
instructed on its use.  
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Appendix 2-2 
Sample Processing and Pooling Approach 
Parents were asked to collect anterior nasal swabs from their children on the same day of every 
week (e.g. sample on Sunday) and to mail them (eg. mail on Monday) as soon as possible to the 
QPID laboratory. The study materials provided to each participating family included swab labels 
with identical numbers to further assist in data management. Once collected, parents labelled the 
swab, completed the swab collection form and sent it by the regular mail at ambient temperature to 
the QPID laboratory where the data were reviewed and lodged and the swabs stored at -80ºC until 
analysis. Nasal swab samples were processed in batches of 96 that comprised 92 nasal swabs and 
four negative controls. A batch was given an identical number and the frozen swabs moved to 4ºC 
for defrosting, after which each swab was vortexed once 2mL of PBS was added to the sample tube.   
 
 
 
 
 
 
 
 
 
  
Each swab suspension was transferred to 
a 2mL barcoded tube (Sterial SmartScan 
tubes, Thermo Scientific Australia). The 
2D barcoded tubes came in a 48-place 
rack format.  Each tube’s barcode 
number was assigned to the 
corresponding swab number and was 
labelled as the sample ID. 
The automated extraction system; QIAxtractor robotic extraction system (Qiagen, Australia).    
From each sample, 200µl was manually 
loaded into a 96-well lysis plate, 
specified for the QIAxtractor. The 
volume was spiked with 5µl of EHV-1. 
The final extract volumes 
(150µl/sample) were eluted into a 96-
well 2D barcoded extraction storage 
rack (Matrix, Thermo Scientific, 
Australia). A barcode number from an 
extraction tube was assigned to the 
corresponding swab number and sample 
ID and was labelled as the extract ID. 
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After passing quality control testing and screening for RV, an extract rack was pooled in a new 96 
well 2D barcoded extract storage rack (Matrix, Thermo Scientific, Australia) using the single 
channel robotic liquid handling system: CAS1200 (Qiagen, Australia).  The software was 
programmed specially for the ORChID study to accomplish a 10x10 pooling approach whereby 
10µL aliquots from ten extracts in a defined column were combined in a defined single well into the 
extract pools rack. Similarly, 10µL aliquots from ten extracts in each row were combined into one 
well.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
The pooling technique resulted in compressing 96 wells (92 extracts and four negative controls) into 
20 wells of an EPR pooled extract rack. Consequently, four extract racks could be combined into 
one EPR.  
 
 
 
 
POOLING COLUMNS: 
 In the 10x10 pooling approach, 10 µl from each 
extract in a column was transferred to a well in 
the extract EPR (same colour per column). As the 
96-well 2D barcode rack came in a 12x8 format, 
columns 11 and 12 were used to complete the set 
of 10 wells for the remaining columns.  
  
 
POOLING ROWS:  
In the 10x10 pooling approach: 10 µl from each 
extract in a row was transferred to a defined 
well in the EPR. As the 96-well 2D barcode 
rack came in a 12x8 format, columns 11 and 12 
were used to complete the set of 10 rows.  
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Pooled extract racks were screened for respiratory viruses other than RV. Appropriate respiratory 
viruses positive controls were loaded into the free wells of the examined pools rack according to the 
real-time PCR or real-time RT-PCR assay performed. When positive results were obtained from a 
column pools well and a row pools well from a specific extract rack, the extract located in the joint 
well was tested to confirm positivity. When a positive result was obtained from a column pools well 
only or a row pools well only, the whole column or row in the corresponding extract rack was 
tested.  
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Appendix 2-3 
Kit Evaluation. 
The quality control work included an evaluation of six commercial PCR and RT-PCR kits (three 
kits each) to help choose those providing the optimal sensitivity, specificity, reproducibility time 
and price. Table-2.3 summarises the main features of these kits and some of our testing details.  
 
Table 2.3 Comparing three PCR kits and three RT-PCR kits regarding their price, reproducibility time, manufacturer 
names and some of our testing details (number of assays tested, performance of multiplex assays) 
 Kit  Reproducibility 
time (standard 
conditions/run)* 
Price/ 20 
µL reaction  
($AUD) 
Manufacturer  Testing details 
No. Of 
assays  
Multi-
plexes? 
Clinical 
samples? 
PCR  QuantiFast 
Probe PCR  
56 min. 1.52 Qiagen 1  
        
 
X 
QuantiTect 
Probe PCR*  
1:50h. 1.79 Qiagen 2  
        
 
 
SensiMix II 
Probe  
1:38 h 1.51 Biloine 2   
        
 
 
RT-
PCR  
QuantiFast 
Probe No-
ROX 1-Step  
1:38 h 2.12 Qiagen 1  
        
 
X 
One-step 
RT-PCR*  
2:20 h 2.85 Qiagen 4  
        
 
 
SensiFast 
Probe RT-
PCR 
2:02 h 1.51 Bioline  4  
        
 
 
*Reproducibility time does not include nucleic acid extraction or master mixes preparation  
*PCR refers to amplifying DNA targets and RT-PCR to amplifying RNA target runs that include a cDNA step.  
*Both Quantitect probe PCR and One-step RT-PCR (Qiagen) are used in our lab and provide good performance.  
As initial assessments of the Quantifast kits were unsuccessful, no further evaluation of these kits were 
performed.  
 
The initial evaluations were performed using the PyVs WU/KI and PIVs 1-3 triplexes and serial 
dilutions of previously characterised positive controls. When good performance was observed, 
further evaluations were held utilising: the quality control duplex (EHV-1/ERV-3) assay for 
competitive inhibition effects, hCoV triplex (hCoV-229E, hCoV-NL63 and hCoV-OC43), hMPV 
singleplex and RV singleplex assays, using serial dilutions of positive controls, and positive and 
negative clinical samples. The competitive inhibition effect was tested using the (EHV-1/ERV-3) 
assay. The reaction mixes were spiked with 20µL of EHV-1 (Ct=28) and ERV-3 was used as the 
gradual template. 
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Overall, the best performance and pricing was observed with the two bioline kits (SensMix II probe 
and SensiFast Probe RT-PCR). Therefore, these two kits were used in this longitudinal study. To 
ensure consistency of performance, an arrangement was reached with the manufacturer to supply 
the same batches used in the earlier evaluation for the rest of the study.  
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Chapter 3 
Respiratory virus infections during the first year of life: 
General results 
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3.1 Background 
Our current knowledge of respiratory viruses in young children is derived mainly from hospital-
based studies, many relying upon testing specimens of convenience (Arden and Mackay, 2010; 
Sloots et al., 2006).  Such studies sample from only a small fraction of respiratory virus infections 
and so community-based studies are needed to gain a greater understanding of the true burden of 
disease.  However, older community-based studies had only classical culture techniques available to 
them and are likely to have under-estimated the true burden of respiratory virus disease (Monto , 
2002) when compared with contemporary, highly-sensitive molecular-based detection techniques 
used increasingly during the last decade (Calvo et al., 2007; Chonmaitree et al., 2008; Hall et al., 
2009; Heymann et al., 2004; Jackson et al., 2008). One of the best methods of determining the true 
community burden of viral respiratory infections in early life, which is a critical developmental 
phase in lung growth, is to prospectively follow infant birth cohorts.  Unfortunately, the few recent 
studies involving infant cohorts and employing molecular-based detection assays have suffered 
from several methodological limitations.  For example, many have sampled from highly selected 
populations (especially those deemed to be at high risk of atopy), lacked adequate controls, had 
limited sampling frequency and observation periods or tested for a limited range of viruses (Jackson 
et al., 2012; Kusel et al., 2006; Legg et al., 2005; Regamey et al., 2008; van der Gugten et al., 
2013).  Consequently, there remain important knowledge gaps regarding the frequency and types of 
respiratory viruses affecting healthy infants in their first year of life.  The ORChID study described 
in earlier chapters seeks to address these limitations.   
 
The main aims of this chapter are to describe the nature and shedding patterns of respiratory viruses 
detected in the first year of life from a cohort of 72 healthy infants nested within the ORChID study.  
I also describe the association between virus detection, ARI episodes and viral loads.  I wish to 
address the following hypotheses:   
 
 RV is the most frequently detected respiratory virus associated with symptoms in otherwise 
healthy infants. 
 Various host and environmental factors influence rates of respiratory virus infections and 
associated symptoms; including age, gender, breast feeding, household size, exposures to 
other children and to environmental tobacco smoke, and season. 
 ARIs that involve multiple respiratory viruses last longer than ARIs involving single viruses  
 Ct values obtained from RV real-time RT-PCR (a semi-quantitative marker of viral load) are 
not closely associated with the presence or severity of symptoms.  
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3.2 Methods 
Samples for these analyses were collected weekly from birth until the end of the first year of life. 
The overall recruitment and management strategies for the cohort, as well as respiratory virus 
testing, were described in detail in chapter-2.  Below are the additional methods relating specifically 
to this chapter.   
 
3.2.1 Study cohort and episode definitions 
ORChID study infants born between September 2010 and November 2011 inclusive comprised this 
nested cohort.  For the work described in this chapter, an “ARI” was defined as any URTI or LRTI 
episode.  Any episode with any combination of dry cough, runny nose, nasal congestion or ear 
infection alone was considered an URTI, whereas episodes associated with any of the following:    
(i) breathing difficulty, (ii) wheeze, or (iii) wet cough or rattly chest were considered to be a LRTI 
(Kusel et al., 2006).  An ARI was considered febrile only if body temperature data were provided 
and exceeded 37.5°C.  A “new ARI episode” occurred if there were more than three symptom-free 
days between ARI episodes. Respiratory virus detection was performed by real-time PCR, as 
described previously (Chapter-2).  A “new viral detection episode” (VDE) was defined when a 
virus was detected 14 days or more since the last detection; this included two negative intervening 
nasal swabs.  If one of these intervening samples was missing, 30 days were required to define a 
new infection episode.   
 
3.2.2 Outcomes of interest and confounders 
The outcomes of interest for this analysis included subcategories of all VDEs; (i) viral ARIs, which 
were defined as any ARI episode associated with a VDE and (ii) asymptomatic VDEs, which were 
any VDEs that was not associated with ARI symptoms and/or signs. For both outcomes, eight 
confounding variables related to infant characteristics were included: the age quarter of which the 
outcomes of interest occur, gender, exposure to smoking, maternal vaccination status, number of 
siblings in the household, feeding status, childcare and season. The variable exposure to smoking 
included three categories depending upon: parental smoking (mother or father) and the absence of 
this exposure.  For feeding status, three categories were included; (i) if the infant was exclusively 
breastfed, (ii) if other milk was introduced and (iii) after solids have been introduced.  For childcare 
status, the outcome of interest was any infant who attended (i) formal childcare, (ii) informal 
childcare, (iii) both formal and informal childcare and (iv) no childcare.  Informal childcare was 
defined as care arranged by a parent and provided by an unpaid carer (family member of friends).  
Three additional variables were included to examine outcomes for asymptomatic VDEs, two of 
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which were related to infant characteristics: (i) order of infant in the family, and (ii) household size, 
while the third was related to the outcome characteristic, namely the number of viruses detected. 
 
3.2.3 Statistical analysis 
The association between variables of interest and outcomes was investigated using mixed-effects 
logistic regression models, with infants included as a random intercept to account for the possibility 
of correlated outcomes within each infant. Both univariate and multivariate analyses were 
conducted, with the multivariate analysis being adjusted for all potential confounding variables.  
Analyses were conducted using Stata statistical software v.11.0 (StataCorp, College Station, TX, 
USA). 
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3.3 Results 
3.3.1 Study cohort and demographic data 
From September 2010 to November 2011, 94 infants were recruited into the ORChID study.  Of 
these, 9 infants were lost to follow-up and 13 were withdrawn for personal reasons within the 
family (these include caring responsibilities, postnatal depression, illness of a family member or 
separation for 10 infants or moving from the study area for another 3 infants). The remaining 72 
infants (37 female) remained within ORChID during their first year of life coinciding with the time 
available for my PhD studies and therefore were included in this analysis. Their median gestational 
age was 40.2 weeks (range 37-42 weeks) and the median birth weight 3505g (range 2794-4830; 
figure 3.1).  
 
 
Figure 3.1 Gestation (weeks) and birth weight (grams), stratified by gender. There were no significant differences in 
gestational age or birth weight between male and female infants.  
 
Most (n=49, 68.1%) were first born children. The median household size for this cohort was three 
(range 3-9). All of the infants lived with both parents in the household and six lived with at least 
one additional adult. Twenty four infants shared the household with at least one other child (range 
1-6 children). Nine infants (12.5%) lived with at least one parent who was an active smoker (1 
mother and 8 fathers). Most mothers (n=53, 73%) reported receiving the seasonal IFV vaccine at 
least once. Of them, 33 mothers specified receiving the vaccine during the 12 months prior to their 
infant’s enrolment in the study. 
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3.3.2 Symptom data and ARI episodes  
Overall, the retained cohort provided 25,808 of a possible 26,322 (98%) person-days of symptom 
data during the first year of life. The days per infant ranged from 209-366 (day of birth was 
included) with an average of 357.4 days (Table 3.1).  
 
 Table 3.1 Observation days provided by 72 infants of the one year old cohort and their ARI episodes 
SID 
Days 
available 
Missing 
days 
Symptoms 
days 
Symptoms free 
days 
No. ARIs 
reported 
Median 
duration 
001 366 0 63 303 8 8 
002 366 0 48 318 6 9.5 
003 366 0 98 268 9 8 
004 366 0 124 242 7 7 
005 366 0 49 317 8 4.5 
006 366 0 56 310 8 5.5 
010 366 0 141 225 6 11.5 
012 294 72 54 240 4 12 
013 366 0 5 361 4 1 
015 366 0 0 366 0 0 
016 360 6 205 155 8 18 
017 366 0 116 250 8 17.5 
018 366 0 60 306 8 6 
019 223 143 68 155 2 34 
020 366 0 34 332 5 7 
021 366 0 113 253 9 12 
023 366 0 61 305 11 4 
024 366 0 5 361 1 5 
025 366 0 82 284 6 7 
027 366 0 176 190 7 13 
028 366 0 33 333 1 33 
029 366 0 134 232 7 23 
030 366 0 63 303 10 5 
031 366 0 18 348 5 2 
032 366 0 33 333 6 4 
034 366 0 52 314 6 9 
035 366 0 55 311 9 6 
038 366 0 18 348 3 5 
039 365 1 0 365 0 0 
041 366 0 125 241 7 11 
042 366 0 36 330 3 4 
043 366 0 58 308 8 5 
044 210 156 0 210 0 0 
045 364 2 32 332 2 16 
046 330 36 10 320 2 5 
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Table 3.1 continued. Observation days provided by 72 infants of the one year old cohort and their ARI episodes 
SID 
Days 
available 
Missing 
days 
Symptoms 
days 
Symptoms free days 
No. ARIs 
reported 
Median 
duration 
048 366 0 0 366 0 0 
049 366 0 54 312 15 2 
050 366 0 34 332 3 11 
051 366 0 31 335 5 6 
052 366 0 46 320 5 12 
054 366 0 109 257 9 13 
055 327 39 21 306 5 4 
056 366 0 123 243 10 5 
058 366 0 50 316 7 8 
060 366 0 50 316 3 14 
061 279 87 6 273 2 3 
062 366 0 76 290 7 9 
063 365 1 13 352 4 3 
064 366 0 110 256 8 11.5 
065 366 0 44 322 11 4 
066 366 0 94 272 9 10 
067 366 0 27 339 4 6 
068 366 0 270 96 6 23 
071 366 0 26 340 3 9 
072 366 0 54 312 10 3.5 
075 366 0 39 327 5 2 
076 366 0 4 362 1 4 
077 366 0 40 326 9 3 
078 366 0 22 344 5 3 
079 366 0 57 309 5 11 
080 366 0 53 313 11 3 
081 366 0 3 363 2 1.5 
084 366 0 113 253 7 8 
085 366 0 90 276 8 11 
087 366 0 17 349 6 2.5 
088 366 0 36 330 5 6 
089 365 1 77 288 9 11 
090 366 0 21 345 4 3.5 
091 366 0 31 335 3 9 
092 366 0 35 331 5 7 
094 366 0 131 235 10 11.5 
095 366 0 102 264 9 11 
Total 25808 544 4334 21474 424 7 
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The missing symptom data were from eleven infants (15.2%); five of whom failed to provide 
symptom data for less than seven days at the end of the study. The remaining six infants did not 
provide symptom data for a total of 533 days (mean 88.8 (SD 55.0); median 79.5) days per infant; 
range 36-156).  
 
In total, 424 ARIs were identified in 68 infants (94.4%) who experienced at least one ARI during 
their first year of life. The data provided by the remaining four infants did not meet the definition of 
an ARI (infants 015, 039, 044 and 048; Tables 3.1 and 3.2). The median number of ARIs per 
subject was six (range 0-15 ARIs) with a median symptom duration for each episode of  seven 
(range 1-192) days. This gave a total of 4334 person-symptom days that represent 16.8% of the total 
observation period (Table 3.1). The incidence rate was 1.64 ARIs per 100 child-days (95% 
confidence interval (CI); 1.49-1.76) or six ARIs per child-year (95% CI 0.46-11.54). ARI episodes 
were observed during the first week of life in two infants. One experienced fever on their second 
day of life and the other had several days of nasal discharge.  
 
Overall, two peaks for ARI episodes were observed during the two year study period. The first was 
identified in August-2011 while the second occurred between May-2012 and July-2012. Similarly, 
ARI episodes declined twice during the same period. The first was in January-2012 and the second 
in August-2012 (Figure 3.2).  
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3.3.2.1 ARI episode characteristics 
The 424 ARIs included 356 URTI episodes (84%) and 68 LRTI episodes (16%). URTI episodes 
were observed in 68 infants (94% of all infants and 100% with ARIs) with a median of five 
episodes per infant (IQR 3-7.25). Thirty two (44%) had only URTI episodes, while 37 (51%) had at 
least one LRTI episode during their first year of life. The maximum number of URTI episodes in a 
single infant was 15 with a median duration of 2.5 days per episode (Infant 049; Appendix-1; Page: 
XIII). For all infants, the total number of days involving URTI symptoms was 3347 days (12.9% of 
total observation days) with a median duration of six (IQR 3-11) days per episode (Figure 3.3).  
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Figure 3.2 The number of swabs positive and negative for any respiratory virus (columns) and associated percentages 
(lines) for the duration of the study.  
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Figure 3.3 A comparison between the duration of URTI (n=356) and LRTI (n=68) episodes among our first year old 
cohort. The center lines show the medians; box limits indicate the 25th and 75th percentiles; whiskers extend 1.5 times 
the IQR from the 25th and 75th percentiles. Episodes represented by dots were outliers; crosses represent sample means 
while the grey bars indicate the limits of the 95% CI.  
 
Prolonged URTI episodes were also observed in our population. Eight infants experienced 
continuous symptoms of an URTI (2.2% of total URTI episodes) for more than six weeks, including 
two with continuous symptoms recorded for 102 and 192 consecutive days respectively (Infants 027 
and 068; Appendix-1; Page; VII & XVIII respectively).  
 
The 68 LRTI episodes involved 983 days (3.8% of total available observation days) and affected 37 
infants (median of one LRTI episode (interquartile range (IQR) 1-2) per infant). One infant had six 
LRTI episodes (median 11 (IQR 11-17] days per episode; Infant 094; Appendix-1; Page XXIV). 
The median (IQR) duration of LRTI among infants was 11 (7-16.5) days per episode (Figure 3.3). 
Prolonged LRTI episodes were observed in four infants, each of whom had symptoms for more than 
30 days consecutively (figure 3.3).  (Infant 084; Appendix-1; Page XXI).  
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3.3.3 Nasal swab return and respiratory virus detection 
3.3.3.1 Nasal swab return 
During the first year of life, 3,446 swabs (92.1% of 3,744 expected) were obtained from the study 
infants. Four infants who provided weekly nasal swab samples without accompanying daily 
symptom data had their swabs excluded from this analysis (31 nasal swabs excluded, comprising 1, 
3, 8 and 19, from each of four infants respectively). The remaining 3,415 swabs (91.2% expected) 
had accompanying symptom data. All 72 infants provided their first nasal swab within the first 
week of life. By the end of their first year of life the median number of weekly nasal swabs was 49 
per infant (range 32-53 nasal swabs) (Table 3.2). 
 
Of the 424 ARIs identified, 421(99.3%) had at least one nasal swab returned. Only three ARIs 
(0.7%), were un-accompanied by swabs. Overall, 596 nasal swabs were collected during days 
containing ARI episodes, of which 461 nasal swabs were collected during an URTI (13.49% of total 
swabs) and 135 during a LRTI (3.9% of total swabs).  
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Table 3.2 Nasal swab returns and virus detections per individual infant  
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001 32 10 31.3 1 10.0 8 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 
002 33 10 30.3 1 10.0 8 0 0 0 0 0 2 0 1 0 0 0 0 0 0 0 0 
003 43 4 9.3 2 50.0 3 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 1 
004 53 13 24.5 1 7.7 6 0 0 0 0 1 1 1 1 0 0 0 0 1 0 2 1 
005 51 15 29.4 3 20.0 8 0 0 0 1 0 1 1 1 4 0 0 0 1 0 0 1 
006 52 11 21.2 0 0.0 7 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 2 
010 45 19 42.2 4 21.1 14 0 0 0 0 1 0 0 0 0 0 0 0 3 2 3 2 
012 35 7 20.0 0 0.0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
013 49 8 16.3 0 0.0 6 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 
015 53 6 11.3 0 0.0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
016 47 14 29.8 0 0.0 12 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 
017 49 12 24.5 2 16.7 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 
018 51 6 11.8 0 0.0 3 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 
019 29 11 37.9 3 27.3 4 0 0 0 0 0 0 0 0 0 0 0 0 4 4 0 2 
020 52 11 21.2 1 9.1 10 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 
021 53 12 22.6 0 0.0 10 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 
023 51 23 45.1 3 13.0 20 0 0 1 0 0 2 0 1 0 0 0 0 0 2 0 0 
024 51 5 9.8 0 0.0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
025 52 18 34.6 4 22.2 12 0 0 0 0 0 3 0 0 0 0 0 0 5 2 0 0 
027 52 29 55.8 8 27.6 23 0 0 0 0 0 0 0 0 2 0 0 0 3 7 0 2 
028 52 6 11.5 0 0.0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 
029 50 15 30.0 0 0.0 13 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 
030 44 14 31.8 2 14.3 8 0 0 0 0 0 0 0 0 0 0 0 0 2 0 4 2 
031 52 3 5.8 0 0.0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
032 53 9 17.0 1 11.1 6 0 0 0 0 0 1 0 0 0 0 0 0 0 0 3 0 
034 50 11 22.0 0 0.0 8 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 1 
035 52 13 25.0 0 0.0 12 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 
038 53 8 15.1 1 12.5 6 1 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 
039 42 14 33.3 3 21.4 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6 1 
041 52 15 28.8 3 20.0 12 0 0 0 0 0 0 0 0 1 0 0 2 0 1 0 2 
042 49 22 44.9 2 9.1 21 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 3 
043 50 16 32.0 0 0.0 12 0 0 0 0 0 2 0 0 0 0 0 0 0 2 0 0 
044 30 6 20.0 0 0.0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
045 48 10 20.8 0 0.0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
046 47 21 44.7 2 9.5 14 0 0 1 0 0 0 0 0 0 0 0 0 2 0 6 0 
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Table 3.2 continued. Nasal swab returns and virus detections per individual infant 
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048 50 2 4.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 
049 49 10 20.4 4.0 40.0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 2 
050 40 7 17.5 0.0 0.0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 
051 51 13 25.5 0.0 0.0 12 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
052 43 10 23.3 0.0 0.0 8 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 
054 49 15 30.6 2.0 13.3 13 0 0 0 0 0 1 0 0 0 0 0 0 0 2 0 1 
055 41 10 24.4 0.0 0.0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 
056 52 17 32.7 3.0 17.6 13 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 4 
058 49 7 14.3 0.0 0.0 5 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
060 53 13 24.5 0.0 0.0 10 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 
061 39 7 17.9 1.0 14.3 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 
062 46 20 43.5 1.0 5.0 18 0 0 1 0 0 1 0 0 0 0 0 0 1 1 0 0 
063 49 2 4.1 0.0 0.0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
064 51 18 35.3 6.0 33.3 16 0 0 0 0 0 0 0 0 1 0 0 0 2 2 3 2 
065 48 17 35.4 1.0 5.9 15 0 0 0 0 0 2 0 0 0 0 0 0 1 0 0 0 
066 52 13 25.0 0.0 0.0 11 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 
067 50 17 34.0 3.0 17.6 12 0 0 0 0 0 0 0 0 0 2 0 0 0 0 4 2 
068 51 10 19.6 2.0 20.0 7 0 0 0 0 0 0 0 0 0 0 0 0 2 0 3 0 
071 48 11 22.9 0.0 0.0 10 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
072 49 18 36.7 1.0 5.6 13 0 0 0 0 0 2 0 0 2 0 0 0 1 0 0 1 
075 49 12 24.5 0.0 0.0 11 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
076 48 5 10.4 0.0 0.0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
077 51 6 11.8 0.0 0.0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
078 37 11 29.7 0.0 0.0 10 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
079 53 8 15.1 0.0 0.0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
080 50 11 22.0 0.0 0.0 9 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 
081 48 9 18.8 0.0 0.0 5 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 3 
084 44 3 6.8 0.0 0.0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
085 49 16 32.7 3.0 18.8 11 0 0 0 0 1 0 0 0 0 0 0 0 0 0 4 3 
087 52 6 11.5 0.0 0.0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
088 46 13 28.3 2.0 15.4 10 0 0 0 0 1 0 0 0 0 0 0 0 1 2 0 1 
089 47 6 12.8 0.0 0.0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
090 49 15 30.6 0.0 0.0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 0 
091 52 5 9.6 0.0 0.0 4 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 
092 48 9 18.8 2.0 22.2 9 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 
094 51 16 31.4 1.0 6.3 13 0 0 0 0 0 1 0 2 0 0 0 0 1 0 0 0 
095 33 14 42.4 1.0 7.1 14 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
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3.3.3.2 Quality control testing 
Prior to respiratory virus testing, the quality of extraction was examined by screening individual 
sample extracts using the quality control real-time PCR assays (described in section 2.1.4.2). 
Overall, 3,415 sample extracts were positive for EHV-1 with an average Ct value of 33.28. As per 
the ORChID quality control protocol, only sample extracts that passed the EHV-1 specific batch-to-
batch criteria were eligible for subsequent respiratory virus panel screening. For samples from this 
cohort, 54 extracts did not meet the EHV-1 criteria (described in section 2.1.4.2) and were, 
therefore, re-extracted and re-tested prior to their inclusion in the analysis.  
 
For ERV-3, which was used to test for the presence of human DNA, the average Ct value was 34.45 
(range 22.86 to 43.91) cycles. There were 562 (16.4%) sample extracts that tested negative for 
ERV-3, all of which though were included in the analysis (for further details see chapter-4). 
 
3.3.3.3 Respiratory virus detection in nasal swabs and infection episodes 
Overall 829 (24.3%) swabs were positive for any respiratory virus. All infants provided at least two 
positive nasal swabs (median 11 [IQR 7-15]) per infant. The highest number of positive swabs 
observed in one infant was 29 (56% of provided swabs) (Table 3.2). All 17 respiratory viruses were 
detected in the cohort. The median (IQR) number of different viruses detected during the first year 
of life in each infant was three (2-4) and ranged from one to eight with the latter number observed 
in two infants (Table 3.2; infants 004 and 005).   
 
The overall number of swabs positive for any RNA virus (n=80; 2.4%) other than RV was 
significantly lower than the number of swabs positive for any DNA virus (n=179; 5.5%) 
(P<0.0001). Of the 172 VDEs observed, the number of RNA-VDEs (68 RNA-VDEs; 39.5%) was 
also significantly lower than the number of DNA-VDEs (104 DNA-VDEs; 60.5%) (P=0.0002). The 
distribution of DNA-VDEs and RNA-VDEs was as follows: 29 (40.3% of infants) had both DNA 
and RNA-VDEs, 20 (27.7%) had only DNA-VDEs and 12 (16.7%) had only RNA-VDEs. For the 
remaining 11 infants, only RV-DEs were observed (Table 3.2).  
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3.3.3.4 Most frequently detected respiratory viruses  
RVs were the most frequently detected respiratory viruses. The number of swabs positive for RV 
was 659 (19.1%) causing 327 rhinovirus detection episodes (RV-DEs) in 71 infants (98.6%). Only 
one infant (infant 048; Table 3.2) failed to have a RV detected in any of their nasal swabs. The 
median (IQR) number of RV-DEs in the positive infants was four (3-6) with a maximum of nine 
detection episodes in one infant. The median (IQR) duration of RV-shedding in all episodes was 
one (1-3) week and the maximum duration recorded for a single episode was nine weeks. Table 3.3 
describes respiratory virus detection and VDEs among the infants.  
  
84 
 
Table 3.3 Descriptive summary of respiratory virus detection in nasal swabs, viral detection episodes (VDEs) and acute respiratory infections (ARIs) and their association with respiratory 
viruses  
 Feature  RV IFV-A IFV-B PIV-1 PIV-2 PIV-3 RSV-A 
RSV-
B 
hCoV-
OC43 
hCoV-
NL63 
hCoV-
229E 
hCoV-
HKU1 
hMPV HAdV WUV KIV hBoV 
No virus 
identifie
d 
N
a
sa
l 
sw
a
b
s 
d
et
ec
ti
o
n
 r
es
u
lt
s 
(n
=
3
4
1
5
) No. of infants 
(%)a 
71 (98.6) 3 (4.2) 
2 (2. 
8) 
4 (5.6) 1 (1.4) 9 (12.5) 
15 
(20.8) 
8 
(11.1) 
9 (12.5) 5 (6.9) 1 (1.4) 1 (1.4) 6 (8.3) 
23 
(31.9) 
12 
(16.7) 
17 (23.6) 
31 
(43.1) 
0 
No. of 
positive 
samples (%) 
659 
(19.1) 
3 (0.09) 
2 
(0.06) 
4 (0.12) 
1 
(0.03) 
9 (0.26) 
22 
(0.64) 
8 
(0.23) 
11 
(0.32) 
10 
(0.29) 
2 (0.06) 1 (0.03) 7 (0.2) 
38 
(1.11) 
30 
(0.88) 
57 (1.67) 
54 
(1.58) 
2586 
(75.7) 
Mean number 
of positive 
samples per 
infant (Min-
max) 
9.1 (0-
23) 
0.04 (0-1) 
0.03 
(0-1) 
0.06 (0-
1) 
0.01 
(0-1) 
0.13 (0-
1) 
0.31 (0-
3) 
0.11 
(0-1) 
0.15 (0-
2) 
0.14 (0-
4) 
0.03 (0-
2) 
0.01 (0-1) 
0.1 (0-
2) 
0.53 
(0-5) 
0.42 (0-
7) 
0.79 (0-6) 
0.75 
(0-4) 
 
Median Ct 
value 
(Min-max) 
31.5 
(18.1-
48) 
32.4 
(30.2-
38.2) 
29.6 
(29.6-
29.7) 
39.9 
(32.8-
42.5) 
28.2 
(28.2-
28.3) 
30.9 
(25 -
37.6) 
35.1 
(25.7-
42.5) 
30.2 
(26.8-
37.3) 
29.1 
(26.1-
36) 
33.5 
(29.2-
36.9) 
32.1 
(27.6-
36.6) 
34.9 
(34.9-
34.9) 
35.2 
(33.7-
39.2) 
34.9 
(24.8-
41) 
28.8 
(18.1-
37.2) 
31.9 
(18.3-
40.1) 
30.4 
(16.9-
42.9) 
- 
Mean Ct 
value  
32 33.6 29.7 38.8 28.3 30.3 34.6 31.1 29.8 33.2 32.1 34.9 35.4 34.3 28.3 31.1 30.5 - 
V
D
E
s 
in
 p
a
rt
ic
ip
a
n
ts
 
No. of VDEs 
in infants 
327 3 2 4 1 9 18 8 9 5 2 1 6 31 15 25 33 - 
No. of 
asymptomati
c VDE (%) 
110 
(33.6) 
1 (33.3) 1 (50) 2 (50) 0 0 5 (27.7) 
1 
(12.5) 
3 (33.3) 0 0 0 1 (16.6) 
8 
(25.8) 
3 (21.4) 12 (48) 
12 
(36.3) 
 
Median 
VDEs per 
infant (min-
max)  
4 (1-9) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-2) 1 (1-1) 1 (1-1) 1 (1-1) 2 (2-2) 1 (1-1) 1 (1-1) 1 (1-3) 1 (1-3) 1 (1-3) 1 (1-2) - 
Median 
duration of 
VDE (min-
max) 
1 (1-9) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-3) 1 (1-1) 1 (1-2) 2 (1-4) 1 (1-1) 1 (1-1) 1 (1-2) 1 (1-4) 2 (1-4) 2 (1-6) 1 (1-4) - 
No. of 
months in 
which VDEs 
were 
observed 
24 2 2 4 1 8 12 6 5 5 2 1 4 12 11 17 14 - 
Peak monthb August 
11 
Septembe
r 11 
Augus
t 11 
Octobe
r 11 
Januar
y 11 
Octobe
r 11 
October
-11 
March-
11 
April 11 
August
-11 
July-11 
August-
12 
July-11 July-11 
October
-11 
Novembe
r 11 
July-
12 
- 
a Percentage of total population, n=72 
b Peak month was determined by calculating incidence rates (per 100 child-days). 
c Percentage of episodes accompanied by samples 
d Including co-detection 
e Percentage of positive infants    
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Table 3.3 continued. Descriptive summary of respiratory virus detection in nasal swabs, viral detection episodes (VDEs) and acute respiratory infections (ARIs) and their association 
with respiratory viruses 
 
Feature  RV IFV-A IFV-B PIV-1 PIV-2 PIV-3 RSV-A 
RSV-
B 
hCoV-
OC43 
hCoV-
NL63 
hCoV-
229E 
hCoV-
HKU1 
hMPV HAdV WUV KIV hBoV 
No virus 
identified 
F
ea
tu
re
s 
o
f 
A
R
I 
ep
is
o
d
es
 
Number of ARIs with 
virus identified /total 
number of ARIs 
(n=424; %) c,d 
239 
(56.4) 
2 (0.5) 1 (0.2) 2 (0.5) 1 (0.2) 8 (1.9) 12 (2.8) 7 (1.7) 5 (1.2) 2 (0.5) 6 (1.4) 0 5 (1.2) 22 (5.2) 13 (3.1) 12 (2.8) 
22 
(5.2) 
144 (33.9) 
URTI (% of total 356 
URTIs) c,d 
204 
(57.3) 
1 (0.3) 1 (0.3) 1 (0.3) 1 (0.3) 7 (2) 6 (1.7) 4 (1.1) 4 (1.1) 0 6 (1.7) 0 2 (0.6) 15 (4.2) 12 (3.4) 11 (3.1) 
18 
(5.1) 
121 (33.9) 
LRTI (%of total 68 
LRTIs) c,d 
35 
(51.5) 
1 (1.5) 0 1 (1.5) 0 1 (1.5) 6 (8.8) 3 (4.4) 1 (1.5) 2 (2.9) 0 0 3 (4.4) 7 (10.3) 1 (1.5) 1 (1.5) 4 (5.9) 23 (33.8) 
Median duration of 
ARIs in days 
9 9.5 3 9.5 5 11.5 9 10 18 9.5 11.5 0 10 15.5 12 8 15.5 4 
Number of months of 
study in which virus 
was identified 
23 2 1 1 1 6 8 6 4 5 2 1 2 12 10 11 12 25 
Peak month of ARIs 
associated with viruse 
May-
12 
Jun-11 
Aug-
11 
Mar-
12 
Jan-11 
Aug-
11 
Oct-11 
Mar-
11 
Jun-11 
Aug-
12 
Jul-11 
Aug-
12 
Jul-11 Jun-11 Oct-11 Dec-11 Aug-11 Sep-10 
Number of infants  67  2  1  1  1  8  10  6  5  5 1 1 4  18  9  9  21  56 
a Percentage of total population, n=72 
b Peak month was determined by calculating incidence rates (per 100 child-days). 
c Percentage of episodes accompanied by samples 
d Including co-detection 
e Percentage of positive infants  
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The number of RV-DEs peaked in August-2011, with 28 RV-DEs and declined in August-2012 with 
only three RV-DEs (Figure 3.4) as most infants by then had reached their first birthday and left my 
nested cohort..  
 
 
 
 
 
 
 
  
Figure 3.4 Number of infection episodes in 72 infants during two years of investigation from September-2010 to 
November-2012. RV-detection episodes were the most common. IFVs were observed in the first year of the study only. 
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After RV, the next four most commonly detected viruses were all DNA-viruses: KIV, hBoV, HAdV 
and WUV. Of these, KIV was the most prevalent. It was detected in 57 (1.7%) nasal swabs from 17 
(23.6%) infants (Table 3.3). The median duration of KIV-DEs was two weeks and, notably, recurrent 
detections were observed in seven of 17 (41.2%) affected infants with a median of four (IQR 1-3) 
weeks between episodes.  
 
Overall, hBoV was the second most commonly detected DNA virus and was observed in 31 (43.0%) 
infants. The median duration of hBoV shedding in the 31 episodes was one week with a maximum 
duration of four weeks observed in two infants who experienced only one hBoV-DEs each. HAdV 
followed as it was identified in 38 nasal swabs (1.1%) collected from 23 infants (32%) leading to 31 
HAdV-DEs. The median duration of HAdV-shedding was one (IQR 1-1.5) week and the maximum 
duration of four consecutive weeks was observed in only one infant who experienced this sole infection 
episode (Infant 019; Table 3.2 and Appendix-1; Page V). Finally, WUV was detected in 30 nasal swabs 
(0.9%) collected from just 12 infants (16.7%). Similar to other DNA-viruses, the median duration of 
WUV-shedding was two weeks and the maximum duration of WUV-shedding of four weeks was 
observed in two infants (Table 3.3).  
 
After RV, the second most frequently detected RNA virus in both the nasal swabs and in the infants 
was RSV-A, which was detected in 22 nasal swabs collected from 15 (20.8%) infants (Table 3.3). 
Recurrent episodes were observed for RSV-A on only one occasion 20 days after the initial detection. 
During this time, two intervening swabs were returned by the participating family and both were found 
negative for RSV-A. The Ct value in the initial RSV-A detection was (Ct = 29.18 cycles) compared to 
the second detection (Ct value = 34.59 cycles) (Infant 065; Table 3.2; Appendix-1; Page XVII).  
 
hCoV-OC43 was detected in eleven nasal swabs (0.3%) leading to nine detection episodes in nine 
infants (12.5%) with a median shedding duration of one week. The maximum shedding duration among 
RNA viruses other than RVs was identified for hCoV-NL63, which was detected in ten nasal swabs 
(0.3%) leading to five episodes in five infants (6.9%). The longest hCoV-NL63-DE of four weeks was 
observed once in an infant who had a sole hCoV-NL63-DE (Infant 005; Table 3.2; Appendix-1; Page 
II). PIV-3 was the most commonly observed PIV virus and was detected in nine nasal swabs (0.3%) 
associated with nine episodes in nine infants (12.5%). Next came RSV-B detected in eight nasal (0.2%) 
swabs associated with eight episodes in eight infants (11.1%). For hMPV, which was detected in six 
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infants (8.3%), all cases were identified in the winter and spring months (Figure 3.4). PIV-1 was 
observed over four consecutive months from four infants (5.3%). For IFVs, IFV-A and IFV-B, few 
positive samples were identified during the first year of the study (July2011- September2011), and 
were only detected among five different infants (6.9%) (Figure 3.4; Table 3.2). hCoV-229E was 
detected twice in the same study infant. The duration of shedding for these two episodes was one week 
each with 21 interval days between the infection episodes (Infant 067; Table 3.2; Appendix-1; Page 
XVIII). Finally, PIV-2 and hCoV-HKU1 were detected only once each (0.03%) in a single VDE 
(1.3%) (Table 3.2).  
 
3.3.3.5 Multiple detections 
Multiple virus detections were observed in 80 samples (2.3% of total swabs obtained from 34 [47.2%] 
infants). Overall, RV was more frequently co-detected with a DNA virus than an RNA virus, while 
hBoV was the most common DNA virus co-detected with another respiratory virus (Table 3.4).  
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Table 3.4 Respiratory virus detection in nasal swab samples from 72 subjects, including multiple detections for each respiratory virus 
Virus Sole 
Co-detection Average Ct value Swabs with multiple viruses  
no. % Average Av. Sole 
Av. Co-
detection 
RV PIV-1 PIV-3 RSV-A RSV-B hCoV-
NL63 
HAdV 
 
WUV KIV hBoV 
 
RV 590 69 10.5 31.6 32.1 31.4 0 1 2 2 0 2 18 14 19 17 
KIV 36 21 36.8 32.0 32.2 29.4 19 0 1 0 0 0 0 0 0 2 
hBoV 31 23 42.6 30.4 31.6 28.5 17 0 0 1 0 0 1 2 2 0 
HAdV 19 19 50.0 34.9 33.5 35.0 18 0 0 0 0 0 0 0 0 1 
WUV 13 17 56.7 28.9 27.5 28.8 14 0 0 2 0 1 0 0 0 2 
RSV-A 16 6 27.3 35.2 35.1 33.2 2 0 0 0 1 0 0 2 0 1 
hCoV-OC43 11 0 0.0 29.1 29.8 0.0 0 0 0 0 0 0 0 0 0 0 
hCoV-NL63 7 3 30.0 33.5 33.0 33.5 2 0 0 0 0 0 0 1 0 0 
PIV-3 6 3 33.3 30.9 29.7 31.4 2 0 0 0 0 0 0 0 1 0 
RSV-B 7 1 12.5 30.2 31.1 31.1 0 0 0 1 0 0 0 0 0 0 
hMPV 7 0 0.0 35.3 35.4 0.0 0 0 0 0 0 0 0 0 0 0 
PIV-1 3 1 25.0 40.0 39.0 38.5 1 0 0 0 0 0 0 0 0 0 
IFV-A 3 0 0.0 32.4 33.6 0.0 0 0 0 0 0 0 0 0 0 0 
IFV-B 2 0 0.0 29.7 29.7 0.0 0 0 0 0 0 0 0 0 0 0 
hCoV-229E 2 0 0.0 32.2 32.2 0.0 0 0 0 0 0 0 0 0 0 0 
PIV-2 1 0 0.0 28.3 28.3 0.0 0 0 0 0 0 0 0 0 0 0 
hCoV-HKU1 1 0 0.0 34.9 34.9 0.0 0 0 0 0 0 0 0 0 0 0 
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Figure 3.5 illustrates different VDEs where multiple viruses were identified and compares their 
percentages with single-virus VDEs. Although RV was the most frequently detected virus, more than 
80% of RV-DEs were singletons (i.e. no other virus was detected). DNA-viruses were more often co-
detected with RV compared to RNA-viruses. Moreover, 80% of WUV-DEs were associated with at 
least one other virus, and this occurred commonly with other DNA-viruses too, namely KIV (64% of 
total KIV-DEs), HAdV (54.8% of total HAdV-DEs) and hBoV (48.5% of total hBoV-DEs). In 
contrast, RSV-B was the only virus that was not accompanied by RV co-detection.  
 
 
 
 Figure 3.5 The percentage of multiple virus detection episodes for ten respiratory viruses. The denominator used is the overall number of 
VDEs 
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3.3.3.6 Respiratory virus Ct values 
Overall, the median RV Ct value for the 656 RV-positive samples was 31.6 cycles (range 18.1-48.1 
cycles), which was comparable to KIV, hBoV, WUV and the remaining RNA viruses. In contrast,    
PIV-1 and RSV-A provided relatively high Ct values in nasal swab samples (Table 3.4). HAdV 
positive samples provided Ct values that were significantly higher than all other DNA viruses and most 
RNA viruses (P= 0.01 compared to each of RV, WUV, KIV, WUV and the remaining grouped RNA 
viruses). The median Ct value obtained from the 38 samples positive for HAdV was 34.9 (range 24.9-
41.0) cycles.  
 
3.3.4 Respiratory virus infection episodes and ARIs 
Of the 421 ARI episodes accompanied by samples, 220 (52.3%) were associated with one respiratory 
virus, 47 (11.2 %) were associated with two, 11 (2.7 %) were associated with three and three (0.7%) 
were associated with four respiratory viruses. No virus was detected in the remaining 141 (33.5%) ARI 
episodes. RV was the most commonly observed virus and was associated with 239 (56.7%) ARI 
episodes accompanied by samples. Table 3.3 describes the main features of ARI episodes associated 
with respiratory virus detection. The median (IQR) duration of all ARI episodes associated with viruses 
was nine (4-12) days, which was significantly longer than when no viruses were detected (median      
(1-36) days: P < 0.001; Mann Whitney U test). In general, ARI episodes associated with a sole virus 
were of shorter duration than episodes associated with more than one virus. For URTIs, the median 
duration of ARI episodes associated with RV alone (eight days) was significantly shorter than those 
associated with RV and other co-detected viruses (13 days; P < 0.001; Mann Whitney U test). 
Similarly, the median duration of LRTIs with RV alone (8.5 days) was significantly shorter than LRTIs 
associated with RV co-detected with other viruses (20 days; P < 0.01; Mann Whitney U test). For 
respiratory viruses other than RV, sole detection was also associated with shorter duration of URTI 
symptoms (n=28, median six days) than when multiple viruses were detected (n=3, median ten days) 
though numbers were too small to allow a robust comparison. Similarly, LRTI episodes associated with 
sole respiratory virus detections (n=2, median eleven days) and those associated with multiple viruses 
(other than RV; n=9, median nine days) were too small in number for any conclusions to be drawn. 
Figure 3.6 further compares the duration of URTI and LRTI episodes when RV or other viruses were 
detected and when no respiratory virus was detected.   
92 
 
 
 
 
 
Figure 3.6 Comparison between the duration of URTI (left) and LRTI (right) episodes among our one year old cohort 
according to the respiratory viruses detected. The centre lines show the medians; box limits indicate the 25th and 75th 
percentiles; whiskers extend 1.5 times the IQR from the 25th and 75th percentiles. Episodes represented by dots were 
outliers; crosses represent sample means.  
 
3.3.5 ARIs with virus detected and demographic data 
Among the possible confounding factors only age and season had a significant impact upon the number 
of ARI episodes that were associated with virus detection (Table 3.5). The number of ARIs associated 
with viruses increased significantly in the second half of the first year of life (n=198; 72.5% of total 
ARIs in this age group) compared to the first six months of life (n=82; 52.2% of total ARI in this age 
group) (crude OR 2.22; 95% CI 1.46-3.36). The number of days involving ARIs during the last six 
months of infancy (3026 days) was also significantly greater than the numbers of days of ARI 
symptoms during the first 6 months of life (1359 days; P < 0.001; Mann Whitney U test) (Table 3.5; 
Figure 3.7).  
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Figure 3.7 the number of days available for observation during the 52 weeks of the first year of life (grey) and the 
percentage of days with symptoms (black). The percentage of days with ARI symptoms increased by age.  
 
 
Winter months were more likely to contain higher numbers of ARIs associated with viruses than other 
seasons (adjusted OR 2.4; 95% CI 1.29-4.69; P < 0.006). The association between the remaining 
confounding factors and ARI episodes with virus was limited. Table 3.5 provides a comprehensive 
univariate and multivariate analyses for the demographic data and the study outcomes.  
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Table 3.5 ARI episodes identified during the first year of life and their association with the cohort characteristics  
Variable 
 
Total ARIs  ARIs with virus associated 
No of infants with 
ARIs (% of total) 
No. of ARI 
episodes (%) 
No of episodes 
(%)  
Univariate 
OR (95%); P value 
Multivariatea 
OR (95%); P value 
Age quarter (mths) 
0-3 30 (14.9) 52 (12.3) 26 (50) 1 1 
3-6 55 (27.4) 99 (23.3) 56 (56.5) 1.44 (0.69-2.9); 0.32  1.7 (0.79-3.85); 0.167 
6-9 56 (27.9) 132 (31.1) 96 (72.7) 3.08 (1.49-6.37); 0.002 3.1 (1.24-8.06); 0.016 
9-12 60 (29.8) 141 (33.3) 102 (72.3) 2.78 (1.36-5.66); 0.005 4.38 (1.64-11.71); 0.003 
Gender 
Male 34 (50) 195 (45.99) 132 (67.7) 1 1 
Female 34 (50) 229 (54.01) 148 (64.6) 0.79 (0.47-1.35); 0.405 0.68 (0.39-1.19); 0.182 
Exposure to 
smoking 
Mother 1 (1.5) 5 (1.2) 4 (80) 2.06 (0.15-27.25); 0.582 1.66 (0.12-23.0); 0.704 
Father 8 (12.1) 46 (11.1) 29 (63.04) 0.80 (0.35-1.84); 0.605 0.54 (0.22-1.37); 0.199 
No exposure  57 (86.4) 362 (87.7) 239 (66.02) 1 1 
Mother IFV 
vaccine status 
Had IFV vaccine 50 (74.6) 328 (77.7) 218 (66.4) 1.04 (0.56-1.95); 0.887 1.2 (0.63-2.28); 0.568 
No IFV vaccine 17 (25.4) 94 (22.3) 61 (64.9) 1 1 
Number of children 
in the householdb  
No children  43 (63.2) 261 (61.6) 168 (64.4) 1 1 
One child 18 (26.4)  113 (26.7) 80 (70.8) 1.28 (0.69-2.34); 0.423 1.61 (0.8-3.2); 0.18 
≥ two children 7 (10.3) 50 (11.8) 32 (64) 0.99 (0.43-2.23); 0.983 1.04 (0.44-2.4); 0.92 
Feeding 
Exclusively 
breastfed (BF)  
40 (36.4) 
78 (18.4) 
41 (52.6) 
1 1 
BF and other milk 66 (60) 332 (78.3) 232 (69.8) 2.09 (1.21-3.61); 0.008 1.06 (0.49-2.2); 0.87 
Solids  4 (3.64) 14 (3.3) 7 (50) 0.68 (0.17-2.62); 0.17 0.29 (0.06-1.38); 0.121 
Childcare status 
Formal 23 (23.9) 80 (18.9) 53 (66.3)) 1.005 (0.55-1.83); 0.98 0.69 (0.33-1.43); 0.323 
Informal 9 (9.4) 26 (6.1) 15 (57.7) 0.782 (0.29-2.10); 0.627 0.43 (0.15-1.26); 0.129 
Formal and 
informal 
2 (2.1) 
2 (0.47) 
2 (100) 
Not includedw Not includedw 
No childcare 62 (64.6) 316 (74.5) 210 (66.5) 1 1 
Season 
Spring  50 (23.9) 97 (22.9) 56 (57.7) 1 1 
Summer 45 (21.5) 73 (17.2) 47 (64.4) 1.26 (0.65-2.47); 0.491 1.2 (0.59-2.53); 0.569 
Autumn  55 (26.3) 124 (29.2) 79 (63.7) 1.23 (0.691-2.21); 0.474 1.4 (0.74-2.64); 0.298 
Winter  59 (28.2) 130 (30.7) 98 (75.4) 2.23 (1.22-4.08); 0.009 2.4 (1.29-4.69); 0.006 
a Adjusted for all variables in the table.  
b other than the participating infant. 
w Small number of observations, so the univariate OR and 95% CI were omitted.  
Values in bold indicate statistical significance. 
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3.3.6 Asymptomatic VDEs 
Overall, 147 VDEs (29.4%) were unaccompanied by symptoms. These asymptomatic VDEs were 
associated with twelve viruses (Table 3.3). More than two-thirds of the symptom-free VDEs (69%) 
were RV-DEs, including 110 RV-DEs (34% of total RV-DEs). Table 3.6 summarises the number of 
asymptomatic VDEs identified for different viruses. Almost half of the episodes associated with IFV 
(2/5) and KIV (12/25) were asymptomatic, but the numbers of episodes for the former in particular are 
very small. For the twelve respiratory viruses, Ct values obtained from asymptomatic VDEs were 
comparable to Ct values from symptomatic VDEs (P ≥0.05= for all viruses). Further, median virus 
shedding duration for the VDEs associated with symptoms were comparable to the median shedding 
duration in VDEs not associated with symptoms (one vs one week; P ≥0.05 for all viruses). As shown 
in Table 3.6, while the number of asymptomatic VDEs remained roughly constant throughout the first 
year of life, their proportion fell as the overall number of VDEs increased with age. Asymptomatic 
VDEs were also less likely during the winter months compared to other seasons and when multiple 
rather than sole viruses were detected. In other words, to turn these results around, increasing age in the 
second half of infancy, the winter season and detecting multiple respiratory viruses are independent 
risk factors for ARI symptoms. There was also weak evidence that not being exclusively breast fed and 
those born higher in the birth order were less likely to have asymptomatic VDEs, though numbers of 
siblings and household size did not appear to have an effect and there were signals that possible 
confounding factors were influencing the results in both directions.    
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Table 3.6 Asymptomatic VDEs identified during the first year of life and their association with the cohort characteristics  
 
 
Variable 
 
number of 
subjects 
(% of all 
subjects) 
No. of VDEs 
(%) 
Asymptomatic VDEs  
No. (%) 
Univariate 
OR (95%); P value 
*Multivariate 
 OR (95%); P value 
Age quarter 
  (months) 
0-3 44 (18.9) 64 (14.8) 35 (54.7) 1 1 
3-6 57 (24.5) 87 (20.1) 38 (43.7) 0.57 (0.27-1.23); 0.157 0.7 (0.3-1.66); 0.425 
6-9 67 (28.8) 155 (35.9) 44 (28.6) 0.25 (0.12-0.52); 0.001 0.54 (0.19-1.56); 0.262 
9-12 65 (27.9) 126 (29.2) 30 (23.8) 0.18 (0.08-0.38); 0.001 0.31 (0.09-0.96); 0.043 
Gender 
Male 35 (48.6) 217 (50.2) 77 (35.7) 1 1 
Female 37 (51.4) 215 (49.8) 70 (32.6) 0.96 (0.49-1.88); 0.92 1.34 (0.64-2.81); 0.427 
Exposure to smoking 
Mother 1 (1.4) 7 (1.7) 3 (42.8) 2.2 (0.17-29.3); 0.54 2.69 (0.16-44.9); 0.49 
Father 8 (11.4) 54 (12.9) 20 (37.0) 1.2 (0.48-3.49); 0.608 1.7 (0.55-5.26); 0.351 
No exposure  61 (87.1) 358 (85.4) 117 (32.7) 1 1 
Mother IFV vaccine 
status 
Had  IFV vaccine  53 (74.7) 327 (76.9) 107 (32.8) 0.9 (0.44-1.9); 0.86 0.74 (0.32-1.72); 0.495 
No IFV vaccine  18 (25.3) 98 (23.1) 34 (34.7) 1 1 
Participant infant 
order (mother) 
First born 49 (68.1) 276 (63.9) 98 (35.6) 1 1 
Second 14 (19.4) 98 (22.7) 34 (34.7) 0.97 (0.43-2.2); 0.95 0.21 (0.03-1.27); 0.091 
Third 7 (9.7) 44 (10.2) 13 (29.5) 0.67 (0.22-2.1); 0.49 0.05 (0.001-2.29); 0.130 
Other 2 (2.8) 14 (3.2) 2 (14.3) 0.2 (0.02-2.1) 0.02 (0002-2.13); 0.103 
Number of children in 
the household a 
No children in the 
household 
46 (63.9) 257 (59.5) 89 (34.8) 1 1 
One other child 18 (25) 122 (28.2) 44 (36.4) 1.06 (0.49-2.2); 0.866 0.73 (0.31-1.74); 0.48 
≥ two other children 8 (11.1) 53 (12.3) 14 (26.4) 0.57 (0.19-1.71) 0.323 0.39 (0.11-1.3); 0.137 
Household size b 
3 49 (68.1) 238 (55.1) 79 (33.3) 1 1 
4 14 (19.4) 107 (24.8) 39 (36.4) 1.24 (0.55-2.78); 0.59 0.86 (0.33-2.24); 0.77 
5 7 (9.7) 69 (15.9) 25 (36.2) 1.001 (0.38-2.61); 0.998 0.68 (0.22-2.11); 0.506 
≥ 6 2 (2.8) 18 (4.2) 4 (22.2) 0.52 (0.08-3.06); 0.473 0.62 (0.09-4.1); 0.627 
Feeding 
Exclusively breastfed 46 (38.7) 91 (21.1) 50 (54.9) 1 1 
Other milk 70 (58.8) 335 (77.6) 94 (28.1) 0.24 (0.13-0.44); 0.001 0.41 (0.16-1.01); 0.053 
Solids  3 (2.5) 6 (1.4) 3 (50) 0.57 (0.07-4.81); 0.612 1.03 (0.1-9.8); 0.979 
Childcare status 
Formal 19 (19) 67 (15.7) 18 (27.3) 0.48 (0.22-1.07); 0.075 0.99 (0.39-2.47); 0.983 
Informal  10 (10) 24 (5.6) 8 (33.3) 0.78 (0.24-2.49); 0.675 1.61 (0.44-5.8); 0.466 
Formal and informal 4 (4) 10 (2.3) 5 (50) 1.78 (0.29-10.66); 0.524 3.2 (0.39-26.2); 0.278 
No childcare  67 (67) 326 (76.3) 112 (34.3) 1 1 
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Table 3.6 continued. Asymptomatic VDEs identified during the first year of life and their association with the cohort characteristics 
 
Variable 
 
number of 
subjects 
(% of all 
subjects) 
No. of VDEs 
(%) 
Asymptomatic VDEs 
No. (%) 
Univariate 
OR (95%); P value 
*Multivariate 
 OR (95%); P value 
Season 
Spring 53 (23.1) 101 (23.4) 40 (39.6) 1 1 
Summer 56 (24.4) 81 (18.8) 33 (40.7) 1.17 (0.59-2.34); 0.63 0.83 (0.39-1.79); 0.648 
Autumn 58 (25.3) 113 (26.2) 37 (33.0) 0.75 (0.39-1.43); 0.39 0.56 (0.27-1.15); 0.12 
Winter 62 (27.1) 137 (31.7) 37 (27.0) 0.45 (0.23-0.85); 0.015 0.34 (0.16-0.7); 0.003 
Number of 
respiratory viruses  
One virus 72 (6739) 377 (87.3) 139 (36.9) 1 1 
≥ 2 viruses 34 (32.1) 55 (12.7) 8 (14.5) 0.27 (0.11-0.64); 0.003 0.29 (0.12-0.82); 0.019 
Adjusted for all variables in the table.  
a Other than the participating infant. 
b Including the participating infant.  
Values in bold indicate statistical significance.  
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3.4 Discussion 
This analysis of a subset of infants participating in the ORChID study provides important data on 
respiratory viruses detected during the first year of life, including their shedding characteristics and 
association with ARI symptoms.  
 
3.4.1 Prevalence of different respiratory viruses during the first year of life 
In otherwise healthy infants, RVs were the most frequently detected viruses. This finding is broadly 
consistent with other infant cohort studies. Comparisons though are difficult because of varying 
study designs, including differences in study populations, sampling frequency, collection techniques 
and study duration.   
 
The number and proportion of IFV detections in this sub-set of the ORChID community-cohort was 
low with only five infection episodes (3 IFV-A, 2 IFV-B) observed. Symptoms were associated 
with their detection in three of these cases. Similar low rates were also observed for many of the 
other established respiratory pathogens (eg. hMPV and PIV viruses) with the exception of HAdV 
(discussed below) and RSV A. This however is not to say that these viruses are not important 
viruses in the community (Nair et al., 2010), but simply in cohort studies of this nature they are 
observed less frequently. Overall, the rates observed differ from the higher proportions observed in 
hospital-based studies, and are likely due to more severe ARIs leading to hospital presentations, and 
hence over-representation in hospital cohorts. Similar observations have been made in other 
community-based birth and infant cohort studies. For example, in an Australian community-based 
study investigating the cost of influenza-like illnesses (ILIs) and economic burden in Australian 
children attending child care, a low prevalence of IFVs was observed despite using similar nasal 
swab and sample transport techniques to ORChID and the study being conducted during IFV season 
(Yin et al., 2013). Likewise, other community-based studies involving infants, older children and 
those attending day care, have found that RV and to a lesser extent RSV have predominated with 
low detection rates for the other RNA viruses, including influenza (Budge et al., 2014; Fairchok et 
al., 2010; Kusel et al., 2006; Lambert et al., 2007; Legg et al., 2005; Martin et al., 2013; van der 
Gugten et al., 2013; van der Zalm et al., 2009). Nevertheless, the rate of RSV detection we observed 
was lower than expected (Simoes, 1999; Woensel et al., 2003). This might be because of the lower 
sensitivity of nasal swabs for detecting mild RSV cases where viral loads are likely to be low and is 
an observation that has been reported elsewhere (Meerhoff et al., 2010). It also probably reflects the 
nature of the cohort (many from single child, non-smoking families, high breast feeding rates and 
low child care attendance) and that we only investigated the first year of life. RSV rates are likely to 
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increase in the second year of life and by their second birthday almost 90% of children should have 
had at least one RSV infection (Simoes, 1999). Further data will be available after the completion of 
the ORChID study. 
 
An alternative explanation for the low prevalence of respiratory viruses other than RV detected in 
this cohort could be that by taking nasal swabs and mailing them into the laboratory there may have 
been some loss of sensitivity in detecting these viruses.  However, on the whole this would seem 
unlikely based upon our own experience and studies conducted by others. Direct comparisons 
between health care worker collected specimens and those performed by parents and mailed into the 
laboratory showed no decrease in sensitivity (van der Zalm et al., 2006). Similarly, there was no 
loss in detection yields between samples immediately frozen and those sent by regular mail over 
long distances (O’Grady et al., 2011). Furthermore, stability of viruses at room temperature and in 
the mail was examined in a pilot study in the laboratory.  Briefly, five influenza-A positive NPAs 
with different concentrations were used to inoculate a total of 45 Virocult swabs. Each strain was 
inoculated onto nine swabs which were then treated in nine different ways including being 
immediately frozen, left on the laboratory bench for 1, 3, 5 and 7 days, or otherwise sent by post 
and received back within 1, 3 5 and 7 days prior to freezing and testing. Compared to the 
immediately frozen swabs, there was no substantial change to the Ct values of the influenza-A 
detection, irrespective if they sat on the bench or mailed, or over time; all average Ct values were 
within 3 cycles showing that any decrease in viral load was within 1 log. Frequent and regular 
sampling may also help overcome any mild loss of sensitivity, especially for HAdV where adding 
oropharyngeal swabs can increase detection yields (Hammitt et al., 2011; Meerhoff et al., 2010).  
 
It was also interesting that after RV, DNA viruses were the next four most commonly detected 
viruses (KIV, hBoV, HAdV and WUV). These were the only four DNA viruses investigated. While 
HAdV is a well-recognised respiratory pathogen, the clinical significance of the human 
polyomaviruses KIV and WUV, and of hBoV in childhood remains controversial (Babakir-Mina et 
al., 2013; Bialasiewicz et al., 2007; Payungporn et al., 2008; Schildgen et al., 2008), The Ct values 
observed for HAdV real-time PCR were typically very high compared with almost all other viruses. 
Such high values are indicative of low viral loads and raise questions over whether such low loads 
are indeed consistent with disease. On the other hand, HAdVs exhibit much sequence diversity and 
thus the observed Ct values could be due to technical problems with the PCR assay itself, which in 
light of the discussion in the previous paragraph might also impact adversely upon assay sensitivity. 
This potential issue is explored in chapter-5.  
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3.4.2 Prolonged viral shedding? 
Previous studies have suggested that DNA viruses are shed for longer periods than RNA viruses 
(Gangell et al., 2014; Martin et al., 2010), which is in general agreement with our observations. 
Prolonged VDEs of three or more consecutive weeks were observed mainly in DNA viruses: KIV, 
WUV, HAdV, and hBoV, although this also occurred on occasions with some RNA viruses, namely 
hCoV-NL63, RSV-A and RV. However, given the high prevalence of RV infections in our study, 
combined with the known diversity in RV and HAdV genotypes, I hypothesised that the longer 
duration of shedding observed within RV was unlikely to be caused by a single virus in each case, 
and that genotype analysis would reveal diverse RV strains (Jartti et al., 2008; van der Zalm et al., 
2011). For instance, a prolonged RV-DE was identified in infant 023 (see Appendix-1; Page VI). 
This RV-DE continued for nine weeks (63 observation days) with only one RV-negative interval 
swab. Symptoms were first reported on day 37 following the initial detection and continued until 
the last day of detection (day 63). During the nine weeks of RV detection no other virus was 
detected. RV-genotyping is important not only to further understand the patterns of the prolonged 
RV-DEs, but also to investigate the clinical role of different RV-genotypes. Hence, the application 
of RV genotyping to our RV-positive samples could help address questions relating to the clinical 
significance of individual RV strains, and forms the basis of studies conducted in chapter-6 of this 
thesis.  
 
3.4.3 VDEs and ARIs 
Overall for our cohort, 65% of ARIs were associated with at least one respiratory virus. This 
proportion is similar to rates observed in an earlier Australian community-based cohort of infants at 
high risk for asthma (69%), but lower than the 79-85% reported for infant cohort studies from 
overseas (Kusel et al., 2006; Legg et al., 2005; Regamey et al., 2008). Differences in methodologies 
and ARI definitions used in these studies may partially account for this observation. For instance, 
the ORChID study employed daily symptom diaries and weekly parent-collected specimens without 
needing health care workers to contact the family. This strategy, as well as the broader definition of 
ARI episodes used, may have increased the total number of captured ARI episodes, including those 
with milder symptoms, which serve as the denominator (Regamey et al., 2008). While Kusel et al 
also used symptom diaries to collect clinical data, health care workers still needed to visit the family 
and the mean number of captured ARI episodes was 4.1 compared to a mean of 6.29 ARI episodes 
identified in our study (Kusel et al., 2006). However, the method of data collection by its own 
should not eliminate other important factors such as geographic location and demographic features 
of the study cohorts. Three participating infants did not report any ARIs during their first year of 
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life, despite viruses being detected in 14 of the provided swabs (infants 015, 044 and 048; Tables: 
3.2 and 3.3). A broader definition of ARI did not change these outcomes significantly (data not 
shown), a finding that suggests an ARI-free year for these infants. Similar cases have been 
described by another cohort study in which 22% of the study population (n=88) did not experience 
any ARI during their first year of life, though the documentation of ARIs relied upon the family 
contacting research staff and thus some episodes may have been missed (Legg et al., 2005; van der 
Zalm et al., 2006).    
 
Another interesting observation was detecting different viruses at different time-points during the 
same ARI episode. This was noted during both brief and prolonged ARIs. An example of this was 
during a 46-day ARI episode observed for infant 010, from whom three different viruses were 
detected in each of the six swabs provided during this episode (infant 010; Appendix-1-; Page III); 
starting with a sole hBoV detection, followed by a four week RV-DE, which itself preceded a two 
week HAdV-DE. Similar multiple VDEs during single ARIs were observed for infant 019 
(Appendix-1; Page V), Infant 027 (Appendix-1; Page VII), and infant 062 (Appendix-1; Page XVI). 
It is likely that these multiple VDEs underpin what many parents believe to be a single “ARI” 
episode. The numbers here are too small to provide any meaningful data, however it is envisaged 
that such questions will be answered upon completion of the broader ORChID project. 
 
Similar to above, we also observed numerous single ARIs that had multiple viruses detected at the 
same time point (i.e. co-detections; Tables 3.3 and 3.5). Co-detections are often observed in hospital 
cohorts and in some other studies where they can be associated with more severe disease (Greer et 
al., 2009; Lauinger et al., 2013; Schildgen et al., 2008). Here we found that co-detections are also 
very common in the community and that they too were more likely to be associated with symptoms 
(Jartti et al., 2008). They also pose a challenge when trying to determine which viruses may be 
responsible for causing the presenting illness. This is a finding that is being explored further in the 
larger ORChID cohort (chapter-7 further discusses this point).  
 
Both age and season had a significant influence over the frequency of recorded ARI episodes. ARIs 
were less likely in the first six months of life, probably because of protective maternal antibodies 
from the placenta, breast feeding and to a lesser likelihood of being enrolled in day care. While for 
season, the increase in ARI episodes during winter could be explained by greater exposure to 
circulating respiratory viruses, which survive better in the conditions of lower temperature and 
humidity levels encountered at these times. In addition, the cooler and dry winter environment can 
dry out nasal mucous membranes impairing local defence barriers against viruses, lower levels of 
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sunlight lead to declining vitamin D levels, potentially further impairing innate and adaptive 
immunity. Finally, winter is associated with increased indoor or household crowding, further 
increasing the risk of respiratory virus transmission.  
  
3.4.4 Asymptomatic VDEs as nascent infections before symptoms develop  
A further factor that complicates the symptom data was that respiratory viruses were often detected 
immediately prior to the onset of an ARI episode, but were not always detected a week later during 
the ARI episode. An example of the latter was a single detection of PIV-3 that was observed two 
days prior to an 18 day ARI episode for infant 010 (Appendix-1; Page III). Although none of the 
three subsequent swabs collected during this ARI were positive for any respiratory virus, this PIV-3 
detection was still considered associated with the ARI. The subsequent failure to detect PIV-3 for 
this infant may have been caused by a rapid decline in viral load beyond the sensitivity of the assay, 
and thus may indicate early clearance of infection. If so, this highlights the usefulness of the weekly 
sampling strategy used in this study to maximise the probability of capturing respiratory virus 
associated ARIs. Alternatively, it is also possible that the PIV-3 detection in this case was unrelated 
to the subsequent ARI, and thus could potentially overestimate virus-associated ARIs.  
 
3.4.5 Questions over parental-collected nasal swabs and symptom data 
While swab and diary return rates were high overall, analysis of the real-time PCR and symptom 
data did raise questions regarding the quality of collection for some infants, despite the discussion 
outlined in section 3.4.1. For the nasal swabs collection, infant 048 is one particular example. This 
infant did not have any recorded ARI symptoms and was negative for RV during their first year of 
life. While plausible, this was unusual within the characteristics of this cohort. In addition to infant 
048, there were 11 other infants who were negative for all respiratory viruses (other than RV) and 
had lower proportions of RV detected compared to other infants. These findings raised further 
questions regarding the quality of nasal swab sample collection and sample transportation and 
became the subject of further analysis described in chapter-4.   
 
3.5 Conclusion and directions 
This study described respiratory virus shedding during the first year of life, including those 
associated with ARIs. The high sample and data return rates obtained from participating infants by 
the end of their first year of life provide a strong basis to better understand the patterns of viral-
associated ARIs in this age group. It was observed that RV was the most frequently detected virus 
in ARIs in otherwise healthy infants. Ct values were not associated with symptoms in this setting 
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however and further analysis is needed to confirm this preliminary finding. The rate of ERV-3 
negative samples and further observations obtained from nasal swab samples provided by some 
infants raised questions over the quality of sample collection. Further, PCR results obtained from 
HAdV screening and emerging information of HAdV sequence variation raised concerns about the 
suitability of the assay used for this longitudinal, multiple season study. These technical aspects are 
covered in the following chapters (chapter-4 and 5). Finally, given the overall high rates of RV-DEs 
described in this chapter, further investigations became warranted to study the nature of RV-DEs. In 
chapter-6, I investigate the RV genotypes contributing to these episodes, whether prolonged 
shedding is associated with genotype or strain substitutions, and their association with symptoms.  
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Chapter 4 
The quality of nasal swab samples:  
Importance of optimal collection and transportation for pragmatic 
community-based studies. 
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4.1 Overview  
Recently introduced molecular-based viral diagnostic techniques have much improved sensitivity 
compared with previous classical culture and phenotypic-based methods and have also led to the 
discovery of new respiratory viruses (Beck and Henrickson, 2010). However, contemporary studies 
employing these new techniques have often used convenience samples obtained from patients 
admitted to hospital or attending Emergency Department clinics (Arden et al., 2006; Calvo et al., 
2010; Sloots et al., 2006). Similarly, community-based studies have relied upon clinic or home 
visits by trained healthcare workers to collect specimens during an ARI episode. For community-
based studies the latter can impose restrictions upon busy families and may lead to biased disease 
estimates and specimen availability (Jartti et al., 2008; Legg et al., 2005; van der Zalm et al., 2006). 
In addition, the cost and feasibility of using healthcare workers may impinge upon study feasibility, 
particularly when large longitudinal, community-based cohort studies, involving frequent specimen 
collections, are planned. To help address these limitations, we and others have begun testing parent-
collected, anterior nasal swab specimens that have been transported to the research laboratory using 
the standard mail (Heikkinen et al., 2002; Meerhoff et al., 2010; van der Zalm et al., 2011, 2009). 
This approach is considered to be safe, convenient and cost-effective (Lambert et al., 2008a).  
 
Importantly, when using highly sensitive PCR assays, the detection of respiratory viruses is roughly 
similar for both anterior nasal swab specimens and samples collected by the more traditional NPA 
technique (Lambert et al., 2008b; Waris et al., 2007). Building on this information, later studies 
have also shown that PCR testing for respiratory viruses provided similar results from parent-
collected anterior nasal swab specimens and from either nasopharyngeal swabs or NPAs collected 
by healthcare professionals (Lambert et al., 2008a; Meerhoff et al., 2010). Other studies examining 
sample transport have also shown that mailing swabs at ambient temperature has limited or no 
impact upon respiratory virus detection by PCR (Akmatov et al., 2011; O’Grady et al., 2011; van 
der Zalm et al., 2011), although the need to further investigate the effects of transporting samples 
for extended periods and at higher temperatures was highlighted in one study (O’Grady et al., 
2011). 
 
As described in the preceding chapters, the ORChID project is a prospective community-based, 
dynamic, longitudinal cohort study, which seeks to describe the nature and timing of respiratory 
viruses detected in Australian children during the first two years of life (Lambert et al., 2012). The 
study commenced in late 2010 and involves parents collecting and mailing nasal swabs weekly to 
the research laboratory for PCR-based respiratory virus screening. During the first year of the study 
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mould was seen in some samples reaching the laboratory and we became concerned about the 
impact of this contaminant upon sample integrity. Therefore, in this study, we undertook a broader 
investigation of sample quality, examining collection and transportation and how these impact upon 
respiratory virus detection. Our objectives were first to determine the quality of specimen collection 
by testing for the presence of human DNA (ERV-3) and then to investigate sample quality by 
analysing PCR performance when visible mould is present in samples reaching the laboratory. 
 
The hypotheses were:  
1- ERV-3 as a marker for human DNA can be used to inform the quality of nasal collection.  
2- Visible mould in the arriving nasal swabs are due to prolonged times in reaching the 
laboratory and other environmental factors.  
3- Visible mould may impact upon the performance of real-time PCR.  
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4.2 Material and methods 
Nucleic acids were extracted from nasal swabs collected as part of ORChID and tested as outlined 
in chapter-2. Additional methods relating to this chapter (and not detailed in chapter-2) are provided 
below. 
 
4.2.1 Fungal testing  
During the initial phases of the study, mould was observed on some nasal swabs at the time of their 
arrival at the laboratory. In light of this observation, before extraction all swabs were inspected 
visually for mould and were assigned a semi-quantitative score according to a sliding scale (0 to 3), 
whereby 0 = no mould observed, 1 = low, 2 = medium, and 3 = high levels of visible mould present 
(Figure 4.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level 2 
 Medium growth 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level 1 
Low growth 
 
No mould 
growth 
 
Level 3 
Heavy growth 
 
Figure 4.1 Mould growth was observed in some swabs reaching the laboratory. The level 
of mould growth was assigned a semi-quantitative sliding scale. 
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DNA sequencing was used to identify the types of fungi present on a subset of swabs exhibiting 
varying degrees of visible mould growth (ten swabs where no mould was seen, and 20 each where 
low, medium and high levels of mould contamination were present respectively).  
 
PCR amplification of a highly conserved fungal internal transcribed spacer (ITS) region was 
performed using 10 pmoles of forward and reverse primers (ITS1 forward primer 
TCCGTAGGTGAACCTGCGG and ITS4-reverse primer TCCTCCGCTTATTGATATGC (Pryce 
et al., 2006), 25µL of Qiagen SYBR® master mix (Qiagen, Australia) and 5µL of template in a 
50µL reaction mix. Amplification was performed using the following conditions: 95°C for 15-
minutes followed by 45 cycles of 95°C for 30-seconds, 50°C for 30-seconds and 72°C for 60-
seconds and a melting step of 60-95°C at the end of the thermal cycling during which florescence 
data were acquired continuously. An aliquot of each PCR product was examined using 2% agarose 
gel electrophoresis and the remaining PCR product was sent to the Australian Genome Research 
Facility (The University of Queensland, Brisbane) for automated sequencing.  
 
4.2.2 Exclusion criteria 
For this study, samples that failed EHV-1 criteria (as mentioned in chapter-2; section 2.1.4.2) or 
were not inspected for mould growth were excluded from the analysis. 
 
4.2.3 Data analysis 
The association between variables of interest and binary outcomes was investigated using mixed 
effects logistic regression models, with participants included as a random intercept to account for 
possible correlated outcomes within each infant. The association with continuous outcomes was 
investigated using mixed-effects linear regression. When examining the association of mould level 
with sample quality and respiratory virus detection we conducted both univariate and multivariate 
analyses, with multivariate analyses adjusting for the potential confounders of the child’s age, sex, 
relationship of collector to participant (e.g. father, mother or others), the season the specimen was 
collected, and time from specimen collection to being frozen in the laboratory. Analyses were 
conducted using Stata statistical software v.11.0 (StataCorp, College Station, TX, USA). 
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4.3  Results  
4.3.1 Sample numbers  
Between September 2010 and July 2012, 152 infants were recruited into the study. All participants 
lived within the greater Brisbane metropolitan area and none were from rural communities. One-
hundred and twenty-five recruits remained active study participants up until the date of this 
analysis. Of the 27 withdrawals, four had moved out of the study area, two others were later 
deemed ineligible, ten withdrew for personal reasons and eleven were unable to fulfil sampling 
requirements. For the remaining families, swab return rates were >90% yielding almost 35,000 
child-days of observation. In total, 4,933 weekly nasal swab specimens (~510 nasal swabs/month) 
were batched in 56 (96 well) racks, extracted and tested. The median time from collection to swab 
arrival in the laboratory was two days (interquartile range 2-4 days); however 10.9% of swabs were 
received more than seven days after their collection. 
 
4.3.2 Excluded samples 
During EHV-1 extraction and inhibition testing, 42 (0.81%) DNA extracts failed to achieve the 
specified EHV-1criteria and were excluded. The initial 1,525 samples were not inspected for mould 
growth during the early stages of the study and therefore were also excluded from further analysis. 
 
4.3.3 ERV-3 detection  
Of the remaining 3,366 samples, there were 2,718 (80.7%) samples positive for ERV-3 with PCR 
amplification Ct values ranging from 23-45 (median 36) cycles. Overall, ERV-3 was not detected in 
649 (19.2%) samples. During the first eight months of batching and screening conducted in the 
laboratory, the number of ERV-3 negative samples ranged from 11 to 25 in each of the 56 
extraction runs with a median of 17 negative samples per run (Figure 4.2).  
 
However, following a cluster of samples that were negative for ERV-3 (Figure 4.2; batches 41, 43, 
44) study nurses contacted parents and reminded them of the optimal swab collection technique 
they had been shown at enrolment of their infant. After this feedback the numbers of ERV-3 
negative samples declined. 
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Figure 4.2 Number of samples negative for ERV-3 during screening of each sample extraction batch (92 samples per batch). A total of 56 extraction batches were performed in the 
first 20-months of the study. The quality of each batch was tested using EHV-1/ERV-3 PCR, following which every four batches were pooled and pools were screened for 
respiratory viruses other than RV. The batches included in the analysis are indicated by the solid line. 
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4.3.4 Respiratory viruses detected  
The respiratory virus detections for the infant cohort that I followed have been detailed already in 
chapter-3. Of the 3,366 samples from this particular study at least one respiratory virus was detected 
in 885 (26.2%) samples. Dual or multiple virus detections were observed in 105 (2.14%) samples. 
RV was the most frequent virus detected, being present in almost 20% of nasal swab samples, 
followed by hBoV, KIV, HAdV and RSV-A (Table 4.1).  
 
Table 4.1 Results for respiratory virus screening from 3366 parent collected nasal swab specimens between July 2011 
and July 2012 and fulfilling the EHV-1 criteria 
Virus No. of infants No. of samples % of all samples 
RV 105 726 21.57 
hBoV 26 46 1.37 
KIV 17 41 1.22 
HAdV 23 30 0.89 
RSV-A 26 30 0.89 
WUV 13 28 0.83 
hCoV-NL63 12 16 0.48 
IFV-B 11 11 0.33 
hCoV-229E 3 6 0.18 
PIV-1 6 6 0.18 
HMPV 5 5 0.15 
PIV-3 3 3 0.09 
hCoV-HKU1 3 3 0.09 
IFV-A 2 2 0.06 
RSV-B 2 2 0.06 
hCoV-OC43 1 1 0.03 
PIV-2 0 0 0 
RV,  rhinovirus; HAdV, human adenovirus; hBoV, human bocavirus; hCoV, human coronavirus; 
HMPV, human metapneumovirus; IFV, influenza virus; PIV, parainfluenza virus;  
KIV, KI-polyomavirus RSV, respiratory syncytial virus WUV, WU- polyomavirus;  
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4.3.5 Mould 
Of 3,366 swab samples visually inspected for mould, 99 (2.9%) had high, 252 (7.5%) medium and 
411 (12.2%) had low levels present, while 2,604 swabs (77.4%) had no visible signs of mould. The 
mean (SD) time from collection until being frozen at the laboratory for samples with no observed 
mould was 2.9 (3.0) days. In comparison for low level mould it was 4.9 (3.6) days (crude mean 
difference compared with no mould; = 1.7; 95% CI 1.4 – 2.1 days), for medium level mould it was 
7.4 (4.9) days (3.9; 95%CI 3.4 – 4.3), and for high level mould 11.4 (10.7) days (7.1; 95%CI         
6.4 – 7.8). The mean difference in time from collection until being frozen between each mould 
group and the no mould group was statistically significant (P<0.001 for each comparison). A 
significant association was also observed between mould and season. In specimens collected in 
summer, mould was observed in 28.2% of swabs. In comparison mould detection rates were 31.0% 
in spring (crude OR 1.08; 95% CI 0.87 – 1.34), 15.8% in autumn (OR 0.47; 95%CI 0.37 – 0.59) 
and 13.7% in winter (OR 0.40; 95%CI 0.29 – 0.53). However, when considering samples that 
contained mould, there was no statistically significant association between season and level of 
mould. 
 
Fungal identification was achieved for 48 of 70 swabs subjected to PCR and DNA sequencing 
(Table 4.2). A diverse range of species was observed with Epicoccum nigrum and Cladosporium 
cladosporioides the most prevalent. 
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Table 4.2. Species detected in samples with different levels of fungal growth 
Species. Number of swabs 
contaminated by this 
species. 
Number of swabs and degree of 
contamination.  
(high; medium; low; no visible mould) 
Epicoccum nigrum 15 (7,2,4,2) 
Cladosporium cladosporioides 7 (3,3,1,0) 
Aureobasidium pullulan 4 (1,1,2,0) 
Cryptococcus flavescens 3 (1,2,0,0) 
Alternaria alternata 2 (1,1,0,0) 
Alternaria tenuissima 1 (0,0,1,0) 
Aspergillus westerdijkiae 1 (0,0,1,0) 
Candida parapsilosis 1 (0,1,0,0) 
Cladosporium silenes 1 (0,0,0,1) 
Cladosporium tenuissimum 1 (0,1,0,0) 
Cladosporium uredinicola 1 (1,0,0,0) 
Cochliobolus lunatus 1 (0,1,0,0) 
Curvularia brachyspora 1 (0,1,0,0) 
Curvularia trifolii 1 (0,1,0,0) 
Leptosphaerulina australis 1 (0,1,0,0) 
Paraphaeosphaeria sp 1 (1,0,0,0) 
Penicillium fellutanum 1 (0,0,1,0) 
Penicillium oxalicum 1 (0,1,0,0) 
Penicillium polonicum 1 (0,0,0,1) 
Penicillium spinulosum 1 (0,0,1,0) 
Phoma herbarum 1 (0,0,1,0) 
Rhodotorula slooffiae 1 (0,1,0,0) 
Total 48  
 
4.3.6 ERV-3, visible mould and respiratory virus detection  
Of the 2,718 samples that were ERV-3 positive, 810 (37.2%) had at least one respiratory virus 
detected by PCR. In contrast, the respiratory virus detection rate in ERV-3 negative samples was 
significantly lower (75/649, 11.5%; crude OR 0.35; 95% CI 0.27-0.44) when ERV-3 was absent in 
swab specimens. We also observed that among ERV-3 positive swabs, the average ERV-3 Ct value 
for samples positive for any respiratory virus (32.8 cycles) was significantly lower (indicating 
greater ERV-3 load) than the average Ct value (35.4 cycles) in samples negative for all viruses 
(crude difference = 2.6, 95% CI 2.3 – 2.9; Figure 4.3).  
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Figure 4.3 Comparison between average ERV-3 cycle threshold (Ct) values in respiratory virus positive (dark bars) 
versus negative (light bars) samples. In ERV-3-positive samples, the average ERV-3-Ct values (32.8) in samples 
positive for any virus was significantly lower than the average ERV-3-Ct values (35.4) in samples negative for all 
viruses (difference = 2.6, 95% confidence interval 2.3-2.9).  
 
Moreover, there was a significant difference in ERV-3 Ct values (P=0.001) in samples that had a 
single respiratory virus detection (average = 33.01 cycles) compared with samples that had multiple 
respiratory viruses detected (average = 31.27 cycles).  
 
Of the 762 samples with visible mould, 529 (69.4%) were positive for ERV-3, which was 
significantly lower than rates in samples without visible mould (84.0%; crude OR 0.35, 95% CI 
0.28-0.43). The proportion of samples with visible mould and positive respiratory virus testing 
(178/762; 23.4%) was significantly lower than proportion of samples without mould (707/2606; 
27.1%; crude OR 0.70, 95% CI 0.57-0.86). 
 
Table 4.3 examines the association between ERV-3 and respiratory virus detection and potential 
explanatory and confounding variables. ERV-3 positive sample rates increased with age, varied by 
season and declined with increasing mould levels and time taken for samples to reach the laboratory 
and to be frozen. Similarly, respiratory virus detection rates increased with age, specimen collection 
outside the summer months, and time taken to reach the laboratory, while decreasing as visible 
mould levels in samples reaching the laboratory increased. 
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Table 4.3 ERV-3 and respiratory virus positive samples detected by polymerase chain reaction assays in 3366 parent-collected nasal swab specimens 
Variable 
No. samples 
(%) 
ERV-3 Positive Respiratory virus positive 
No. samples 
(%) 
Univariate *Multivariate 
 OR (95%); P value 
No. samples 
(%) 
Univariate *Multivariate 
 OR (95%); P value OR (95% CI); P value OR (95% CI); P value 
Age (months) 
< 6 1293 (38.4) 995 (77.0) 1 1 208 (16.1) 1 1 
6-<12 1295 (38.5) 1061 (81.9) 1.20 (0.94-1.53); 0.15 1.28 (0.98-1.68); 0.07 411 (31.7) 2.59 (2.07-3.24); <0.001 2.38 (1.89-3.01); <0.001 
≥12 778 (23.1) 662 (85.1) 1.49 (1.06-2.10); 0.02 1.93 (1.27-2.93); 0.002 266 (34.2) 2.98 (2.26-3.92); <0.001 2.16 (1.57-2.99); <0.001 
Sex 
Male 1647 (48.9) 1335 (81.1) 1 1 461 (28.1) 1 1 
Female 1719 (51.06) 1383 (80.4) 0.81 (0.54-1.22); 0.32 0.87 (0.58-1.29); 0.48 424 (24.7) 0.82 (0.60-1.12); 0.21 0.83 (0.61-1.12); 0.23 
Collector 
Mother 2845 (84.5) 2307 (81.1) 1 1 766 (26.9) 1 1 
Father 441 (13.1) 342 (77.6) 0.91 (0.66-1.27); 0.60 0.87 (0.62-1.22); 0.42 109 (24.7) 0.94 (0.70-1.26); 0.67 0.88 (0.65-1.19); 0.41 
Research 
staff 
45 (1.3) 40 (88.9) 2.71 (1.00-7.36); 0.05 1.76 (0.65-4.81); 0.27 3 (6.7) 0.24 (0.07-0.79); 0.02 0.36 (0.11-1.21); 0.10 
Other 35 (1.0) 29 (82.9) 1.31 (0.49-3.51); 0.59 1.39 (0.46-4.16); 0.56 7 (20.0) 0.72 (0.30-1.74); 0.47 0.87 (0.35-2.13); 0.76 
Season 
Summer 926 (27.5) 729 (78.7) 1 1 178 (19.2) 1 1 
Autumn 1059 (31.5) 802 (75.7) 0.90 (0.71-1.13); 0.37 0.74 (0.58-0.96); 0.02 304 (28.7) 1.99 (1.59-2.49); <0.001 1.74 (1.38-2.20) ;<0.001 
Winter 541 (16.1) 482 (89.1) 2.63 (1.87-3.70); <0.001 2.41 (1.67-3.49); <0.001 198 (36.6) 3.06 (2.36-3.97); <0.001 2.63 (2.01-3.45); <0.001 
Spring 840 (25.0) 705 (83.9) 1.39 (1.07-1.79); 0.01 1.50 (1.13-1.99); 0.005 205 (24.4) 1.27 (1.00-1.61); 0.05 1.43 (1.11-1.84); 0.005 
Mould 
None 2604 (77.4) 2189 (84.1) 1 1 707 (27.2) 1 1 
Low 411 (12.2) 308 (74.9) 0.47 (0.36-0.62); <0.001 0.69 (0.52-0.93); 0.01 97 (23.6) 0.73 (0.56-0.95); 0.02 0.81 (0.61-1.07); 0.14 
Medium 252 (7.5) 163 (64.7) 0.27 (0.20-0.37); <0.001 0.47 (0.33-0.66); <0.001 60 (23.8) 0.70 (0.50-0.96) ; 0.03 0.70 (0.49-0.99); 0.05 
High 99 (2.9) 58 (58.6) 0.20 (0.13-0.33); <0.001 0.40 (0.24-0.66); <0.001 21 (21.2) 0.57 (0.34-0.96); 0.04 0.53 (0.31-0.93); 0.03 
Time to reach 
Laboratory 
(days) 
0-3 2281 (67.8) 1983 (86.9) 1 1 587 (25.7) 1 1 
4- 7 723 (21.5) 513 (71.0) 0.32 (0.25-0.40); <0.001 0.39 (0.30-0.50); <0.001 187 (25.9) 0.96 (0.78-1.18); 0.69 1.03 (0.82-1.29) ;0.80 
>7 362 (10.8) 222 (61.3) 0.17 (0.13-0.24); <0.001 0.24 (0.17-0.34); <0.001 111 (30.7) 1.16 (0.89-1.52); 0.28 1.42 (1.05-1.94); 0.02 
a Adjusted for all variables in the table. 
b Values in bold indicate statistical significance.  
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4.4 Discussion 
The ORChID project is an ongoing comprehensive community-based study using PCR assays to 
detect respiratory viruses in anterior nasal swab specimens taken weekly by parents from their 
infants throughout the first two years of life. This requires parents following a standardised protocol 
of obtaining swabs regularly and mailing them promptly to our laboratory. However, we have 
observed that suboptimal sample collection and prolonged sample transport, as determined by ERV-
3 detection and presence of visible mould in swab samples reaching the laboratory negatively affect 
sample quality and impact on respiratory virus detection.  
 
The data from the first 20-months of our longitudinal study indicate that respiratory virus detection 
is associated with the overall DNA ERV-3 load in nasal swab specimens. Swabs negative for     
ERV-3, presumably from sub-optimal collection and not from the presence of inhibitors, had 
reduced respiratory virus detection rates compared with samples containing ERV-3. Furthermore, in 
those specimens positive for ERV-3, a higher ERV-3 load was associated with a higher likelihood 
of respiratory virus detection. Overall, this shows the importance of measuring human DNA as a 
marker for cellular component (epithelial or inflammatory) swab samples, which if tested and 
monitored in real time, can identify problems associated with collection that can be quickly 
addressed. This is illustrated in the current study when a sudden increase in ERV-3 negative 
samples was observed.  
  
We were also concerned at finding mould on some samples, which occurred despite the commercial 
swab tubes containing antifungal agents. Most fungal species identified in the swabs were 
saprophytic, and the most common fungus found, Epicoccum nigrum, is a known contaminant of 
clinical specimens (Domsch et al., 1980). The relationship between fungal air spora counts and 
meteorological conditions is complex and impacts at the species level (Rutherford et al., 1997). In 
Brisbane, Cladosporium and Alternaria airspora are detected commonly throughout the year, but as 
with Epicoccum sp their levels peak during the warmer, humid months. Other factors, such as 
rainfall and wind speed, can also influence fungal air spora composition (Rees, 1964; Rutherford et 
al., 1997). In our study, mould was associated mainly with longer time intervals between swab 
collection and arrival at the laboratory. However, this was especially evident during the warm, 
humid spring and summer months, which led me to speculate that fungal contamination occurred 
during sample collection and was influenced by the aforementioned environmental factors. 
Unfortunately, we could not explore this further as it was beyond the scope of the present study. In 
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addition, while mould growth proved to be an issue in the subtropical climate of Brisbane, this may 
be less of a problem in more temperate climates with lower temperatures and humidity levels. 
As a result of these findings, study nurses began regularly reminding parents about sample 
collection protocols and prompt mailing of swabs after their collection. Following which, there was 
a decline in ERV-3 negative sample rates towards baseline levels and a decrease in the number of 
late swabs and consequently a decrease in mould observed in the swabs. Of interest however, was 
that respiratory virus detection rates were not affected by prolonged transport times, but in fact 
appeared to increase with time taken to reach the laboratory. While the observed increase was 
unexpected and may have occurred simply by chance, it is plausible that viral nucleic acids were 
protected to some extent by being encapsulated within the viral capsid, and by using viral transport 
medium in the swabs.  
 
Fungi were found to be associated with fewer ERV-3 detections and, at high levels, significantly 
reduced respiratory virus detections. At least three points emerge from this study. First, although 
commercial swabs may contain antimicrobial agents, the risk of fungal and potentially bacterial 
contamination may still arise when they are exposed to warmer temperatures for increasingly long 
periods of time. Second, the times between swab collection and laboratory arrival should be 
monitored and feedback provided if delays occur. Finally, if delays are expected, swabs should be 
placed in the household refrigerator until mailed to the laboratory (O’Grady et al., 2011).  
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4.5 Conclusion  
We found that ERV-3 as a marker for human DNA and by inference, respiratory epithelial and 
inflammatory cells, was also an important indicator of sample quality for our study. For 
community-based investigations similar to our own, which rely upon self or parent-collected 
specimens, real-time sample processing and ERV-3 detection can facilitate rapid interventions to 
maintain sample quality and to optimise respiratory virus detection. Indeed, this may have broader 
implications as nasal swabs are beginning to replace the traditional, but more invasive 
nasopharyngeal swab or NPA samples in hospitals and clinics (Lambert et al., 2008a),  especially 
more recently following the 2009 influenza pandemic. Thus, if studies in community health centres 
show similar results to our own, comparable ERV-3 testing strategies could be used by diagnostic 
laboratories to improve or monitor sample collection quality for optimal respiratory virus detection. 
Finally, the potential problem of visible mould contamination of swabs taken during community-
based studies can be minimised by ensuring samples are transported promptly to the laboratory.  
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Chapter 5 
Laboratory issues impacting upon PCR-based detection of 
respiratory viruses in longitudinal studies 
 
 
 
 
 
 
 
 
 
 
 
Publications based on this chapter 
o Alsaleh, A. N., Grimwood, K., Sloots, T. P., & Whiley, D. M. (2014). A retrospective 
performance evaluation of an adenovirus real-time PCR assay. Journal of Medical Virology, 
86(5), 795–801. doi:10.1002/jmv.23844  
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5.1 Introduction 
In the previous studies that utilised nasal swabs for sample collection, it was noted that HAdV Ct 
values were typically much higher than those of the other viruses (Echavarria et al., 2006; Lambert 
et al., 2008a), which agree with the results obtained from this PhD study cohort (see chapter-3 
discussion). However, the high levels of variation observed in the gene target of the selected HAdV 
real-time PCR assay selected for the ORChID study, as well as the age of the assay raised further 
concerns over how it might perform in a longitudinal study spanning several years. Having 
previously identified collection and transport issues, in this chapter we explored whether specific 
laboratory protocols selected for this study may have influenced the findings above.  
 
HAdVs (Genus Mastadenovirus, Family Adenoviridae), which were first isolated from the 
respiratory tract by tissue culture in 1953 (Rowe et al., 1953), are known to cause a wide range of 
human disease, including respiratory, gastrointestinal, ocular, urinary and central nervous system 
infections (Lynch et al., 2011). Although HAdV infections are typically mild and self-limiting, they 
can be severe in immunocompromised (especially transplant) patients (La Rosa et al., 2001; Lion, 
2014; Zahradnik et al., 1980) in neonates and previously healthy infants on rare occasions  
(Henquell et al., 2009; Mistchenko et al., 1998; Ronchi et al., 2014) and when a new variant 
emerges (Louie et al., 2008).  HAdVs can also cause localised outbreaks in small and crowded 
populations, such as in boarding schools and military facilities (Caldwell et al., 1974; Yu et al., 
2013).  
 
NAATs, such as PCR assays, provide high levels of sensitivity compared with cell culture and 
serology. With reduced turnaround time, NAATs are also superior to other viral detection methods 
for routine clinical diagnostic laboratory testing and in large epidemiological studies. PCR has been 
used to detect HAdV in clinical samples since the 1990s (Allard et al. 1990; Pring-Akerblom and 
Adrian 1994; Echavarria et al. 1999). However, designing a diagnostic PCR assay that is 
comprehensive for all human HAdV types can be difficult. HAdVs are sub-grouped into seven 
species (A to G) that include more than 60 different types of HAdVs (Matsushima et al., 2013; 
Robinson et al., 2011). Notably, there are considerable genetic differences between HAdV types, 
and these differences are likely to impact upon the performance of diagnostic PCR assays if not 
accounted for, relying as they do upon highly conserved target sequences.    
 
In 2003, the first real-time PCR method was developed for pan-HAdV detection (Heim et al., 2003) 
and since then this assay (called HAdV-PCR hereafter) has been used widely (Lambert et al. 2008a; 
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Kwofie et al. 2012; Tsou et al. 2012; Ayoub et al. 2013). The original description of the method 
considered the extent of HAdV genetic variation known at the time, and importantly, showed that 
the assay was able to detect a broad range of HAdV types despite known mismatches being present 
(Heim et al., 2003). However, in view of the negative impact that genetic variation may have upon 
PCR assay performance ( Whiley & Sloots 2005; Whiley & Sloots 2006), I was concerned by the 
(i) potential for false-negative results and (ii) delayed Ct values arising from the appearance of new 
HAdV types or variants. To address this, an in-silico analysis of recent HAdV sequence data was 
undertaken initially and the stability of the target sequence determined. Two new HAdV PCR 
assays were then designed and used to retest respiratory samples collected from the ORChID study. 
 
My hypotheses were:  
1- Sequence variation associated with changes in HAdV strains alters real-time PCR 
performance either qualitatively of quantitatively.  
2- High level of variation may exist in the HAdV hexon gene targeted by the HAdV-PCR 
oligonucleotides.  
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5.2 Methods 
5.2.1 Sequence analysis of HAdV-PCR oligonucleotides 
To investigate the extent of sequence variation in the HAdV-PCR primer and probe targets, HAdV 
hexon gene sequences from the GenBank database were downloaded and analysed. Briefly, these 
comprised representative sequences of all 68 known human HAdV types, excluding genotypes 57 
and 60 as sequence data for these HAdV-PCR targets were unavailable. Sequences were aligned 
using BioEdit software (version 7.0.4.1) and the number and location of mismatches in each 
oligonucleotide target identified (Figures 5.1-5.3).  
 
5.2.2 Assay design 
Based on the above sequence data, two additional assays (defined as Mod1-PCR and Mod2-PCR) 
were designed. For Mod1-PCR assay, the same sequence targets as used for the HAdV-PCR were 
used, except that degenerate bases were incorporated at appropriate positions to accommodate 
sequence mismatches; three forward primers, three reverse primers and two probes were designed 
subsequently (Table 5.1). The Mod2-PCR assay was designed with the aid of Primer Express 
(Applied Biosystems, version 2.0; Foster City, USA) and targeted sequences flanking those of the 
above HAdV-PCR and Mod1-PCR methods. Similar to the Mod1-PCR, multiple oligonucleotides 
with degenerate bases in various positions were used to accommodate the observed sequence 
variation; two forward primers, two reverse primers and one probe (Table 5.1).  
 
Table 5.1 Oligonucleotides used for the Mod1-PCR and Mod2-PCR methods 
Designation Oligonucleotide sequence (5`-3`) Position± 
Mod1-PCR assay   
Mod1-P1 
Mod1-P2 
TCGGRGTACCTSAGTCCGGGTCTGGTGCA 
TCGGAGTACCTGAGCCCSGGKCTGGTGCA 
18401-18430 
Mod1-F1 
Mod1-F2 
Mod1-F3 
GCCSCARTGGGCATACATGCACATC 
GCCGCAGTGGKCKTACATGCACATC 
GCCCCAGTGGKCKTACATGCACATC 
18362-18387 
Mod1-R1 
Mod1-R2 
Mod1-R3 
GCCACTGTGGGGTTTCTAAAYTT 
GCCACSGTGGGGTTYCTAAACTT 
GCTACGGTRGGATTTCTAAACTT 
18471-18494 
Mod2-PCR assay    
Mod2-P1 CTGGTGCAGTTYGCCCGYGCMAC  
18422-18446 
Mod2-F1 
Mod2-F2 
ACATGCACATCTCGGGCCAGGA 
ACATGCACATCGCCGGRCAGGA 
 
18376-18398 
Mod2-R1 
Mod2-R2 
CGGTCSGTGGTCACATCRTGGGT 
CGGTCGGTGGTCACRTCGTGSGT 
18498-18521 
±Position according to HAdV-D type 16, GenBank accession number JN860680 
  
131 
 
5.2.3 Real-time PCR reaction mix and cycling conditions  
The real-time PCR reactions for all three assays were performed using the Qiagen Quantitect Probe 
PCR kit (Qiagen; Doncaster, Australia). The reaction mixes consisted of a total reaction volume of 
20.0µL, including 10.0µL of Qiagen Quantitect Probe mix (Qiagen; Doncaster, Australia) and 
2.0µL of sample extract or control. For the HAdV-PCR, 8.0 pmoles of the previously described 
forward and reverse primers, and 2.0 pmoles of probe were used (Heim et al., 2003). For the Mod1-
PCR, 2.6 pmoles each of the three forward primers (mod1-F1, F2 and F3; Table 5.1), 2.6 pmoles 
each of the three reverse primers (mod1-R1, R2 and R3; Table 5.1), and 2.0 pmoles of each probe 
(Mod1-P1 and P2; Table 5.1) were employed. Similarly, the Mod2-PCR, comprised 4.0 pmoles 
each of the two forward primers (mod2-F1 and F2; Table 5.1), 4.0 pmoles each of the two reverse 
primers (mod2-R1 and R2; Table 5.1), and 2.0 pmoles of the probe (Mod2-P1; Table 5.1). All three 
methods were cycled on the Rotorgene-Q (Qiagen; Doncaster, Australia). Cycling was performed 
under the following conditions: initial activation at 95°C for 15 min and 45 cycles of 95°C for 15s 
and 60°C for 1 min.  
 
5.2.4 HAdV cultures 
The performance of the three PCR methods was assessed initially using eight HAdV isolates of 
various types (Table 5.2). Briefly, ten-fold dilutions of DNA extracted from each isolate were tested 
in all three methods and the detection limits and associated Ct value data compared. 
 
5.2.5 Community-based respiratory samples 
Assay performance was also investigated using 8,800 nasal swab samples collected between 
September 2010 and April 2012 as part of the ORChID study. Briefly, samples were pooled and 
tested as per above, except that only the HAdV-PCR and Mod1-PCR assays were used, the Bioline 
SensiMix II Probe Kit (Bioline; Sydney, Australia) was used instead of the Qiagen Quantitect Probe 
mix and cycling was performed on an ABI7500 (Applied Biosystems; Melbourne, Australia). The 
decision not to use the Mod2-PCR assay for this testing was based on the similarity of results 
obtained when using the Mod1-PCR and Mod2-PCR methods to test the above virus cultures and 
clinical samples (Table 5.2).  
 
5.2.6 Performance of assay using clinical samples 
The performance of the HAdV-PCR was investigated retrospectively by retesting clinical samples 
using both the Mod1-PCR and Mod2-PCR assays. All respiratory specimens were provided by the 
Central Laboratory, Pathology Queensland (Herston, Queensland) and collected during the year 
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2012. These included 79 samples that had tested positive previously by the HAdV-PCR assay at 
Pathology Queensland as well as an additional 700 de-identified respiratory specimens. The latter 
700 samples were pooled (ten samples per pool) for testing. All samples from pools providing 
positive results by any method were then tested individually by all three assays (HAdV-PCR, 
Mod1-PCR and Mod2-PCR) in parallel and the results compared.        
 
5.2.7 HAdV-PCR sequence target analysis  
DNA sequencing was used to investigate sequence variation in the HAdV-PCR targets in all control 
isolates, as well as ORChID and clinical samples providing discrepancies between the three PCR 
methods. Briefly, a sequence of 489 bases (from HAdV-E type 4; GenBank accession number 
EF371058) was amplified by PCR using primers flanking the above assay targets 
(ACTCTGAACAGCATCGTGGGT, this study; and CAGCACGCCGCGGATGTCAAAGT; 
Allard et al. 1990). The 25µL reaction mix comprised the following: 12.5µL of QuantiTect SYBR 
Green PCR Master Mix (Qiagen-Australia) and 5.0µL of sample extract and 0.4µM of each primer. 
The amplification was performed under the following conditions: an activation step of 95ºC for    
15-minutes, 45 cycles of (1) a denaturation step at 95ºC for 30-seconds and (2) annealing and 
elongation steps at 50ºC for 30-seconds and 72ºC for 60-seconds then one melting step at 60-95ºC 
for 60-seconds. PCR target sequence amplicons underwent melting curve analysis and gel 
electrophoresis. For gel electrophoresis, an aliquot of approximately 8µL of each PCR product was 
examined using 2% agarose gel electrophoresis. Once a positive result was obtained, the remaining 
PCR product was purified using QIAquick purification kit (Qiagen, Australia) following the 
manufacturer instructions. The purified DNA was submitted to the Australian Genome Research 
Facility (The University of Queensland, Brisbane) for automated sequencing. 
 
5.2.8 HAdV genotyping 
HAdV genotyping was performed to determine the genotypes of the discrepant clinical samples and 
to further investigate circulating HAdV genotypes in the local population. Twenty randomly-
selected HAdV-positive clinical samples (from the 2012 Pathology Queensland sample set above) 
were also subject to HAdV genotyping. The hyper-variable region-7 (HVR7) in the hexon gene was 
amplified using previously designed primers (the sequence of the forward primer was: 5`-
CTGATGTACTACAACAGCACTGGCAACATGGG-3` and the reverse primer sequence was: 5`-
GCGTTGCGGTGGTGGTTAAATGGGTTTACGTTGTCCAT-3`) (Sarantis et al., 2004). The 
25µL reaction mix comprised the following: 12.5µL of QuantiTect SYBR Green PCR Master Mix 
(Qiagen-Australia) and 5.0µL of sample extract and 0.4µM of each primer. The amplification was 
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performed under the following conditions: an activation step of 95ºC for 15-minutes, 45 cycles of 
(1) a denaturation step at 95ºC for 30-seconds and (2) annealing and elongation steps at 50ºC for 
30-seconds and 72ºC for 60-seconds, then one melting step at 60-95ºC for 60-seconds. The 
acquisition of the PCR product signal occurred during the annealing and elongation step and the 
melting step. PCR results interpretation was performed using both melting curve analysis and gel 
electrophoresis. PCR product purification and sequencing was performed as described in section 
5.2.7. 
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5.3 Results 
5.3.1 Sequence analysis of HAdV-PCR oligonucleotide targets  
Overall, 334 (90%) of the 370 HAdV hexon gene sequences available on the GenBank database had 
at least two mismatches with the HAdV-PCR forward primer and 215 (58%) sequences had at least 
three mismatches (Figure 5.1).  
 
Likewise, 254 (69%) of the sequences had at least two mismatches with the HAdV-PCR reverse 
primer (Figure 5.2). The HAdV-PCR probe was the most conserved with 304 (82%) sequences 
having either one or no mismatches (Figure 5.3). In general, the highest level of variation was 
observed amongst HAdV subspecies B1 and B2 (data not shown). This variation involved 
predominantly the forward primer, with three mismatches observed typically.  
     5’  GCCCCAGTGGTCTTACATGCACATC 3’  
7   .........................  
22   ...G..................... 
3   ......A..................  
3   ............A............  
1   ..........G.............. 
1   ...T........G............  
1   ...G.................T... 
43   ..........G.A............  
6   ...G..A.................. 
3   ......A...G.............. 
39   ..........G.G............  
9   ...G........A............  
6   ...G......G..............  
2   ......A.....A............  
9   ...G........G............  
94   ...G......G.G............  
113   ......A...G.A............  
1   ...G..A.....A............  
1   ...G......G.A............  
2   ...G..A...G..............  
1   ..........G.G.....A......  
1   ...A........G...........T 
2   ...G..A...G.A............ 
  
(Total = 370)  
 Figure 5.1 Sequence alignment of the HAdV-PCR 
forward primer with 370 HAdV sequences from 
the Genbank database. Dots indicate a match 
whereas capitalised bases indicate mismatches with 
the primer sequence     
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5.3.2 Evaluation of HAdV assays using culture isolates  
Testing ten-fold dilutions of the control isolates revealed similar detection limits between the three 
assays (within one-tenfold dilution) for all isolates (data not shown). However, significant 
differences in Ct values were observed between assays for some isolates (Table 5.2). Notably, 
isolates 1 and 2 (HAdV types 34 and 11, both B species) showed significantly lower Ct values in 
the Mod1-PCR and Mod2-PCR assays by ten and five cycles respectively compared with the 
HAdV-PCR (Table 5.2). In contrast, Ct values for all other control isolates (3 C, 1 E, 1 F and 1 B 
species) differed by only one to two cycles between assays. DNA sequencing of the HAdV-PCR 
targets for the control isolates (Table 5.2) revealed mismatches for primer and probe targets for all 
isolates. However, the greatest number of mismatches were observed for control isolates 1 and 2 
(HAdV types 34 and 11 (both B species), with three mismatches present in both the forward and 
reverse primers of each isolate.  
 
  
 5’ TGCACCAGACCCGGGCTCAGGTACTCCGA 3’    
92    .............................  
02    ........G....................  
207    ..............A..............  
2    .......A.....................  
1    .................G...........  
32        ..............A..G...........  
1    ..............A..A...........  
14    ........C..G.................  
5    ...........G..A.............. 
1    ........C..G..A..............  
1    .....A..C..G.................  
1    ........C..G.....T...........  
7    ..............A..G......C....  
1    G........T....A..............  
1    ........C..G..A........T.....  
1    .....G..G..G..A..............  
1    AA.TG.........A..G...........  
 
(Total = 370)  
 
Figure 5.3 Sequence alignment of the HAdV-PCR 
probe with 370 HAdV sequences from the GenBank 
database. Dots indicate sequence identity whereas 
capitalised bases indicate mismatches with the probe 
sequence     
 
5’ GCCACGGTGGGGTTTCTAAACTT 3’   
02        ....................... 
45        .....C................. 
01        .................G.....  
45        .....T.................  
23        ..............C........  
02        ........A.....C........  
115       .....C........C........  
40        ..T........A...........  
84        .....T..............T..  
4         .....A.....A..C........  
1         ..T..A.....A...........  
3         ..T.....A..A...........  
1         ..T........A..........C  
1         ..Y..C........C........  
1         .G...C........C........  
1         .....A........C..G..... 
1         .....C..A.....C..G..T..  
 
(Total = 370)  
 
Figure 5.2 Sequence alignment of the HAdV-
PCR reverse primer with 370 HAdV sequences 
from the GenBank database. Dots indicate 
sequence identity whereas capitalised bases 
indicate mismatches with the primer sequence     
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Table 5.2. Cycle threshold (Ct) values for eight control isolates and 13 selected positive clinical samples for adenovirus (HAdV) as tested by the HAdV-PCR, Mod1-PCR and Mod2-
PCR assays. Sequence alignment of the HAdV-PCR oligonucleotides with target sequences are also provided where available. Dots indicate matching bases 
Sample info. 
 
HAdV 
type 
(species) 
Ct values Mismatches between HAdV-PCR oligonucleotides and HAdV genotypes 
HAdV
-PCR 
Mod1-
PCR 
Mod2-
PCR 
F-Primer (5’–3’) 
GCCCCAGTGGTCTTACATGCACAT 
Probe (5’–3’) 
TCGGAGTACCTGAGCCCGGGTCTGGTGCA 
R-Primer (5’–3’) 
GCCACGGTGGGGTTTCTAAACTT 
Control isolates 
(2000) 
       
 1  34 (B2)  26.72 16.21 15.24 ......A...G.A........... ..............T.............. ..T.....A..A........... 
 2                 11 (B1)  21.04 16.2 15.22 ......A...G.A........... ..............T.............. ..T........A...A....... 
 3                04 (E)  21.81 22.55 20.43 ..........G.G........... ..............T.............. .....C........C........ 
 4                 14 (B2)  20.29 20.51 19.22 ..........G.A........... ..............T.............. ..T........A........... 
 5                40 (F)  17.51 18.35 18.78 ...G..A................. ....................C........ .................G..... 
 6                06 (C) 21.25 21.69 20.88 ...G.................... .................C..G........ .....C................. 
 7                 02 (C) 25.24 25.51 24.94 ...G.................... .................C..G........ .....C................. 
 8                05 (C) 20.63 20.78 20.56 ...G.................... .................C..G........ .....C................. 
Clinical samples 
(2012) 
       
1 03 (B1)a 24.19 20.2 18.39 ......A...G.A........... ..............T.............. .....T..............T.. 
2  03 (B1)a   16.99 12.17 11.65 ......A...G.A........... ..............T.............. .....T..............T.. 
3 n/a 38.09 nd nd n/a n/a n/a 
4  n/a 35.41 nd 33.47 n/a n/a n/a 
5  n/a 35.35 37.16 nd n/a n/a n/a 
6  02 (C) a 36.33 36.7 nd n/a n/a n/a 
7  02 (C)a  nd 38.52 33.95 n/a n/a n/a 
8  02 (C)a  nd 36.23 32.6 n/a n/a n/a 
9  01 (C)a  nd 38.9 35.57 n/a n/a n/a 
10  n/a nd 37.97 35.49 n/a n/a n/a 
11  03 (B1)a  19.29 13.51 12.88 ......A...G.A........... ..............T.............. .....T..............T.. 
12  n/a 41.69 34.76 33.05 n/a n/a n/a 
13  03 (B1)a   41.91 33.49 32.75 n/a n/a n/a 
nd = not detected; n/a = not available; abased on genotyping of the hyper variable region 7 in the HAdV hexon gene. 
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5.3.3 Community-based respiratory samples 
The testing of the 8,800 nasal swab samples provided almost identical results for both the       
HAdV-PCR and Mod1-PCR assays. Fifty-three samples were positive by both methods with similar 
Ct values (i.e. <3 cycles difference between assays) for 51 samples with Ct values ranging from 
23.1 to 41 cycles (mean 34 cycles) in the Mod1-PCR. A further two samples were positive by both 
methods, but provided earlier Ct values in the Mod1-PCR (34 and 35.2 cycles respectively) 
compared to the HAdV-PCR (39.1 and 41.4 cycles respectively). 
 
5.3.4 Clinical samples 
For the 79 HAdV-positive specimens from Pathology Queensland, the three methods were positive. 
Similar Ct values (ie. <3 cycles difference between assays) resulted for 67 samples (12 to 38.8 
cycles in the HAdV-PCR; mean 27 cycles). A further two samples were positive by all three 
methods, but produced earlier Ct values (>3 cycles difference) in both the Mod1-PCR and Mod2-
PCR assays (samples 1 and 2; Table 5.2).  One sample was positive by the HAdV-PCR only 
(sample 3; Table 5.2), one sample positive by both the HAdV-PCR and Mod2-PCR assays only 
(sample 4; Table 5.2), two samples were positive by HAdV-PCR and Mod1-PCR only (samples 5 
and 6; Table 5.2) and there were two samples that were negative by all three methods. Of note, was 
that there were four additional samples negative by the HAdV-PCR, but positive by both the Mod1-
PCR and Mod2-PCR assays (samples 7 to 10; Table 5.2). To further investigate the latter, all four 
samples were retested in duplicate in the HAdV-PCR; two samples provided positive results in both 
replicates, and two samples were positive in one of the two replicates.  
 
The additional testing of 70 respiratory pools (representing 700 respiratory virus extracts) identified 
ten positive pools in all methods and an additional two pools positive by the Mod2-PCR only (total 
of 12 positive pools for this method). The 120 individual samples from these twelve pools were 
subsequently tested with all three assays and twelve samples were found positive by all three 
methods (ie. one positive sample/pool). Of the twelve positive samples, nine provided similar Ct 
values in all three methods (23.7 to 34.8 cycles in the HAdV-PCR; mean 29.8 cycles). Three 
samples provided earlier Ct values in the Mod1-PCR and Mod2-PCR assays compared to the 
HAdV-PCR (samples 11 to 13; Table 5.2).   
 
DNA sequencing of the HAdV-PCR targets was attempted for all thirteen clinical samples 
providing discordant results (samples 1 to 13; Table 5.2).  Of these, the HAdV-PCR sequence 
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targets could only be sequenced for three samples (samples 1, 2 and 11; Table 5.2) with the highest 
viral load (based on the PCR Ct values).  
 
5.3.5 Additional HAdV genotyping 
HVR7 genotyping was successful in eight of the 13 samples providing discordant typing results 
(Table 5.2). Similar to the results of the control isolates, samples 1, 2 and 11 had a total of five 
mismatches in the primers, were members of species B1, and correlated with the late Ct values 
observed in the HAdV-PCR. HVR7 genotyping of the additional 20 randomly selected           
HAdV-positive clinical samples revealed four types from three species; nine comprised HAdV 
type-1 (species C), eight had HAdV type-2 (species C), two were typed as HAdV type-3 (species B) 
and only one sample was typed as an HAdV type-4 (species E). 
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5.4 Discussion 
The concerns over the HAdV-PCR assay performance were instigated because of the higher Ct 
values obtained from the study cohort and the age of the assay. These two factors raised the 
possibility of new HAdV genotypes or their variants being present and leading to either delayed Ct 
values or false-negative results  
 
The in-silico sequence analysis showed a high level of variation in the HAdV-PCR oligonucleotide 
targets, particularly for the primers, which validate the initial concerns. However, the variation 
observed was similar to that described originally (Heim et al. 2003). In addition, the experimental 
data showed that despite considerable variation in the HAdV-PCR targets, few false-negative 
results were observed in the HAdV-PCR. The samples that were negative by HAdV-PCR, but 
positive by either Mod1-PCR or Mod2-PCR had typically low viral loads (as indicated by their 
respective high Ct values; clinical samples 7 – 10; Table 5.2), and so low template load may explain 
these results. This explanation is supported by observing that these samples provided positive 
results upon repeat testing in the HAdV-PCR assay. In addition, other samples positive by HAdV-
PCR at high Ct values were negative by one or both of the other two methods (clinical samples 3-6; 
Table 5.2).  
 
Overall, these results suggest an unexpected tolerance of the HAdV-PCR assay for mismatches, 
further confirming Heim et al.’s original data. The explanation for this tolerance is likely to be due 
to variation being largely absent from the extreme 3’ end of the primers (Figures 5.1 and 5.2), 
which is the critical region for primer hybridisation and optimal assay performance. It should be 
noted however that false-positive results in the HAdV-PCR could explain the failure of the Mod1-
PCR and Mod2-PCR assays to confirm the HAdV-PCR results, particularly for sample 3 (Table 
5.2). The most logical way to explore the potential for false-positive results here would be to use 
DNA sequencing. However, we did not attempt this as the real-time Ct values involved were very 
high, making this very difficult. The main problem though is that failure to obtain a clear HAdV 
sequence could lead us to incorrectly conclude HAdV was absent, whereas a small amount of 
specific HAdV-PCR product might still be present, but mixed with the various non-specific 
products, which occur typically towards the end of PCR cycling.  
  
While the results indicate the HAdV-PCR remains suitable for routine detection of HAdVs, the data 
suggest that variation does have some impact upon amplification, insofar as Ct values were delayed. 
For example, control isolates 1 and 2 (HAdV types 34 and 11) had three mismatches in both the 
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forward and reverse primers that led to significant delays in Ct values (five to ten cycles) compared 
to the Mod1-PCR or Mod2-PCR methods. Similar issues were observed for the clinical samples. 
While not affecting qualitative detection, these results do suggest however that the HAdV-PCR 
assay would be unsuitable for quantitative purposes and that the Mod1-PCR or Mod2-PCR assays 
may be more suitable for such use.  
 
For the ORChID study, this means that a small proportion of the late Ct values may have arisen as a 
result of sequence variation impacting on PCR amplification or PCR-product detection efficiency. 
Reassuringly, this means that most of the ORChID results were accurate and the late Ct values were 
not an artefact of the PCR, but instead indicate HAdVs are typically present at lower loads in nasal 
swab specimens. This observation reaffirms the findings of the previous studies (Echavarria et al., 
2006; Lambert et al., 2008b) and implies the importance of assessing the quality of sample 
collection to further eliminate possible factors that may impact upon HAdV Ct values (as discussed 
in chapter-4). The fact that we have now confirmed that the HAdV Ct values and hence viral loads 
are indeed typically lower than the other viruses raises further questions over the role of these 
viruses in the community and whether nasal swabs alone are necessarily the best specimens for 
detecting these viruses (Hammitt et al., 2011) (and is discussed in more detail in chapter-7).  
 
In light of these findings I elected to replace the HAdV-PCR assay with the Mod1-PCR so as to 
optimise screening of the ORChID samples for this virus in my studies.  
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Chapter 6 
Molecular epidemiology of human rhinoviruses in an infant 
cohort 
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6.1 Background 
Across all age groups, RVs are the most frequently detected viruses in respiratory secretions and 
this includes their presence in both symptomatic and asymptomatic individuals. Traditionally, RVs 
were considered to consist of ~100 serotypes, divided into either A or B species based on their 
phylogeny and recognised solely as URTI pathogens since they were thought to replicate 
principally in the cooler temperatures of the upper airways. However, temperature preferences vary 
between RV types and some replicate at the higher temperatures of the lower airway (Jacobs et al., 
2013). Indeed, earlier studies reported the ability of RVs to infect and replicate in the LRT and 
provided experimental support for clinical studies reporting an association between RVs and LRTIs, 
especially for acute exacerbations of some chronic pulmonary disorders, such as asthma and chronic 
obstructive pulmonary disease (COPD) (Johnston et al., 1995; Papadopoulos et al., 1999). More 
recent data show that RVs are associated with increased risk of subsequent wheezing illnesses and 
asthma following severe LRTI associated with wheeze during early childhood (Calışkan et al., 
2013; Jackson, 2010; Jackson et al., 2008; Lemanske et al., 2005).  
 
This recognition of an expanded role for RVs during infancy has been facilitated by the recent 
introduction of molecular methods for their diagnosis and characterisation, which now allow a more 
comprehensive description of RV infection rates. These techniques led to the discovery of a new 
divergent group of RV sequences that has since been categorised as a novel RV species: RV-C 
(Arden et al., 2006; Kistler et al., 2007). In addition to diagnosing and identifying novel types, these 
molecular-based techniques have resulted in changes in the classification system of RV types and 
provided new insight into characterising RV-infections, such as those associated with upper and 
lower airway involvement, prolonged-shedding, co-detection and subclinical infections (Bruce et 
al., 1990; McIntyre et al., 2013; Mori and Clewley, 1994; Simmonds et al., 2010). However, we still 
have a limited understanding of these particular disease patterns, particularly as they relate to RV 
infections in the community. Thus, carefully conducted longitudinal studies of otherwise-healthy 
infants are necessary to further understand the types of illnesses, including the shedding 
characteristics, associated with these viruses.  
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6.1.1 RV genome structure 
The RVs are non-enveloped viruses possessing a single-stranded, positive sense RNA genome that 
is approximately 7.2 kb in length. The length of the single open reading frame (ORF) is 
approximately 6.5 kb. The ORF regions in RV-A and RV-B have more Adenine and Uracil (A+U) 
positions compared to RV-C (Arden and Mackay, 2011; Gama et al., 1989; Lu et al., 2008) and in 
all species the ORF is bracketed by two untranslated regions (UTR). The 5`UTR comprises 
approximately 650 nucleotides and starts with a small viral protein (VPg) that serves as a primer for 
the genome replication. The 5`UTR functions, by way of several structural sequences, as a regulator 
for the replication and translation for the viral genome. The 3`UTR, in contrast, is shorter and 
consists of approximately 50 nucleotides that end with a polyA chain and serves as a regulator of 
transcription (Arden and Mackay, 2010; Jacobs et al., 2013; Palmenberg et al., 2009; Paul et al., 
1998).  The ORF can be divided into three regions (P1, P2 and P3). The first encodes four structural 
proteins (viral proteins 4, 2, 3 and 1, which together form the virion’s capsid), while the remaining 
regions of the ORF encode seven non-structural proteins that are essential for infection and 
replication, including protease, RNA-dependant polymerase, VPg and other proteins.   
 
6.1.2 RV classification  
The three RV species; Rhinovirus A, Rhinovirus B and Rhinovirus C are members of the genus 
Enterovirus, family Picornavirdae. These three species encompass more than 160 serotypes and 
genotypes (hereafter called types). The two well established species, RV-A and B have been sub-
classified using various approaches according to their serological profiles, tissue tropism, antiviral 
susceptibility and phylogeny, as well as their cell entry mechanisms and cellular receptors. All RV-
B and most RV-A types use the intracellular adhesion molecule-1 (major) receptor for cell entry, 
while a minor subset of RV-A types use a low density lipoprotein receptor (Bochkov et al., 2011). 
By 1987, more than 100 RV-A and B serotypes were recorded (Hamparian et al., 1987). Later 
efforts for RV-A and RV-B type classification employed molecular methods, which in the early 
1990s targeted the 5` UTR or VP4/VP2 gene regions in the RV genome (Bruce et al., 1990; Mori 
and Clewley, 1994). For genotype nomenclature, species letter and type number are now used 
respecting the historical naming system (Liggett et al., 2014). For RV-C, type classification 
methods are slightly different. The discovery of this species was achieved using purely molecular 
techniques (Arden et al., 2006). Since its discovery in 2006, growing RV-C in vitro has not been 
possible using standard cell lines and a system for in vitro RV-C replication was not available until 
2011. Only two RV-C isolates were successfully propagated, initially in sinus organ culture of nasal 
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epithelial cells (Bochkov et al., 2011). Thus, typing of RV-C has relied upon genomic comparisons 
(Simmonds et al., 2010).  
Full genomic analyses of all known sequences of RV-A and RV-B and selected sequences of RV-C 
was achieved in 2009 by sequencing the previously described serotypes and ten additional field 
samples (Palmenberg et al., 2009). The analysis revealed that ten of twelve possible recombination 
events in the RV genome involve the 5`UTR. Additional studies have revealed that most 5`UTR 
sequences obtained from species C are genetically similar to some species A sequences (McIntyre 
et al., 2010). These data highlight a limitation of using the 5`UTR for classification purposes. Due 
to the considerable heterogeneity in the capsid genes (VP1 and VP4/VP2) and their resulting 
phylogenetic clustering, VP1 and VP4/VP2 sequencing has now gained wider acceptance for RV 
genotyping in a system similar to that used for the assignment of new and existing Enterovirus 
types. A threshold of 10% divergence was suggested when using the VP4/VP2 genes, while when 
using the VP1 gene, a threshold of 13% divergence was proposed (Simmonds et al., 2010).   
 
6.1.3 RV diagnosis 
RVs can be detected from most respiratory specimens at high titre, including nasopharyngeal swabs 
or aspirates, nasal washes and nose/throat swabs (for URTIs) and BAL or bronchial aspirates (for 
LRTIs) (Versalovic et al., 2011). RV detection methods are similar to the detection methods used 
for other respiratory viruses and therefore can encounter similar challenges (discussed in chapter 1; 
section 1.4). Due to the high diversity of RV types and the lack of available serological data and 
universal reagents, both cell culture and serodiagnosis/antigen detection-based methods have 
proven to be insensitive, costly and also time consuming for routine RV detection. The gold 
standard detection technique is now conventional and real-time RT-PCR methods. The majority of 
RV PCR assays use 5`UTR for the detection target, particularly the ‘Gama’ assay site - being one of 
the most highly conserved regions in all RV genomes [OL26 and OL27], (Gama et al., 1989). This 
method has also been used for classification purposes in cases where primary typing methods (eg. 
VP1 or VP4/VP2) have failed to provide typing data (Arden et al., 2010; Bruce et al., 1990). 
Despite the ‘Gama’ assay site being highly conserved, the high level of heterogeneity in RV types 
has still created challenges for developing a comprehensive real-time PCR assay since a real-time 
PCR requires an additional conserved site for an oligoprobe (i.e. in addition to the primer targets). 
In 2008, the first comprehensive RV real-time PCR detection method was finally described (Lu et 
al., 2008).  
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6.1.4 Burden of RV infections during infancy and early childhood  
Depending upon severity, RVs are among the most commonly detected viruses during infancy and 
early childhood ARIs. Previous serological and virological analyses performed in children younger 
than two years of age have found that approximately 90% had already acquired at least one RV 
infection (Blomqvist et al., 2002). For young children, RV infections are associated with a variety 
of clinical presentations in both the URT and LRT. For example, RVs are associated with URTIs 
including the common cold, sinusitis (Alho, 2005) and AOM (Chonmaitree et al., 2008), while RVs 
are also associated with LTRIs including bronchiolitis (Calvo et al., 2010; Mansbach et al., 2012; 
McErlean et al., 2008) and pneumonia (Daleno et al., 2013; Juvén et al., 2000). Key studies 
examining RV disease are summarised below. 
 
6.1.4.1 RVs and URTIs  
RVs were the most frequently detected virus in respiratory secretions collected from both 
hospitalised infants and children, including those at high risk of atopy from previous community-
cohort studies (Kusel et al., 2006; Miller et al., 2011).  The viral aetiology of the common cold has 
been the subject of many studies worldwide. In one study in which 194 young children with the 
common cold were investigated, RVs were detected in 71% (Ruohola et al., 2009).  RVs were also 
detected in up to 41% of middle ear fluid samples collected from infants and children with AOM 
(Blomqvist et al., 2002).  
 
6.1.4.2 RVs and LRTIs 
The significant role of RVs in young children hospitalised due to LRTIs has been recognised 
recently. In the US, RV infections were detected in five hospitalisations per 1000 children under 
five years of age (Miller et al., 2007). Moreover, fatal RV infections were reported from an 
outbreak in two orphanages in Vietnam during 2012. Seven of the twelve children who were 
hospitalised for severe ARI were younger than six months of age and none survived. Their samples 
were tested for eleven different respiratory viruses, including RV, which was the only virus detected 
in five of these infants, while in the remaining two, RSV and HAdV were also detected (Hai et al., 
2012). In an investigation that included 643 children hospitalised with community-acquired 
pneumonia, all three RV-species were identified in 76.3% of the 198 RV-positive samples with a 
predominance of RV-A across all age groups in this particular study, followed by RV-C and rarely 
RV-B (Daleno et al., 2013).  
 
149 
 
RVs were detected in 17-26% of infants hospitalised with severe bronchiolitis (Calvo et al., 2010; 
Mansbach et al., 2012) and it has been suggested that such individuals are at increased risk of 
receiving an asthma diagnosis later in childhood. (James et al., 2012). In a long-term follow up of 
post-bronchiolitis cases at seven years of age, asthma was more common in infants with a prior 
history of RV-induced bronchiolitis (52%) than those with previous RSV-induced bronchiolitis 
(15%) (Jartti and Korppi, 2011). There are two possible explanations for these clinical observations. 
The first is that severe RV LRTI in young infants may damage epithelial cells during a critical 
phase in airway development leading to a sequence of events resulting in airflow limitation and 
wheezing. Alternatively, severe RV infection may occur primarily in those who are genetically 
predisposed to wheezing, amplifying this process and resulting in asthma symptoms from early 
childhood (Calvo et al., 2007).  
 
6.1.4.3 RVs, asthma and asthma exacerbation 
 The relationship between RV-infections and asthma exacerbation is well recognised. 
Approximately two-thirds of viral asthma exacerbation episodes are associated with RVs. This was 
investigated at RV-species level, and in one study RV-C type 10 (RV-C10) was detected in 23% of 
children hospitalised with an asthma exacerbation (Arden et al., 2010). In contrast, for non-
hospitalised asthmatic children, RV-A types were associated with longer symptom duration when 
compared to RV-C types. The latter were also detected as singletons (i.e. the only virus detected) 
more frequently (Arden and Mackay, 2010). This indicates that although RV-A and RV-C may play 
a role in asthma exacerbation and wheezing, their infection characteristics may lead to different 
clinical outcomes. As above, the frequent wheezing events caused by RV infections imply they may 
have a role in either unmasking or feature in the causal pathways leading to asthma in children at 
high risk of atopy, especially if they were sensitised previously by aeroallergens, as explained by 
the ‘dual hit’ hypothesis (Calışkan et al., 2013; Holt and Sly, 2012; Jackson et al., 2008; Lemanske 
et al., 2005). 
 
6.1.4.4 RVs and other chronic diseases  
RV infections are also associated with worsening of other chronic pulmonary disorders, such as 
cystic fibrosis (CF) at all ages (Kieninger et al., 2013; Wat et al., 2008) and COPD in adults (Mallia 
et al., 2011). For CF, RVs have been identified as the predominant agent during virus-associated 
exacerbations in children (Burns et al., 2012; Wat et al., 2008). The prevalence of RV in CF 
children from a community-based study was as high as 73% (Emerson et al., 2013) and they were 
associated with more severe and protracted respiratory symptoms than in healthy controls. 
Interestingly, the load of RV was significantly higher in BAL samples collected from CF children 
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than from asthmatic children and heathy controls, while local anti-inflammatory and anti-viral 
mediators in the BAL fluid were negatively associated with RV load, suggesting impaired RV 
clearance mechanisms in CF patients. (Kieninger et al., 2013).  
 
The severity of RV-infections is linked to several host-related factors, such as their age, maturity of 
their innate and adaptive immune responses, and presence of any chronic underlying diseases (e.g. 
cardiorespiratory, neuromuscular or immunodeficiency disorders) as well as co-detection with other 
respiratory viruses and possibly the RV-species associated with infection (Lee et al., 2012; Miller et 
al., 2011). In contrast with the recent study in Italian children with pneumonia (Daleno et al., 2013), 
RV-C and not RV-A was found to be the predominant RV species associated with ARIs in 
hospitalised children (Cox et al., 2013; Lauinger et al., 2013; Linsuwanon et al., 2009; Renwick et 
al., 2007). Interestingly, community-based studies have also found that RV-A was the dominant 
species associated with milder ARIs not requiring admission to hospital (Lee et al., 2012).   
 
Age may be an important factor in determining the severity of symptoms caused by a RV infection. 
For example, one study has shown that members of the RV-C species were more likely to cause 
severe symptoms in children younger than three years of age (Lauinger et al., 2013), while another 
noted roughly equal proportions of RV-A and RV-C during infancy, but RV-A dominated after one 
year of age (Daleno et al., 2013). Further, the season in which a RV-infection occurs may also play 
a role in the severity of the illness. In the northern hemisphere, there is a clear seasonal pattern for 
RV-infections and symptom severity. Infections that occur in summer months were more likely to 
be associated with milder respiratory symptoms compared to autumn and winter months (Lee et al., 
2012). Whether these differences in severity are from an inoculum effect related to more crowding 
indoors during winter, drying of the nasal mucous membranes from breathing cool, low humidified 
air or low vitamin D levels affecting anti-viral defences is unknown (Bryson et al., 2014).  
 
6.1.5 Nature of RV infections detected in the post-molecular era 
The advent of molecular methods, which helped to generate renewed interest in RVs, has led to a 
better understanding of RV-infections, including observing RVs frequently in asymptomatic 
individuals, prolonged detection after symptom disappearance and co-detection with other 
respiratory viruses. These are summarised below.  
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6.1.5.1  Asymptomatic RV infections  
Asymptomatic RV infections were recognised after the increased use of PCR assays for viral 
detection, and were found to be relatively common in infants. For example, RVs were detected in 
38% of 988 nasopharyngeal samples collected from 433 healthy children participating in a 
randomised controlled trial of a pneumococcal conjugate vaccine in the Netherlands and who had 
undergone serial testing between the ages of six to 24 months (van den Bergh et al., 2012). A 
previous community-based study in ‘high-risk’ infants of atopic parents from Western Australia 
showed that 11.4% of 456 samples collected during asymptomatic periods were positive for RV 
(Kusel et al., 2006), while another from Wisconsin in the US (the COAST study) that investigated 
285 infants who were also at ‘high-risk’ of asthma reported higher RV-detection rate (35%) during 
asymptomatic periods (Jartti et al., 2008). Variations in study design could help explain these 
differences. Although these two birth cohort studies investigated RV-infections during the first year 
of life, the former obtained respiratory samples only during two asymptomatic periods (one in 
winter and one in summer) (Kusel et al., 2006), while the latter collected samples during five 
routine scheduled visits throughout the first year of life (Jartti et al., 2008). This single variation in 
design suggests that in infants at high risk of asthma, the likelihood of detecting asymptomatic RV-
infections can increase by simply escalating the frequency of sample collection. Overall, and to 
place this within a clinical context, the detection of RV in asymptomatic infants can be due to any 
one of the following circumstances: (i) symptoms are present, but go unrecognised, (ii) a nascent or 
incubating infection that leads to subsequent symptoms, (iii) a recent infection that has resolved, or 
(iv) a genuine subclinical infection. 
  
6.1.5.2 Prolonged detection    
RV shedding is typically considered to last between 11-21 days (Gern et al., 2000; Lu et al., 2008), 
although RV-B types can have slower replication and longer periods of viral shedding (Nakagome 
et al., 2014). Nevertheless, prolonged detection of RVs for more than four consecutive weeks has 
been reported by studies using PCR-based detection methods in clinical samples obtained from both 
healthy and immunocompromised children (Jartti et al., 2004; Kling et al., 2005). The median 
duration of RV-shedding in young immunocompromised patients was four-times longer than in 
immunocompetent healthy children (Peltola et al., 2013). However, without using genotyping 
techniques, little is known about possible type replacement during prolonged RV-detection periods. 
Indeed, prolonged detection of RV is now thought to be caused by strain replacement or 
overlapping RV infections rather than persistent shedding of the same type. A small study by van 
der Zalm and colleagues (2011) has demonstrated that in 19 otherwise healthy children, the 
perception of prolonged shedding was instead due to a series of sometimes overlapping infections 
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by different types. However, the median age of these children was 3.6 years and no details about the 
virus exposure status of these children were provided (i.e. childcare or school attendance). 
Longitudinal and more comprehensive data to support these assumptions in otherwise healthy 
infants are still lacking.  
 
6.1.5.3 Co-detection  
Another aspect of RV-infections that became apparent after the introduction of molecular methods 
was the frequent co-detections of RV with other respiratory viruses. In fact, it was  due to the 
common co-detection of RV and other respiratory viruses that the clinical role of RV was 
questioned (Jacobs et al., 2013). A previous study examined the association between RVs and 16 
other respiratory viruses in 1257 clinical specimens from different seasons. RVs were statistically 
less likely to be associated with many other respiratory viruses (Greer et al., 2009). Together these 
studies confirm that RVs have a leading role in respiratory illness rather than being mere passengers 
as has been suggested previously (Arden and Mackay, 2010; Mackay, 2008) and that the observed 
high rates of RV co-detections are more likely to be caused by the high rates of RV-infections in 
general. Likewise, previous studies have also shown that mixed RV/RV co-detections also occur 
(Lee et al., 2007; Renwick et al., 2007). Although the rate of RV/RV co-detection was relatively 
low in samples obtained from hospitalised patients (2/101 clinical samples) (Lee et al., 2007), the 
possibility of RV/RV co-detection in RV positive individuals in the community is unknown.  
 
6.1.6 Study objectives  
This chapter aims to describe RV infections in infants living within the community, including their 
incidence, prevalence, shedding, co-detection and seasonality, as well as catalogue basic clinical 
features of infected infants during the first year of life.  
 
My hypotheses were:  
1- RV-C infections in infants are more likely to be associated with symptoms than the other 
two RV species.  
2- Prolonged detection of RV in otherwise healthy infants is from type replacement and 
overlapping RV infections rather than by persistent infection of a single type.    
 
To achieve these aims, RV-positive samples from the cohort described in chapter-3 underwent 
VP4/VP2 typing to define their RV-genotype.   
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6.2 Methods       
6.2.1 Study cohort and sample population  
The same infant cohort described in chapter-3 (section 3.2.1) was used for this analysis. RV-
genotypes were investigated in RV-positive nasal swabs collected from infants (n=3446) during 
their first year of life and from their parents (n=134) during the initial visit undertaken shortly after 
the birth of the study infants (chapter-2, section; 2.1.2.1). To investigate the clinical impact upon 
infants infected with different RVs, a sub-set of 3415 child swabs, which were accompanied by 
comprehensive symptom data were analysed (chapter-3; section: 3.3.3.1).  
 
6.2.2 RV-TDE and ARI definitions  
A new RV type detection episode (RV-TDE) was defined when a new RV-type was first detected or 
when the same RV-type was detected more than 14 days after a previous detection with the same 
genotype. During the 14 RV-free days, two negative intervening nasal swabs should be available. If 
one of these interval samples was missing, 30 days were required to define a new infection episode.  
Each untypeable RV detection was defined as a new RV-DE. ARI episodes were defined as 
described in chapter-3 (section 3.2.1).  
 
6.2.3 RV screening and principal VP4/VP2 genotyping assay  
Nucleic acid purification and RV screening were performed as per the ORChID study protocol 
(chapter-2; sections 2.1.4.2 and 2.1.4.3). The initial RV-typing workflow used in this project is 
illustrated in Figure 6.1. 
  
154 
 
 
 
 
Figure 6.1 The workflow of RV-typing and description of two sample populations according to the availability of 
symptom data. The first sample population (yellow background) was used to study the molecular epidemiology of RV 
types and the second (green background) was used to analyse the clinical picture in patients with these types. 
 
A previously described nested PCR assay was used for VP4/VP2 typing (Wisdom et al., 2009). The 
primers for all reaction rounds are listed in Table 6.1; Assay-1. The 20µL reaction mix for the first 
round, a RT step, comprised the following: 10µL SensiFast No Rox OneStep Mix (Bioline-
Australia), 2µL of template, 0.4µL of RNase inhibitor enzyme, 0.2 RT-Taq polymerase enzyme and 
0.6µM of each VP4/VP2 forward and reverse primers. The amplification was performed in the 
following conditions: a RT step at 45ºC for 20-minutes followed by an RT inactivation/Taq 
activation step of 94ºC for 2-minutes, 35 cycles of (1) a denaturation step at 94 ºC for 18-seconds 
and (2) two annealing and elongation steps at (a) 50ºC for 21-seconds and (b) 72ºC for 90 seconds, 
then a final elongation step of 72ºC for 7-minutes. A 2ul aliquot of the RT-PCR product resulting 
from first round RT-PCR was used as a template for the second round of PCR that comprised a 
20µL reaction mix containing the following: 4 µL MyTaq HS DNA polymerase reaction buffer 
(Bioline, Australia), 0.1µL of MyTaq HS DNA polymerase and 1.75 mM of MgCl2. The second 
round PCR was performed under the following cycling conditions: a polymerase activation step of 
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94ºC for 1-minutes, 35 cycles of (1) a denaturation step at 94 ºC for 18-seconds and (2) annealing 
and elongation steps at 50ºC for 21-seconds and 72ºC for 90-seconds, then a final elongation step of 
72ºC for 7-minutes. An 8µL aliquot of each amplification reaction was examined by electrophoresis 
through a 2% agarose gel. The remaining PCR product from all positive reactions was purified 
using a QIAquick purification kit (Qiagen, Australia) by following the manufacturer instructions.  
 
Table 6.1 Conventional RT-PCR and PCR assays used for RV-genotyping  
Assay name; 
round  
Primer name  Primer sequence  Genome 
target 
Type of 
assay 
References 
Assay-1: VP4/VP2a 
VP4/VP2 
Nested 
RT-PCR 
(Wisdom et 
al., 2009) 
Round 1 (outer 
primer pair) 
VP4/VP2-OF b CCGGCCCCTGAATGYGGCTAA 
VP4/VP2-OR b ACATRTTYTSNCCAAANAYDCCCAT 
Round 2 (inner 
primer pair) 
VP4/VP2-IF b ACCRACTACTTTGGGTGTCCGTG 
VP4/VP2-IR b TCWGGHARYTTCCAMCACCANCC 
Assay-2: 5`UTRc 5`UTR-F GCACTTCTGTTTCCCCC 5`UTR 
RT-
PCR  
(Gama et al., 
1989) 5`UTR-R CGGACACCCAAAGTAG 
a VP: viral protein.  
b OF; outer forward primer, OR; outer reverse primer, IF: inner forward primer, IR: inner reverse primer. 
c UTR: untranslated region  
 
Troubleshooting steps: Where VP4/VP2 amplification failed, the assay was repeated (Figure 6.1). 
For samples that produced more than one PCR product band when electrophoresed, each band was 
extracted from the gel and purified using QIAquick gel extraction kit (Qiagen, Australia) following 
the manufacturer instructions. The purified DNA for each band was sent to the Australian Genome 
Research Facility (The University of Queensland, Brisbane) for automated Sanger sequencing. 
Sequence data were compared to the Genbank database using BLASTn and analysed using 
Geneious version 5.5.7 (Biomatters Ltd). For VP4/VP2 genotyping, a nucleotide sequence identity 
of 90% or greater was required to assign the virus as a variant of a known RV genotype (McIntyre 
et al., 2013; Simmonds et al., 2010). To visualize the RV types, infer species and observe 
relationships, a neighbour-joining phylogenetic tree was constructed by MEGA version 5.2 using 
the generated VP4/VP2 sequences. The number of bootstrap replications was 2000 and p-distance 
was used for branch length. To root the tree, Enterovirus C (EV-C) sequences were used.  
   
6.2.4 Alternative RV-typing RT-PCR assay (5`UTR) 
Previous studies have shown that a small number of samples may fail to genotype using the 
VP4/VP2 method (Lee et al., 2007) and a 5’UTR typing method was established for such samples. 
Here, the 5`UTR assay was performed using previously designed primers (listed in Table 6.1; 
Assay-2) and reaction conditions. The 20µL reaction mix included the same components used in the 
first round of the VP4/VP2 reaction, while the amplification process was performed using slightly 
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different conditions as in the following: a RT step at 45ºC for 20-minutes followed by an activation 
step of 94ºC for 2-minutes, 40 cycles of (1) a denaturation step at 94ºC for 20-seconds, (2) two 
annealing and elongation steps at (a) 55ºC for 20-seconds and (b) 72ºC for 50-seconds, then a final 
elongation step of 72ºC for 10-minutes. The post-PCR sequencing and sequence analysis steps were 
performed as mentioned above. For 5`UTR, a sequence identity of 96% or greater was required for 
assignation (Lee et al., 2007).    
 
6.2.5 Outcomes of interest and confounders 
The outcomes of interest for the analyses performed in this chapter included subcategories of all 
RV-species; RV-A, RV-B, RV-C and episodes caused by untypeable samples. For all outcomes, 
twelve confounding variables were included. These were the age quarter of which the outcomes of 
interest occur, gender, exposure to smoking, maternal vaccination status, the participating infant’s 
order in the family, number of siblings in the household, feeding status, childcare, season, co-
detection with other respiratory viruses and the association between the outcome of interest and 
symptoms. The variable exposure to smoking included three categories, depending on parental 
smoking (mother or father) and the absence of this exposure. For feeding status, the measurement of 
outcome was compared in three cases; (i) when the infant was exclusively breastfed, (ii) when other 
milk was introduced and (iii) when solids were introduced. For childcare status the occurrence of 
the outcome of interest was examined for any infant who attended (i) formal childcare, (ii) informal 
childcare, (iii) both formal and informal childcare and (iv) no childcare. Informal childcare was 
defined as care arranged by a parent and provided by an unpaid carer (family member or friends).  
 
6.2.6 Statistical analysis 
The association between variables of interest and outcomes was investigated using mixed effects 
logistic regression models, with infants included as a random intercept to account for the possibility 
of correlated outcomes within each infant. Both univariate and multivariate analyses were 
conducted, with the multivariate analysis adjusted for age, gender, number of siblings in the house 
and season. Analyses were conducted using Stata statistical software v.11.0 (StataCorp, College 
Station, TX, USA).  
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6.3 Results 
6.3.1 RV detection and the study cohort  
In total, 667/3580 (18.6%) nasal swabs collected from participating infants and parents were 
positive for RV detection. These comprised, 659/3446 (19.1%) child nasal swabs collected during 
their first year of life and 8/134 (5.9%) parental nasal swabs that were collected at the beginning of 
the study and shortly after the birth of the participating infant. The distribution of RV-positive 
swabs was described in chapter-3 (section 3.3.3.3) with six additional RV-positive swabs included 
here that were part of the 31 nasal swabs not associated with symptoms data and were, therefore, 
excluded from the original analysis in chapter-3. These six RV-positives included four additional 
samples for infant 019 and one each from infant 044 and 055.  
 
6.3.2 Genotyping  
Of the 667 RV-positive samples selected for sequencing, 475 (71.1%) were sequenced successfully 
using the VP4/VP2 region. These included 471 samples collected from infants and four from 
parents. The remaining 193 samples that failed the VP4/VP2 sequencing (189 child and four parent 
samples) underwent further investigations as mentioned below.  
 
In the 471 typable samples, 99 different sequences related to the genus Enterovirus were identified 
during the 26 months of investigation. Of these, 87 were assigned to previously defined RV-types. 
Ten other types did not meet sequence homology criteria and were unable to be assigned to a 
specific RV-type (hereafter named; unclassified VP4/VP2 sequences). Four other types were related 
to other Enterovirus species.  
 
Unclassifiable VP4/VP2 sequences were identified from 60 samples collected from 31 infants. 
Eight sequences were most closely related to VP4/VP2 sequences from species C (C/seq-1 to C/seq-
8) while the remaining two sequences were closely related to species A (A/seq-1 and A/seq-2). 
Figure 6.2 illustrates the phylogeny of these VP4/VP2 sequences and the closely related types. 
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Figure 6.2 Two neighbour-joining trees to show the phylogeny of the ten unclassified VP4/VP2 sequences (Appendix-1). The two trees were constructed based upon 
representative full-length VP4/VP2 sequences. The trees are rooted using sequences from EV-C. Relevant nodes are labelled with bootstrap values (%). Multiple sequences 
from the same RV-species are shown as triangles, the height and depth corresponding to the number and divergence of the sequences used respectively. (A) Illustrates two 
unclassified sequences that were closely related to RV-A (in bold; hollow diamonds). (B) Illustrates eight unclassified sequences were identified as RV-C (B. Underlined; 
hollow diamonds).    
(B) 
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For types C/seq-1 and C/seq-6, which were closely related to RV-C35, the pairwise identity of the two 
sequences was 83.4%, which is below the required level by 6.6%. For sequence C/seq-3, the highest 
identity value of 91% was obtained from a relatively low coverage of 84%, while higher coverages 
consistently produced identities below 90%. The ten unclassifiableVP4/VP2 sequences are listed in 
Appendix 6-1. Four other Enterovirus species were identifed, a sole detection of echovirus-7 was 
identified in one infant nasal swab sample, while the remaining three were co-detected with RV. To 
investigate the multiple detections, each of the six PCR products was sequenced. For the three samples, 
sequencing of the smaller size bands provided uninterpretable sequence data, while sequencing the 
larger size bands indicated one EV-D68 and two human coxackievirus-B3 viruses.   
 
RV-A was the most commonly detected species in infant swabs (n=210; 31.9 % of the total RV-
positive infant swabs) followed closely by RV-C (n=199; 30.2%) and then by RV-B (n=61; 9.3%). 
There was almost identical degree of types diversity observed in RV-A and RV-C whereas 44 distinct 
RV-A types and 43 RV-C types were identified. For RV-B, only 7 types identified (Table 6.2).  
 
Table 6.2 Features of RV-species identified in the first year of life in 71 infants  
Feature   A B C UT samples 
Number of types detected  44 7 43 - 
Most frequently detected type in nasal 
swabs   
A/seq-2 B/84 C/02 - 
Most frequently detected type in infants  A/seq-2 B/84 C/02 - 
Number of positive swabs (% of 659 
positive swabs)a 
210 (31.9) 61 (9.3) 199 (30.2) 189 (28.7) 
Number of positive infants (% of 71 
positive infants) a 
59 (83.1) 29 (40.8) 64 (90.1) 64 (90.1) 
Number of RV-TDEs (% of 520 total DEs) a 127 (24.4) 38 (7.3) 164 (31.5) 189 (36.3) 
Median duration of RV-TDEs. (min-max) 1 (1-5) 1 (1-5) 1 (1-3) - 
Number of months in which RV-TDEs were 
identified  
23 16 20 21 
Peak month  October-
2011 
May-2011 May-2012 August & December-2011 
Number of RV-TDE associated with ARIs 
(% of 520 total RV-TDEs) 
86 (16.5) 13 (2.5) 115 (22.1) 102 (19.6) 
Multiple viruses RV-TDEs (% of RV-
TDEs).  
25 (19.6) 4 (10.5) 20 (12.2) 14 (7.4) 
KIV 5 2 4 2 
RSV-A 1 1 0 1 
hBoV 5 0 6 4 
HAdV 7 1 6 3 
HCoV-NL63 0 0 1 1 
WUV 4 0 3 2 
PIV-1 1 0 0 0 
PIV-3 2 0 0 1 
a Including the detected human echovirus 
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The median number of different RV-types identified among positive infants, including the unclassified 
RV-sequences, was five types per infant with a maximum of ten different types, which were identified 
in two infants each (infants 010 and 094). Overall, 520 RV-TDEs were identified during the first year 
of life, including those that were caused by untypeable samples, with a median incidence of seven RV-
TDEs per infant (IQR 5-9) (Table 6.2) and a maximum of 14 RV-TDEs in infant 042 (Table 6.3).  
Table 6.3 Descriptive analysis of different RV-genotypes identified during the first year of life in the 71 infants who tested 
positive for RV 
RV 
type 
No. positive 
infants (% in 
71 positive 
participants) 
No. of 
positive 
samples 
(% of 
typeable 
samples 
(459) 
% in 
samples 
from same 
species; 
(A=210; 
B=61; 
C=172) 
No. of 
TDEs. 
(% of 
520 
TDEs.) 
No. 
multiple 
virus 
TDEs. (% 
of TDEs) 
No. 
symptomatic 
TDEs (% of 
TDEs) 
No. 
symptomatic 
and multiple 
TDEs. 
A/seq-2a 13 (18.3) 31 (6.8) 14.8 13 (2.5) 5 (38.5) 11 (84.6) 4 
A/78 9 (12.7) 25 (5.4) 11.9 11 (2.1) 4 (36.3) 9 (81.8) 3 
A/63 8 (11.3) 16 (3.5) 7.6 8 (1.5) 1 (12.5) 7 (87.5) 1 
A/22 8 (11.3) 12 (2.6) 5.7 8 (1.5) 0 (0) 5 (62.5) 0 
A/59 7 (9.9) 10 (2.2) 4.8 7 (1.3) 2 (28.6) 4 (57.1) 2 
A/19 6 (8.5) 8 (1.7) 3.8 7 (1.3) 1 (14.3) 5 (71.4) 1 
A/24 6 (8.5) 8 (1.7) 3.8 6 (1.2) 1 (16.7) 3 (50) 1 
A/80 5 (7) 8 (1.7) 3.8 5 (1) 0 (0) 5 (100) 0 
A/12 4 (5.6) 7 (1.5) 3.3 4 (0.8) 0 (0) 3 (75) 0 
A/58 4 (5.6) 6 (1.3) 2.9 4 (0.8) 1 (25) 3 (75) 1 
A/01 4 (5.6) 5 (1.1) 2.4 4 (0.8) 1 (25) 1 (25) 0 
A/60 4 (5.6) 5 (1.1) 2.4 4 (0.8) 0 (0) 2 (50) 0 
A/85 3 (4.2) 5 (1.1) 2.4 3 (0.6) 1 (33.3) 2 (66.7) 1 
A/20 2 (2.8) 4 (0.9) 1.9 2 (0.4) 0 (0) 2 (100) 0 
A/45 3 (4.2) 4 (0.9) 1.9 3 (0.6) 0 (0) 2 (66.7) 0 
A/56 3 (4.2) 4 (0.9) 1.9 3 (0.6) 0 (0) 1 (33.3) 0 
A/103 2 (2.8) 3 (0.7) 1.4 2 (0.4) 1 (50) 1 (50) 1 
A/33 1 (1.4) 3 (0.7) 1.4 1 (0.2) 0 (0) 1 (100) 0 
A/36 2 (2.8) 3 (0.7) 1.4 2 (0.4) 0 (0) 2 (100) 0 
A/38 1 (1.4) 3 (0.7) 1.4 1 (0.2) 0 (0) 0 (0) 0 
A/55 1 (1.4) 3 (0.7) 1.4 1 (0.2) 0 (0) 0 (0) 0 
A/68 2 (2.8) 3 (0.7) 1.4 2 (0.4) 1 (50) 2 (100) 1 
A/89 3 (4.2) 3 (0.7) 1.4 3 (0.6) 0 (0) 2 (66.7) 0 
A/90 3 (4.2) 3 (0.7) 1.4 3 (0.6) 0 (0) 1 (33.3) 0 
A/21 1 (1.4) 2 (0.4) 1.0 1 (0.2) 0 (0) 0 (0) 0 
a Unclassified sequence from RV-A 
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Table 6.3 Continued. Descriptive analysis of different RV-genotypes identified during the first year of life in 71 infants 
RV 
type 
No. positive 
infants (% in 
71 positive 
participants) 
No. of 
positive 
samples 
(% of 
typeable 
samples 
(459) 
% in 
samples 
from same 
species; 
(A=210; 
B=61; 
C=172) 
No. of 
TDEs. 
(% of 
520 
TDEs.) 
No. 
multiple 
virus 
TDEs. (% 
of TDEs) 
No. 
symptomatic 
TDEs (% of 
TDEs) 
No. 
symptomatic 
and multiple 
TDEs. 
A/47 2 (2.8) 2 (0.4) 1.0 2 (0.4) 0 (0) 2 (100) 0 
A/49 1 (1.4) 2 (0.4) 1.0 1 (0.2) 0 (0) 0 (0) 0 
A/54 1 (1.4) 2 (0.4) 1.0 1 (0.2) 0 (0) 0 (0) 0 
A/07 1 (1.4) 2 (0.4) 1.0 1 (0.2) 0 (0) 1 (100) 0 
A/71 1 (1.4) 2 (0.4) 1.0 1 (0.2) 0 (0) 0 (0) 0 
A/81 1 (1.4) 2 (0.4) 1.0 1 (0.2) 1 (100) 0 (0) 0 
A/09 1 (1.4) 2 (0.4) 1.0 1 (0.2) 0 (0) 1 (100) 0 
A/seq-1 1 (1.4) 2 (0.4) 1.0 1 (0.2) 0 (0) 0 (0) 0 
A/101 1 (1.4) 1 (0.2) 0.5 1 (0.2) 0 (0) 1 (100) 0 
A/18 1 (1.4) 1 (0.2) 0.5 1 (0.2) 1 (100) 1 (100) 1 
A/28 1 (1.4) 1 (0.2) 0.5 1 (0.2) 0 (0) 1 (100) 0 
A/31 1 (1.4) 1 (0.2) 0.5 1 (0.2) 0 (0) 1 (100) 0 
A/32 1 (1.4) 1 (0.2) 0.5 1 (0.2) 1 (100) 1 (100) 1 
A/39 1 (1.4) 1 (0.2) 0.5 1 (0.2) 1 (100) 1 (100) 1 
A/40 1 (1.4) 1 (0.2) 0.5 1 (0.2) 1 (100) 1 (100) 1 
A/46 1 (1.4) 1 (0.2) 0.5 1 (0.2) 1 (100) 1 (100) 1 
A/82 1 (1.4) 1 (0.2) 0.5 1 (0.2) 0 (0) 0 (0) 0 
A/94 1 (1.4) 1 (0.2) 0.5 1 (0.2) 0 (0) 0 (0) 0 
B/84 8 (11.3) 20 (4.4) 32.8 8 (1.5) 1 (12.5) 4 (50) 0 
B/06 7 (9.9) 14 (3.1) 23.0 8 (1.5) 1 (12.5) 2 (25) 0 
B/35 7 (9.9) 8 (1.7) 13.1 7 (1.3) 0 (0) 1 (14.3) 0 
B/52 6 (8.5) 9 (2) 14.8 6 (1.2) 0 (0) 1 (16.7) 0 
B/42 5 (7) 6 (1.3) 9.8 5 (1) 1 (20) 3 (60) 0 
B/26 2 (2.8) 2 (0.4) 3.3 2 (0.4) 1 (50) 1 (50) 1 
B/14 1 (1.4) 2 (0.4) 3.3 1 (0.2) 0 (0) 1 (100) 0 
C/02 18 (25.4) 28 (6.1) 16.3 19 (3.7) 2 (10.5) 14 (73.7) 1 
C/36 12 (16.9) 18 (3.9) 10.5 14 (2.7) 1 (7.1) 8 (57.1) 1 
C/10 8 (11.3) 11 (2.4) 6.4 9 (1.7) 1 (11.1) 7 (77.8) 0 
C/15 8 (11.3) 11 (2.4) 6.4 9 (1.7) 1 (11.1) 8 (88.9) 1 
C/06 10 (14.1) 13 (2.8) 7.6 10 (1.9) 3 (30) 8 (80) 3 
C/40 8 (11.3) 10 (2.2) 5.8 8 (1.5) 2 (25) 6 (75) 1 
C/seq-4b 9 (12.7) 9 (2) 5.2 9 (1.7) 0 (0) 6 (66.7) 0 
C/43 7 (9.9) 10 (2.2) 5.8 8 (1.5) 3 (37.5) 5 (62.5) 2 
C/20 6 (8.5) 7 (1.5) 4.1 6 (1.2) 1 (16.7) 3 (50) 1 
b Unclassified sequence from RV-C 
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Table 6.3 Continued. Descriptive analysis of different RV-genotypes identified during the first year of life in 71 infants  
HRV 
type 
No. positive 
infants (% in 
71 positive 
participants) 
No. of 
positive 
samples  
(% of 
typeable 
samples 
(459) 
% in 
samples 
from same 
species; 
(A=210; 
B=61; 
C=172) 
No. of 
TDEs. 
(% of 
520 
TDEs.) 
No. 
multiple 
virus 
TDEs. (% 
of TDEs) 
No. 
symptomatic 
TDEs (% of 
TDEs) 
No. 
symptomatic 
and multiple 
TDEs. 
C/05 4 (5.6) 6 (1.3) 3.5 4 (0.8) 0 (0) 3 (75) 0 
C/12 4 (5.6) 5 (1.1) 2.9 4 (0.8) 0 (0) 3 (75) 0 
C/14 3 (4.2) 5 (1.1) 2.9 3 (0.6) 0 (0) 1 (33.3) 0 
C/seq-2b 4 (5.6) 5 (1.1) 2.9 4 (0.8) 1 (25) 2 (50) 0 
C/42 4 (5.6) 4 (0.9) 2.3 4 (0.8) 0 (0) 1 (25) 0 
C/51 4 (5.6) 4 (0.9) 2.3 4 (0.8) 0 (0) 4 (100) 0 
C/seq-6b 4 (5.6) 4 (0.9) 2.3 4 (0.8) 0 (0) 4 (100) 0 
C/13 2 (2.8) 3 (0.7) 1.7 2 (0.4) 0 (0) 2 (100) 0 
C/17 3 (4.2) 3 (0.7) 1.7 3 (0.6) 0 (0) 3 (100) 0 
C/19 3 (4.2) 3 (0.7) 1.7 3 (0.6) 0 (0) 2 (66.7) 0 
C/38 3 (4.2) 3 (0.7) 1.7 3 (0.6) 0 (0) 2 (66.7) 0 
C/seq-1b 3 (4.2) 3 (0.7) 1.7 3 (0.6) 0 (0) 2 (66.7) 0 
C/01 1 (1.4) 2 (0.4) 1.2 1 (0.2) 0 (0) 1 (100) 0 
C/11 2 (2.8) 2 (0.4) 1.2 2 (0.4) 0 (0) 2 (100) 0 
C/39 1 (1.4) 1 (0.2) 0.6 1 (0.2) 0 (0) 1 (100) 0 
C/41 1 (1.4) 1 (0.2) 0.6 1 (0.2) 0 (0) 1 (100) 0 
C/48 1 (1.4) 1 (0.2) 0.6 1 (0.2) 0 (0) 0 (0) 0 
C/seq-5 b 1 (1.4) 1 (0.2) 0.6 1 (0.2) 1 (100) 1 (100) 1 
C/seq-7 b 1 (1.4) 1 (0.2) 0.6 1 (0.2) 0 (0) 1 (100) 0 
b Unclassified sequence from RV-C 
 
 
RV-A type detection episodes (RVA-TDEs) were detected in all months, except for September-2012, 
while RVC-TDEs and RVB-TDEs were absent in four and eight months respectively (Figure 6.3). 
There were two peaks of RV-TDEs; the first was in August-2011 and the second was observed in May-
2012.  However, at a species level this double-peak model was not obvious for either RVA-TDEs or 
RVB-TDEs (Figure 6.3).  
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Figure 6.3 A comparison between the overall number of RV-detection episodes before typing (RV-DEs) and RV-type 
detection episodes after typing (RV-TDEs) (bottom).  Number of RV-type detection episodes by species A (RVA-TDEs, 
orange), B (RVB-TDEs, blue) and C (RVC-TDEs, green) (middle) and the number of detection episodes that were 
untypeable (UT-DEs, top) during the 26 months of investigation.  
 
For RV-A, the most frequently detected sequence was the unclassified type RV-A/seq-2, which was 
found to be closely related to the second most frequently detected type, RV-A/78. The latter was 
identified in 21 nasal swab samples (4.4% of typed samples) in nine infants (12.7% of positive infants) 
leading to eleven RV-TDEs, 81.8% of which were associated with symptoms (Table 6.3). The median 
duration of shedding in RV-A genotypes was one week (IQR 1-2 weeks). The maximum duration of 
shedding in RV-A types was observed in RV-A/seq-2 with five consecutive weeks in only one infant. 
Among RVA-TDE, 23 (18.1% of total RVA-TDEs) included another respiratory virus and two 
Month  
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detection episodes included two additional respiratory viruses (Table 6.2). RV-A/seq-2 was the most 
common type to be detected with other respiratory viruses, where five detection episodes (38.5% of 
total RV-A/seq-2 TDEs) contained another virus followed by RV-A/78 with four co-detections (Table 
6.3).  
 
For RV-C, RV-C/02 was identified in 18 infants (25.4% of positive infants) causing 19 rhinovirus C-
type detection episodes (RVC-TDEs) (3.7% of total RV-TDEs), which is the highest detection rate 
among all identified RV-types. The median duration of shedding for RV-C types was one week and the 
maximum shedding duration of three weeks was observed in three detection episodes caused by three 
types; these were RV-C/5, RV-C/14 and RV-C/15. For RVC-TDEs, 20 episodes (12.2% of total RVC-
TDEs) contained another virus and there was no episode that contained more than one other respiratory 
virus. For these, only one episode was accompanied by an RNA virus, which was hCoV-NL-63, while 
the remaining 19 episodes were accompanied by DNA viruses (Table 6.2). For RV-C/02, the most 
frequently detected amongst the RV-C species, only two episodes were accompanied by another virus, 
which was hBoV in both. Both RV-C/43 and RV-C/06 were the most common RV-C types to be 
detected with another respiratory virus, where each of three detection episodes from each type were 
accompanied by another respiratory virus (37.5% and 30% of total detection episodes respectively) 
(Table 6.3).  
 
For RV-B, the most frequently observed type was RV-B/84, which was detected in 20 nasal swabs 
(4.4% of total typeable swabs) collected from eight participants (11.3% of total positive participants) 
and causing eight RVB-TDEs with a median incidence in the first year of life of one episode per 
positive participant. The median duration of shedding for RV-B types was two weeks and the 
maximum of five weeks was observed in RV-B/84. Four RVB-TDEs (10.5% of total RVB-TDEs) were 
accompanied by another virus. These were KIV in two episodes (RV-B/06 and RVB-84), HAdV in one 
RV-B/26 detection episode and RSV-A in one RV-B/42 detection episode. 
 
6.3.3 RV-species in infants  
To investigate the association between RV-species and clinical outcome, 3415 nasal swabs with 
accompanying clinical data were included in this analysis (Figure 6.1). This excludes a total of 31 nasal 
swabs, two RVA-TDEs and two RVB-TDEs.  The success of VP4/VP2 typing differed between 
infants. Only six had 100% typing rates (infants; 094,092,039,081,063 and 091). (Table 6.4).   
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Table 6.4 Distribution of RV-species and number of types and RV-TDEs in infants  
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094 51 13 (25.5) 10 5 (38.5) 3 3 0 (0) 0 0 7 (53.8) 7 7 0 (0) 
027 52 23 (44.2) 9 10 (50) 4 5 6 (30) 3 3 2 (10) 2 2 3 (13) 
046 47 14 (29.8) 9 3 (27.3) 3 3 0 (0) 0 0 6 (54.5) 6 6 3 (21.4) 
065 48 15 (31.3) 8 7 (53.8) 4 4 3 (23.1) 2 2 2 (15.4) 2 2 2 (13.3) 
067 50 12 (24) 8 4 (36.4) 2 2 0 (0) 0 0 6 (54.5) 6 6 1 (8.3) 
072 49 13 (26.5) 8 7 (58.3) 4 4 2 (16.7) 1 1 3 (25) 3 3 1 (7.7) 
095 33 14 (42.4) 8 6 (60) 4 4 1 (10) 1 1 3 (30) 3 3 4 (28.6) 
042 49 21 (42.9) 7 6 (37.5) 3 3 5 (31.3) 2 3 2 (12.5) 2 3 5 (23.8) 
078 36 10 (27.8) 7 3 (37.5) 2 2 0 (0) 0 0 5 (62.5) 5 5 2 (20) 
088 46 10 (21.7) 7 4 (44.4) 3 3 1 (11.1) 1 1 3 (33.3) 3 3 1 (10) 
001 32 8 (25) 6 4 (57.1) 3 3 1 (14.3) 1 1 2 (28.6) 2 2 1 (12.5) 
016 47 12 (25.5) 6 2 (28.6) 2 2 2 (28.6) 2 2 2 (28.6) 2 2 5 (41.7) 
017 49 10 (20.4) 6 4 (50) 2 2 0 (0) 0 0 4 (50) 4 4 2 (20) 
023 51 20 (39.2) 6 6 (37.5) 2 2 3 (18.8) 1 1 3 (18.8) 3 5 4 (20) 
025 52 12 (23.1) 6 5 (71.4) 4 4 0 (0) 0 0 2 (28.6) 2 2 5 (41.7) 
051 51 12 (23.5) 6 1 (14.3) 1 1 2 (28.6) 2 2 3 (42.9) 3 3 5 (41.7) 
054 49 13 (26.5) 6 4 (50) 3 3 0 (0) 0 0 3 (37.5) 3 3 5 (38.5) 
055 44 9 (20.5) 6 3 (42.9) 2 2 1 (14.3) 1 1 3 (42.9) 3 3 2 (22.2) 
060 53 10 (18.9) 6 3 (42.9) 2 2 0 (0) 0 0 4 (57.1) 4 4 3 (30) 
062 46 18 (39.1) 6 4 (33.3) 1 1 1 (8.3) 1 1 4 (33.3) 4 4 6 (33.3) 
066 52 11 (21.2) 6 3 (33.3) 2 2 0 (0) 0 0 4 (44.4) 4 4 2 (18.2) 
075 48 11 (22.9) 6 1 (12.5) 1 1 2 (25) 1 1 4 (50) 4 4 3 (27.3) 
092 48 9 (18.8) 6 4 (44.4) 2 2 2 (22.2) 1 1 3 (33.3) 3 3 0 (0) 
019 48 8 (16.7) 5 3 (50) 3 3 2 (33.3) 1 2 1 (16.7) 1 1 2 (25) 
020 51 10 (19.6) 5 4 (50) 2 2 1 (12.5) 1 1 2 (25) 2 2 2 (20) 
035 52 12 (23.1) 5 4 (57.1) 2 2 0 (0) 0 0 3 (42.9) 3 3 5 (41.7) 
038 53 6 (11.3) 5 3 (60) 3 3 1 (20) 1 1 1 (20) 1 1 1 (16.7) 
041 52 12 (23.1) 5 3 (50) 2 2 1 (16.7) 1 1 2 (33.3) 2 2 6 (50) 
043 50 12 (24) 5 8 (80) 3 3 0 (0) 0 0 2 (20) 2 2 2 (16.7) 
050 40 6 (15) 5 2 (40) 2 2 0 (0) 0 0 3 (60) 3 3 1 (16.7) 
056 52 13 (25) 5 3 (33.3) 2 2 3 (33.3) 1 1 2 (22.2) 2 3 4 (30.8) 
064 51 16 (31.4) 5 3 (33.3) 2 2 0 (0) 0 0 3 (33.3) 3 3 7 (43.8) 
071 48 10 (20.8) 5 6 (75) 4 4 0 (0) 0 0 1 (12.5) 1 1 2 (20) 
080 50 9 (18) 5 2 (28.6) 1 1 0 (0) 0 0 4 (57.1) 4 4 2 (22.2) 
085 49 11 (22.4) 5 2 (28.6) 1 1 0 (0) 0 0 4 (57.1) 4 4 4 (36.4) 
002 33 8 (24.2) 4 4 (57.1) 2 2 0 (0) 0 0 2 (28.6) 2 2 1 (12.5) 
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Table 6.4 Continued. Distribution of RV-species and number of types and RV-TDEs in infants  
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004 53 6 (11.3) 4 1 (25) 1 1 0 (0) 0 0 3 (75) 3 3 2 (33.3) 
029 50 13 (26) 4 8 (88.9) 3 3 0 (0) 0 0 1 (11.1) 1 1 4 (30.8) 
030 44 8 (18.2) 4 4 (66.7) 3 3 0 (0) 0 0 1 (16.7) 1 1 2 (25) 
039 42 10 (23.8) 4 5 (50) 2 2 2 (20) 1 1 1 (10) 1 2 0 (0) 
045 47 10 (21.3) 4 0 (0) 0 0 4 (50) 2 2 2 (25) 2 2 2 (20) 
068 51 7 (13.7) 4 4 (66.7) 2 2 0 (0) 0 0 2 (33.3) 2 2 1 (14.3) 
079 53 7 (13.2) 4 1 (20) 1 1 0 (0) 0 0 3 (60) 3 3 2 (28.6) 
090 49 10 (20.4) 4 2 (40) 2 2 0 (0) 0 0 2 (40) 2 2 5 (50) 
005 51 8 (15.7) 3 1 (33.3) 1 1 0 (0) 0 0 2 (66.7) 2 2 5 (62.5) 
012 35 7 (20) 3 2 (66.7) 2 2 0 (0) 0 0 1 (33.3) 1 1 4 (57.1) 
013 49 6 (12.2) 3 0 (0) 0 0 1 (25) 1 1 2 (50) 2 2 2 (33.3) 
044 38 7 (18.4) 3 1 (33.3) 1 1 1 (33.3) 1 1 1 (33.3) 1 1 4 (57.1) 
049 49 8 (16.3) 3 5 (100) 3 3 0 (0) 0 0 0 (0) 0 0 3 (37.5) 
061 39 5 (12.8) 3 1 (33.3) 1 1 1 (33.3) 1 1 1 (33.3) 1 1 2 (40) 
077 51 6 (11.8) 3 2 (50) 1 1 0 (0) 0 0 2 (50) 2 2 2 (33.3) 
081 47 5 (10.6) 3 2 (40) 1 1 0 (0) 0 0 2 (40) 2 2 0 (0) 
087 52 6 (11.5) 3 0 (0) 0 0 0 (0) 0 0 3 (100) 3 3 3 (50) 
003 43 3 (7) 2 0 (0) 0 0 0 (0) 0 0 2 (100) 2 2 1 (33.3) 
006 52 7 (13.5) 2 3 (75) 1 1 0 (0) 0 0 1 (25) 1 1 3 (42.9) 
015 53 6 (11.3) 2 4 (80) 1 1 0 (0) 0 0 1 (20) 1 1 1 (16.7) 
021 53 10 (18.9) 2 5 (100) 2 2 0 (0) 0 0 0 (0) 0 0 5 (50) 
028 52 3 (5.8) 2 0 (0) 0 0 0 (0) 0 0 2 (100) 2 2 1 (33.3) 
034 50 8 (16) 2 2 (40) 1 1 3 (60) 1 1 0 (0) 0 0 3 (37.5) 
052 43 8 (18.6) 2 0 (0) 0 0 5 (83.3) 1 1 1 (16.7) 1 1 2 (25) 
058 49 5 (10.2) 2 1 (50) 1 1 0 (0) 0 0 1 (50) 1 1 3 (60) 
063 49 2 (4.1) 2 1 (50) 1 1 1 (50) 1 1 0 (0) 0 0 0 (0) 
089 47 6 (12.8) 2 0 (0) 0 0 0 (0) 0 0 2 (100) 2 2 4 (66.7) 
091 52 4 (7.7) 2 0 (0) 0 0 0 (0) 0 0 2 (50) 2 3 0 (0) 
018 51 3 (5.9) 1 0 (0) 0 0 0 (0) 0 0 1 (100) 1 1 2 (66.7) 
024 50 5 (10) 1 0 (0) 0 0 2 (100) 1 1 0 (0) 0 0 3 (60) 
031 52 3 (5.8) 1 0 (0) 0 0 0 (0) 0 0 1 (100) 1 1 2 (66.7) 
032 52 6 (11.5) 1 1 (100) 1 1 0 (0) 0 0 0 (0) 0 0 5 (83.3) 
076 48 4 (8.3) 1 1 (100) 1 1 0 (0) 0 0 0 (0) 0 0 3 (75) 
084 44 3 (6.8) 1 0 (0) 0 0 0 (0) 0 0 1 (100) 1 1 2 (66.7) 
048 49 0 (0) 0 0 (0) 0 0 0 (0) 0 0 0 (0) 0 0 0 (0) 
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The lowest proportion of typeable samples was observed in one infant (032; table 6.4) with just one of 
the six RV-positive samples able to be genotyped. This type was RV-A/18, which was also the only 
RV-A/18 positive sample identified among all typeable samples (Table 6.3). The distribution of RV-
genotypes in infants was highly variable (Table 6.4).  
 
At the species level, and when excluding untypeable samples, only one species was identified in twelve 
infants (16.9% of total RV-positive infants). RV-C was the only species identified in eight infants (003, 
018, 028, 031, 084, 087, 089 and 091) with ten different RV-C genotypes observed (RV-C/02, RV-
C/05, RV-C/06, RV-C/10 RV-C/19, RV-C36, RV-C/51, RV-C/seq-4, RV-C/seq-7 and RV-C/seq-8) 
(Tables 6.3 and 6.4). Typeable RV-A was the only species identified in four infants (049, 021, 076 and 
032) (Table 6.4). Among the four infants, five RV-A genotypes were identified (RV-A/18, RV-A/22, 
RV-A/60, RV-A/63 and RV-A/78). While for RV-B, it was the only species detected in just one infant 
(024) with only one genotype RV-B/84 found (Table 6.3 for details about genotypes distribution). 
Other than the above mentioned sole RV-species detections, RV-B was not observed in a further 31 
infants (total of 42 RV-B negative infants; 58.3% of total RV-positive infants), RV-A species was not 
observed in four infants (total of twelve RV-A negative infants; 16.9% of total RV-positive infants), 
and RV-C was not observed in two further infants (total of nine RV-C negative infants; 12.7% of total 
RV-positive infants).  
 
As shown in Table 6.5, after adjustment in the multivariate regression model for possible confounding 
factors, RVA-TDEs were significantly less likely to be observed in the second quarter of the first year 
of life and during the autumn months. Because of small numbers the model could not be applied to co-
detections of RVA-TDEs with other viruses, although with the univariate analysis there was a 
significant association with DNA-viruses and weak evidence for an association with RNA-viruses too. 
Unexpectedly, the number of RVA-TDEs was significantly higher in infants whose mothers had 
received the influenza vaccine sometime prior to delivery.   
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Table 6.5 Analysis of RVA-TDEs with possible confounding factors; the multivariate regression was adjusted to age, 
gender, number of children in the house and season  
 
wSmall number of observations, so the OR and 95% CI were omitted. 
 
Similarly, as displayed in Table 6.6, in the regression model RVB-TDEs were significantly less likely 
to be encountered in infants older than six months of age and in female infants. They were more 
  Variable 
Total number 
of episodes  
RV-A  
No. (%) 
Univariate OR (95%);  
P value 
Multivariate OR 
(95%); P value 
Age  
(months) 
0-3  67 (13.1) 18 (26.9) 1 1 
3-6    116 (22.6) 14 (12.1) 0.37 (0.17-0.81); 0.013 0.36 (0.16-0.79); 0.012 
6-9   174 (33.9) 50 (28.7) 1.09 (0.58-2.05); 0.773 1.13 (0.58-2.17); 0.708 
9-12    156 (30.4) 43 (27.6) 1.035 (0.54-1.97); 0.915 1.01 (0.51-1.96); 0.986 
Gender 
Male 249 (48.5) 61 (24.5) 1 1 
Female 264 (51.5) 64 (24.2) 0.98 (0.65-1.47); 0.946 0.95 (0.62-1.45); 0.819 
Exposure to 
smoking 
Mother 8 (1.6) 3 (37.5) 1.12 (0.58-2.13); 0.735 2.79 (0.61-12.81); 0.185 
Father 54 (11.02) 14 (25.9) 1.91 (0.45-8.16); 0.378 0.99 (0.49-2.0); 0.<982 
No exposure  428 (87.4) 102 (23.8) 1 1 
Mother IFV 
vaccine status 
Any IFV vaccine  384 (76.7) 102 (26.6) 1.75 (1.03-2.98); 0.038 1.85 (1.04-3.28); 0.034 
No IFV vaccine  117 (23.4) 20 (17.1) 1 1 
Infant order  
(mother) 
First born 324 (63.2) 73 (22.5) 1 1 
Second 120 (23.4) 31 (25.8) 1.19 (0.73-1.94); 0.466 1.26 (0.42-3.82); 0.672 
Third 55 (10.7) 16 (29.1) 1.41 (0.74-2.66); 0.29 1.90 (0.21-16.5); 0.56 
Other 14 (2.7) 5 (35.7) 1.91 (0.62-5.87); 0.259 4.87 (0.39-60.6); 0.218 
Number of 
children in 
the household  
No other children in 
the household 
298 (58.1) 68 (22.8) 1 1 
One child 151 (29.4) 38 (25.2) 1.13 (0.72-1.79); 0.58 1.07 (0.66-1.73); 0.765 
≥ two children 64 (12.5) 19 (26.7) 1.42 (0.78-2.6); 0.245 1.2 (0.64-2.24); 0.555 
Household 
size  
3 282 (54.9) 63 (22.3) 1 1 
4 130 (25.3) 33 (25.4) 1.18 (0.72-1.91); 0.497 1.1 (0.67-1.8); 0.688 
5 82 (15.9) 23 (28.1) 1.35 (0.77-2.36); 0.285 1.12 (0.62-2); 0.714 
≥ 6 19 (3.7) 6 (31.6) 1.6 (0.58-4.39); 0.358 2.04 (0.725.8); 0.181 
Feeding 
Exclusively breastfed  114 (22.2) 20 (17.5) 1 1 
Other milk  387 (75.4) 100 (25.8) 1.67 (0.96-2.79); 0.07 1.63 (0.69-3.83); 0.258 
Solids  12 (2.3) 5 (41.7) 3.35 (0.96-11.7); 0.057 2.39 (0.54-10.59); 0.248 
Childcare 
status 
Formal  93 (18.3) 28 (30.1) 1.47 (0.88-2.43); 0.135 1.3 (0.76-2.36); 0.298 
Informal  35 (6.8) 8 (22.3) 1.01 (0.44-2.3); 0.979 0.9 (0.36-2.22); 0.827 
Formal and informal 6 (1.2) 3 (50) 3.41 (0.67-17.21); 0.137 2.2 (0.41-11.71); 0.355 
No childcare  375 (73.7) 85 (22.7) 1 1 
Season 
Spring  125 (24.4) 41 (32.8) 1 1 
Summer 89 (17.4) 29 (32.6) 0.99 (0.55-1.76); 0.974 1.2 (0.63-2.13); 0.625 
Autumn 147 (28.7) 21 (14.3) 0.34 (0.18-0.62); 0.001 0.35 (0.19-0.65); 0.001 
Winter 152 (29.6) 34 (22.4) 0.59 (0.34-1.01); 0.053 0.61 (0.34-1.05); 0.077 
Co-detection 
with other 
viruses  
DNA-viruses 54 (10.5) 21 (38.9) 2.2 (1.22-3.99); 0.008 Not includedw 
RNA-viruses  5 (0.9) 3 (60) 5.2 (0.86-31.62); 0.073 Not includedw 
Both DNA and RNA 2 (0.4) 0 Not includedw Not includedw 
No co-detection 452 (88.1) 101 (22.4) 1 Not includedw 
Clinical 
outcome 
URTIs 264 (51.5) 70 (26.5) 1.5 (0.97-2.34); 0.069 1.89 (0.92-3.87); 0.082 
LRTIs 47 (9.2) 16 (34.0) 2.2 (1.07-4.33); 0.031 1.43 (0.89-2.27); 0.136 
No symptoms 202 (39.4) 39 (19.3) 1 1 
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commonly observed in summer compared to other seasons, but less likely to be associated with 
symptoms, significantly so for URTIs.  
 
Table 6.6 Analysis of RVB-TDEs with possible confounding factors; the multivariate regression was adjusted to age, 
gender, number of children in the house and season  
 
  Variable 
Total number 
of episodes  
RV-B 
No. (%) 
Univariate OR (95%);  
P value 
Multivariate OR 
(95%); P value 
Age  
(months) 
0-3  67 (13.1) 8 (11.9) 1 1 
3-6   116 (22.6) 15.12.9) 1.09 (0.43-2.7); 846 0.95 (0.36-2.46); 0.92 
6-9   174 (33.9) 8 (4.6) 0.35 (0.12-0.98): 0.048 0.33 (0.12-0.95); 0.04 
9-12   156 (30.4) 5 (3.2) 0.24 (0.07-0.77); 0.017 0.24 (0.75-0.81); 0.021 
Gender 
Male 249 (48.5) 24 (9.6) 1 1 
Female 264 (51.5) 12 (4.55) 0.44 (0.21-0.91); 0.027 0.38 (0.18-0.81); 0.013 
Exposure to 
smoking 
Mother 8 (1.6) 1 (12.5) 1.76 (0.21-14.8); 0.599 1.01 (0.11-9.46); 0.992 
Father 54 (11.02) 3 (5.6) 0.72 (0.21-2.46); 0.610 0.70 (0.19-2.55); 0.592 
No exposure  428 (87.4) 32 (7.5) 1 1 
Mother IFV 
vaccine status 
Any IFV vaccine  384 (76.7) 27 (7.1) 0.92 (0.41-1.98); 0.809 0.88 (0.37-2.06); 0.772 
No IFV vaccine  117 (23.4) 9 (7.7) 1 1 
Infant order  
(mother) 
First born 324 (63.2) 24 (7.4) 1 Not includedw 
Second 120 (23.4) 7 (5.8) 0.77 (0.32-1.84): 0.970 Not includedw 
Third 55 (10.7) 4 (7.3) 0.08 (0.32-2.94); 0.72 Not includedw 
Other 14 (2.7) 1 (7.1) 0.96 (0.12-7.66); 0.97 Not includedw 
Number of 
children in 
the household  
No other children in 
the household 
298 (58.1) 
20 (6.7) 1 1 
One child 151 (29.4) 11 (7.3) 1.09 (0.5-2.34); 0.821 1.03 (0.46-2.28); 0.934 
≥ two children 64 (12.5) 5 (7.8) 1.17 (0.42-3.26); 0.753 1.82 (0.62-5.38); 0.273 
Household 
size  
3 282 (54.9) 19 (6.7) 1 1 
4 130 (25.3) 7 (5.4) 0.78 (0.32-1.92); 0.6 0.77 (0.31-1.94); 0.586 
5 82 (15.9) 8 (9.7) 1.46 (0.62-3.55); 0.361 1.39 (0.55-3.448);0.475 
≥ 6 19 (3.7) 2 (10.5) 1.62 (0.35-7.57); 0.534 2.72 (0.54-13.52); 0.22 
Feeding 
Exclusively breastfed  114 (22.2) 16 (14.0) 1 1 
Other milk  387 (75.4) 20 (5.2) 0.33 (0.16-0.66); 0.002 0.5 (0.19-1.34); 0.173 
Solids  12 (2.3) 0 Not includedw Not includedw 
Childcare 
status 
Formal  93 (18.3) 4 (4.3) 1.01 (0.3-3.41); 0.981 Not includedw 
Informal  35 (6.8) 3 (8.8) 1.17 (0.3-4.56); 0.818 Not includedw 
Formal and informal 6 (1.2) 0 Not includedw Not includedw 
No childcare  375 (73.7) 28 (7.5) 1 1 
Season 
Spring  125 (24.4) 3 (2.4) 1 1 
Summer 89 (17.4) 10 (11.2) 5.16 (1.36-19.52); 0.015 4.62 (1.19-17.9); 0.027 
Autumn 147 (28.7) 11 (7.5) 3.3 (0.89-12.29); 0.074 3.07 (0.81-11.5); 0.097 
Winter 152 (29.6) 12 (7.9) 3.49 (0.96-12.69); 0.58 3.24 (0.87-12.04); 0.078 
Co-detection 
with other 
viruses  
DNA-viruses 54 (10.5) 3 (5.6) Not includedw Not includedw 
RNA-viruses  5 (0.9) 0 Not includedw Not includedw 
Both DNA and RNA 2 (0.4) 0 Not includedw Not includedw 
No co-detection 452 (88.1) 33 (7.3) Not includedw Not includedw 
Clinical 
outcome 
URTIs 264 (51.5) 11 (4.2) 0.32 (0.15-0.67); 0.003 0.40 (0.18-0.88); 0.023 
LRTIs 47 (9.2) 1 (2.1) 0.16 (0.02-1.22); 0.078 0.24 (0.03-1.94); 0.184 
No symptoms 202 (39.4) 24 (11.8) 1 1 
 wSmall number of observations, so the OR and 95% CI were omitted. 
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Finally, Table 6.7 demonstrates that in contrast, the regression model showed that RVC-TDEs were 
significantly more common in infants in the second half of their first year of life, occurred more often 
during autumn and were more likely to be associated with symptoms of URTIs and LRTIs.   
 
Table 6.7 Analysis of RVC-TDEs with possible confounding factors; the multivariate regression was adjusted to age, 
gender, number of children in the house and season  
 
  Variable 
Total number 
of episodes  
RV-C 
No. (%) 
Univariate OR (95%); 
P value 
Multivariate OR 
(95%); 
P value 
Age  
(months) 
0-3  67 (13.1) 12 (17.9) 1 1 
3-6    116 (22.6) 32 (27.6) 1.74 (0.82-3.67); 0.143 1.73 (0.81-3.68); 0.152 
6-9   174 (33.9) 64 (36.8) 2.66 (1.32-5.35); 0.006 2.6 (1.32-5.4); 0.006 
9-12    156 (30.4) 56 (35.9) 2.56 (1.26-5.19); 0.009 2.77 (1.35-5.69): 0.005 
Gender 
Male 249 (48.5) 79 (31.7) 1 1 
Female 264 (51.5) 85 (32.2) 1.02 (0.7-1.48); 0.9 1.04 (0.71-1.53); 0.805 
Exposure to 
smoking 
Mother 8 (1.6) 3 (37.5) 1.3 (0.3-5.52); 0.72 1.18 (0.26-5.28); 0.827 
Father 54 (11.02) 17 (31.5) 0.99 (0.54-1.83); 0.993 0.96 (0.5-1.85); 0.924 
No exposure  428 (87.4) 135 (31.5) 1 1 
Mother IFV 
vaccine status 
Any IFV vaccine  384 (76.7) 118 (30.7) 0.85 (0.55-1.32); 0.481 0.93 (0.58-1.5); 0.796 
No IFV vaccine  117 (23.4) 40 (34.2) 1 1 
Infant order 
(mother) 
First born 324 (63.2) 104 (32.1) 1 1 
Second 120 (23.4) 41 (34.2) 1.09 (0.7-1.71); 0.68 1.26 (0.49-3.24); 0.621 
Third 55 (10.7) 14 (25.5) 0.72 (0.37-1.38); 0.327 1.77 (0.23-13.2); 0.576 
Other 14 (2.7) 5 (35.7) 1.17 (0.38-3.59); 0.777 2.88 (0.26-31.95); 0.388 
Number of 
children in 
the household  
No children in the 
household 
298 (58.1) 96 (32.2) 1 1 
One child 151 (29.4) 51 (33.7) 1.07 (0.71-1.62); 0.739 1.14 (0.74-1.75); 0.537 
≥ two children 64 (12.5) 17 (26.6) 0.7 (0.41-1.39); 0.377 0.76 (0.41-1.43); 0.411 
Household 
size  
3 282 (54.9) 88 (31.2) 1 1 
4 130 (25.3) 46 (35.4) 1.2 (0.78-1.87); 0.4 1.28 (0.81-2.02); 0.278 
5 82 (15.9) 24 (29.3) 0.91 (0.53-1.56); 0.738 0.97 (0.56-1.71); 0.941 
≥ 6 19 (3.7) 6 (31.6) 1.01 (0.37-2.78), 0.973 0.86 (0.30-2.42); 0.778 
Feeding 
Exclusively breastfed  114 (22.2) 21 (18.4) 1 1 
Other milk  387 (75.4) 141 (36.4) 2.5 (1.51-4.25); <0.001 1.98 (0.97-4.04); 0.06 
Solids  12 (2.3) 2 (16.7) 0.88 (0.18-4.34); 0.881 0.72 (0.13-4.08); 0.720 
Childcare 
status 
Formal  93 (18.3) 30 (32.3) 0.98 (0.61-1.61); 0.965 0.74 (0.43-1.26); 0.277 
Informal  35 (6.8) 7 (20) 0.51 (0.21-1.23); 0.138 0.45 (0.18-1.1); 0.082 
Formal and informal 6 (1.2) 3 (50) 2.07 (0.41-10.5); 0.377 1.84 (0.34-9.77); 0.472 
No childcare  375 (73.7) 122 (32.5) 1 1 
Season 
Spring 125 (24.4) 32 (25.6) 1 1 
Summer 89 (17.4) 23 (25.8) 1.02 (0.54-1.88); 0.968 1.14 (0.6-2.18); 0.672 
Autumn 147 (28.7) 55 (37.4) 1.73 (1.03-2.92); 0.038 1.86 (1.09-3.19); 0.023 
Winter 152 (29.6) 54 (35.5) 1.6 (0.95-2.69); 0.077 1.69 (0.98-2.89); 0.055 
Co-detection 
with other 
viruses  
DNA-viruses 54 (10.5) 19 (35.2) 0.46 (0.05-4.23); 0.494  Not includedw 
RNA-viruses  5 (0.9) 1 (20) 1 (0.54-1.84); 0.992 Not includedw 
Both DNA and RNA 2 (0.4) 0 Not includedw Not includedw 
No co-detection 452 (88.1) 144 (31.9) 1 Not includedw 
Clinical 
outcome 
URTIs 264 (51.5) 96 (36.4) 1.88 (1.21-2.92); 0.004 1.72 (1.09-2.67); 0.018 
LRTIs 47 (9.2) 20 (42.5) 2.43 (1.23-4.82); 0.011 2.09 (1.04-4.18); 0.036 
No symptoms 202 (39.4) 48 (23.7) 1 1 
wSmall number of observations, so the OR and 95% CI were omitted. 
171 
 
Table 6.8 shows that there were no statistically significant independent associations for RV-DEs caused 
by untypeable samples with any of the variables included in the model.  
 
 
Table 6.8 Analysis of RV-DEs caused by untypeable samples with possible confounding factors; the multivariate regression 
was adjusted to age, gender, number of children in the house and season  
 
 
Variable 
Total number 
of episodes  
Episodes with untypeable RV-samples  
No of 
samples (%) 
Univariate OR (95%);  
P value 
*Multivariate OR 
(95%); 
P value 
Age  
(months) 
0-3   67 (13.1) 29 (43.3) 1 1 
3-6     116 (22.6) 55 (47.4) 1.23 (0.65-2.32); 0.512 1.29 (0.68-2.44); 0.425 
6-9    174 (33.9) 51 (29.3) 0.55 (0.3—1); 0.051 0.55 (0.3-1); 0.053 
9-12   156 (30.4) 52 (33.3) 0.65 (0.35-1.19); 0.169 0.61 (0.33-1.14); 0.123 
Gender 
Male 249 (48.5)  84 (33.7) 1 1 
Female  264 (51.5) 103 (390 1.24 (0.84-1.84); 0.274 1.3 (0.87-1.95); 0.192 
Exposure to 
smoking 
Mother  8 (1.6) 20 (37) 0.23 (0.02-2.18); 0.02 0.24 (0.02-2.31); 0.219 
Father  54 (11) 1 (12.5) 1.01 (0.52-1.92); 0.976 1.14 (0.57-2.28); 0.69 
No exposure  480 (87.4)  158 (36.9) 1 1 
Mother IFV 
vaccine status 
Any IFV vaccine  384 (76.7)  136 (35.4) 0.79 (0.49-1.26); 0.327 0.68 (0.42-1.09); 0.116 
No IFV vaccine   117 (23.4) 48 (41) 1 1 
Infant order 
(mother) 
First born 324 (63.2)  122 (37.7) 1 1 
Second  120 (23.4) 41 (34.2) 0.86 (0.53-1.39); 0.545 0.89 (0.34-2.3); 0.819 
Third  55 (10.7) 21 (38.2) 1.02 (0.53-1.94); 0.941 0.45 (0.04-5.07); 0.52 
Other  14 (2.7) 3 (21.4) 0.45 (0.11-1.79); 0.262 0.12 (0.01-2.14); 0.152 
Number of 
children in the 
household  
No children in the 
household 
298 (58.1)  113 (37.9) 1 1 
One child  151 (29.4) 51 (33.8) 0.83 (0.53-1.31); 0.438 0.8 (0.51-1.27); 0.351 
≥ two children  64 (12.5) 23 (35.9) 0.923 (0.49-1.72) ? 0.94 (0.50-1.74): 0.425 
Household size  
3 282 (54.9)  111 (39.4) 1 1 
4  130 (25.3) 44 (33.9) 0.78 (0.49-1.3); 0.324 0.75 (0.47-1.21); 0.245 
5  82 (15.9) 27 (32.9) 0.74 (0.42-1.32); 0.313 0.81 (0.46-1.44); 0.494 
≥ 6  19 (3.7) 5 (26.3) 0.56 (0.18-1.69); 0.302 0.51 (0.16-1.57); 0.241 
Feeding 
Exclusively 
breastfed  
114 (22.2)  57 (50) 1 1 
Other milk   387 (75.4) 125 (30.3) 0.46 (0.22-0.73); 0.001 0.59 (0.31-1.14); 0.118 
Solids   12 (2.3) 5 (41.7) 0.73 (0.20-2.6); 0.622 0.91 (0.21-3.75); 0.895 
Childcare 
status 
Formal  93 (18.3) 31 (33.3) 0.83 (0.51-1.38); 0.488 1.04 (0.6-1.79); 0.882 
Informal   35 (6.9) 17 (48.6) 1.61 (0.77-3.3; 0.2 2.04 (0.93-4.46); 0.073 
Formal and 
informal 
 6 (1.2) 0 
Not includedw Not includedw 
No childcare  375 (73.7)  139 (37.1) 1 1 
Season 
Spring  125 (24.4)  49 (39.2) 1 1 
Summer  89 (17.4) 27 (30.3) 0.66 (0.63-1.2); 0.177 0.54 (0.29-1); 0.05 
Autumn  147 (28.7) 60 (40.8) 1.04 (0.63-1.7); 0.854 0.95 (0.57-1.59); 0.859 
Winter  152 (29.6) 51 (33.5) 0.77 (0.46-1.27); 0.316 0.72 (0.42-1.21); 0.217 
wSmall number of observations, so the OR and 95% CI were omitted.
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6.3.3.1 Prolonged RV-DEs and type replacement  
As reported already, prolonged detection of RV was observed in this infant cohort (chapter-3; section 
3.3.3.4 and table 3.3). Overall, there were 39 RV-DEs (11.9% of 327 RV-DEs) that persisted for more 
than three consecutive weeks with a median duration of five weeks and a maximum of nine weeks 
(IQR 4-6 weeks). The VP4/VP2 genotyping revealed only eight RV-TDEs (1.5% of total RV-TDEs) 
that could be defined as prolonged RV-DEes with continued shedding of the same RV-type for more 
than three weeks. These episodes were caused by five distinct RV-A types (two RV-A/seq-2, one RV-
A/38, one RV-A/78, one RV-A/59 and one RV-A/63) and two RV-B types (one RV-B/06 and one 
B/84). One of the RV-A/seq-2 episodes was accompanied by PIV-1 and was also the only episode, of 
the eight prolonged RV-TDEs, that was associated with ARI symptoms. Untypeable RV-detections 
were observed in 31 of the 39 prolonged RV-DEs (79.5%), sixteen of which (41%) contained one or 
more interval of untypeable detections and in all cases, a new RV-type was detected in the following 
nasal swab.  For one RV-DE that continued for four consecutive weeks, all four swabs contained 
untypeable RV detections.  
 
Figure 6.4 illustrates the prolonged detection of RV-DEs in infant 027 and the results of RV-typing 
demonstrating the diverse and dynamic nature of the different types and species.  
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Figure 6.4 Data obtained from one infant participating in the study (infant 027). Vertical bars indicate sampling events (nasal swabs-grey bars) and ERV-3 Ct values 
(blue bars,Y axis). RV-detection is identified by shape in the legend and different colors refer to RV-species (A-blue, B-green, C-yellow and untypeable samples-
orange). The numbers inside each box refers to the genotype. Different shapes indicate respiratory virus detections and their associated Ct values. The presence of acute 
respiratory illness symptoms over time is displayed at the top of the graph (green dots) and two major confounding factors, breastfeeding and childcare are also shown at 
the top (solid lines) and bottom (grey dots) of the figure respectively.  
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6.3.3.2 The first RV-TDEs 
By the age of six months, 65 infants (90.2% of total infants) had experienced at least one RV-TDE. 
Six infants (8.3% of total infants) did not have their first RV until the second half of the first year 
and one infant did not experience any RV-DEs. Overall, the first RV-DEs included 34 different RV-
types: 17 RV-A types caused 19 episodes, 12 RV-C types 17, and five RV-B types caused 11 
episodes. The remaining 24 first RV-TDEs were caused by untypeable RV-detections. In total, 34 
(47.8%) of the first RV-TDEs were associated with symptoms and 14 of these symptomatic RV-
TDEs were RVC-TDEs (Figure 6.5).  
 
 
 
Figure 6.5 The age and number of infants for which the first RV-TDE was detected. The contribution of RV-A (red-
filled bars) surpassed that of RV-C (green filled bars). The diagonally lined bars illustrate the number of first RV-TDEs 
that were associated with symptoms. 
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6.3.4 RV-TDEs and ARIs  
Overall, 424 ARI episodes were reported for members of the infant cohort (described in chapter-3; 
section 3.3.4).  Of these episodes, 234 were associated with 79 RV-types with a median of one type 
per episode and a maximum of five types in one continuous ARI episode only (Figure 6.4). 
 
 RV-C was more likely to be associated with symptoms. Of 164 RVC-TDEs, 116 (70.7%) were 
associated with both URTIs and LRTIs. LRTIs were also more likely to be associated with RVC-
TDEs (Table 6.7). RV-A was the next most common species associated with symptoms where 86 of 
127 (67.7%) RVA-TDEs were symptomatic (Table 6.5). Compared to other RV-species, RV-B was 
significantly less likely to be associated with symptoms (12/37; 32.4%; Table 6.6) and this was 
statistically significant for URTIs. For RV-A types, all of the five RV-A/80 detection episodes were 
associated with symptoms, none of which were accompanied by another respiratory virus (Table 
6.3), while for RV-C types, association with symptoms by type was not as obvious, with the 
exception of types RV-C/51 and RV-C/seq-6 for which all of their eight detection episodes were 
associated with symptoms (Table 6.3).   
 
6.3.5 RV-types in initial swabs from parents 
Of the eight positive RV nasal swabs provided by parents during the initial visit, four were 
successfully typed (50%). Three of these were collected from mothers and all contained RV-A 
types (RV-A/19, RV-A/63 and RV-A/78), while the only positive swab collected from one father 
contained the unclassified RV-C/seq-1. None of these types identified in the parental swabs were 
detected in their infants during the first three months of life. The same types, however, were 
detected in two infants in the last three months of their first year. Figure 6.6 illustrates the dynamic 
nature of RV types during the first year of life in infants whose parents were positive for RV at the 
time of their birth. 
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Figure 6.6 Respiratory virus detection during the first year of life in six infants whose parents were RV-
positive at the time of initial visit and sampling by research staff within one-to-two days of birth  
 
6.3.6 Investigation of untypeable samples  
Overall, there were 189 samples (28.3% of RV-positive samples) that provided negative results for 
the VP4/VP2 typing protocol and these were investigated further. Both the quality of RV-
amplification curves obtained from the initial real-time PCR screening and the Ct values for RV-
positives in both typeable and untypeable samples were compared. The nonparametric Mann-
Whitney U test was performed to identify any associations with Ct values from the screening RV 
RT-PCR assay. 
 
The average RV-Ct value for the 470 typeable samples (30.2; 95%CI 29.7-30.5) was significantly 
lower, indicating greater RV-template load, than the average RV-Ct values for the 189 untypeable 
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ones (36.5; 95%CI 35.7-37.2; P<0.0001), Accordingly, samples that provided Ct values numerically 
higher than 35.7 cycles (n=121) were excluded from any further investigation and were not 
subjected to the 5`UTR typing because they were unlikely to provide a typing result due to low 
template load (Figure 6.7).  
 
 
 
Figure 6.7 Comparison between RV cycle threshold (Ct) values in typeable (blue bars) versus untypeable (orange bars) 
samples. In typeable samples, the average RV-Ct values (30.2) was significantly lower (higher RNA load) than the 
average RV-Ct values (36.5) from untypeable samples (crude difference=6.3).   
 
The analysis of the amplification curves obtained from the initial RV-screening revealed three 
categories of amplification curve shape that were defined as: optimal (sigmoidal), semi-linear (some 
curving) and linear (Figure 6.8). For the optimal curves, the phases of the amplification could be 
clearly distinguished as described in chapter-2 (section 2.1.4).  
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Overall, there were 343 samples producing optimal amplification curves, of which 303 (88.3%) 
were typeable; 194 samples provided semi-linear amplification curves, of which 127 (65.5%) were 
typeable, and 130 samples provided linear signal, of which only 39 (30.0%) were typeable. For the 
latter, the average Ct value of these samples was relatively high (average= 37.3, 95%CI 35.9-38.7). 
Therefore, all samples that provided linear amplification curves were excluded from further 
investigations.  
 
6.3.7 5`UTR typing  
Overall, 107 RV-positive samples were examined using the 5`UTR typing assay because they could 
not be typed using the VP4/VP2 assay (Table 6.1) of which, 28 samples had provided optimal 
amplification curves with Ct values >35.7 cycles, while another 15 samples provided semi-linear 
curves and Ct values >35.7 cycles. However, only two samples (4.7%) were successfully amplified; 
they provided uninterpretable sequences.  
 
 
  
Figure 6.8 Comparison between the types of amplification curves showing the final VP4/VP2 results   
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6.4 Discussion  
This chapter described RV-infections during the first year of life in a subset of 72 infants 
participating in the ORChID study. This included the incidence and prevalence of different RV-
species and their association with ARIs (URTIs and LRTIs), the RV-types acquired during the first 
year of life, multiple detection of RV-species with other respiratory viruses, the seasonality of RV-
species and prolonged RV shedding that in some infants continued for as long as nine consecutive 
weeks. All RV-positive samples underwent VP4/VP2 typing and samples that failed typing were 
investigated further by targeting the more conserved 5`UTR in the RV-genome without additional 
success.  
 
6.4.1 Incidence and prevalence  
Overall, when compared with the other respiratory viruses, we observed an overall high incidence 
and prevalence of RV infections during the first year of life, and this was accompanied by a high 
degree of diversity in the RV-genotypes. During the course of this study, other community-based 
cohort studies were published that investigated RV genotypes in children. Van der Zalm et al (2011) 
described RV genotypes in a healthy, yet older child cohort, while Lee et al (2012) described RV 
types in otherwise healthy infants with one or both atopic parents. The former study collected 
samples regardless of ARI symptoms being present (van der Zalm et al., 2011), while the latter 
obtained samples only during periods of illness (Lee et al., 2012). Both studies showed a high 
diversity amongst the RV genotypes detected. Our nested cohort RV detection prevalence of 19.1% 
was approximately half that found in these two aforementioned studies (37% and 46.4% 
respectively). Possible explanations for this difference include the reduced potential for exposure in 
our infant cohort compared to an older aged one (van der Zalm et al., 2011), the screening of many 
samples that were collected independently of ARI symptoms as well as other possible technical 
aspects of this study. These factors are discussed further in chapter 7.  
 
The prevalence of RVA-TDEs increased in infants of mothers who had received the IFV vaccine 
recently. Maternal vaccination with inactivated IFV vaccine can reduce IFV illness by as much as 
63% in infants up to six months of age due to the passive immunity from transplacentally acquired 
maternal antibodies (Zaman et al., 2008). However, in agreement with our findings, another study it 
was found that there was an associated increased risk of infection with other (non-IFV) respiratory 
viruses (Cowling et al., 2012). The reasons for this increased susceptibility to other virus infections 
is unknown, although the authors suggested that vaccination could somehow interfere with innate or 
cell mediated immune responses.  Alternatively, one might also speculate that parents gained a false 
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sense of security following maternal vaccination and allowed their infants to be exposed to infection 
risks that they may have ordinarily avoided had vaccination not taken place. Interestingly, this 
association between RV-species and IFV vaccination was only observed in RVA-TDEs, which if 
based upon biological principles rather than changes in behaviour raises further questions over the 
role of IFV vaccine either in somehow protecting against RV-species other than RV-A or in 
increasing the risk of RV-A infections.  
 
6.4.2 RV-types, including association with ARI episodes 
During the 26 months of investigation, 97 different RV-genotypes were identified in 71 infants. 
RV-C/02 and RV-A/78 were among the most frequently observed types in otherwise healthy 
infants. The same findings were reported from infants and children hospitalised with community-
acquired pneumonia (Daleno et al., 2013). In our cohort, 17% of detection episodes caused by the 
two types were associated with wet cough, however none were associated with pneumonia. Despite 
the small difference in the proportions of RV-A and RV-C, RV-A species provided the greatest 
diversity, which agrees with the findings of other community-based studies (Lee et al., 2012); 
Peltola et al., 2008; van der Zalm et al., 2011). The low prevalence of RV-B observed in our study 
is also consistent with other community and hospital cohort studies (Lee et al., 2012; Miller et al., 
2011; van der Zalm et al., 2011). RV-C types were significantly more often associated with ARIs, 
including LRTIs, followed by RV-A, while RV-B had the least clinical impact. This agrees with a 
previous study in children under five years of age from Perth that reported a strong association 
between RV-C and wheezing illnesses from a prospective cohort of 197 children who presented to 
hospital with acute wheezing episodes, while no such association was observed in children with 
either RV-A or RV-B infections (Cox et al., 2013). Furthermore, those with RV-C presentations 
were also more likely to have had an increased risk of prior and subsequent hospital admissions for 
respiratory illnesses, especially if they were also atopic. In contrast, another hospital-based, but 
retrospective, study from Hong Kong, reported both RV-A or RV-C were associated with wheezing 
ARIs in children without a history of asthma (Mak et al., 2011). These disparities in results could be 
due to differences in geographic locations, study population or design. Nevertheless, both studies 
indicated the significant association between RV-C and wheezing illnesses. Recent studies have 
found that RV-C species have higher G + C content than either RV-A or RV-B and it has been 
speculated that this could signify its adaptability to replicating at higher temperatures in the lower 
airways, providing a mechanistic explanation for its apparent higher pathogenicity in ARIs, 
including inducing wheeze, than the other two RV species (Ashraf et al., 2013; Linsuwanon et al., 
2011). 
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In this study, 60 samples contained ten unclassified RV sequences. All of these matched sequences 
reported on the GenBank database from other study groups since 2011. This suggests that these 
unclassified types were not newly emerged RVs, nor were they restricted to a specific geographic 
area. The patterns of shedding, co-detection with other viruses and association with symptoms for 
these RV-types were not different to the patterns of other assigned RV-types. Except for one type, 
RV-A/seq-2, the prevalence of the unclassified types was comparable to the assigned types as well. 
Nevertheless, further investigation is needed to fully understand the evolutionary position of these 
particular RV types.  
 
The high number of untypeable samples in this study was not unique. In one of the abovementioned 
community-based studies, 30% of 101 RV positive samples collected from children were also 
untypeable (van der Zalm et al., 2011). Similar to ours, this study investigated RV-genotypes in 
samples collected at regular intervals, independent of respiratory symptoms being present. In 
contrast, in a recent hospital-based cohort, only 10.8% of 204 RV-positive samples were untypeable 
(Lauinger et al., 2013). Host biology, geography and technical factors that result in low template 
loads could be major reasons for genotyping failures as well as the possibility that further RV, or 
other Enterovirus, variants may exist. Untypeable samples were observed throughout the study 
without evidence of clustering and pose some limitations upon our analyses. In particular, every 
untypeable RV detection was considered a distinct RV-TDE, while for other RV-species 
consecutive detections of the same type were considered to be part of the same RV-TDEs. This may 
lead to overestimating RV-TDEs. However, until better RV typing methods are established we see 
this as an unavoidable limitation.   
 
As an interesting aside, I identified EV-D68 on a single occasion from an untypeable RV sample 
from infant 062 in January-2012, who remained asymptomatic during and after this viral detection 
episode. This virus was first detected in California in 1962 and until recently had been sought and 
reported rarely. However, it has been implicated recently in two outbreaks of severe ARIs in the US 
Midwest where young children with prior wheezing illnesses seem to be particularly susceptible 
(Stephenson, 2014). The full spectrum of illness caused by EV-D68 is unknown, but my results 
suggest it can also cause subclinical infection.      
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6.4.3 Co-detection with other respiratory viruses  
For RV-A there was a significantly higher proportion of co-detection with DNA-viruses. However, 
because of limited numbers of co-detections involving RNA-viruses a full regression model could 
not be completed. Caution must therefore be exercised when interpreting these data as the results 
may be from random fluctuations involving small numbers or simply because of the higher 
proportions and shedding durations of DNA-viruses compared to RNA-viruses and the high 
proportion of RV-A species.  
    
6.4.4 Seasonality  
While RV-A was least likely to be detected during autumn, this was the season where RV-C was 
the most common RV species found in the infant cohort. Previous studies suggested that differences 
in geographic locations appear to influence seasonal patterns of RV-species (Lau et al., 2010). 
There are some reports of a higher activity of RV-C in late autumn, early winter or wet seasons in 
most temperate or subtropical regions (Lau et al., 2009; Linsuwanon et al., 2009; McErlean et al., 
2007; Xiang et al., 2008). RV-A is reported to be more common in Aboriginal children in 
Kalgoorlie, Western Australia during the hot, dry summer months (Annamalay AA et al., 2012), 
while in Hong Kong RV-A has also shown autumn peaks on occasions (Lau et al., 2009). Recent 
observers have proposed a theory of alternating activity between RV-A and RV-C species (Lau et 
al., 2009) however, this was not confirmed in my study, although it only covered two autumn 
seasons and thus could miss such patterns if they emerge over more time. In this cohort, RVB-DEs 
were more likely to occur in the summer months, unlike previous reports of autumn peaks (Lau et 
al., 2009). This result may simply reflect the small numbers of RV-B identified in this study and it 
is worth noting that autumn and winter seasons were also well represented by RV-B detections. 
Finally, it should be noted that with the exception of the Kalgoorlie study, the available data for 
seasonality of RV-species were mainly derived from hospital-based studies investigating samples 
from clinically attended ARIs. Thus, their conclusions may not be completely representative of 
young infants in the community.  
 
6.4.5 Prolonged RV-detection  
The prolonged detection of RV for more than three weeks during RV-screening in the ORChID 
study was due to RV-type replacements and not because of continuous shedding of the same RV-
type. In fact, prolonged shedding of the same RV-type was very uncommon in this otherwise 
healthy birth-cohort.  Even with prolonged detection of the same RV-species, intraspecies type 
replacement was frequently observed and was more frequent than replacement of genotypes by 
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those from a different species. Shedding of the same RV type for more than four weeks was more 
likely to be observed with RV-B types. This is possibly due to the slower replication of this RV 
species compared to RV-A and RV-C but may relate to these types eliciting more mild immune 
responses. Although not very common, there are some factors that may generate the appearance of 
interruption to continuous RV-TDE. These include poor sample collection that may lead to negative 
RV results and failure in typing some RV-positive samples that were sometimes observed in the 
middle of continuous RV-TDEs.  
 
6.5 Conclusion 
The relatively long duration of this investigation, large number of participating families, high 
frequency of sampling and comprehensive testing compared to other studies created a rich data set 
to support the hypotheses of this investigation. The predominant RV-species during the first year of 
life were RV-A followed closely by RV-C, while RV-B was observed in smaller numbers. The 
majority of RV-C episodes were associated with symptoms and with a relatively high likelihood of 
an LRTI episode. The highest variability of genotypes was observed however in RV-A species. 
Finally, the prolonged detection of RV in our longitudinal study was due to RV-type replacement. 
Persistent shedding of the same RV-type in otherwise healthy infants was uncommon.  
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Appendix 6-1 Ten unclassified VP4/VP2 sequences identified in 60 samples collected from 31 infants 
 
 
 
 
                   10        20        30        40        50        60        70        80        90       100                   
          ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
A/seq-1   TCTAAGTATAAACCTATTTGATGATGTGTCTGGATGTGTTGGTTTGTCAATGGCATTACCATCAATATCAAATAAATATTGAGGCCAAACACCATATCCA  
A/seq-2   ---------------ATTGGATGATGTGTCTGGTTGTGTTGGTTTGTCAATTGCAAATGCATCCTTTGCAGTGAGATAACTGGGCCAAACTCCATATGCC  
C/seq-1   -----GGTGTAAACGGTCGGCAGATGTTTCAGGGTGGGTGGGCTTGTCAACTGATGTGGCATCTAATGCTGAAAGGTATTCAGGCCATTCACCATAAGCA  
C/seq-2   ----------AACCGATCAGTTGATGTTTCTGGATGGGTAGGTTTATCAACTGCACTGGCGTCCAGATCACTTAGGTACTGTGGCCACTCTCCGTAGGCC  
C/seq-3   ------------CCGGTCCGTAGATGTCTCAGGATGAGTGGGTTTATCCACAGCACTAGCATCAATGTCTTTTAGGTATTCAGGCCATTCCCCATAAGCC  
C/seq-4   --------AGAATCTATCAGCTGAAGTTTCTGGGTGTGTTGGTTTGTCTATTGATGAGGCATCTATGTCAGATAAATACTCAGGCCACTCTCCATATGCC  
C/seq-5   -----------ATCTATCAGATGATGTTTCAGGATGGGTCGGTTTGTCAACAGAGGTTGCATCTATATCAGATAGATACTGAGGCCATTCCCCATAAGCC  
C/seq-6   TTGAGGGTGTAGACGGTCGGCGGATGTTTCCGGGTGAGTGGGTTTATCAACTGATGTGGCATCTAATGCTGATAGATATTCCGGCCATTCGCCATAGGCG  
C/seq-7   ------------TCTATCTGCTGATGTCTCAGGATGGGTGGGTTTGTCTACTGATGTGGCATCCAAATCTGAAAGATATTCTGGCCACTCACCATAAGCT  
C/seq-8   ----------AATCTATCCGCTGATGTTTCTGGGTGTGTAGGTTTATCAACTGATGTAGCATCGATGTCAGAAAGATACTGTGGCCATTCCCCATAAGCA  
 
                  110       120       130       140       150       160       170       180       190       200          
          ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
A/seq-1   ACCACAGCATTACCTATGTCCTGTGATGTAATAGTGAAGTTTCCACAAGTTATTTGGATAATCCTATCTGAATATCCACATGCCTCTACTGATGGTGATT  
A/seq-2   ACCACCGCATTACCTATATCTTGAAATGTTATGGTAAAATCCCCCCTTGTTATCTGTATAATTCTATCAAAATACCCACATGCCTCAACAAATGGAAATT  
C/seq-1   AGAACTGTTTGTAGAGTGTCCTGGGTTGTTATTGTCGAATTCCCGATAGTGATTTGTTTAAGCCTATCAGAGAATCCACAAGCCTCAATACTGGGTGACA  
C/seq-2   ACGATTGTGTGGAGTGTATCCTGAGTTGTTATAGTGGAGCTCCCGATAGTAATTTGCTTTAGCCTATCGGAGAAACCACAAGCTTCAATACTAGGACTCA  
C/seq-3   ACAATTGTATTGAGAGTGTCCTGTGTTGTGATTGTGGAGCTACCGATAGTGATTTGTTTAAGCCTATCGGAGAATCCACAAGCTTCAATGCTGGGGCTCA  
C/seq-4   ACAACACTATTTAGTGTATCTTGGGTTGTTATGGTGGAATCTCCAATTGTAATCTGCTTGAGTCTGTCAGAGTAACCACAAGCCTCAATGCTGGGCGACA  
C/seq-5   AAGACAGTATTCAAGCTATCCTGTGTAGTAATTGTGGAGTTTCCGATAGTGATTTGTTTTAGCCTATCAGAATATCCACACGCCTCAACGCTGGGTGACA  
C/seq-6   AGGACTGTCTGCAAGGAATCCTGGGTTGTAATTGTTGAATTCCCGATAGTGATTTGCTTGAGCCTATCTGAGAATCCGCAGGCTTCGACACTAGGTGACA  
C/seq-7   AGCACACTATTGAGTGAATCTTGTGTTGTAACTGTGGAGTTACCGATAGTAATTTGCTTGAGCCTATCGGAAAACCCACAAGCCTCAACACTAGGTGACA  
C/seq-8   AGAACTGTGTGTATAGCATCTTGGGTAGTAATTGTGGAGTTACCGATAGTGATTTGTTTGAGCCTATCGGAAAATCCACATGCTTCTACTGAGGGAGACA  
 
                  210       220       230       240       250       260       270       280       290       300          
          ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
A/seq-1   GTAATGTTGGTACTCCTTTTATTAAAACATCTTTAACTGGATCAGTAAATTTACTAGGATCTTGAAAAAAGTCTAAACGTGAAGCACCGTTAAATGAACC  
A/seq-2   GAAGTGTTGGTATTCCTTTATTTAACACATCCTTAACTGGGTCAGTGAATTTGCTTGGATCTTGCAAAAAATCAAGTCTGGATGCTCCAAAGGAAGCTGC  
C/seq-1   TAAGTGCCGGG------TTTGTTAATGCTTCAGCTAAGGGTTGTGTGAATTTGGATGGATCCTGTGAAAAATCTTGTTTTGTTAACCCTGAGCTAGCAGA  
C/seq-2   TCAGTGCAGGA------TTTGTCATTGCTTCAGCGATTGGCTTCGTAAATTTTTCAGGGTCCATGGAAAAATCCTGCTTACTCAACCCACTACTGGCTGA  
C/seq-3   TTAAGGCTGGG------TTGGTCATTACTTCAGCAATGGGTTTGGTAAATTTCTCTGGGTCCATGGAAAAATCCTGTTTACTCAGACCACTACTAGCTGA  
C/seq-4   TGAGTGCAGGA------TTAGTCAAGACATCAGCAAGTGGTTGTGTGAACTTGGATGGGTCTTGTGAGAAATCTTGTTTAGAAAGTCCTGAACTAGCAGC  
C/seq-5   TTAATGCTGGG------TTTGTCAAAGCATCTGCCAAGGGTTGTGTAAATTTTGAAGGATCCTGAGAAAAATCTTGTTTTGTCAAACCTGAGCTGGCTGA  
C/seq-6   TGAGTGCTGGA------TTGGTCAATGCCTCAGCCAGAGGTTGTGTGAATTTAGAAGGGTCCTGGGAGAAATCTTGCTTTGTCAATCCAGAGCTAGCTGA  
C/seq-7   TAAGTGCCGGG------TTAGTGAGAACATCTGCTATAGGTTGAGTGAACTTGGAAGGATCCTGAGAAAAGTCTTGCTTTGTAAGACCTGAGCTGGCAGA  
C/seq-8   TTAAGGCAGGG------TTTGTCAATGTGTCAACAAGAGGCTGTGTAAACTTANACGGATCTTGAGAAAAATCCTGTTTGGTTAAACCTGAGCTAGCAAA  
 
 
 
 
195 
 
 
 
 
 
 
 
 
 
                  310       320       330       340       350       360       370       380       390       400          
          ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
A/seq-1   GTCCTTAAAATAATTGATGTTAAAATAGTTTAGGCTAAAACCATTACCAACCGTATTCTGAGTAAAATGGGTACCAACATTTTGTCTTGAAACCTGACCG  
A/seq-2   ATCTTTAAAATAATTGATGTTAAAGTAATTTAAACTTGAGCCGTTTGAAACCAAGTTTTGTGTTGAGTGAGTACCAACATTCTGCCTTGATACTTGAGCG  
C/seq-1   ATCCTTGTAATAATTGATGTTAAAATACTTGATAACTGAACCTCCTGTGGCGGAAACAGAGTTTTCGTGCGAGCCAACATTTTGTTTACTCACTTGGGCA  
C/seq-2   GTCTTTATAGTAGTTGATATTGAAATACTTGATAACTGATCCTGATGATGCTGAGATACCACTCTCATGCGAGCCAACATTCTGTTTGCTAACCTGTGCA  
C/seq-3   GTCCTTGTAATAGTTAATATTAAAATACTTAATAACTGATCCTGAAGATGCTGATATGCCACTCTCATGTGAACCAACATTTTGTTTACTCACCTGTGCG  
C/seq-4   ATCCTTATAGTAATTGATGTTAAAATACTTAACCACTGAGCCACTTTGTGCTGCAATAGTATTATCATGCGATCCAACCTTTTGTTTAGTCACCTGAGCG  
C/seq-5   ATCCTTGTAGTAATTAATGTTAAAGTATTTTATAACTGAACCTCCCGTAGCTGAAACTGAATTCTCATGTGAGCCAGTATTTTGCTTACTCACCTGTGCA  
C/seq-6   GTCCTTGTAGTAGTTGATGTTAAAATACTTAATAACTGAGCCACCAGTAGCGGAAACAGAGTTTTCATGTGAACCAACATTTTGCTTGCTCACCTGGGCA  
C/seq-7   ATCTTTGTAATAATTGATATTGAAGTATTTAATAACAGAACCACTAGAAGCATTGATACCGCTTTCATGTGAACCAACATTCTGCTTGCTCACCTGTGCG  
C/seq-8   GTCCTTATAGTAGTTAATATTGAAATACTTAATCACACCTCCATTGTTGGCATTAATTGCATTTTCGTGAGATCCAGTGTTTTGCTTGGACACTTGTGCA  
 
                  410       420       430       440       450       460       470       480       490         
          ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|.. 
A/seq-1   CCCATGATGACAAATATAAATTCTTATACTTGTCACCATGAACTAA--------TTTA----AAAAATAA-AAGGAAA--------------  
A/seq-2   CCCATGATGACAAATATATCTATATACACTTGTCACCATAAGCAAT--------AATA----AAAAAAAACAAGGAAACACG----------  
C/seq-1   CCCATAGTTACAAACTTGAT-ACACAAATTTGTAACCATGAGACAG-------TGATT----G-GTAAA-ACAGGAAACACGGA--------  
C/seq-2   CCCATGATTACT------------TATG-TTGTAACCATAGGATGC-------AAATA---TAAAGAATAAAAGGAAACACGGACAC-----  
C/seq-3   CCCATGGTTACTG-----------TATAATTGTAACCATAAGACAC-------TCAT----TAAGTTAAAAAGAGAAACACGGACAC-----  
C/seq-4   CCCATGATTACAGATCTATTCGCATAAACCTGTAACCATAAGACGA---------ATG---TAAAAGAAAAAGTGAAACACGGACACCCA--  
C/seq-5   CCCATGATTACAC-----------TATACTTGTAACCATGAGACAC-------ACATA----ATAAAAATAAAGGAAA--------------  
C/seq-6   CCCATGGTCACAAATCTGAT-ACACAAATTTGTAACCATAGGACAA-------CAATA----AAGAAAA-ACAGGAAACACG----------  
C/seq-7   CCCATGATCACAATATATAT-ACACTATATTGTGACCATATGACAT-------CAAAA----GTTAAAA--TAGGAAACACGGACACCCAAG  
C/seq-8   CCCATGGTAATCAA--------CATATACTTATCAATATATGTTGTCACCATGANATAAAATAAGGTATAAAAGGAAACACGGA--  
196 
 
Chapter 7 
General discussion  
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7.1 Overview  
ARIs caused by viruses are the most common illnesses experienced by all age groups. They are 
particularly important in children younger than two years of age who experience the highest rate of 
infections and complications. Most of the available data are derived from hospital-based studies that 
represent less than 2% of children with viral ARIs (Lambert et al., 2008). The relatively few 
previous community-based studies have suffered from one or more important methodological 
limitations, including using less sensitive detection methods, targeting of particular (often high-risk) 
groups that are not necessarily representative of the general population, screening for only a limited 
number of respiratory viruses, and only sampling from those with more severe symptoms (e.g. fever 
with wet cough or wheeze, suggesting lower respiratory involvement) or from a relatively short 
period of time (Budge et al., 2013; Kusel et al., 2006; Legg et al., 2005; Regamey et al., 2008; van 
der Zalm et al., 2009).  
Molecular-based methods, used for both the diagnosis and characterisation of respiratory viruses, 
have led to further understanding of the role and characteristics of the established respiratory 
viruses, including RSV, IFV, PIV, HAdV, hCoV-OC43, hCoV-229E and RV. They have also led to 
the discovery of several other novel respiratory viruses. Between 2000 and 2010, seven newly 
identified respiratory viruses have been described. These include hBoV, hMPV, two PyVs: KIV and 
WUV, and three coronaviruses, SARS-CoV, hCoV-NL63 and hCoV-HKU1, as well as a third RV 
species where in 2009 RV-C joined the previously described species RV-A and RV-B. Since 2010, 
other novel viruses have also been identified, including MERS-CoV, and influenza A (H7N9) virus 
(which, in addition to SARS-CoV were not sought as part of this study). These last three mentioned 
respiratory viruses have been associated with outbreaks in specific parts of the world, although none 
have occurred in Australia.   
The increased employment of highly sensitive molecular-based methods for respiratory virus 
diagnosis had also led to other important observations being made, such as the frequent detection of 
more than one respiratory virus in a single sample, the persistent shedding of some viruses, most 
notably RV, HAdV, hBoV and the two PyVs: WUV and KIV, and detecting respiratory viruses in 
samples collected from healthy, asymptomatic individuals. Nevertheless, until this study, we had 
limited knowledge of the nature and epidemiology of respiratory viruses in otherwise-healthy 
infants in the community. 
The ORChID study is a prospective community-based, dynamic, longitudinal cohort study that aims 
to describe the respiratory viruses, including their shedding patterns and association with ARIs, 
encountered in infants and young children during their first two years of life. It was designed to 
198 
 
overcome some of the major limitations of previous studies (Lambert et al., 2012) and required 
parents to collect weekly nasal swab specimens, which were sent to the laboratory by regular mail. 
Progressive recruitment over a two year period allowed testing for respiratory viruses during 
multiple seasons.  
The overall aims of my thesis were to (a) describe respiratory virus detections and their association 
with ARI symptoms during the first year of life in a subset (nested cohort) of 72 healthy infants 
from the ORChID study, (b) examine the impact of some technical issues upon respiratory virus 
detection during this longitudinal study (including the quality of nasal swab sample collection and 
transportation as well as sequence variation in DNA viruses) and (c) describe the nature of 
consecutive RV detections observed in the nested cohort. 
 
My key findings were:  
1. In otherwise healthy infants, RVs were the most frequently detected viruses and they were 
also the virus most commonly associated with ARIs during infancy. 
2. After RVs, the most commonly detected respiratory viruses were the DNA viruses, HAdV, 
hBoV and the two PyVs: KIV and WUV, followed by RSV-A. 
3. Established viruses (e.g. IFA and RSV) may be detected in asymptomatic infants.  
4. ERV-3 was used successfully to measure the quality of nasal swab collection. By 
establishing this association we were able to monitor the quality of nasal swab collection in 
real-time.  
5. Mould in nasal swabs appeared after prolonged periods between the site of collection and 
the laboratory, especially during spring and summer months and adversely affected sample 
quality. As more than 20% of our samples were at risk of mould contamination, this 
highlights the importance of examining samples as soon as they reach the laboratory and 
encouraging participating families to mail samples promptly.  
6. Sequence variation is one factor that may impact upon the performance of real-time PCR 
assays in a longitudinal study. This can be avoided by reviewing the performance of 
established real-time PCR assays by comparison to alternative updated assays.  
7. Detection of RV for more than three weeks in consecutive longitudinal samples was from 
type replacement rather than persistent shedding of a single RV-type.  
8. At any one time, large numbers of different RV-types circulate in a single geographic 
region.  
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9. RV-C appears to be more pathogenic than either RV-A and RV-B. Of the three RV species,    
RV-B was the least likely to be associated with symptoms of an ARI.  
In this chapter, I discuss further issues raised during the course of these studies that relate to clinical 
factors and the general performance of longitudinal studies. These include limitations, possible 
solutions and discussion of further implications of my findings.   
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7.2 Respiratory viruses and disease 
In chapters 3 and 6, I have discussed key findings relating to viral detection and disease. Here I 
explore three factors that I believe warrant further consideration. 
7.2.1 Potential virus-virus interactions  
Understanding the distribution of respiratory viruses in the community helps to improve our 
knowledge of virus-virus interactions. During the course of this study the national IFV surveillance 
program recorded an increase in the activity of IFVs in QLD during August 2012 (Australian 
Government Department of Health and Ageing, 2012). Several theories have been proposed to 
explain the seasonal variation and the prevalence of certain respiratory viruses. These include viral 
interference at a population level whereby the peak activity of a specific virus may at the same time 
inhibit the spread of other viruses in that location (Mackay et al., 2013). The aforementioned peak 
of IFVs in August-2012 was the only reported change in respiratory virus activity throughout the 
study but was not mirrored by extra detections in our cohort. While the data generated from this 
nested infant cohort cannot be assumed to represent the wider general community, it was of interest 
there was also a notable decline in RV proportions in August 2012 too (described in chapter 3; 
section 3.3.3.4). This decrease was also associated with a slight increase in hCoV activity within the 
cohort (Chapter 3; section 3.3.3.4, Table 3.3) and in RV activity in the local hospital-based samples 
(personal communication, Dr. Ian M. Mackay). Although this observation could be simply 
explained by the small number of infants remaining in the study at that time-point, preliminary data 
from the larger ORChID study showed similar respiratory virus activity patterns at the 
aforementioned time-point (data not shown) and others have also reported an inverse relationship 
between RV and hCoV activities (van den Bergh et al., 2012). 
The rates of co-detections in nasal swabs were higher for DNA-viruses compared to RVs (Chapter 
3; Section 3.3.3.5; Table 3.4). This could also be explained by the relatively high prevalence of 
these viruses in the cohort. Nevertheless, previous studies showed that in preschool-aged children, 
RVs were less likely to be co-detected with another respiratory virus than DNA-viruses and co-
detections involving RVs were less than expected by chance alone (Greer et al., 2009; Mackay et 
al., 2013). Both aspects were notable in the cohort (Chapter 3; Section 3.3.3.5, Figure 3.5). 
However, the small number of observations, especially for RNA-viruses, prevents an accurate 
assessment of these interactions between respiratory viruses. Also, the number of VDEs for each 
respiratory virus, other than RV, was relatively small compared to the large number of confounding 
factors present and this prevented a robust regression model being developed for use in this study. 
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Nevertheless, direct comparisons suggest that the rate of co-detection in VDEs caused by DNA-
viruses was relatively higher than in VDEs caused by RV.   
 
7.2.2 Further questions on detecting viruses in symptomatic and asymptomatic 
infants 
Detecting viruses in respiratory secretions from asymptomatic infants can result from: (i) symptoms 
being present, but going unrecognised, (ii) a nascent or incubating infection (iii) a recent infection that 
has resolved or (iv) genuine subclinical infection. The longitudinal design of this study allowed 
nascent and resolved infections to be addressed and helped define the association between VDEs 
and their accompanying symptoms. I found that approximately one-third of RVDEs were 
asymptomatic and were recorded at least once in almost three-quarters of RV infected infants, while 
more than 90% of infants in my cohort had at least one symptomatic RVDE. 
For RV-C, 164 RVC-TDEs were observed and 12.5% of these were associated with LRTIs, 
underlining the significant burden of RV-infections, particularly RV-C, in the community and their 
relatively important clinical role. Nevertheless, almost 30% of RV-C TDEs were asymptomatic. 
Our data and the literature (Daleno et al., 2013) also suggest there may be more virulent RV-C 
types  than others (e.g. RV-C/02, RV-C/15 and RV-C/06). However, studies involving thousands, 
rather than hundreds of positive RV-C samples, are required to substantiate these observations.  
In this cohort, the proportion of IFVs detected was very low. The five IFV-DEs observed 
represented only 0.8% of the overall 618 VDEs (post RV-typing), two of which were 
asymptomatic, two were associated with URTIs and one with symptoms of a LRTI. Of the two 
asymptomatic IFV infections, one was in an infant aged less than three months whose mother was 
vaccinated during pregnancy and maternal antibodies may have provided this infant with some 
degree of protection. Further studies, such as the Australian FluMum national prospective cohort 
study of more than 10,000 mother-infant pairs will help determine the effectiveness of maternal IFV 
vaccination during pregnancy at preventing IFV illness in infants before six months of age 
(O’Grady et al., 2014).  We also observed asymptomatic RSV cases. It is well established that 
maternal antibodies play a protective role against RSV infections in young term infants and the 
timing of birth with respect to the onset of the RSV season is a risk factor for severe disease. Infants 
born in the months prior to the RSV season have a greater risk of severe illness than those born 
once the RSV season is established  (Birkhaug et al., 2013; Englund, 1994; Glezen, 2003; 
Grimwood et al., 2008). Asymptomatic RSV cases may otherwise have arisen from repeated 
infections as observed in infant 065 (Appendix-1; Page XVII). These subclinical infections may 
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however be important as by shedding viruses they may act as a reservoir for transmitting RSV to 
others within the community.  
7.2.3 RV during infancy  
Despite the large number of RV-positive samples, including RVs able to be typed from this cohort, 
the high level of variation in RV-types (ie. the sheer diversity of individual types) prevented further 
analysis of whether specific types were more likely to be associated with ARI symptoms. 
Nonetheless, the data from my nested cohort suggest that some types (e.g. RV-A/78 and RV-C/02; 
Chapter 6, Table 6.3) were of interest given that they were the most frequently detected types in our 
infants, were often associated with symptoms, and have been reported previously to be associated 
with community-acquired pneumonia in older children (Daleno et al., 2013). More data related to 
RV-types, their distribution over a four year sampling period, and their association with ARIs will 
be available at the completion of the ORChID study. Identifying an accurate association between 
specific RV-types and ARIs will help with developing a candidate prophylactic vaccine or possibly 
novel therapeutics, which currently have had limited impact on preventing infection or reducing 
viral replication and duration of symptoms respectively. For vaccine development, a similar 
example is with IFV vaccines, which are updated every year according to the major IFV-serotype 
responsible for epidemics (Papi and Contoli, 2011).  However, due to the high variability of types 
observed and the short duration of my study that only covered eight seasons (Chapter 6; Section 
6.4.4), it was impossible to determine whether the predominant RV types circulating in the 
community could be predicted accurately in a year-on-year basis.   
For the untypable samples, the data show that there are more types yet to be detected and may 
include new RV-divergent species or types, especially from untypable samples with relatively early 
Ct values (Chapter 6; Section 6.3.7).  There may also be further RV-infections that are yet to be 
identified, e.g. RV/RV co-detections have been reported in previous studies (e.g. Lee et al., 2007; 
Renwick et al., 2007) however, this was not examined in our cohort. As we observed so many 
diverse RV genotypes, it is reasonable to speculate that RV/RV co-detections occurred, but went 
undetected by our methods. The VP4/VP2 typing assay was developed to comprehensively type all 
known RV types, as well as some Enterovirus strains (Wisdom et al., 2009). The variation in 
amplicon sizes allows both to be discriminated from one another. However, as RV types have PCR-
products of similar sizes, it is not possible to differentiate accurately between them. Moreover, there 
is a possibility that the assay only amplifies the predominant type in the sample. Support for this 
speculation comes from the high failure rate when attempting to type RV-samples with low viral 
loads (Chapter 6; Section 6.3.6). Therefore, selecting or developing more specific RV-typing 
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protocols may be beneficial for future investigations of RV molecular epidemiology in the 
community.  
This, to my knowledge, was the most comprehensive study investigating the first episode of RV-
DEs in individual infants in the first year of life. Interestingly, only half of the first RV-DEs that 
were observed in the cohort infants were associated with ARI symptoms. Additionally, RV-A types 
were more often seen in the first RV-DEs compared to other RV species, especially in infants who 
experienced their initial infection during the first three months of life. Further questions regarding 
the role of early RV-infections, and how they might influence subsequent respiratory virus 
infections will be answered by the completion of the ORChID study.   
7.3 Issues related to conducting community-based longitudinal studies  
7.3.1 Sensitivity of ARI definitions   
Establishing a definition of ARIs when investigating infants was particularly challenging. The 
symptom diary card used in the ORChID study was designed to maximise the number of the 
recorded ARI episodes. It included all possible categories of ARI symptoms and signs, some of 
which were intended to capture influenza-like symptoms in older children (Lambert et al., 2007; 
Lambert et al., 2012). The ARI definition used in this study, however, considered only respiratory-
related symptoms. Other symptoms, such as headaches, sore throats and muscle pain were excluded 
as non-verbal infants cannot complain of these symptoms and irritability is too non-specific to be 
reliable in this context. From our data, almost one-third of the VDEs were not associated with 
symptoms. This outcome did not change significantly when we included into the ARI definition 
symptoms such as headaches and muscle pain recorded by parents in the symptom diary. Overall, 
given the longitudinal design of the study, this suggests that asymptomatic detections were either 
associated with very mild and unrecognised symptoms of ARIs or were genuine subclinical 
infections. Moreover, this indicates that our ARI definition is not likely to have grossly 
underestimated the total number of ARIs in our community cohort, and therefore is an important 
finding for planning similar studies in the future. 
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7.3.2 Symptom data collection and transformation – the potential benefits of 
new technology?  
One problem that became increasingly evident during the study was that of data management. 
Basically, it was very time consuming, especially when transferring data from the symptom diary 
cards to soft copies. In future studies, replacing regular symptom diary cards with electronic cards 
(E-cards) may help solve this problem. Such E-cards can be developed as smart-phone applications 
for ease of access. Also, simple functions can be added, such as reminder notifications for data 
recording, missing data monitoring or sample collection and transportation. This may be especially 
relevant when considering the sample quality issues raised in chapter 4, namely the failure to mail 
samples promptly. All data can also be synchronised in defined databases to larger on-line 
databases. Similar E-card systems, if supported by data illustration tools, could provide invaluable 
resources for families by educating them about study tasks and helping them to recognise specific 
symptoms and signs of ARI in their infants.  Taken together, these measures may also help with 
cohort maintenance and retention. Finally, taking a much broader ‘over the horizon’ perspective, E-
cards could also be used in the future to help health practitioners monitor ARIs in their patients as 
part of an integrated health care package and for researchers to survey ARIs in a given population 
and to link them to subsequent chronic pulmonary disorders, such as asthma or COPD. 
7.3.3 Communicating with participating families  
In this study, no results were communicated to parents until the completion of the two years of 
investigation (as in the ORChID study). We did however, on occasion, contact them in response to 
issues with the ERV3 PCR results, to remind them of the optimal sample collection methods. This 
lack of communication of results was done deliberately to avoid any possible information bias as 
knowledge of a viral infection may alter the way parents report symptoms (Lambert et al., 2007). 
However, during the course of this study, three significant international outbreaks were reported, all 
of which were caused by newly identified viruses; the novel MERS-CoV and the two IFVs: H9N7 
and H10N8. In my opinion, it is likely the influence of media reports and heightened concerns may 
change participants’ behavior in terms of either reporting symptoms or collection of samples. With 
the volume of gathered data on quality of sample collection (ERV-3; Chapter 4) and by designing 
surveys to measure their awareness, the influence of media reports on participant’s behavior could 
be examined in subsequent studies.   
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7.4 Further laboratory aspects; low viral load and real-time PCR 
sensitivity 
When using real-time PCR for respiratory sample screening, the Ct-values are often used as a semi-
quantitative measure for viral load that can be used to determine whether the latter correlates with 
clinical severity. For more severe illnesses, as seen in patients presenting to hospital or emergency 
clinics, respiratory virus screening often provides early Ct values (indicating high-viral loads) 
(Christensen et al., 2010; Harvala et al., 2012; Ngaosuwankul et al., 2010). This may however, be 
related to several factors, including the method obtained for respiratory sample collection, the 
expertise of those collecting particular specimens (e.g. NPAs), time between collection and 
screening, and the conditions under which samples were transported to the laboratory. Other 
patient-related factors, such as severity of symptoms, timing of sample collection (early vs late in 
the ARI episode) and any underlying chronic health disorders should also be considered. 
 Unlike the above clinical situations, for this community-based study, we adopted sampling 
strategies that would be most acceptable to parents and families in order to optimise cohort 
retention while still conducting intensive viral surveillance. For example, collecting weekly nasal 
swabs and sending them to the laboratory by regular mail at ambient temperatures was accompanied 
by nasal swab specimen return rates exceeding 90% throughout the study. Yet, some technical 
factors should be taken into consideration when using similar strategies in community-based 
studies. Respiratory virus screening data provided in this study indicated that Ct values may not 
always accurately reflect the true viral load and thus cannot be relied upon to measure associations 
between respiratory viruses and illness severity. 
Late (or high) Ct values obtained from respiratory virus screening in community-cohorts risk under-
estimating the true burden of some respiratory viruses by either misreading associations between Ct 
values and disease severity or, more importantly, reporting false-negative results. To overcome the 
latter, the routine weekly sampling strategy obtained in this longitudinal study, was designed to help 
maximise chances of detecting respiratory viruses, even though sampling may not always have 
occurred at the time of peak virus shedding in first days of the infection episode. Therefore, when 
studying or diagnosing infants and children respiratory viruses in the community, taking samples 
within one week of an ARI should still lead to a respiratory virus detection on most occasions.  
One of the aims of this longitudinal study was to determine the kinetics of respiratory virus 
shedding from the respiratory tract. However, this can also be under-estimated when there are false-
negative results due to low template loads and providing a false impression of intermittent virus 
shedding. In addition, low template loads in nasal swab samples collected from community studies 
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may compromise investigations of certain viruses, when less sensitive methods are being employed 
on these samples. An example of this occurred with the RV-typing project where 64% of the 
untypeable samples provided late Ct values (>35.7 cycles). While in these instances the viral load 
may have been genuinely low, some of the preventable technical factors may have contributed to 
produce such late Ct values. These are now discussed further below.   
Nasal swab samples and potential variability Samples such as respiratory swabs have the 
potential for sampling error from poor technique and to introduce considerable variability, even 
when collected by well-trained health professionals. In this study we demonstrated, by using ERV3 
as a marker for collection quality, that considerable variability in specimen quality existed between 
nasal swab specimens collected by parents and that some parents were not as good as others at 
obtaining adequate specimens. An example of this is provided by one infant (Infant 048; Appendix-
1; page XVII) whereby the swabs collected from this infant were consistently negative for all 
respiratory viruses until the last month of the study when KIV was detected in two samples over a 
two week period. By applying the ERV-3 method, we found that ERV-3 load in this infant’s nasal 
swabs were significantly lower than the ERV-3 load in swabs from other infants indicating that the 
swabs obtained from infant 048 were, in general, suboptimal and likely to have been poorly 
collected. The quality of serial nasal swab samples collected from the same subject could vary from 
sample-to-sample and over time. As an example, some parents reported difficulties in collecting 
samples as the study progressed and their infants became older, or when infants experienced ARIs 
some resisted having swabs taken. Establishing a simple system to quantitatively measure the 
quality of sample collections was important for understanding the reasons for any decline in viral 
detection rate for some infants and to address one possible confounding factor that may impact 
upon Ct values.   
Sequence variation: another factor influencing respiratory virus screening To a lesser 
extent, this study also demonstrated that sequence variation in our community samples could 
introduce delayed Ct values for HAdV, and possibly other viruses. For a given established real-time 
PCR assay and when sequence variation could explain delayed Ct values obtained from community 
samples, one suggested strategy is to use an alternative assay that targets different genome areas to 
ensure accurate Ct values are being obtained. This will provide data confirming assay performance 
is not being compromised in a given study population (i.e. the ORChID cohort) prior to making any 
decision upon whether an established assay needs replacing. When choosing the pan-HAdV assay 
for my study I was aware of considerable differences between HAdV types, of new HAdV types 
and variants being identified, and that this assay had been in use for almost a decade. Consequently, 
I employed a modified version of the established assay comprising identical oligonucleotides as an 
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initial quality assurance exercise and I was able to confirm that the established pan-HAdV PCR 
method that was initially selected for the ORChID study was appropriate for viral detection, but not 
for quantification purposes. The modified assay however replaced the established pan-HAdV to 
avoid false-negative results due to true low HAdV load in the nasal swab samples.  
Degenerate bases are commonly adopted to overcome sequence variation when designing 
respiratory virus real-time PCR assays (Arthur et al., 2009; Lu et al., 2008; Orozovic et al., 2010). 
However, the accumulation of degenerate bases in real-time PCR primers or probes are not 
recommended as they increase the background signals due to non-specific binding (Rychlik, 1995). 
This is particularly important when performing large numbers of samples as it may complicate 
interpretation of the results, especially in samples with true low viral loads. Furthermore, balancing 
melting temperatures can be very challenging when designing a degenerate real-time PCR assay 
that is comprehensive for all strains of a specific virus. Therefore, when designing the modified 
assays, I aimed at distributing degenerate bases over several oligonucleotide versions that were, 
otherwise, identical to the targeted sequence. The method proved successful at overcoming the 
problem of sequence variation and avoiding further delays in Ct-values.   
The strategy of using an alternative assay targeting a completely different target was used in the 
RV-typing project that relied upon conventional PCR assays in a carefully designed protocol 
(Chapter 6; sections; 6.2.3, 6.2.4. Figure 6.1). The aim of this protocol was to eliminate most of the 
possible factors that may cause failure in VP4/VP2 typing. The VP4/VP2 typing assay is a nested 
assay that targets a region of the RV-genome comprising high levels of heterogeneity between RV-
types. Consequently, late amplification due to sequence variation was predicted to be the most 
likely cause when the VP4/VP2 typing assay failed in the initial step of the typing strategy. Of the 
221 samples that failed to be typed in the first step, 32 (14.5%) RV-positive samples were typed 
when the VP4/VP2 typing step was repeated. In other words, using this protocol increased the 
chance of producing a detectable amount of VP4/VP2 PCR-product by less than 5%. The remaining 
189 RV-positive samples were subjected to further screening and analysis to confirm positivity and 
Ct values. Once completed, samples with early Ct values were typed using the more conserved 
5`UTR to eliminate the sequence variation factor (Chapter 6; sections 6.3.5, 6.3.6). When this step 
also failed, other possible reasons (see next section) were examined to explain both delayed Ct 
values and failure of typing.       
Quality of real-time PCR templates This involves genome templates resulting from the 
nucleic acid extraction step, which itself may be affected by other factors, including the efficiency 
of the automated system and the performance of the extraction reagents. The high number of nasal 
swabs expected to be submitted over a relatively short period of time required a time-efficient 
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system for nucleic acid extraction. The QIAxtractor robotic system, which is a vacuum-based 
nucleic acid extraction system, was chosen for this purpose. The genomic DNA extraction kit (DX) 
(Qiagen, Australia) was selected on the basis of the QPID laboratory experience and other previous 
studies suggesting its suitability for respiratory virus detection and quantification (Wishaupt et al., 
2011). However, alternative extraction kits that are more specific for viral nucleic acid extraction 
purposes may have provided better results.  The viral nucleic acid extraction kit (VX) (Qiagen, 
Australia), which was introduced after the ORChID study commenced is such an example. In a pilot 
study, I compared the performances of the two kits, using a single batch of ORChID samples. The 
two viral nucleic acid templates used for this comparison were EHV-1 and RV. EHV-1 was selected 
as a representative for viral DNA, while RV was selected to represent the viral RNA component as 
it was the most frequently detected respiratory virus. For the DNA template (EHV-1), the two kits 
performed similarly for both detection rate and Ct values. In contrast, PCR assays using  the viral 
RNA extraction kit had slightly increased detection rates and lower Ct values for RV when 
compared with the QIAxtractor system (data not shown), especially in samples with original low 
RV loads. This suggested that while the DX kit is suitable for broad-based extraction of both 
viruses and bacteria, it may not be necessarily optimal for RV and possibly other RNA viruses. 
While we do not expect this to have any significant effect on the main outcomes of the ORChID 
study, considering its intensive sampling, it may have compromised RV genotyping (i.e. insufficient 
load for the less sensitive typing methods).  
These aforementioned factors highlight that a late Ct-value observed for any given positive 
sample may not necessarily reflect low viral loads for several technical reasons. In addition, my 
results caution against using parent-collected nasal swabs being used to accurately assess viral load 
in samples from community-based studies. While probably not important for understanding the 
nature of respiratory viruses in young children, high load is often used as a marker of active viral 
replication and thus alternative strategies such as frequent sampling and monitoring sample quality 
as employed in ORChID will still need to be used to address this limitation.  
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7.5 Other potential limitations 
The sampling protocol used in the ORChID study, including the swabs used, was established and 
selected according to work published previously involving community-based sampling in 
Australian children, including mailing nasal swab specimens (Lambert et al., 2007; O’Grady et al., 
2010; Yin et al., 2011).  While the available studies report a slightly better performance of flocked 
swabs compared to rayon swabs, those studies compared flocked swabs with liquid universal 
transport media to rayon swabs incorporating a sponge reservoir containing VTM (Esposito et al., 
2010; Hernes et al., 2011). The design of the ORChID study required the parents to mail samples to 
the research laboratory using the regular postal service. Importantly, the Australia Post regulations 
prohibit sending liquid biological samples. Although dry flocked swabs were an option, the absence 
of comparative data was problematic and by using a sponge soaked with VTM to help maintain 
respiratory virus particles at ambient temperatures this allowed rayon budded swabs to be chosen 
for this study.  
    
While the virological data described in this study are important, they may serve as a minimal 
estimate for at least some viruses. The data for some viruses were generated from small numbers of 
infections and therefore they may not be representative of the general community. The ORChID 
study will provide further data to examine the role of these viruses and to understand the 
significance of asymptomatic VDEs in the older cohort.  
 
Additionally, due to the characteristics of this nested cohort, it may not be representative of other 
Australian infants or the global community. The infants lived in small, socioeconomically 
advantaged family units where breast feeding rates were high and daycare attendance and passive 
exposure to tobacco was low. The data were also derived from an urban subtropical environment, 
which may influence the epidemiology, including transmission dynamics, of some respiratory 
viruses as seen with RSV and RV (Chapter 6; Section 6.4.4).  
 
My study included six newly identified viruses. However, the role of other novel respiratory viruses 
during infancy has attracted more attention recently, such as IFV-C and PIV-4. Recent data suggest 
that these viruses may have a role in ARIs during infancy comparable to other more established 
respiratory viruses (Calvo et al., 2013; Fox and Christenson, 2014). 
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7.6 Future directions  
My PhD studies have provided important insights into conducting intensive community-based 
studies of respiratory viruses in young children. In so doing several research questions have also 
been raised by my findings. In regard to determining the severity of symptoms, changes in types of 
respiratory viruses during an ARI were noticed in this cohort and in some cases these were 
associated with increased symptom severity. This observation needs further study with higher 
number of both ARIs and proportions of respiratory viruses to help determine whether mixed or 
sequential infections result in more severe symptoms.   
 
Almost half of the first RV-detections observed in this cohort were asymptomatic. The first RV-
DEs in these infants were caused by different RV-types. This observation can lead to several future 
studies to investigate: (a) the association between RV-types that cause the first RV-detection after 
birth and presence and severity of symptoms, (b) the relationship between the age at which the first 
infection occurs and the number of subsequent RV-detections and (c) the impact of early and/or 
repeated RV exposure upon respiratory health, lung growth and lung function in later childhood.   
 
Longitudinally collected samples and data provide an opportunity to investigate the influence of 
respiratory virus infections and early life events (breast or milk formula feeding, childcare 
attendance, antibiotics, tobacco smoke exposure and other environmental factors) upon establishing 
and maintaining the nasal microbiome during the first two years of life. In addition, these types of 
data may aid in determining the nature of viral-bacterial interactions within the infant’s nasal space, 
including their relationship with ARIs in early childhood and future respiratory health and lung 
function. Previous cross-sectional studies reported positive associations between HAdV and RV and 
both M. catarrhalis and H .influenzae. However, the direction of such associations was not 
determined due to lack of intensive follow up in these studies (Moore et al., 2010; Pitkäranta et al., 
2006).   
 
By providing an insight into the performance of longitudinal nasal swab collection, alternative 
approaches may help in improving the quality of parental sample collection technique. These 
include; the use of a nasal saline spray prior to taking a nasal swab and comparing this with nasal 
swabs alone in this young age group. Previous studies in older children have indicated this method 
provided similar results to those obtained by standard nasal washes and deep nasal or 
nasopharyngeal swabs (Campbell et al., 2013; Emerson et al., 2013). An increased detection 
sensitivity of 7% was found when comparing nasal swab samples collected from children with CF 
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aged six to 18 years before and after instillation of nasal sprays (Emerson et al., 2013). However, 
for young children and when parental collection is required, the level of acceptance of this method 
is unknown.  
 
Finally, virus discovery can be undertaken using shotgun cloning and next generation sequencing, 
especially in samples that were collected during well-documented ARIs, but which were negative 
for all respiratory viruses. Similar techniques could be beneficial in investigating untypable RV-
positive, especially those with early Ct values (<35 cycles), to determine the nature of these samples 
and whether they contained novel RV-divergent types.  
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Appendix-1 
Illustration of data obtained from infants during the first year of 
life. 
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http://www.biomedcentral.com/1471-2334/14/15RESEARCH ARTICLE Open AccessNasal swab samples and real-time polymerase
chain reaction assays in community-based,
longitudinal studies of respiratory viruses: the
importance of sample integrity and quality control
Asma N Alsaleh1,2,3*, David M Whiley1,2, Seweryn Bialasiewicz1,2, Stephen B Lambert1,2,4, Robert S Ware1,5,
Michael D Nissen1,2,6, Theo P Sloots1,2,6 and Keith Grimwood1,2Abstract
Background: Carefully conducted, community-based, longitudinal studies are required to gain further understanding
of the nature and timing of respiratory viruses causing infections in the population. However, such studies pose
unique challenges for field specimen collection, including as we have observed the appearance of mould in some
nasal swab specimens. We therefore investigated the impact of sample collection quality and the presence of visible
mould in samples upon respiratory virus detection by real-time polymerase chain reaction (PCR) assays.
Methods: Anterior nasal swab samples were collected from infants participating in an ongoing community-based,
longitudinal, dynamic birth cohort study. The samples were first collected from each infant shortly after birth and
weekly thereafter. They were then mailed to the laboratory where they were catalogued, stored at −80°C and later
screened by PCR for 17 respiratory viruses. The quality of specimen collection was assessed by screening for human
deoxyribonucleic acid (DNA) using endogenous retrovirus 3 (ERV3). The impact of ERV3 load upon respiratory virus
detection and the impact of visible mould observed in a subset of swabs reaching the laboratory upon both ERV3
loads and respiratory virus detection was determined.
Results: In total, 4933 nasal swabs were received in the laboratory. ERV3 load in nasal swabs was associated with
respiratory virus detection. Reduced respiratory virus detection (odds ratio 0.35; 95% confidence interval 0.27-0.44)
was observed in samples where the ERV3 could not be identified. Mould was associated with increased time of
samples reaching the laboratory and reduced ERV3 loads and respiratory virus detection.
Conclusion: Suboptimal sample collection and high levels of visible mould can impact negatively upon sample
quality. Quality control measures, including monitoring human DNA loads using ERV3 as a marker for epithelial cell
components in samples should be undertaken to optimize the validity of real-time PCR results for respiratory virus
investigations in community-based studies.
Keywords: Nasal swab, Respiratory virus, Real-time polymerase chain reaction, Quality control, Mould,
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http://www.biomedcentral.com/1471-2334/14/15Background
Acute respiratory infections (ARIs) caused by viruses are
the most common illnesses experienced by all age
groups. ARIs are particularly important during early life
as infants have the highest infection rates and they can
transmit infectious agents to other household members
[1]. Recently introduced molecular-based diagnostic tech-
niques have much improved sensitivity compared with
previous classical culture and phenotypic-based methods
and have led to the discovery of new respiratory viruses
[2]. However, contemporary studies employing these new
techniques have often used convenience samples obtained
from patients admitted to hospital or attending Emer-
gency Department clinics [3-5]. Understanding more fully
the ARI disease burden in the community is important for
developing public health interventions, such as vaccin-
ation programs [6], and for understanding the role respira-
tory viruses may play in the pathogenesis of certain
chronic pulmonary disorders, such as asthma [7-9]. This
has led to the instigation of community-based studies.
Such studies do however have some logistical challenges,
particularly concerning respiratory sample collection and
transport. Most studies have relied upon clinic or home
visits by trained healthcare workers to collect specimens
during an ARI episode, which imposes restrictions upon
busy families and may lead to biased disease estimates and
specimen availability [10-12]. Cost and feasibility of using
healthcare workers are also important when large longitu-
dinal, community-based cohort studies, involving frequent
specimen collections, are planned. To help address these
limitations, we and others have begun testing parent-
collected, anterior nasal swab specimens that have been
transported to the research laboratory using the standard
mail [13-16]. This approach is considered to be safe,
convenient and cost-effective [17].
Importantly, when using highly sensitive polymerase
chain reaction (PCR) assays the detection rates for re-
spiratory viruses are similar in both anterior nasal swab
specimens and samples collected by the more traditional
method of nasopharyngeal aspiration [18,19]. Building
on this information, later studies have also shown that
PCR testing for respiratory viruses provided similar results
for parent-collected anterior nasal swab specimens and
either nasal swab or nasoparyngeal aspirates collected
by healthcare professionals [16,17]. Other studies exam-
ining sample transport have also shown that mailing
swabs at ambient temperature has limited or no impact
on respiratory virus detection by PCR [14,20,21], although
investigating further the effects of transporting samples
for extended periods and at higher temperatures was
highlighted in one study [20].
The observational research in childhood infectious dis-
eases (ORChID) project is a longitudinal, community-
based, dynamic birth cohort study, which seeks to describethe nature and timing of respiratory viruses detected in
Australian children during the first 2-years of life [22].
The study commenced in late 2010 and involves parents
collecting and mailing nasal swabs weekly to the research
laboratory for PCR-based respiratory virus screening.
During the first year mould was seen in some samples
as they arrived in the laboratory and we became con-
cerned about the impact of this contaminant upon sam-
ple integrity. Therefore, as part of the ORChID study,
we undertook a broader investigation of sample quality,
examining collection and transportation, and how these
impact on respiratory virus detection. Our objectives were
first to determine the quality of specimen collection by
testing for the presence of human DNA (endogenous
retrovirus3; ERV3) and then to investigate the effects of
sample quality and the presence of visible mould in
samples reaching the laboratory upon PCR performance.
Methods
The cohort
Briefly, as part of ORChID, families expecting a healthy
term baby were recruited antenatally at either the publi-
cally funded Royal Brisbane and Women’s Hospital or the
North West Private Hospital, in Brisbane, Australia, a sub-
tropical city of more than 2 million inhabitants [22].
Ethics statement
The Human Research Ethics Committees of the Children’s
Health Queensland Hospital and Health Service, the
Royal Brisbane and Women’s Hospital and the University
of Queensland approved the study. Parents/caregivers of
each baby provided written, informed consent at the time
of enrolment into the study.
Sample collection
Parents were asked to record from birth a daily symptom
diary and to collect anterior nasal swab samples every
week until their infant’s second birthday. Instructions on
sample collection were provided at the initial visit by
research staff who also demonstrated the technique by
undertaking the initial nasal swab specimen shortly
after delivery of the newborn baby. In addition, parents
were given written instructions on how to collect nasal
swab specimens. They also received regular text messages,
emails or telephone calls as means of research staff keep-
ing in contact with participating families. Regular supplies
of sterile rayon swabs (Virocult, MW950, Medical Wire &
Equipment, England) were provided, which were rotated
against the internal anterior walls of both nostrils and then
placed in the provided transport tube that contained a
viral transport media-soaked foam pad in the base. Parents
were instructed to squeeze the foam pad to release the
fluid and bathe the top of the swab. Ideally within 24-
hours of collection, the nasal swabs were then sent by
Alsaleh et al. BMC Infectious Diseases 2014, 14:15 Page 3 of 9
http://www.biomedcentral.com/1471-2334/14/15regular postal mail (in accordance with Australia Post
regulations [23]) at ambient temperature to our research
laboratory where they were stored at −80°C until analysis.
DNA extraction and quality control measures
Nasal swabs were vortexed in 2 mL of phosphate buffered
saline from which 200 μL was spiked with 5 μL of equine
herpes virus-1 (EHV1) culture supernatant, which served
as an extraction and inhibition control agent, before nu-
cleic acid was extracted using the CAS1820 XtractorGene
automated system (Qiagen-Australia) according to the
manufacturer’s instructions. The final volumes of speci-
men extracts were 150 μL/specimen eluted in 96 well
racks (Matrix, Thermo Scientific, Australia). For each run
(96 extracts/run), extracts were tested using a duplex
real-time PCR assay for EHV1 and ERV3 in the follow-
ing reaction compositions; 10pmoles of each primer,
4pmoles of each probe (Table 1), 10 μL of SensiMix II
Probe PCR Mix (Bioline, Australia) and 2 μL of extract
in a 20 μL final reaction. Cycling conditions used for
amplification were: initial hold at 10 min at 95°C;
followed by 45 cycles of 30 sec at 95°C and 60 sec at 60°C.
The EHV1 component was performed as an extraction
and inhibitor control as described previously [24], while
ERV3 was used as a marker to evaluate the quality of nasal
swab sample collection [25]. Briefly, the samples were
considered to have failed the EHV1 component (ie. failed
extraction or possessed PCR inhibitors) if the EHV1
real-time PCR cycle threshold (Ct) results for individual
samples were more than two standard deviations from
the mean value of all samples, which for this study was
calculated to be approximately 30 cycles [24].
Respiratory virus screening:
Samples that passed EHV1 DNA extraction quality con-
trol testing were screened for respiratory viruses using
previously optimized and described PCR and reverse
transcriptase PCR assays. Virus testing assays included:
rhinovirus (RV) [26], influenza viruses (A and B) [27],
respiratory syncytial viruses (A and B) [28], parainflu-
enza viruses (1–3) [29], human adenoviruses [22], humanTable 1 Oligonucleotide primers for equine herpes
virus-1 (EHV 1) and endogenous retrovirus 3 (ERV3)
used for samples quality control
Name Sequence Reference
EHV1-F GATGACACTAGCGACTTCGA [24]
EHV1-R CAGGGCAGAAACCATAGACA
EHV1-TM Quasar-670-TTTCGCGTGCCTCCTCCAG-bhq2
ERV3-F CATGGGAAGCAAGGGAACTAATG [25]
ERV3-R CCCAGCGAGCAATACAGAATTT
ERV3-TM Fam-TCTTCCCTCGAACCTGCACCATCAAGTCA-bhq1
Sequences are listed 5` to 3`.metapneumovirus [30], human coronaviruses (OC43,
HKU1, 229E, and NL63) [31,32], human bocavirus [33]
and human polyomaviruses (WUPyV and KIPyV) [34].
For all viruses, except RV, samples were tested in a 10 ×
10 pooled format. Briefly, aliquots of the sample extracts
were pooled using the CAS-1200 liquid handling system
(Qiagen-Australia) and pools tested for the presence of
respiratory viruses. For positive pools, individual sample
extracts were then tested to confirm positivity. RV screen-
ing was performed on individual sample extracts, and not
on the pooled extracts, as the number of expected positive
samples was considered too high for there to be any bene-
fits from pooling.
Fungal testing
During the initial phases of the study, mould was observed
growing on a small number of nasal swabs at the time of
their arrival at the Laboratory. In light of this observation,
before extraction all swabs were inspected visually for
mould and were assigned a semi-qualitative score accord-
ing to a sliding scale (0 to 3), whereby 0 = no mould ob-
served, 1 = low, 2 =medium, and 3 = high levels of visible
mould present. DNA sequencing was used to identify
the type of fungi present on a subset of swabs exhibiting
varying degrees of visible mould growth (10 swabs where
no mould was seen, and 20 each where low, medium
and high levels, respectively, of mould contamination
was present).
PCR amplification of a fungal internal transcribed spacer
(ITS) region was performed using 10 pmoles of forward
and reverse primers (ITS1 forward primer TCCGTAGGT
GAACCTGCGG and ITS4-reverse primer TCCTCCGC
TTA TTGATATGC [35], 25 μL of Qiagen SYBR master
mix (Qiagen, Australia) and 5 μL of template in a total
50 μL reaction mix. Cycling was performed using the fol-
lowing conditions: 95°C for 15 min, 45 cycles of 95°C for
30 sec, 50°C for 30 sec and 72°C for 60 sec and a melting
step of 60-95°C at the end of the thermal cycling. PCR
products were examined by gel electrophoresis using a 2%
agarose gel and sent to the Australian Genome Research
Facility (The University of Queensland, Brisbane) for auto-
mated sequencing.
Exclusion criteria
For this study, samples that failed EHV1 criteria or were
not inspected for mould growth were excluded from the
analysis (Figure 1).
Data analysis
The association between variables of interest and binary
outcomes was investigated using mixed effects logistic re-
gression models, with participants included as a random
intercept to account for the possibly correlated outcomes
within each infant. The association with continuous
Figure 1 Number of samples negative for ERV3 during screening of each sample extraction batch (92 samples per batch). A total of 56
extraction batches were performed in the first 20-months of the study. Each batch was tested for quality control (EHV1/ERV3 PCR), following
which every four batches were pooled and pools were screened for respiratory viruses other than rhinovirus. The batches used in the analysis are
indicated by the solid line.
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gression. When examining the association of mould level
with sample quality and respiratory virus detection we
conducted both univariate and multivariate analyses, with
multivariate analyses adjusting for the potential con-
founders of the child’s age, gender, relationship of collector
to participant (e.g. father, mother or others), season speci-
men collected, and time from specimen collection to being
frozen in the laboratory. Analyses were conducted using
Stata statistical software v.11.0 (StataCorp, College Station,
TX, USA).Results
Swab samples
Between September 2010 and July 2012, 152 infants
were recruited into the study. All participants lived
within the greater Brisbane metropolitan area and none
were from rural communities. One-hundred and twenty-
five recruits remained active study participants up until
the date of this analysis. Of the 27 withdrawals, four had
moved out of the study area, two others were later deemed
ineligible, ten withdrew for personal reasons and eleven
were ineligible because they could not fulfill sampling re-
quirements. For the active families, swab return rates were
>90% for almost 35,000 child-days of observation. In total,
4933 weekly nasal swab specimens (~510 nasal swabs/
month) were batched in 56 (96 well) racks, extracted and
tested. The median time from collection to swab arrival
in the laboratory was 2 (interquartile range 2–4) days;however 10.9% of swabs were received more than 7-days
after their collection.
Excluded samples:
For EHV1 extraction and inhibition testing, 42 (0.81%)
DNA extracts failed the EHV1 criteria. The initial 1525
samples were not inspected for mould growth during
the early stages of the study and therefore were excluded
from further analysis.
ERV3 detection
Of the remaining 3366 samples, there were 2718 (80.7%)
samples positive for ERV3 with PCR amplification Ct
values ranging from 23–45 (median 36) cycles. Overall,
ERV3 was not detected in 649 (19.2%) samples. During
the first 8-months of batching and screening conducted
in the laboratory, the number of ERV3 negative samples
ranged from 11 to 25 in each 92 extraction run with a
median of 17 negative samples per run (Figure 1). How-
ever, following a cluster of samples negative for ERV3
(Figure 1; batches 41, 43, 44) we contacted parents and
reminded them of the optimal swab collection technique
they had been shown at enrolment of their baby. After
this feedback the numbers of ERV3 negative samples
declined.
Respiratory viruses detected
At least one respiratory virus was detected in 885
(26.2%) samples. Dual or multiple virus detections were
observed in 105 (2.14%) samples. RV was the most
Table 3 Species detected in 70 samples with different
levels of fungal growth
Species Number
detected
(high; medium; low;
no visible mould)
Alsaleh et al. BMC Infectious Diseases 2014, 14:15 Page 5 of 9
http://www.biomedcentral.com/1471-2334/14/15common virus detected, being present in almost 20% of
specimens, followed by human bocavirus, human poly-
omavirus KIPyV, respiratory syncytial viruses and human
adenoviruses (Table 2).
Mould
Of 3366 swab samples visually inspected for mould, 99
(2.9%) had high, 252 (7.5%) medium and 411 (12.2%)
had low levels present, while 2604 swabs (77.4%) had no
visible signs of mould. The mean (standard deviation)
time from collection until being frozen in the laboratory
for samples with no observed mould was 2.9 (3.0) days.
In comparison for low level mould it was 4.9 (3.6) days
(crude mean difference compared with no mould; 95%
confidence interval (CI) = 1.7; 1.4 – 2.1 days), for medium
level mould it was 7.4 (4.9) days (3.9; 3.4 – 4.3), and for
high level mould 11.4 (10.7) days (7.1; 6.4 – 7.8). The
mean difference in time from collection until being frozen
between each mould group and the no mould group was
statistically significant (P < 0.001 for each comparison). A
significant association was also observed between mould
and season. In specimens collected in summer, mould
was observed on 28.2% of swabs. In comparison mould
detection rates were 31.0% in spring (crude odds ratio
(OR); 95% CI = 1.08; 0.87 – 1.34), 15.8% in autumn
(0.47; 0.37 – 0.59) and 13.7% in winter (0.40; 0.29 – 0.53).
When considering samples that contained mould, thereTable 2 Results for respiratory viruses screening from
3366 parent collected nasal swab specimens between
July 2011 and July 2012 and fulfilling the EHV1 criteria
Virus No. of infants No. of samples % of all samples
RV 105 726 21.57
HBoV 26 46 1.37
KIPyV 17 41 1.22
HAdV 23 30 0.89
RSV-A 26 30 0.89
WUPyV 13 28 0.83
HCoV NL63 12 16 0.48
IV-B 11 11 0.33
HCoV 229E 3 6 0.18
PIV 1 6 6 0.18
HMPV 5 5 0.15
PIV3 3 3 0.09
HCoV HKU1 3 3 0.09
IV-A 2 2 0.06
RSV B 2 2 0.06
HCoV OC43 1 1 0.03
PIV 2 0 0 0
HAdV, Human adenovirus; HBoV, Human bocavirus; HCoV, Human coronavirus;
HMPV, Human metapneumovirus; IV, Influenza virus; PIV, Parainfluenza virus;
PyV, Polyomavirus; RSV, Respiratory syncytial virus, RV, Rhinovirus.was no statistically significant association between season
and level of mould.
Fungal identification was achieved for 48 of 70 swabs
subjected to PCR and DNA sequencing (Table 3). A di-
verse range of species was observed with Epicoccum
nigrum and Cladosporium cladosporioides the most
prevalent.
ERV3, visible mould and respiratory virus detection
Of the 2718 samples that were ERV3 positive, 810
(37.2%) had at least one respiratory virus detected by
PCR. In contrast, the respiratory virus detection rate in
ERV3 negative samples was significantly lower (75/649,
11.5%; crude odds ratio (OR) = 0.35; 95% CI 0.27-0.44)
when ERV3 was absent in swab specimens. We also ob-
served that among ERV3 positive swabs, the average
ERV3 Ct value for samples positive for any respiratory
virus (32.8 cycles) was significantly lower (indicating
greater ERV3 load) than the average Ct value (35.4) in sam-
ples negative for all viruses (crude difference = 2.0, 95% CI
1.4 – 2.6; Figure 2). Moreover, there was a significant
difference in ERV3 Ct values (P = 0.001) in samples thatEpicoccum nigrum 15 (7,2,4,2)
Cladosporium cladosporioides 7 (3,3,1,0)
Aureobasidium pullulan 4 (1,1,2,0)
Cryptococcus flavescens 3 (1,2,0,0)
Alternaria alternata 2 (1,1,0,0)
Alternaria tenuissima 1 (0,0,1,0)
Aspergillus westerdijkiae 1 (0,0,1,0)
Candida parapsilosis 1 (0,1,0,0)
Cladosporium silenes 1 (0,0,0,1)
Cladosporium tenuissimum 1 (0,1,0,0)
Cladosporium uredinicola 1 (1,0,0,0)
Cochliobolus lunatus 1 (0,1,0,0)
Curvularia brachyspora 1 (0,1,0,0)
Curvularia trifolii 1 (0,1,0,0)
Leptosphaerulina australis 1 (0,1,0,0)
Paraphaeosphaeria sp 1 (1,0,0,0)
Penicillium fellutanum 1 (0,0,1,0)
Penicillium oxalicum 1 (0,1,0,0)
Penicillium polonicum 1 (0,0,0,1)
Penicillium spinulosum 1 (0,0,1,0)
Phoma herbarum 1 (0,0,1,0)
Rhodotorula slooffiae 1 (0,1,0,0)
Total 48
Figure 2 Comparison between average ERV3 cycle threshold (Ct) values in respiratory virus positive (dark bars) versus negative (light
bars) samples. In ERV3-positive samples, the average ERV3-Ct values (32.8) in samples positive for any virus was significantly lower than the
average ERV3-Ct values (35.4) in samples negative for all viruses (difference = 2.6, 95% confidence interval 2.3-2.9).
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comparing with samples that had multiple respiratory
viruses detection (average = 31.27).
Of the 762 samples with visible mould, 529 (69.4%) were
positive for ERV3, which was significantly lower than rates
in samples without visible mould (84.0%; crude OR = 0.35,
95% CI 0.28-0.43). The proportion of samples with visible
mould and positive respiratory virus testing (178/762;
23.4%) was significantly lower than that of samples with-
out mould (707/2606; 27.1%; crude OR = 0.70, 95% CI
0.57-0.86).
Table 4 examines the association between ERV3 and
respiratory virus detection and potential explanatory and
confounding variables. ERV3 positive sample rates in-
creased with age, varied by season and declined with in-
creasing mould levels and time taken for samples to reach
the laboratory and to be frozen. Similarly, respiratory virus
detection rates increased with age, specimen collection
outside the summer months, and time taken to reach the
laboratory, while decreasing as visible mould levels in
samples reaching the laboratory increased.
Discussion
The ORChID project is an ongoing comprehensive
community-based study using PCR assays to detect re-
spiratory viruses in anterior nasal swab specimens taken
weekly by parents from their infants throughout the first
2-years of life. This requires parents following a standard-
ized protocol of obtaining swabs regularly and mailing
them promptly to our laboratory. However, we have ob-
served that suboptimal sample collection as determined
by ERV3 detection and presence of visible mould in swabsamples reaching the laboratory can negatively affect sam-
ple quality and potentially respiratory virus detection.
The data from the first 20-months of our longitudinal
study indicate that respiratory virus detection is associ-
ated with the ERV3 load in nasal swab specimens. Swabs
negative for ERV3, presumably from sub-optimal collec-
tion, had reduced respiratory virus detection rates com-
pared with samples containing ERV3. Furthermore, in
those specimens positive for ERV3, a higher ERV3 load
was associated with a higher likelihood of respiratory
virus detection. Overall, this shows the importance of
measuring human DNA as a marker for epithelial cells
in swab samples, which if tested and monitored in real
time during the study, can identify problems associated
with collection that can be addressed quickly. This is il-
lustrated in the current study when a sudden increase in
ERV3 negative samples was observed. Parents were con-
tacted and reminded about sample collection protocols
following which there was a decline in ERV3 negative
sample rates towards baseline levels.
We were also concerned at finding mould on some
samples, which occurred despite the commercial swab
tubes containing antifungal agents. Most fungal species
identified in the swabs were saprophytic, and the most
common fungus found, Epicoccum nigrum, is a known
contaminant of clinical specimens [36]. The relationship
between fungal airspora counts and meteorological con-
ditions is complex and impacts at the species level [37].
In Brisbane, Cladosporium and Alternaria airspora are
detected commonly throughout the year, but as with
Epicoccum,sp their levels peak during the warmer, humid
months. Other factors, such as rainfall and wind speed,
Table 4 ERV3 and respiratory virus positive samples detected by polymerase chain reaction assays in 3366 parent collected nasal swab specimens
Variable No. samples (%) ERV3 Positive Respiratory virus positive
No. samples (%) Univariate *Multivariate No. samples (%) Univariate *Multivariate
OR (95% CI); P value OR (95%); P value OR (95% CI); P value OR (95%); P value
Age (months) < 6 1293 (38.4%) 995 (77.0) 1 1 208 (16.1) 1 1
6- <12 1295 (38.5%) 1061 (81.9) 1.20 (0.94-1.53); 0.15 1.28 (0.98-1.68); 0.07 411 (31.7) 2.59 (2.07-3.24); <0.001 2.38 (1.89-3.01); <0.001
≥12 778 (23.1%) 662 (85.1) 1.49 (1.06-2.10); 0.02 1.93 (1.27-2.93); 0.002 266 (34.2) 2.98 (2.26-3.92); <0.001 2.16 (1.57-2.99); <0.001
Gender Male 1647 (48.9%) 1335 (81.1) 1 1 461 (28.1) 1 1
Female 1719 (51.06%) 1383 (80.4) 0.81 (0.54-1.22); 0.32 0.87 (0.58-1.29); 0.48 424 (24.7) 0.82 (0.60-1.12); 0.21 0.83 (0.61-1.12); 0.23
Collector Mother 2845 (84.5%) 2307 (81.1) 1 1 766 (26.9) 1 1
Father 441 (13.1%) 342 (77.6) 0.91 (0.66-1.27); 0.60 0.87 (0.62-1.22); 0.42 109 (24.7) 0.94 (0.70-1.26); 0.67 0.88 (0.65-1.19); 0.41
Research staff 45 (1.3%) 40 (88.9) 2.71 (1.00-7.36); 0.05 1.76 (0.65-4.81); 0.27 3 (6.7) 0.24 (0.07-0.79); 0.02 0.36 (0.11-1.21); 0.10
Other 35 (1.0%) 29 (82.9) 1.31 (0.49-3.51); 0.59 1.39 (0.46-4.16); 0.56 7 (20.0) 0.72 (0.30-1.74); 0.47 0.87 (0.35-2.13); 0.76
Season Summer 926 (27.5%) 729 (78.7) 1 1 178 (19.2) 1 1
Autumn 1059 (31.5%) 802 (75.7) 0.90 (0.71-1.13); 0.37 0.74 (0.58-0.96); 0.02 304 (28.7) 1.99 (1.59-2.49); <0.001 1.74 (1.38-2.20); <0.001
Winter 541 (16.1%) 482 (89.1) 2.63 (1.87-3.70); <0.001 2.41 (1.67-3.49); <0.001 198 (36.6) 3.06 (2.36-3.97); <0.001 2.63 (2.01-3.45); <0.001
Spring 840 (25.0%) 705 (83.9) 1.39 (1.07-1.79); 0.01 1.50 (1.13-1.99); 0.005 205 (24.4) 1.27 (1.00-1.61); 0.05 1.43 (1.11-1.84); 0.005
Mould None 2604 (77.4%) 2189 (84.1) 1 1 707 (27.2) 1 1
Low 411 (12.2%) 308 (74.9) 0.47 (0.36-0.62); <0.001 0.69 (0.52-0.93); 0.01 97 (23.6) 0.73 (0.56-0.95); 0.02 0.81 (0.61-1.07); 0.14
Medium 252 (7.5%) 163 (64.7) 0.27 (0.20-0.37); <0.001 0.47 (0.33-0.66); <0.001 60 (23.8) 0.70 (0.50-0.96); 0.03 0.70 (0.49-0.99); 0.05
High 99 (2.9%) 58 (58.6) 0.20 (0.13-0.33); <0.001 0.40 (0.24-0.66); <0.001 21 (21.2) 0.57 (0.34-0.96); 0.04 0.53 (0.31-0.93); 0.03
Time to reach
Laboratory (days)
0-3 2281 (67.8%) 1983 (86.9) 1 1 587 (25.7) 1 1
4-7 723 (21.5%) 513 (71.0) 0.32 (0.25-0.40); <0.001 0.39 (0.30-0.50); <0.001 187 (25.9) 0.96 (0.78-1.18); 0.69 1.03 (0.82-1.29);0.80
>7 362 (10.8%) 222 (61.3) 0.17 (0.13-0.24); <0.001 0.24 (0.17-0.34); <0.001 111 (30.7) 1.16 (0.89-1.52); 0.28 1.42 (1.05-1.94); 0.02
*Adjusted for all variables in the Table.
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http://www.biomedcentral.com/1471-2334/14/15can also influence fungal airspora composition [37,38].
In our study, mould was associated mainly with longer
time intervals between taking swabs and their arrival at
the laboratory. However, this was especially evident during
the warm, humid spring and summer months, which leads
us to speculate that fungal contamination occurred during
sample collection and was influenced by the aforemen-
tioned environmental factors. Unfortunately, we could not
explore this further as it was beyond the scope of the
present study. In addition, while mould growth proved to
be an issue in the subtropical climate of Brisbane, this may
be less of a problem in more temperate climates with
lower temperatures and humidity levels.
We now remind parents regularly to mail swabs
promptly after collection. Of interest however, was that
respiratory virus detection rates were not affected by
prolonged transport times, but in fact appeared to in-
crease with time taken to reach the laboratory. While
the observed increase was unexpected and may have
occurred simply by chance, it is plausible that viral
nucleic acids were protected to some extent by being
encapsulated within the viral capsid, and by using viral
transport medium in the swabs.
Fungi were found to be associated with both reduced
ERV3 detection and, at high levels, reduced significantly
respiratory virus detection. At least three points emerge
from this study. First, although swabs may contain
antimicrobial agents, the risk of fungal and potentially
bacterial contamination may still arise. Second, the
times between swab collection and laboratory arrival
should be monitored and feedback provided if delays
occur. Finally, if delays are expected swabs should be
placed in the household refrigerator until mailed to the
laboratory [20].Conclusion
We found that ERV3 as a marker for human DNA and
epithelial cells was also an important indicator of sample
quality for our study. For community-based investigations
similar to our own, real-time sample processing and ERV3
detection can facilitate rapid interventions to maintain
sample quality and to optimize respiratory virus detection.
Indeed, this may have broader implications since nasal
swabs are beginning to replace the traditional, but more
invasive nasopharyngeal swab or aspirate sampling tech-
niques in hospitals and clinics, especially following the
2009 influenza pandemic [17]. Thus, similar ERV3 testing
strategies could be used by diagnostic laboratories to
improve or monitor sample collection quality for opti-
mal respiratory virus detection. Finally, the potential
problem of visible mould contamination of swabs taken
during community-based studies can be minimized by en-
suring samples are transported promptly to the laboratory.Abbreviations
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A Retrospective Performance Evaluation of an
Adenovirus Real-Time PCR Assay
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Human adenoviruses (AdVs) cause a wide range
of diseases. To date, there are at least 60 known
human AdV types and, as these exhibit high
levels of genetic variation this could impact
potentially upon their detection by polymerase
chain reaction (PCR)-based technology. Here, the
sensitivity of a pan-AdV real-time PCR assay
(AdV-PCR) used widely for testing clinical sam-
ples was determined retrospectively. An in silico
analysis was performed initially using the 370
AdV sequences available on the Genbank data-
base. To investigate for potential false-negative
results, two additional AdV-PCR assays were
used to re-evaluate 779 respiratory samples
submitted for virus testing and 1,012 nasal swab
samples collected as part of an ongoing commu-
nity-based study. The results were then com-
pared to those obtained by AdV-PCR. In silico
analysis showed the presence of mismatches in
the AdV-PCR primers and probe for most AdV
sequences available on Genbank. Notably, 215
of the 370 (58%) sequences had at least three
mismatches with the AdV-PCR forward primer.
Of the 779 clinical samples, 88 were identified as
AdV-positive, of which 84 were positive by the
AdV-PCR. The four samples providing false-
negative results in the AdV-PCR had high cycle
threshold values in the other methods suggest-
ing that sampling at low load, rather than
sequence variation, was responsible for the
negative results. No false-negative AdV-PCR re-
sults were observed for the community-based
study samples. Reassuringly, the results show
that despite the high level of sequence variation
in the AdV-PCR assay oligonucleotide targets,
the assay remains suitable for routine detection
of human AdV strains. J. Med. Virol. 86:795–
801, 2014. # 2013 Wiley Periodicals, Inc.
KEY WORDS: diagnosis; mutation; DNA; pri-
mer; sequence variation
INTRODUCTION
Human adenoviruses (AdVs; Genus Mastadenovirus,
Family Adenoviridae), which were first isolated from
the respiratory tract by tissue culture [Rowe et al.,
1953], are known to cause a wide range of human
diseases, including respiratory, gastrointestinal, ocular,
urinary, and central nervous system infections [Lynch
et al., 2011]. Although AdV infections are typically
acute, self-limiting and not fatal, they may have severe
consequences for both immunocompromised patients
[Zahradnik et al., 1980; La Rosa et al., 2001] and on
rare occasions previously healthy infants [Mistchenko
et al., 1998; Henquell et al., 2009]. AdVs can also cause
localized epidemics in small and crowed populations,
such as schools and military facilities [Caldwell et al.,
1974; Yu et al., 2013].
Nucleic acid amplification tests (NAATs), such as
polymerase chain reaction (PCR) assays, provide high
levels of sensitivity and specificity compared with cell
culture and serology. With reduced turnaround time,
NAATs are also superior to other viral detection
methods for routine applications and in large epide-
miological studies. PCR has been used for AdV
detection in clinical samples since the 1990s [Allard
et al., 1990; Pring-Akerblom and Adrian, 1994; Echa-
varria et al., 1999]. However, designing a diagnostic
PCR assay that is comprehensive for all human AdV
types can be problematic. The human AdVs are
subgrouped into seven species (A to G) that include
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at least 60 different types of human AdVs [Robinson
et al., 2011; Matsushima et al., 2013]. Notably, there
are considerable genetic differences between AdV
types, and these differences are likely to impact upon
the performance of diagnostic PCR assays, relying as
they do upon highly conserved target sequences.
In 2003, a real-time PCR method was first devel-
oped for pan-AdV detection [Heim et al., 2003]. Since
then, this AdV-PCR assay has been used widely by
many laboratories for routine detection of AdV in-
fections [Lambert et al., 2008; Kwofie et al., 2012;
Tsou et al., 2012; Ayoub et al., 2013]. The original
description of the method considered the extent of
AdV genetic variation known at the time, and
importantly, showed that the assay was able to detect
a broad range of AdV types despite known mis-
matches [Heim et al., 2003]. However, in view of the
negative impact that genetic variation may have
upon PCR assay performance [Whiley and Sloots,
2005, 2006], concerns were raised about potential
false-negative results arising from the appearance of
new AdV types or variants. These concerns are
reinforced by the more recent publication of newer
pan-AdV PCR methods [Bil-Lula et al., 2012; Alkha-
laf et al., 2013]. It was for these reasons and as part
of standardizing PCR assays for a large longitudinal,
community-based study of respiratory viruses in
young children [Lambert et al., 2012] that a retro-
spective performance evaluation of the AdV-PCR
assay was conducted. An in silico analysis of recent
AdV sequences data was also undertaken to deter-
mine sequence target stability. As further validation,
two additional adenovirus PCR assays were then
used to retest respiratory samples collected for clini-
cal purposes.
METHODS
Sequence Analysis of AdV-PCR Oligonucleotides
To investigate the extent of sequence variation in
the AdV-PCR primer and probe targets, AdV hexon
gene sequences from the Genbank database were
downloaded and analyzed. Briefly, these comprised
representative sequences of all 68 known human AdV
types, excluding types 57 and 60 for which sequence
data for the AdV-PCR targets were not available.
Sequences were aligned using BioEdit software (ver-
sion 7.0.4.1) and the number and location of mis-
matches in each oligonucleotide target identified
(Figs. 1–3).
Assays Design
Based on the above sequence data, two additional
assays (defined as Mod1-PCR and Mod2-PCR) were
designed. For Mod1-PCR assay, identical sequence
targets as the AdV-PCR were used, except that
degenerate bases were incorporated at appropriate
positions to accommodate sequence mismatches;
three forward primers, three reverse primers and two
probes with degenerate bases in various positions
were designed subsequently (Table I). The Mod2-PCR
assay was designed with the aid of Primer Express
(Applied Biosystems, version 2.0; Foster City, CA)
and targeted sequences flanking those of the above
AdV-PCR and Mod1-PCR methods. Similar to the
Mod1-PCR, multiple oligonucleotides with degenerate
bases in various positions were used to accommodate
the observed sequence variation; two forward pri-
mers, two reverse primers, and one probe (Table I).
Real-Time PCR Reaction Mix and Cycling
Conditions
The real-time PCR reactions for all three assays
were performed using the Qiagen Quantitect Probe
PCR kit (Qiagen; Doncaster, Australia). The reaction
mixes consisted of a total reaction volume of 20.0ml,
including 10.0ml of Qiagen Quantitect Probe mix
(Qiagen; Doncaster, Australia) and 2.0ml of sample
extract or control. For the AdV-PCR, 8.0pmoles of the
previously described forward and reverse primers and
2.0pmoles of probe were used [Heim et al., 2003]. For
TABLE I. Oligonucleotides Used for the Mod1-PCR and Mod2-PCR Methods
Designation Oligonucleotide sequence (50–30) Positiona
Mod1-PCR assay
Mod1-P1 TCGGRGTACCTSAGTCCGGGTCTGGTGCA 18401–18430
Mod1-P2 TCGGAGTACCTGAGCCCSGGKCTGGTGCA
Mod1-F1 GCCSCARTGGGCATACATGCACATC 18362–18387
Mod1-F2 GCCGCAGTGGKCKTACATGCACATC
Mod1-F3 GCCCCAGTGGKCKTACATGCACATC
Mod1-R1 GCCACTGTGGGGTTTCTAAAYTT 18471–18494
Mod1-R2 GCCACSGTGGGGTTYCTAAACTT
Mod1-R3 GCTACGGTRGGATTTCTAAACTT
Mod2-PCR assay
Mod2-P1 CTGGTGCAGTTYGCCCGYGCMAC 18422–18446
Mod2-F1 ACATGCACATCTCGGGCCAGGA 18376–18398
Mod2-F2 ACATGCACATCGCCGGRCAGGA
Mod2-R1 CGGTCSGTGGTCACATCRTGGGT 18498–18521
Mod2-R2 CGGTCGGTGGTCACRTCGTGSGT
aPosition according to adenovirus-D type 16, Genbank accession number JN860680.
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the Mod1-PCR, 2.6pmoles each of the three forward
primers (mod1-F1, F2 and F3; Table I), 2.6pmoles
each of the three reverse primers (mod1-R1, R2, and
R3; Table I), and 2.0pmoles of each probe (Mod1-P1
and P2; Table I) were used. Similarly, the Mod2-PCR,
comprised 4.0pmoles each of the two forward primers
(mod2-F1 and F2; Table I), 4.0 pmoles each of the
two reverse primers (mod2-R1 and R2; Table I), and
2.0pmoles of probe (Mod2-P1; Table I). All three
methods were cycled on the Rotorgene-Q (Qiagen;
Doncaster, Australia). Cycling was performed under
the following conditions: initial activation at 95˚C for
15min and 45 cycles of 95˚C for 15 sec and 60˚C for
1min.
Control Isolates
The performance of the three PCR methods was
assessed initially using eight AdV isolates of various
types (Table II). Briefly, 10-fold dilutions of DNA
extracted from each isolate were tested in all three
methods and the detection limits and associated cycle
threshold value data compared.
Clinical Performance
The performance of the AdV-PCR was retrospec-
tively investigated by retesting clinical samples using
both the Mod1-PCR and Mod2-PCR assays. All
respiratory specimens were provided by Pathology
Queensland, Royal Brisbane and Women’s Hospital
(Brisbane, Queensland) and collected during the year
2012. These included 79 samples that had tested
positive by the AdV-PCR assay previously at Patholo-
gy Queensland as well as an additional 700 de-
identified respiratory specimens. The latter 700 sam-
ples were pooled (10 samples per pool) for testing. All
samples from pools providing positive results by any
method were then tested individually by all three
assays (AdV-PCR, Mod1-PCR, and Mod2-PCR) in
parallel and the results compared.
Community-Based Respiratory Samples
Assay performance was also investigated using
1,012 nasal swab samples collected between Sep-
tember 2010 to April 2012 as part of a longitudinal,
community-based study of respiratory viruses in
young children [Lambert et al., 2012]. Briefly,
samples were pooled and tested as per above,
except that only the AdV-PCR and Mod1-PCR
assays were used, the Bioline SensiMix II Probe Kit
(Bioline; Sydney, Australia) was used instead of the
Qiagen Quantitect Probe mix and cycling was
performed on an ABI7500 (Applied Biosystems;
Melbourne, Australia). The decision not to use the
Mod2-PCR assay for this testing was based on the
similar results observed for the Mod1-PCR and
Mod2-PCR methods when used to test the above
control isolates and clinical samples.
AdV-PCR Sequence Target Analysis
DNA sequencing was used to investigate sequence
variation in the AdV-PCR targets in all control isolates,
as well as clinical samples providing discrepancies
between the three PCR methods. Briefly, a sequence of
489 bases (based on AdV-E type 4; genbank accession
number EF371058) was amplified by PCR using pri-
mers flanking the above assays (ACTCTGAACAG-
CATCGTGGGT, this study; and CAGCACGCCGCGG
ATGTCAAAGT; Allard et al., 1990), and submitted for
DNA sequencing to the Australian Genome Research
Facility (The University of Queensland, Brisbane,
Australia). AdV genotyping was also performed on the
discrepant clinical samples, based on the high variable
region 7 (HVR7) in the hexon gene as described
previously [Sarantis et al., 2004].
Additional AdV Genotyping
To further investigate circulating AdV genotypes in
the local population, 20 randomly-selected AdV-posi-
tive clinical samples (from the 2012 sample set above)
were also subject to AdV genotyping.
RESULTS
Sequence Analysis of AdV-PCR Oligonucleotide
Targets
Overall, 334 (90%) of the 370 AdV hexon gene
sequences available on the Genbank database had at
least two mismatches with the AdV-PCR forward
primer and 215 (58%) sequences had at least three
mismatches (Fig. 1). Likewise, 254 (69%) of the
sequences had at least two mismatches with the
AdV-PCR reverse primer (Fig. 2). The AdV-PCR
probe was the most conserved with 304 (82%) of
sequences having either one or no mismatches
(Fig. 3). In general, the highest level of variation was
observed amongst the AdV B species; B1 and B2
(data not shown). This variation involved predomi-
nantly the forward primer, with three mismatches
observed typically.
Control Isolates
Testing 10-fold dilutions of the control isolates
revealed similar detection limits between the three
assays (within 1- to 10-fold dilution) for all isolates
(data not shown). However, for some isolates, signifi-
cant differences were observed between assays with
respect to cycle threshold (Ct) values (Table II).
Notably, isolates 1 and 2 (AdV types 34 and 11
respectively; both B species) showed significantly
lower Ct values in the Mod1-PCR and Mod2-PCR
assays by 10 and 5 cycles, respectively compared
with the AdV-PCR (Table II). In contrast, Ct values
for all other control isolates (3C, 1 E, 1 F, and 1 B
species) differed by only one to two cycles between
assays.
J. Med. Virol. DOI 10.1002/jmv
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DNA sequencing of the AdV-PCR targets for the
control isolates (Table II) revealed mismatches for
primer and probe targets for all isolates. However,
the most number of mismatches were observed for
control isolates 1 and 2 (B species), with three
mismatches present in both the forward and reverse
primers for both isolates.
Clinical Samples
For the 79 AdV-positive specimens from Pathology
Queensland, the three methods were positive and
provided similar Ct values (i.e., <3 cycles difference
between assays) for 67 samples (12–38.8 cycles in the
AdV-PCR; mean of 27 cycles). A further two samples
were positive by all three methods, but provided
earlier Ct values (>3 cycles difference) in both the
Mod1-PCR and Mod2-PCR assays (samples 1 and 2;
Table II). One sample was positive by the AdV-PCR
only (sample 3; Table II), one sample positive by both
the AdV-PCR and Mod2-PCR assays only (sample 4;
Table II), two samples were positive by AdV-PCR and
Mod1-PCR only (samples 5 and 6; Table II) and there
were two samples that were negative by all three
methods. Of note, was that there were four additional
samples negative by the AdV-PCR, but positive by
both the Mod1-PCR and Mod2-PCR assays (samples
7–10; Table II). To further investigate the latter, all
four samples were retested in duplicate in the AdV-
PCR; two samples provided positive results in both
replicates, and two samples were each positive in one
of the two replicates.
The additional testing of 70 respiratory pools (from
700 respiratory virus extracts) revealed 10 positive
pools in all methods and an additional two pools
positive by the Mod2-PCR only (total of 12 positive
pools for this method). The 120 individual samples
from these 12 pools were tested subsequently with all
three assays and 12 samples were found positive by
all three methods (i.e., one positive sample/pool). Of
the 12 positive samples, nine provided similar Ct
values in all three methods (23.7–34.8 cycles in the
AdV-PCR; mean of 29.8 cycles). Three samples pro-
vided earlier Ct values in the Mod1-PCR and Mod2-
PCR assays compared to the AdV-PCR (samples 11–
13; Table II).
DNA sequencing of the AdV-PCR targets and AdV
genotyping was attempted for all the clinical samples
providing discrepancies (samples–13; Table II). Of
these, the AdV-PCR sequence targets could only be
                 5’ GCCCCAGTGGTCTTACATGCACATC 3’  
7     .........................  
22     ...G..................... 
3     ......A..................  
3     ............A............  
1     ..........G.............. 
1     ...T........G............  
1     ...G.................T... 
43     ..........G.A............  
6     ...G..A.................. 
3     ......A...G.............. 
39     ..........G.G............  
9     ...G........A............  
6     ...G......G..............  
2     ......A.....A............  
9     ...G........G............  
94     ...G......G.G............  
113     ......A...G.A............  
1     ...G..A.....A............  
1     ...G......G.A............  
2     ...G..A...G..............  
1     ..........G.G.....A......  
1     ...A........G...........T 
2     ...G..A...G.A............  
(Total = 370)  
Fig. 1. Sequence alignment of the Heim forward primer with
370 adenovirus sequences from the Genbank database. Dots
indicate a match whereas capitalized bases indicate mismatches
with the primer sequence.
                 5’ GCCACGGTGGGGTTTCTAAACTT 3’   
2     ....................... 
45     .....C................. 
1     .................G.....  
45     .....T.................  
23     ..............C........  
2     ........A.....C........  
115     .....C........C........  
40     ..T........A...........  
84     .....T..............T..  
4     .....A.....A..C........  
1     ..T..A.....A...........  
3     ..T.....A..A...........  
1     ..T........A..........C  
1     ..Y..C........C........  
1     .G...C........C........  
1     .....A........C..G..... 
1     .....C..A.....C..G..T..  
(Total = 370)  
Fig. 2. Sequence alignment of the Heim reverse primer with
370 adenovirus sequences from the Genbank database. Dots
indicate a match whereas capitalized bases indicate mismatches
with the primer sequence.
 
                 5’ TGCACCAGACCCGGGCTCAGGTACTCCGA 3’    
92     .............................  
2     ........G....................  
207     ..............A..............  
2     .......A.....................  
1     .................G...........  
32     ..............A..G...........  
1     ..............A..A...........  
14     ........C..G.................  
5     ...........G..A.............. 
1     ........C..G..A..............  
1     .....A..C..G.................  
1     ........C..G.....T...........  
7     ..............A..G......C....  
1     G........T....A..............  
1     ........C..G..A........T.....  
1     .....G..G..G..A..............  
1     AA.TG.........A..G...........  
(Total = 370)  
Fig. 3. Sequence alignment of the Heim probe with 370
adenovirus sequences from the Genbank database. Dots indi-
cate a match whereas capitalized bases indicate mismatches
with the probe sequence.
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sequenced for three samples (samples 1, 2, and 11;
Table II) being the samples with the highest viral
load (based on the PCR Ct values), whereas HVR7
genotyping was successful for eight samples
(Table II). Similar to the results of the control
isolates, samples 1, 2, and 11 had a total of five
mismatches in the primers, were members of the B1
species, and correlated with the late Ct values
observed in the AdV-PCR.
Additional AdV Genotyping
HVR7 genotyping of the 20 randomly selected AdV-
positive clinical samples revealed four types from
three species; nine samples comprised AdV type-1 (C
species), eight samples had AdV type-2 (C species),
two samples typed as AdV type-3 (B species) and only
one sample was typed as an AdV type-4 (E species).
Community-Based Respiratory Samples
The testing of the 1,012 community-based nasal
swab samples provided near identical results in both
the AdV-PCR and Mod1-PCR assays; 53 samples
were positive by both methods with similar Ct values
(i.e., <3 cycles difference between assays) for 51
samples with Ct values ranging from 23.1 to 41
cycles (mean of 34 cycles) in the Mod1-PCR. A
further two samples were positive by both methods,
but provided earlier Ct values in the Mod1-PCR (34
and 35.2 cycles, respectively) compared to the AdV-
PCR (39.1 and 41.4 cycles, respectively).
DISCUSSION
The primary goal of this investigation was to
determine whether the AdV-PCR remains suitable for
routine defection of AdVs in clinical samples, and was
instigated because of concerns over the age of the
assay and the potential for false-negative results
arising from new AdV types or variants [Bil-Lula
et al., 2012; Matsushima et al., 2013; Alkhalaf
et al., 2013]. The in silico sequence analysis showed a
high level of variation in the AdV-PCR oligonucleotide
targets, particularly for the primers, and is consistent
with initial concerns. However, the variation observed
was similar to that described originally [Heim
et al., 2003]. In addition, the experimental data here
showed that despite considerable variation in the
AdV-PCR targets, few false-negative results were
observed in the AdV-PCR. The samples that were
negative by AdV-PCR, but positive by either Mod1-
PCR or Mod2-PCR had typically low viral loads (as
indicated by their respective Ct values; clinical sam-
ples 7–10; Table II), and so low load sampling may
explain these results. This explanation is supported
by observing that these samples provided positive
results upon repeat testing in the AdV-PCR assay. In
addition, other samples positive by AdV-PCR at high
Ct values were negative by one or both of the other
two methods (clinical samples 3–6; Table II).
Overall, these results suggest an unexpected toler-
ance of the AdV-PCR assay for mismatches, further
confirming Heim et al.’s original data. The explanation
for this tolerance is likely to be due to variation being
largely absent from the extreme 30 end of the primers
(Figs. 1 and 2), which is the critical region for primer
performance. It should however be noted that false-
positive results in the AdV-PCR could otherwise ex-
plain the failure of the Mod1-PCR and Mod2-PCR
assays to confirm the AdV-PCR results, particularly for
sample 3 (Table II). The most logical way to explore the
potential for false-positive results here would be the
use of DNA sequencing. However, we did not attempt
this as the real-time Ct values involved were very high,
making this very difficult and prone to error. The main
problem being that failure to obtain a clear AdV
sequence could lead us to determine incorrectly AdV
was absent, whereas a small amount of specific AdV-
CR product might still be present, but mixed with the
various non-specific products that occur typically to-
wards the end of PCR cycling.
While the results indicate the AdV-PCR remains
suitable for routine detection of AdVs, the data suggest
that variation does have some impact upon amplifica-
tion, insofar as Ct values can be delayed. For example,
control isolates 1 and 2 (AdV types 34 and 11) had
three mismatches in both the forward and reverse
primers that led to significant delays in Ct values (5–10
cycles) compared to the Mod1-PCR or Mod2-PCR
methods. Similar issues were observed for the clinical
samples. While not affecting qualitative detection, these
results do suggest however, the AdV-PCR assay would
not be suitable for quantitative purposes and that the
Mod1-PCR or Mod2-PCR assays may be more suitable
for quantitative purposes.
Notwithstanding the above, consideration needs to
be given to biases that may exist for Genbank
sequence data as well as the limited genotypic
diversity of AdVs observed in the sample population
studied here. Likewise, AdV genotypes may vary over
time and between geographical locations. Hence these
data do not preclude the possibility that other AdV
variants exist. Nonetheless, despite the high level of
sequence variation in the oligonucleotide targets,
these results support the ongoing use of the AdV-
PCR for qualitative AdV detection.
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